

# CLH report

## Proposal for Harmonised Classification and Labelling

Based on Regulation (EC) No 1272/2008 (CLP Regulation),  
Annex VI, Part 2

### International Chemical Identification: Mancozeb

**EC Number:** Not listed

**CAS Number:** 8018-01-7

**Index Number:** 006-076-00-1

**Contact details for dossier submitter:** UK Competent Authority  
Chemicals Regulation Directorate  
Health and Safety Executive  
United Kingdom

**Version number:** 2

**Date:** December 2017

# CONTENTS


|            |   |           |
|------------|---|-----------|
| <b>1</b>   | <b>IDENTITY OF THE SUBSTANCE .....</b>  | <b>4</b>  |
| 1.1        | NAME AND OTHER IDENTIFIERS OF THE SUBSTANCE.....  | 4         |
| 1.2        | COMPOSITION OF THE SUBSTANCE .....  | 4         |
| <b>2</b>   | <b>PROPOSED HARMONISED CLASSIFICATION AND LABELLING.....</b>  | <b>6</b>  |
| <b>2.1</b> | <b>PROPOSED HARMONISED CLASSIFICATION AND LABELLING ACCORDING TO THE CLP CRITERIA .....</b>                           | <b>6</b>  |
| <b>3</b>   | <b>HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING .....</b>   | <b>9</b>  |
| <b>4</b>   | <b>JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL.....</b>  | <b>11</b> |
| <b>5</b>   | <b>IDENTIFIED USES .....</b>  | <b>11</b> |
| <b>6</b>   | <b>DATA SOURCES.....</b>  | <b>11</b> |
| <b>7</b>   | <b>PHYSICOCHEMICAL PROPERTIES.....</b>  | <b>12</b> |
| <b>8</b>   | <b>EVALUATION OF PHYSICAL HAZARDS .....</b>   | <b>13</b> |
| <b>9</b>   | <b>TOXICOKINETICS (ABSORPTION, DISTRIBUTION, METABOLISM AND ELIMINATION).....</b>                                     | <b>14</b> |
| 9.1        | SHORT SUMMARY AND OVERALL RELEVANCE OF THE PROVIDED TOXICOKINETIC INFORMATION ON THE PROPOSED CLASSIFICATION(S) ..... | 14        |
| <b>10</b>  | <b>EVALUATION OF HEALTH HAZARDS.....</b>  | <b>15</b> |
| 10.1       | ACUTE TOXICITY .....  | 15        |
| 10.2       | SKIN CORROSION/IRRITATION .....   | 15        |
| 10.3       | SERIOUS EYE DAMAGE/EYE IRRITATION .....   | 15        |
| 10.4       | RESPIRATORY SENSITISATION.....  | 15        |
| 10.5       | SKIN SENSITISATION .....  | 16        |
| 10.5.1     | <i>Short summary and overall relevance of the provided information on skin sensitisation .....</i>                    | <i>18</i> |
| 10.5.2     | <i>Comparison with the CLP criteria .....</i>   | <i>18</i> |
| 10.5.3     | <i>Conclusion on classification and labelling for skin sensitisation .....</i>  | <i>19</i> |
| 10.6       | GERM CELL MUTAGENICITY .....  | 20        |
| 10.6.1     | <i>In vitro.....</i>  | <i>20</i> |
| 10.6.3     | <i>Short summary and overall relevance of the provided information on germ cell mutagenicity.....</i>                 | <i>25</i> |
| 10.6.4     | <i>Comparison with the CLP criteria .....</i>   | <i>25</i> |
| 10.6.5     | <i>Conclusion on classification and labelling for germ cell mutagenicity .....</i>                                    | <i>25</i> |
| 10.7       | CARCINOGENICITY .....   | 26        |
| 10.7.1     | <i>Chronic/carcinogenicity studies in rats .....</i>  | <i>34</i> |
| 10.7.2     | <i>Carcinogenicity studies in mice .....</i>  | <i>37</i> |
| 10.7.3     | <i>Other studies relevant to carcinogenicity .....</i>  | <i>37</i> |
| 10.7.4     | <i>Short summary and overall relevance of the provided information on carcinogenicity .....</i>                       | <i>38</i> |
| 10.7.5     | <i>Comparison with the CLP criteria .....</i>   | <i>40</i> |
| 10.7.6     | <i>Conclusion on classification and labelling for carcinogenicity.....</i>  | <i>41</i> |
| 10.8       | REPRODUCTIVE TOXICITY.....  | 42        |
| 10.8.1     | <i>Adverse effects on sexual function and fertility .....</i>   | <i>42</i> |
| 10.8.2     | <i>Adverse effects on development.....</i>  | <i>42</i> |
| 10.8.3     | <i>Developmental toxicity in rats.....</i>  | <i>51</i> |
| 10.8.4     | <i>Developmental toxicity in rabbits .....</i>  | <i>58</i> |
| 10.8.5     | <i>Developmental neurotoxicity in rats .....</i>  | <i>59</i> |
| 10.8.6     | <i>Recent/key developmental toxicity study on ETU in rats .....</i>   | <i>62</i> |
| 10.8.7     | <i>Other relevant information to the assessment of developmental toxicity .....</i>                                   | <i>65</i> |
| 10.8.8     | <i>Short summary and overall relevance of the provided information on adverse effects on development .....</i>        | <i>65</i> |
| 10.8.9     | <i>Comparison with the CLP criteria .....</i>   | <i>65</i> |
| 10.8.10    | <i>Adverse effects on or via lactation .....</i>  | <i>67</i> |
| 10.8.11    | <i>Conclusion on classification and labelling for reproductive toxicity.....</i>                                      | <i>67</i> |
| 10.9       | SPECIFIC TARGET ORGAN TOXICITY-SINGLE EXPOSURE .....  | 68        |
| 10.10      | SPECIFIC TARGET ORGAN TOXICITY-REPEATED EXPOSURE .....  | 68        |

|           |   |            |
|-----------|---|------------|
| 10.10.1   | Oral.....   | 89         |
| 10.10.2   | Other routes .....  | 94         |
| 10.10.3   | Short summary and overall relevance of the provided information on specific target organ toxicity – repeated exposure ..... | 95         |
| 10.10.4   | Comparison with the CLP criteria .....  | 96         |
| 10.10.5   | Conclusion on classification and labelling for STOT RE .....  | 99         |
| 10.11     | ASPIRATION HAZARD.....  | 99         |
| <b>11</b> | <b>EVALUATION OF ENVIRONMENTAL HAZARDS.....</b>   | <b>100</b> |
| 11.1      | RAPID DEGRADABILITY OF ORGANIC SUBSTANCES .....   | 100        |
| 11.1.1    | Ready biodegradability .....  | 102        |
| 11.1.2    | BOD <sub>5</sub> /COD.....  | 103        |
| 11.1.3    | Hydrolysis .....  | 103        |
| 11.1.4    | Other convincing scientific evidence.....   | 104        |
| 11.1.4.1  | Field investigations and monitoring data (if relevant for C&L).....   | 104        |
| 11.1.4.2  | Inherent and enhanced ready biodegradability tests.....   | 104        |
| 11.1.4.3  | Water, water-sediment and soil degradation data (including simulation studies) .....  | 104        |
| 11.1.4.4  | Photochemical degradation.....  | 107        |
|           | Summary and discussion of degradation.....  | 107        |
| 11.2      | ENVIRONMENTAL TRANSFORMATION OF METALS OR INORGANIC METALS COMPOUNDS.....   | 108        |
| 11.3      | ENVIRONMENTAL FATE AND OTHER RELEVANT INFORMATION.....  | 108        |
| 11.3.1    | Adsorption/Desorption.....  | 108        |
| 11.3.2    | Volatilisation.....   | 108        |
| 11.4      | BIOACCUMULATION .....   | 108        |
| 11.4.1    | Estimated bioaccumulation.....  | 109        |
| 11.4.2    | Measured partition coefficient and bioaccumulation test data .....  | 109        |
|           | Summary and discussion of aquatic bioaccumulation .....   | 109        |
| 11.5      | ACUTE AQUATIC HAZARD.....   | 110        |
| 11.5.1    | Acute (short-term) toxicity to fish.....  | 115        |
| 11.5.2    | Acute (short-term) toxicity to aquatic invertebrates .....  | 116        |
| 11.5.3    | Acute (short-term) toxicity to algae or other aquatic plants .....  | 118        |
| 11.5.4    | Acute (short-term) toxicity to other aquatic organisms .....  | 119        |
| 11.6      | LONG-TERM AQUATIC HAZARD .....  | 120        |
| 11.6.1    | Chronic toxicity to fish.....   | 123        |
| 11.6.2    | Chronic toxicity to aquatic invertebrates.....  | 124        |
| 11.6.3    | Chronic toxicity to algae or other aquatic plants .....   | 125        |
| 11.6.4    | Chronic toxicity to other aquatic organisms.....  | 125        |
| 11.7      | COMPARISON WITH THE CLP CRITERIA .....  | 125        |
| 11.7.1    | Acute aquatic hazard.....   | 125        |
| 11.7.2    | Long-term aquatic hazard (including bioaccumulation potential and degradation).....   | 125        |
| 11.8      | CONCLUSION ON CLASSIFICATION AND LABELLING FOR ENVIRONMENTAL HAZARDS ....   | 127        |
| <b>12</b> | <b>EVALUATION OF ADDITIONAL HAZARDS.....</b>  | <b>127</b> |
| 12.1      | HAZARDOUS TO THE OZONE LAYER.....   | 127        |
| 12.1.1    | Short summary and overall relevance of the provided information on ozone layer hazard.....                                  | 127        |
| 12.1.2    | Comparison with the CLP criteria .....  | 128        |
| 12.1.3    | Conclusion on classification and labelling for hazardous to the ozone layer.....  | 128        |
| <b>13</b> | <b>ADDITIONAL LABELLING .....</b>   | <b>129</b> |
| <b>14</b> | <b>REFERENCES.....</b>  | <b>130</b> |
| <b>15</b> | <b>ANNEXES.....</b>   | <b>135</b> |
|           | ANNEX I: MANCOZEB AND THYROID CARCINOGENICITY: MODE OF ACTION ANALYSIS USING THE WHO/IPCS MOA FRAMEWORK                     |            |
|           | ANNEX II: EVALUATION OF DEVELOPMENTAL TOXICITY, POSSIBLE MODES OF ACTION AND RELEVANCE TO HUMANS                            |            |
|           | ANNEX III: SUPPLEMENTARY DATA ON THE DEGRADANTS OF MANCOZEB   |            |
|           | ANNEX IV: INFORMATION ON FORMULATIONS (CONFIDENTIAL - SEPARATE DOCUMENT)  |            |
|           | ANNEX V: CONFIDENTIAL REFERENCES (CONFIDENTIAL - SEPARATE DOCUMENT)   |            |

## 1 IDENTITY OF THE SUBSTANCE

### 1.1 Name and other identifiers of the substance

**Table 1: Substance identity and information related to molecular and structural formula of the substance**

|   |  |
|---|--|
| Name(s) in the IUPAC nomenclature or other international chemical name(s)                             | manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt  |
| Other names (usual name, trade name, abbreviation)  | Mancozeb, Dithane M45  |
| ISO common name (if available and appropriate)  | Mancozeb   |
| EC number (if available and appropriate)  | Not listed   |
| EC name (if available and appropriate)  | Not listed   |
| CAS number (if available)   | 8018-01-7  |
| Other identity code (if available)  | CIPAC-34   |
| Molecular formula   | $(C_4H_6MnN_2S_4)_x(Zn)_y$   |
| Structural formula  |  <p>Mancozeb is a polymeric complex of the monomer illustrated.</p> |
| SMILES notation (if available)  |  |
| Molecular weight or molecular weight range  | 271.3 g/mol  |
| Information on optical activity and typical ratio of (stereo) isomers (if applicable and appropriate) | Not relevant   |
| Description of the manufacturing process and identity of the source (for UVCB substances only)        | Not relevant   |
| Degree of purity (%) (if relevant for the entry in Annex VI)  | ≥ 85%  |

### 1.2 Composition of the substance

**Table 2: Constituents (non-confidential information)**

| Constituent<br>(Name and numerical identifier)  | Concentration range (% w/w minimum and maximum in multi-constituent substances) | Current CLH in Annex VI Table 3.1 (CLP)                                    | Current self-classification and labelling (CLP)                         |
|---|---|--|---|
| Mancozeb<br>Mancozeb is a coordination complex of manganese ethylenebis(dithiocarbamate) and zinc | ≥ 85.0%   | Skin Sens 1; H317;<br>Repr. 2; H361d***;<br>Aquatic Acute 1; H400 (M = 10) | Skin Sens 1; H317;<br>Repr. 2; H361d;<br>Aquatic Acute 1; H400 (M = 10) |

Further information on the substance identity can be found in the confidential attachments (Volume 4 of the Renewal Assessment Report) which are provided with the IUCLID.

**Table 3: Impurities (non-confidential information) if relevant for the classification of the substance**

| Impurity<br>(Name and numerical identifier)                           | Concentration range<br>(% w/w minimum and maximum) | Current CLH in Annex VI Table 3.1 (CLP)   | Current self-classification and labelling (CLP) | The impurity contributes to the classification and labelling |
|---|--|---|---|--|
| Ethylenethiourea (ETU)<br>(2- Imidazolidinethione)<br>CAS No. 96-45-7 | Max 0.09%  | Acute Tox 4*: H302;<br>Repr. 1B: H360D*** |   | No (It is present at less than 0.1% by weight, of mancozeb)  |

The only process impurity of potential toxicological and environmental significance is ethylenethiourea (ETU), which is classified as shown in table 3 above. The content of this impurity is less than or equal to 0.09% (which is less than the relevant generic concentration limit of 0.3% for classification as Repr 1B) and therefore does not impact on the classification proposed in this dossier. Further information on the impurities is considered to be confidential but full details are provided in the technical dossier.

**Table 4: Additives (non-confidential information) if relevant for the classification of the substance**

| Additive<br>(Name and numerical identifier) | Function   | Concentration range<br>(% w/w minimum and maximum) | Current CLH in Annex VI Table 3.1 (CLP)  | Current self-classification and labelling (CLP) | The additive contributes to the classification and labelling |
|---|------------|--|--|---|--|
| Hexamethylene tetramine<br>CAS No. 100-97-0 | Stabiliser | Max 2.5%   | Flam. Sol. 2: H228<br>Skin Sens. 1: H317 |   | No   |

The purity of mancozeb (the coordination complex) tested in the studies ranged from 80% - 92.3%. Information on the actual purity used is provided in the relevant summaries and tables of this report.

## 2 PROPOSED HARMONISED CLASSIFICATION AND LABELLING

### 2.1 PROPOSED HARMONISED CLASSIFICATION AND LABELLING ACCORDING TO THE CLP CRITERIA

Table 5:

|                             | Index No     | International Chemical Identification                                      | EC No | CAS No    | Classification                    |   | Labelling                      |  |                                 | Specific Conc. Limits, M-factors | Notes |
|-----------------------------|--------------|--|-------|-----------|-----------------------------------|---|--------------------------------|--|---------------------------------|----------------------------------|-------|
|                             |              |  |       |           | Hazard Class and Category Code(s) | Hazard statement Code(s)                              | Pictogram, Signal Word Code(s) | Hazard statement Code(s)                               | Suppl. Hazard statement Code(s) |                                  |       |
| Current Annex VI entry      | 006-076-00-1 | manganese ethylenebis (dithiocarbamate) (polymeric) complex with zinc salt | -     | 8018-01-7 | Skin Sens 1                       | H317  | GHS09<br>GHS08<br>GHS07<br>Wng | H317   |                                 | M = 10                           |       |
|                             |              |  |       |           | Repr. 2                           | H361d***  |                                | H361d***   |                                 |                                  |       |
|                             |              |  |       |           | Aquatic Acute 1                   | H400  |                                | H400   |                                 |                                  |       |
| Dossier submitters proposal | 006-076-00-1 | manganese ethylenebis (dithiocarbamate) (polymeric) complex with zinc salt | -     | 8018-01-7 | <b>Confirm</b><br>Skin Sens 1     | <b>Confirm</b><br>H317                                | GHS09<br>GHS08<br>GHS07<br>Wng | <b>Confirm</b><br>H317                                 |                                 | <b>Confirm</b><br>M = 10         |       |
|                             |              |  |       |           | <b>Remove</b><br>Repr. 2          | <b>Remove</b><br>H361d                                |                                | <b>Remove</b><br>H361d                                 |                                 |                                  |       |
|                             |              |  |       |           | <b>Add</b><br>STOT RE 2           | <b>Add</b><br>H373<br>(thyroid, nervous system)(oral) |                                | <b>Add</b><br>H373<br>(thyroid, nervous system) (oral) |                                 |                                  |       |
|                             |              |  |       |           | <b>Confirm</b><br>Aquatic Acute 1 | <b>Confirm</b><br>H400                                |                                | <b>Confirm</b><br>H400                                 |                                 |                                  |       |
|                             |              |  |       |           | <b>Add</b><br>Aquatic chronic 1   | <b>Add</b><br>H410                                    |                                | <b>Add</b><br>H410                                     |                                 |                                  |       |

|   |              |  |   |           |                   |                                      |                                |                                       |  |  |        |
|---|--------------|--|---|-----------|-------------------|--------------------------------------|--------------------------------|---------------------------------------|--|--|--------|
| Resulting Annex VI entry if agreed by RAC and COM | 006-076-00-1 | manganese ethylenebis (dithiocarbamate) (polymeric) complex with zinc salt | - | 8018-01-7 | Skin Sens 1       | H317                                 | GHS09<br>GHS08<br>GHS07<br>Wng | H317                                  |  |  |        |
|   |              |  |   |           | STOT RE 2         | H373 (thyroid, nervous system)(oral) |                                | H373 (thyroid, nervous system) (oral) |  |  |        |
|   |              |  |   |           | Aquatic Acute 1   | H400                                 |                                | H400                                  |  |  | M = 10 |
|   |              |  |   |           | Aquatic chronic 1 | H410                                 |                                | H410                                  |  |  | M = 10 |

**Table 6: Reason for not proposing harmonised classification and status under public consultation**

| Hazard class  | Reason for no classification                                 | Within the scope of public consultation |
|---|--|---|
| Explosives  | Hazard class not addressed in this proposal                  | No                                      |
| Flammable gases (including chemically unstable gases)       | Hazard class not applicable                                  | No                                      |
| Oxidising gases   | Hazard class not applicable                                  | No                                      |
| Gases under pressure  | Hazard class not applicable                                  | No                                      |
| Flammable liquids   | Hazard class not applicable                                  | No                                      |
| Flammable solids  | Hazard class not addressed in this proposal                  | No                                      |
| Self-reactive substances                                    | Hazard class not addressed in this proposal                  | No                                      |
| Pyrophoric liquids  | Hazard class not applicable                                  | No                                      |
| Pyrophoric solids   | Hazard class not addressed in this proposal                  | No                                      |
| Self-heating substances                                     | Hazard class not addressed in this proposal                  | No                                      |
| Substances which in contact with water emit flammable gases | Hazard class not addressed in this proposal                  | No                                      |
| Oxidising liquids   | Hazard class not applicable                                  | No                                      |
| Oxidising solids  | Hazard class not addressed in this proposal                  | No                                      |
| Organic peroxides   | Hazard class not applicable                                  | No                                      |
| Corrosive to metals   | Hazard class not addressed in this proposal                  | No                                      |
| Acute toxicity via oral route                               | Hazard class not addressed in this proposal                  | No                                      |
| Acute toxicity via dermal route                             | Hazard class not addressed in this proposal                  | No                                      |
| Acute toxicity via inhalation route                         | Hazard class not addressed in this proposal                  | No                                      |
| Skin corrosion/irritation                                   | Hazard class not addressed in this proposal                  | No                                      |
| Serious eye damage/eye irritation                           | Hazard class not addressed in this proposal                  | No                                      |
| Respiratory sensitisation                                   | Hazard class not addressed in this proposal                  | No                                      |
| Skin sensitisation  | <b>Harmonised classification proposed</b>                    | <b>Yes</b>                              |
| Germ cell mutagenicity                                      | <b>Data conclusive but not sufficient for classification</b> | <b>Yes</b>                              |
| Carcinogenicity   | <b>Data conclusive but not sufficient for classification</b> | <b>Yes</b>                              |
| Reproductive toxicity                                       | <b>Data conclusive but not sufficient for classification</b> | <b>Yes</b>                              |
| Specific target organ toxicity-single exposure              | Hazard class not addressed in this proposal                  | No                                      |
| Specific target organ toxicity-repeated exposure            | <b>Data conclusive but not sufficient for classification</b> | <b>Yes</b>                              |
| Aspiration hazard   | Hazard class not addressed in this proposal                  | No                                      |
| Hazardous to the aquatic environment                        | <b>Harmonised classification proposed</b>                    | <b>Yes</b>                              |
| Hazardous to the ozone layer                                | Hazard class not addressed in this proposal                  | No                                      |

### 3 HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING

Mancozeb is a pesticidal active substance in the scope of Directive 91/414/EEC (and now Regulation 1107/2009). It was included in Annex I of Council Directive 91/414/EEC (Commission Directive 2005/72/EC) and is an approved active substance under Regulation (EC) 1107/2009 as specified in Commission Implementing Regulation (EU) No. 540/2011 of 25 May 2011. The Review Report for mancozeb (SANCO/4058/2001 – rev. 4.4 July 2009) provides conclusions and endpoints agreed in the original EU review for Annex I inclusion. Supplementary dossiers, recently submitted in support of the application for renewal of the approval of mancozeb under Commission Implementing Regulation (EU) 844/2012 of 18 September 2012, are under review by the UK.

The harmonised classification and labelling of mancozeb was originally considered in November 1993 by the Commission Working Group on the Classification and Labelling of Dangerous Substances and then again in 2003-2006 by the Technical Committee on Classification and Labelling (TC C&L). On both occasions, the Commission Working Group of Specialised Experts (SE) in the field of reproductive toxicity was consulted. As a consequence of these earlier reviews, the current Annex VI entry for mancozeb includes the following classification: Skin Sens. 1 (H317: May cause an allergic skin reaction); Repr. 2 (H361d: Suspected of damaging the unborn child) and Aquatic Acute 1 (H400: Very toxic to aquatic life) with acute M factor = 10.

Concern for developmental toxicity was raised due to the observation of malformations in a rat study with mancozeb (Anonymous, 1980). However, these effects only occurred at a dose causing severe maternal toxicity (death, paralysis, suffering, total litter loss). In 1993 it was concluded that the malformations were attributed to the formation of ETU, but as ETU levels produced by the parent compound would not reach the threshold for teratogenic effects, classification was not justified.

The classification was considered again between 2003-2006 by the Technical Committee on Classification and Labelling (TC C&L). It was agreed that classification for carcinogenicity was not warranted but there was no consensus regarding the classification for developmental toxicity and it was referred to the SE group.

The conclusion of the SE group from February 2005 is reproduced below.

“Mancozeb<sup>1</sup> has been shown to cause a high frequency of a specific pattern of major malformations in the rat at dose levels that cause marked maternal toxicity. There is sufficient evidence from metabolic studies with these compounds and from developmental toxicity studies with ETU to assume that the malformations induced by mancozeb are directly caused by the metabolite ETU. Mancozeb causes a similar spectrum of malformations to ETU, which is classified as a Cat.2 (DSD)<sup>2</sup> developmental toxicant. In addition, ETU does not cause maternal toxicity at developmentally toxic dose levels. Therefore the developmental toxicity of mancozeb is not a secondary nonspecific consequence of maternal toxicity. **As a consequence, the SE agreed unanimously that classification of mancozeb for developmental toxicity was warranted.**

The above conclusion in itself points to a Cat.2 (DSD) classification for developmental toxicity. However, there was no consensus among the SE about Cat.2 versus Cat.3 classification. Additional arguments were put forward considering either a Cat.2 or a Cat.3 classification.

The developmental effects were observed only at dose levels with severe maternal toxicity, which suggests that mancozeb may be of less concern than substances that show developmental toxicity in the presence of no or slight maternal toxicity.

There is uncertainty about the dose-response relationship for maternal toxicity and developmental toxicity between 100 and 500 mg/kg/day in rat developmental studies. It is not therefore known if maternal or developmental toxicity is the most sensitive effect.

The critical short- and long term general toxicological target of Mancozeb relates to inhibition of thyroid hormone synthesis. The effect is mediated by the inhibition of thyroid peroxidase by ETU. Thyroid hormone is crucial for brain development in mammals. Recent studies have suggested that transient impairment of maternal thyroid hormone levels in the rat and in man may affect neural brain organization and behaviour. Therefore there is a concern that Mancozeb and other EBDC may cause developmental neurotoxicity, which would argue for a Cat.2 classification.

There is a species difference in kinetics and metabolism of Mancozeb including the formation of ETU as shown between rats and mice, which may partially explain the higher susceptibility of rats to ETU developmental toxicity. There is no information on the comparative kinetics and metabolism in man.

**In conclusion, there was consensus among the SE about the need for classification of Mancozeb for developmental toxicity. There was an equal distribution of opinions among the SE present towards classification into Repr. Cat. 2, R 61 or Repr. Cat. 3, R 63 for both substances.**

The SE had the following additional remarks:

It is advisable to study the developmental neurotoxicity (e.g. according to OECD 426) of EBDC's to address the concern about thyroid effects and brain development.

The severe maternal toxicity at the developmentally toxic doses sheds doubt about the acceptability of these studies especially with regard to the ethical aspects. However, the developmental toxicity studies with Mancozeb provided clear evidence of the mechanistic link to ETU and were therefore an important contribution to the assessment of classification of Mancozeb.”

<sup>1</sup> Note that mancozeb and maneb were discussed together in the meeting. The references to maneb have been removed.

<sup>2</sup> Classification in accordance with DSD (Dir 67/548/EEC). Category 2 DSD = Category 1B (CLP). Category 3 (DSD) = Category 2 (CLP).

As noted in the above conclusion, the opinion of the SE group was that classification of mancozeb for developmental toxicity was warranted, but there was no consensus whether this should be Repr. Cat. 2; R61 or Repr. Cat. 3; R63 (equivalent to Repr. 1B; H360 and Repr. 2; H361 respectively under CLP). At the TC C&L in Arona (21st-24th March 2006) it was agreed to classify mancozeb with Repr. Cat. 3; R63. This was published in the 31st ATP to DSD (2009) and the classification translated to Repr. 2; H361d - Suspected of damaging the unborn child, under CLP.

#### **4 JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL**

Reason for a need for action at Community level:

*Change in existing entry due to new data*

*Change in existing entry due to new interpretation/evaluation of existing data*

Mancozeb is a pesticidal active substance in the scope of Directive 91/414/EEC (and now Regulation 1107/2009). Supplementary dossiers, supporting the application for renewal under (EU) 844/2012, are under consideration by the UK. New data are available; including two developmental neurotoxicity (DNT) studies with mancozeb (to address the concerns raised by the SE group in the 2005 conclusion – see above) and several studies to investigate the potential of mancozeb to cause developmental toxicity, the role of metabolism to ETU and species differences in metabolism of ETU when considering human relevance.

Whilst mancozeb already has a harmonised classification, these new data support a review and revision of the current entry.

It is noted that this proposal is targeted and only addresses those hazard classes and differentiations for which there is new data or potential for a new interpretation of existing data.

#### **5 IDENTIFIED USES**

Mancozeb is used as a fungicide within the EU.

#### **6 DATA SOURCES**

The data sources used to complete this CLH report are the regulatory reports and published literature used in the original and supplementary dossiers under Council Directive 91/414/EEC (Commission Directive 2005/72/EC) and Regulation (EC) 1107/2009. Supplementary dossiers, recently submitted in support of the application for renewal under Commission Implementing Regulation (EU) 844/2012 of 18 September 2012 are under review by the UK.

At the time of submission, mancozeb is not registered under REACH.

## 7 PHYSICOCHEMICAL PROPERTIES

Table 7: Summary of physicochemical properties

| Property                                     | Value  | Reference   | Comment (e.g. measured or estimated)  |
|--|--|---|---|
| <b>Physical state at 20°C and 101,3 kPa</b>  | Yellow powder<br><br>(Mancozeb technical is yellow powder with musty odour)  | Bos MWS, 2014<br>Study DL 14-006<br><br>Wasser, 1995b | Visual<br>Purity; 92.3%<br><br>Mancozeb technical; 80%                      |
| <b>Melting/freezing point</b>                | 189 °C   | Bos MWS, 2014<br>Study DL 14-006                      | EC A2 (DSC)<br>Purity; 92.3%  |
| <b>Boiling point</b>                         | Mancozeb decomposes at 210 °C before boiling   | Bos MWS, 2014<br>Study DL 14-006                      | EC A2 (DSC)<br>Purity; 92.3%  |
| <b>Relative density</b>                      | 2.11   | Bos MWS, 2014<br>Study DL 14-006                      | CIPAC MT 3.2.1  |
| <b>Vapour pressure</b>                       | < 5.6 x 10 <sup>-5</sup> Pa at 25 °C   | Diepenhorst PC, 1994<br>Study DL 93-029               | EC A.4<br>OECD 104 (estimation, modified Watson correlation)<br>Purity; 89% |
| <b>Surface tension</b>                       | Not required - water solubility < 1mg/L  |   |   |
| <b>Water solubility</b>                      | At 20 °C<br>0.2 mg/L (pH 4-5)<br>0.2mg/L (pH 6-8)<br>0.3 mg/L (pH9-10)   | Bos MWS, 2014<br>Study DL 14-006                      | EC A6<br>Purity; 92.3%  |
| <b>Partition coefficient n-octanol/water</b> | At 20 – 25 °C<br>Log P <sub>ow</sub> = 2.3 (pH 6 – 8)<br>Log P <sub>ow</sub> = 2.3 (pH 9 - 10)<br>Log P <sub>ow</sub> = ∞ (pH 4 - 5) | Bos MWS, 2014<br>Study DL 14-006                      | OECD 107 (shake flask method)<br>Purity; 92.3%                              |
| <b>Flash point</b>                           | Not applicable, substance is a solid with melting point of 189 °C  | -   | -   |
| <b>Flammability</b>                          | Not highly flammable in the sense of EC A.10   | Maarsingh P, 2005<br>Study DL 04-092                  | EC A10<br>Purity; 91%   |
| <b>Explosive properties</b>                  | Mancozeb does not contain structural groups indicative of explosive properties.  |   |   |

| Property  | Value  | Reference                            | Comment (e.g. measured or estimated) |
|---|--|--------------------------------------|--------------------------------------|
| Self-ignition temperature   | 157 °C   | Maarsingh P, 2005<br>Study DL 04-092 | EC A16<br>Purity; 91%                |
| Oxidising properties  | No oxidising properties  | Maarsingh P, 2005<br>Study DL 04-092 | EC A17<br>Purity; 91%                |
| Granulometry  | No data provided   |                                      |                                      |
| Stability in organic solvents and identity of relevant degradation products | Stable in organic solvents   |                                      |                                      |
| Dissociation constant   | $K = 8.2 \times 10^{-13}$<br>(theoretical determination from water solubility)<br><br>Mancozeb has no affinity to water and the solubility is low. It will not dissociate in water. This has been confirmed using conductometric method. | Bos MWS, 2014<br>Study DL 14-006     | OECD 112                             |
| Viscosity   | Substance is a solid.  |                                      |                                      |

## 8 EVALUATION OF PHYSICAL HAZARDS

Not considered further in this proposal.

## 9 TOXICOKINETICS (ABSORPTION, DISTRIBUTION, METABOLISM AND ELIMINATION)

### 9.1 Short summary and overall relevance of the provided toxicokinetic information on the proposed classification(s)

The absorption, distribution, metabolism and excretion (ADME) properties of mancozeb in mammals (rats, mice and monkeys) were evaluated previously (DAR – Draft Assessment Report, 2000) under Directive 91/414/EEC in studies (both regulatory and from the open literature) that were considered to be acceptable. The only new information available is a comparative interspecies *in vitro* metabolism study (Foster, 2015), a new data requirement under Regulation 1107/2009.


In studies in laboratory animals, mancozeb is only partially absorbed but rapidly excreted. Rats given single oral doses of <sup>14</sup>C-labelled mancozeb absorbed about 50% of the dose (calculated by adding the radioactivity present in urine, bile and tissues). Most of the dose was excreted within 24 hours with about half eliminated in the urine and half in the faeces. Less than 4% was found in the tissues after 96 hours, with the thyroid containing the highest residual levels. Most of the <sup>14</sup>C dose in faeces was unabsorbed, since only 2-8% of the dose was found in bile.

Ethylenethiourea (ETU) was the major metabolite. The other metabolites identified were ethyleneurea (EU), N-acetylenediamine (N-acetyl-EDA), ethylenediamine (EDA), ethylenebisisothiocyanatesulfide (EBIS) and N-formylethylenediamine (N-formyl-EDA), N-acetylglycine, and glycine. The bioconversion of mancozeb to ETU in the rat was 6.8% on a weight basis and ~20% on a mole/mole basis; the average bioconversion factor for all the EBDCs was 7.5%. The bioconversion of mancozeb to ETU was determined in the study of Anonymous, 1986g (“Metabolism of <sup>14</sup>C-mancozeb in the rat”). This is reported in the RAR, Vol3\_ CA\_B6 (2017). In this study the conversion was calculated based on the recovery of ETU from urinary and bile samples (18.2% of administered dose) following an oral dose of mancozeb. The bioconversion of mancozeb to ETU on weight percentage basis was 6.8% (average 18.2% of the administered <sup>14</sup>C mancozeb dose recovered as ETU in urine and bile  $\times 102 \text{ g ETU/mole}/271 \text{ g mancozeb/mole} = 6.8\%$ ).

This was compared with the conversion factor for other EBDCs where an overall EBDC bioconversion factor of approximately 7.5% in rats was determined (Kocialski, 1989 & 1994; in the JMPR 1993 evaluation of mancozeb). ETU is further broken down to moieties that are incorporated into natural compounds such as oxalic acid, glycine, urea and lactose. Metabolism of ETU in humans, dog, rabbit and mouse appears more efficient than in rats. In monkeys, oral doses of mancozeb were very poorly absorbed, with faeces being the predominant route of excretion. Exposure during field application of mancozeb revealed an elimination half time of ETU in the urine of about 100 hours in some workers indicating slow dermal absorption (JMPR 1993 in the RAR, 2017).

Elimination half times of ETU in humans have been estimated to be 19-23 hours (Aprea et al, 1996, Lund et al 2008 in the RAR, 2017), while in the rat most of the ETU is excreted within 24 hours (RAR, 2017).

The spectrum of metabolites produced was similar in laboratory and farm animals, pointing to two common metabolic pathways which both lead ultimately to the formation of glycine and incorporation of the metabolites into natural products. In the quantitatively predominant pathway, the dithiocarbamate linkages in mancozeb are hydrolysed to produce EDA directly, and EDA is oxidised to glycine, joining the intermediary metabolic pool at this point. The other involves oxidation to EBIS and then to ETU, various derivatives of ETU, and EU before re-joining the main pathway with conversion to EDA, glycine, and incorporation into other products.



## 10 EVALUATION OF HEALTH HAZARDS

### 10.1 Acute toxicity

Not addressed in this dossier.

### 10.2 Skin corrosion/irritation

Not addressed in this dossier.

### 10.3 Serious eye damage/eye irritation

Not addressed in this dossier.

### 10.4 Respiratory sensitisation

Not addressed in this dossier.

## 10.5 Skin sensitisation

The skin sensitisation potential of mancozeb has been investigated in three Buehler tests and three guinea-pig maximisation tests.

**Table 8: Summary table of animal studies on skin sensitisation**

| Method, guideline, deviations if any   | Species, strain, sex, no/group  | Test substance, dose levels duration of exposure  | Results   |  |     |     |                   |      |      |      |    |
|--|---|---|---|--|-----|-----|-------------------|------|------|------|----|
| Modified Buehler method<br>OECD 406 (1992)<br>GLP<br>Anonymous, 1988a            | Guinea pigs, Hartley, males, 20 in test groups & 10/ group in negative and positive control groups. | <u>Induction:</u> 0.4 mL 50.0% w/v in distilled water, three 6 hour topical applications (1/week for 3 weeks)<br><u>Challenge:</u> 0.4 mL 50% w/v in distilled water, topical<br>Dithane® M-45<br>Purity 80% minimum  | <b>Negative</b><br><table border="1"> <thead> <tr> <th></th> <th>24h</th> <th>48h</th> <th>Positive reaction</th> </tr> </thead> <tbody> <tr> <td>Test</td> <td>1/20</td> <td>1/20</td> <td>5%</td> </tr> </tbody> </table><br>All positive responses consisted of grade 1 erythema |  | 24h | 48h | Positive reaction | Test | 1/20 | 1/20 | 5% |
|  | 24h   | 48h   | Positive reaction   |  |     |     |                   |      |      |      |    |
| Test   | 1/20  | 1/20  | 5%  |  |     |     |                   |      |      |      |    |
| Buehler method<br>OECD 406 (1992)<br>GLP<br>Anonymous, 1986a                     | Guinea pigs, Dunkin-Hartley, females, 20  | <u>Induction:</u> 0.5 mL, 50% w/w in distilled water, 9 topical applications (3/week for 3 weeks)<br><u>Challenge:</u> 0.5 mL 50% w/w in distilled water, topical<br>Mancozeb technical<br>Purity 83.4%   | <b>Positive</b><br>2/10 (20%) animals positive response   |  |     |     |                   |      |      |      |    |
| Buehler method<br>OECD 406 (1992)<br>GLP<br>Anonymous, 2007a                     | Guinea pigs, Hartley, males, 20   | <u>Induction:</u> 0.5g in 0.7ml corn oil, 3 topical applications (1/week for 3 weeks)<br><u>Challenge:</u> 0.5g in 0.7ml corn oil, topical  | <b>Negative</b><br>No skin reactions observed following challenge in test group or negative controls.   |  |     |     |                   |      |      |      |    |
| Guinea pig maximisation test (GPMT)<br>OECD 406 (1992)<br>GLP<br>Anonymous, 1994 | Guinea pigs, Dunkin-Hartley, males, 20 in test groups & 10 in control groups                        | <u>Intradermal induction:</u> 0.1ml Freund's complete adjuvant (FCA) 50/50 in physiological saline, 0.1ml test substance 50% with distilled water, & 0.1ml test substance 50% with 50/50 FCA and distilled water (pairs).<br><u>Topical induction:</u> irritation induced with 0.5 mL of 10 % sodium lauryl sulphate (days 5-7) then 0.2 ml of test substance 50% with distilled water for 48 hours (days 6-8).<br><u>Challenge:</u> 0.1 mL 50% test substance for 24 hours, topical<br>Mancozeb technical<br>Purity not reported | <b>Positive</b><br>7/20 (35%) test animals  |  |     |     |                   |      |      |      |    |

| Method, guideline, deviations if any   | Species, strain, sex, no/group   | Test substance, dose levels duration of exposure  | Results   |  |     |     |                   |         |      |      |    |      |      |      |     |
|--|--|---|---|--|-----|-----|-------------------|---------|------|------|----|------|------|------|-----|
| Guinea pig maximisation test (GPMT)<br>OECD 406 (1992)<br>GLP<br>Anonymous, 1997a                              | Guinea pigs, Hartley, males and females, 20 in test groups & 10 in control groups. | <u>Intradermal Induction:</u> 0.1mL Freund's complete adjuvant (FCA) 50/50 in distilled water, 0.1ml 14.28% test substance in distilled water & 14.28% test substance in 50/50 FCA and distilled water (pairs).<br><br><u>Topical Induction:</u> irritation induced with 0.5ml of 10% sodium laurel sulphate in Vaseline (day 6) then 200 mg of test substance moistened with distilled water for 48 hours.<br><br><u>Challenge:</u> 200 mg of test substance moistened with distilled water for 24 hours, topical.<br><br>Mancozeb technical<br>Purity 85% minimum | <b>Negative</b><br><table border="1"> <thead> <tr> <th></th> <th>24h</th> <th>48h</th> <th>Positive response</th> </tr> </thead> <tbody> <tr> <td>Control</td> <td>0/10</td> <td>0/10</td> <td>0%</td> </tr> <tr> <td>Test</td> <td>3/20</td> <td>3/20</td> <td>15%</td> </tr> </tbody> </table><br>All positive responses consisted of grade 1 erythema. |  | 24h | 48h | Positive response | Control | 0/10 | 0/10 | 0% | Test | 3/20 | 3/20 | 15% |
|  | 24h  | 48h   | Positive response   |  |     |     |                   |         |      |      |    |      |      |      |     |
| Control  | 0/10   | 0/10  | 0%  |  |     |     |                   |         |      |      |    |      |      |      |     |
| Test   | 3/20   | 3/20  | 15%   |  |     |     |                   |         |      |      |    |      |      |      |     |
| Guinea pig maximisation test (GPMT)<br>Guideline not stated<br>GLP not stated<br>Matshushita <i>et al</i> 1976 | Guinea pigs, Hartley, female, 10/group   | <u>Intradermal induction:</u> 5% mancozeb<br><br><u>Topical induction:</u> 25% mancozeb<br><br><u>Challenge:</u> 2% or 0.5% mancozeb<br><br>Topical   | <b>Positive</b><br>100% of mancozeb treated animals responded positively after 24 and 48 hours.   |  |     |     |                   |         |      |      |    |      |      |      |     |

**Table 9: Summary table of human data on skin sensitisation**

| Type of data/report   | Test substance  | Relevant information about the study (as applicable)  | Observations   |
|---|-----------------|---|--|
| Worker exposure study (EUROPIT)<br>Swaen <i>et al</i> 2008  | EBDC pesticides | Overall there were 248 EBDC exposed and 231 non-occupationally exposed subjects in four countries (the Netherlands, Finland, Italy and Bulgaria) who were examined to evaluate the possible association between occupational exposure to EBDCs and allergy. A self-administered questionnaire was used to collect information on skin irritation, contact dermatitis, allergic rhinitis and food allergy. | No association was found between exposure status, EBDC levels and allergic contact dermatitis, allergic rhinitis, food allergy, and atopy. |
| Human studies of manufacturing workers have detected sporadic reports of contact allergic hypersensitivity. |                 |   |  |

### 10.5.1 Short summary and overall relevance of the provided information on skin sensitisation

The original DAR (2000) under Directive 91/414 describes two Buehler tests (Anonymous, 1988; Anonymous, 1986) conducted in guinea-pigs and three guinea-pig maximisation studies (Matshushita et al., 1976; Anonymous, 1994; Anonymous, 1997). The results of the majority of these studies (Anonymous., 1986; Matshushita et al., 1976; Anonymous, 1994c) show that mancozeb is a skin sensitiser. Since then, another skin sensitisation study (Anonymous, 2007) has become available. This study conformed to GLP and OECD test guideline 406. Mancozeb (88.6% pure) was tested in male guinea pigs according to the Buehler method. Mancozeb was negative in this study. However, it is noted that the Buehler method is less sensitive than the M+K method. Overall, therefore, the results of this study are not inconsistent with the studies in the original DAR (2000) under Directive 91/414.

In the Buehler assay by Anonymous (1988), grade 1 erythema was noted in 1/20 mancozeb-treated animals 48 hours after challenge, and in 1/20 mancozeb-treated animals 24 hours after re-challenge. However, this was not the same animal that exhibited erythema during the challenge phase. Appropriate responses were seen with positive and sham controls. In this study mancozeb did not induce a positive response.

In the second Buehler study (Anonymous, 1986) 2/10 animals had slight to well-defined erythema with or without slight or well-defined oedema at 24 and 48 hours following challenge with 50% mancozeb. Similar reactions were not seen in negative control animals; therefore it was concluded that under the test conditions mancozeb is a skin sensitiser.

Guinea pig maximisation studies were conducted by Anonymous (1994) and Anonymous (1997a). In the study by Anonymous (1994) none of the control animals reacted positively to the dermal challenge. However, seven animals of the test group showed discrete to patchy erythema during the topical challenge, after both 24 and 48 hours. As 35% (7/20) of animals gave a positive response in this adjuvant test it is concluded that a skin sensitising potential was demonstrated under the conditions of this study.

In the second guinea pig maximisation test conducted by Anonymous (1997a) 3/20 animals exhibited grade 1 erythema at both 24 and 48 hours following challenge. As a 15% positive response was observed in this second adjuvant test it was concluded that mancozeb was not a skin sensitiser under the conditions of this study.

### 10.5.2 Comparison with the CLP criteria

On the basis of the positive results obtained in 3 out of the 6 available studies, the current classification of mancozeb for skin sensitisation in category 1 is confirmed. This endpoint has however been addressed in this targeted proposal to consider whether sub-categorisation in category 1A or 1B in accordance with the provisions of the 2<sup>nd</sup> ATP to the CLP Regulation might be appropriate.

The sub-categorisation of skin sensitisers on the basis of the guinea pig maximisation test according to the provisions of the 2<sup>nd</sup> ATP to the CLP Regulation is shown below.

**Table 10: Potency on basis of the guinea pig maximisation test**

| Concentration for intradermal induction (% w/v) | Incidence sensitised guinea pigs (%) | Potency  | Predicted subcategory |
|---|--------------------------------------|----------|-----------------------|
| ≤ 0.1   | ≥ 60                                 | Extreme  | 1A                    |
| ≤ 0.1   | ≥ 30 - < 60                          | Strong   | 1A                    |
| >0.1 - ≤ 1.0                                    | ≥ 60                                 | Strong   | 1A                    |
| >0.1 - ≤ 1.0                                    | ≥ 30 - < 60                          | Moderate | 1B                    |
| > 1.0   | ≥ 30                                 | Moderate | 1B                    |

Three studies using this method are available. Of these, two were positive (Matshushita et al., 1976; Anonymous, 1994). In the study by Matshushita et al. (1976), a 5% intradermal induction gave a positive response in 100% of the animals. In the study by Anonymous (1994) a 50% intradermal injection gave a positive response in 7/20 test animals (35%). Both studies indicate that mancozeb should be classified for skin sensitisation in at least sub-category 1B. However since a concentration below 1% was not tested then the exclusion of sub-category 1A based on the results of the guinea pig maximisation tests is not possible.

The sub-categorisation of skin sensitisers on the basis of the Buehler assay according to the provisions of the 2<sup>nd</sup> ATP to the CLP Regulation is shown below.

**Table 11: Potency based on the Buehler assay**

| Concentration for intradermal induction (% w/v) | Incidence sensitised guinea pigs (%) | Potency  | Predicted subcategory |
|---|--------------------------------------|----------|-----------------------|
| ≤ 0.2   | ≥ 60                                 | Extreme  | 1A                    |
| ≤ 0.2   | ≥ 15 - < 60                          | Strong   | 1A                    |
| >0.2 - ≤ 20                                     | ≥ 60                                 | Strong   | 1A                    |
| >0.2 - ≤ 20                                     | ≥ 15 - < 60                          | Moderate | 1B                    |
| > 20  | ≥ 15                                 | Moderate | 1B                    |

Three studies using this method are available. Of these, one was positive (Anonymous, 1986) as 20% of test animals responded at an induction dose of 50%. On this basis, classification in category 1B is warranted. However as a concentration below 20% was not tested it was not possible to exclude sub-categorisation into category 1A on the basis of the Buehler assay.

In situations where it is not possible to exclude category 1A for skin sensitisation the guidance on the application of the CLP criteria recommends that the default position of category 1 (i.e. without sub-categorisation) should be adopted. Therefore based upon the GPMT that gave a positive response in 35% of animals at a 50% induction dose and the Buehler assay that gave a positive response in 20% of animals at a 50% challenge concentration it is proposed that mancozeb be classified in category 1 for skin sensitisation. This is supported by some negative studies, which would seem to indicate that mancozeb is not a strong sensitiser.

Although human studies of workers have indicated no evidence of skin sensitisation (Swan *et al*, 2008), sporadic reports of contact allergic hypersensitivity have occurred in manufacturing workers. This further supports the current classification of mancozeb with Skin Sens 1.

### 10.5.3 Conclusion on classification and labelling for skin sensitisation

|  |
|--|
| <b>Skin Sens 1; H317 – May cause an allergic skin reaction</b> |
|--|

## 10.6 Germ cell mutagenicity

The genotoxic potential of mancozeb has been investigated in a series of *in vitro* and *in vivo* studies. The original DAR (2000) under Directive 91/414 provided the following preliminary statement regarding the use of polar solvents as vehicles in genotoxicity studies of mancozeb:

“A critical issue in the evaluation of genotoxicity studies of mancozeb is the effect of using DMSO and other highly polar, reactive solvents as vehicles. While DMSO is commonly used in genetic toxicity testing, the use of DMSO invalidates genotoxicity tests of mancozeb because it is rapidly degraded in this medium, with concomitant liberation of metal ions which are known to affect DNA maintenance and replication *in vitro*. The half-life for <sup>14</sup>C-mancozeb in DMSO is only 36 minutes (Schweitzer, 1990) in comparison to 5.8 to 55 hours in aqueous media (Lawrence, 1979; 2.5.1/02). As examples of the types of genotoxic effects that can result from prematurely rapid release of metal ions into cell culture, Thompson *et al* (1989) showed that inorganic zinc salts can cause mutations in mouse lymphoma L5178Y cells and chromosomal aberrations in CHO cells. Similarly, Zakour *et al.* (1981) have shown that manganese (II) ions are among the metal ions which decrease the fidelity of DNA synthesis *in vitro*, and the U.S. National Toxicology Program has recently reported both sister chromatid exchanges (SCEs) and chromosomal aberrations with manganese (II) sulfate in CHO cells (NTP, 1992). It is recognized that such effects will not occur *in vivo* because absorption and metabolism of these essential nutrients is tightly regulated in mammalian organisms. Consequently, studies in which DMSO and other polar, reactive solvents have been used as a vehicle must be regarded as scientifically invalid as descriptions of the genotoxic potential of mancozeb.”

New studies have been submitted. These include an *in vitro* micronucleus study and an *in vitro* photogenotoxicity test as a modified reverse mutation test in bacteria. In addition, an Ames test which used DMSO as a solvent was recently submitted; this was considered invalid and so has not been evaluated.

### 10.6.1 *In vitro*

The potential of mancozeb to induce gene mutations in bacterial cells, gene mutation/clastogenicity in mammalian cells and clastogenicity/aneuploidy in mammalian cells has been investigated in a series of *in vitro* studies. In order to satisfy new data requirements under Regulation 1107/2009, a photogenotoxicity test as a modified reverse mutation test in bacteria has also become available. In addition, an *in vitro* micronucleus study has been conducted to strengthen the robustness of the *in vitro* dataset.

**Table 12: Summary table of mutagenicity/genotoxicity tests *in vitro***

| Method, guideline, deviations if any  | Test system (Organism, strain)                                      | Test substance                                 | Concentrations tested   | Result |     | Remarks and information on cytotoxicity |
|---|---|--|---|--------|-----|---|
|   |   |  |   | -S9    | +S9 |   |
| <b>1. Gene mutation tests</b>   |   |  |   |        |     |   |
| <b>1.A. Bacterial gene mutation tests</b>                                   |   |  |   |        |     |   |
| Reverse mutation in bacteria (AMES)<br>OECD 471 (1997)<br>GLP<br>Chism 1984 | <i>Salmonella typhimurium</i><br>TA 1535, TA 1537, TA 98 and TA 100 | Mancozeb<br>88%<br>Vehicle:<br>Distilled water | 2.5, 7.5, 25, 75 and 250 µg / plate<br><br>+/- metabolic activation | neg    | neg | Toxicity at 75µg/plate and 250µg/plate  |
| Reverse mutation in bacteria (AMES)<br>OECD 471 (1997)<br>GLP               | <i>Salmonella typhimurium</i><br>TA 98 and TA 100                   | Mancozeb<br>89.8%<br>Vehicle: Not reported     | 65.2 to 8000 mg/L<br><br>+/- metabolic activation                   | neg    | neg | Toxicity not reported                   |

| Method, guideline, deviations if any   | Test system (Organisms, strain)   | Test substance   | Concentrations tested  | Result                                   |     | Remarks and information on cytotoxicity                                  |
|--|---|--|--|--|-----|--|
|  |   |  |  | -S9                                      | +S9 |  |
| Slabbert 1994  |   |  |  |  |     |  |
| Reverse mutation in bacteria (AMES)<br>OECD 471 (1997)<br>GLP<br>Wilmer 1982     | <i>Salmonella typhimurium</i><br>TA 1535, TA 1537, TA 1538, TA 98<br>TA 100   | Mancozeb<br>87.3%<br>Vehicle: Not reported                         | 0.62, 1.85, 5.56, 16.67 and 50 µg/plate.<br>+/- metabolic activation   | neg                                      | neg | Toxicity not reported  |
| Reverse mutation in bacteria (AMES)<br>OECD 471 (1997)<br>GLP<br>Prabhu 1999     | <i>Salmonella typhimurium</i><br>TA 1535, TA 1537, TA 98, TA 100, TA 102  | Mancozeb<br>technical purity not reported<br>Vehicle: Not reported | 1.95 to 31.25 µg/plate (-S9) & 15.62 to 250µg/plate (+S9)  | neg                                      | neg | Toxicity at 312.5 to 5000 µg/plate (+S9) & 156.25 to 5000µg/plate (-S9)  |
| Host mediated assay in mice<br>Derived from OECD 471<br>GLP<br>McCarroll 1985    | <i>S.typhimurium</i><br>TA 1530 (2ml intraperitoneal injection) to mice, B6C3F1, male, 10/group killed 2 or 4 hours after inoculation | Mancozeb<br>88%<br>Vehicle: corn oil                               | Orally treated with 0 (control), 0.5, 2.0 or 5.0 g/kg bw   | NA                                       | neg | Host provides metabolic activation                                       |
| <b>1.B In vitro mammalian gene mutation assays</b>                               |   |  |  |  |     |  |
| Gene mutation assay in mammalian cells<br>OECD 476<br>GLP<br>Foxall & Byers 1984 | Chinese Hamster Ovary cells   | Mancozeb<br>88%<br>Vehicle: distilled water                        | 0.25 to 45 µg/ml<br>+/- metabolic activation   | neg                                      | neg | Adequate cytotoxicity levels were achieved<br>Positive controls included |
| Mouse lymphoma mutation assay<br>EEC guideline compliant<br>GLP<br>Riach 1996    | Mouse lymphoma L5178Y   | Mancozeb<br>purity not reported<br>Vehicle: not reported           | 0.005, 0.1, 0.2, 0.4, 0.8, 1.6 & 0.1, 0.2, 0.4, 0.8, 1.6, 3.2 µg/ml (+S9)<br>0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75 & 0.9, 1.2, 1.5, 1.8, 2.1, 2.4, 2.7 µg/ml (-S9) | Equivocal +/- S9                         |     | Equivocal<br>Positive controls included                                  |
| <b>2. Chromosomal damage and aneugenicity</b>                                    |   |  |  |  |     |  |
| Chromosomal aberration assay<br>EEC guidelines                                   | Chinese hamster ovary cells, CHO  | Mancozeb<br>purity 89.1<br>Vehicle:                                | Test 1: 1.6, 3, 6 µg/ml (+S9) & 1.25, 2.5, 5 µg/ml (-  | Pos +/- S9 but invalid because of use of |     | Toxicity at 6µg/ml (+S9) & 5µg/ml (-S9)<br>clastogenic in CHO            |

| Method, guideline, deviations if any  | Test system (Organisms, strain)   | Test substance   | Concentrations tested  | Result   |     | Remarks and information on cytotoxicity  |
|---|---|--|--|----------|-----|--|
|   |   |  |  | -S9      | +S9 |  |
| GLP<br>Innes 1995   |   | DMSO   | S9)  | DMSO     |     | cell at 6-8µg/ml (+S9) & 5µg/ml (-S9)  |
| Micronucleus test<br>OECD 487 (2016)<br>GLP<br>Gilby, 2017  | Human lymphocytes   | Mancozeb<br>Purity: 86.1%<br>Vehicle: ethanol                | 2-10 µg/ml (± S9)  | Negative |     | No precipitation and cytotoxicity up to limit concentration of 10 µg/ml (± S9, 3 hr)<br>No precipitation but cytotoxicity at top concentration of 10 µg/ml (- S9, 20 hr) |
| <b>3. DNA damage</b>  |   |  |  |          |     |  |
| <b>3.A Unscheduled DNA synthesis in mammalian cells</b>   |   |  |  |          |     |  |
| DNA damage and repair, unscheduled DNA synthesis in mammalian cells<br>OECD 482<br>GLP<br>O'Neil & Frank 1988       | Rat F344 hepatocytes, male, adult   | Mancozeb<br>Purity 82.4%<br>Vehicle: not reported            | Concentrations of mancozeb from 0.1 to 10 µg/mL scored               | neg      | neg | Toxicity at 2 to 10µg/ml<br>Precipitation at 100 to 1000µg/ml<br>Positive control included   |
| <b>3.B Sister chromatid exchange in mammalian cells</b>   |   |  |  |          |     |  |
| Sister chromatid exchange assay<br>OECD 479<br>GLP<br>Ivett 1985  | Chinese hamster ovary cells   | Mancozeb<br>purity 88%<br>Vehicle: Serum free culture medium | 1 to 20 µg / ml  | pos      | neg | Toxicity at 15µg/ml (-S9) & 12.5-20µg/ml (+S9)<br>Positive controls included   |
| <b>4. Photogenotoxicity</b>   |   |  |  |          |     |  |
| Reverse mutation in bacteria with and without UV irradiation<br>OECD 471 (1997) & 432 (2004)<br>GLP<br>Schreib 2014 | <i>Salmonella typhimurium</i><br>TA 98, TA 1537, TA 100, TA 1535 and TA 102 | Mancozeb technical<br>Purity 86%<br>Vehicle: not reported    | 0.050 to 50 µg/plate<br>+/- metabolic activation<br>& UV irradiation | neg      | neg | Toxicity at 3.16µg/plate & 5.0µg/plate<br>Precipitation at 25µg/plate & 50µg/plate<br>Not photogenotoxic   |

The *in vitro* genotoxic potential of mancozeb has been investigated in four bacterial gene mutation assays. All of these were reliable and well conducted guideline compliant tests. There was no indication of a genotoxic response to mancozeb in any of these assays, either with or without metabolic activation. Adequate levels of cytotoxicity were reported in all but one of these tests, indicating that required concentrations had been reached. These negative results were supported by a well conducted host mediated bacterial gene mutation test in mice (McCarroll 1985), in which mancozeb did not demonstrate a mutagenic response.

In a mammalian cell gene mutation assay (Foxhall and Byers 1984), mancozeb was not mutagenic at the HGPRT locus of Chinese hamster ovary cells up to cytotoxic concentrations (ranging from 0.25 to 45 µg/ml) either with and without metabolic activation. However, an equivocal response was observed *in vitro* in a mouse lymphoma mutation assay (Riach 1996). In subsequent ancillary studies of DNA damage in mammalian cells (in vitro UDS and SCE) mancozeb tested negative.

One unscheduled DNA synthesis assay was available (O'Neil & Frank 1998) in which concentrations of mancozeb from 0.1 to 10 µg / ml were scored. No increase in UDS or S-phase was detected at any of the test article concentration evaluated; therefore mancozeb did not induce UDS in rat hepatocytes up to concentrations causing precipitation.

In all of these assays, adequate levels of cytotoxicity were reported and the inclusion of positive controls ensured the validity of the results.

A weakly positive response was observed in a sister chromatid exchange assay in mammalian cells (Ivett 1985), which may be explained by the interference of manganese and/or zinc with DNA repair and replication enzymes. In addition a positive chromosomal damage assay result (Innes 1995) was considered invalid because of the use of DMSO as a solvent.

In a recently conducted guideline *in vitro* micronucleus test in human lymphocytes, mancozeb tested negative for clastogenicity and aneugenicity up to the limit concentration (10 µg/ml) for this assay with and without metabolic activation (Gilby, 2017).

In a recently conducted *in vitro* photogenotoxicity study in Salmonella typhimurium (Schreib, 2014), no biologically relevant increases in revertant colony numbers of any of the five tester strains were observed following treatment with mancozeb at any concentration level, neither with nor without concomitant UV irradiation. Overall, under the experimental conditions of this photogenotoxicity test, mancozeb did not cause gene mutations with or without UV irradiation. Therefore, mancozeb is considered to be non-mutagenic in this bacterial reverse mutation assay for evaluation of photogenotoxicity.

### 11.6.2 *In vivo*

The potential of mancozeb to induce chromosomal damage in somatic cells has been investigated in four micronucleus tests in rats and mice and two cytogenetics studies in rats and mice.

**Table 13: Summary table of mutagenicity/genotoxicity tests in mammalian somatic or germ cells *in vivo***

| Method, guideline, deviations if any  | Species, strain, sex, No/group     | Test substance                               | Concentrations tested   | Result   |
|---|------------------------------------|--|---|--|
| <i>In vivo</i> cytogenetic study in rats.<br>OECD 475<br>GLP<br>Anonymous, 1984 | Rats, F344, males, 30/group        | Mancozeb<br>Purity 88 %<br>Vehicle: corn oil | 0 (control), 0.44, 1.76 or 4.4 g/kg bw, Single oral (gavage) dose.<br>Sacrificed after 6, 24 or 48 hours. | <b>Negative</b><br>50 metaphases spreads examined per animal.<br>Clinical signs of toxicity noted in the high dose groups.<br>No increase in the incidence of chromosomal aberrations in any dose group.<br>Positive control group included. |
| Micronucleus test in bone marrow of mice.<br>OECD TG 474                        | Mice, CD1, males & females, 10/sex | Mancozeb<br>Purity 85%                       | 2000 mg/kg bw (limit dose), oral doses at 0 and 24 hours.<br>Bone marrow sampled at 48 hours.             | <b>Negative</b><br>No increase in the incidence of micronuclei.<br>Positive control group  |

| Method, guideline, deviations if any  | Species, strain, sex, No/group                   | Test substance  | Concentrations tested  | Result  |
|---|--|---|--|---|
| GLP<br>Anonymous, 1997  |  |   |  | included.   |
| Micronucleus test in bone marrow of mice.<br>OECD TG 474<br>GLP<br>Anonymous, 1987a | Mice, CD1, males & females, 15/sex/dose          | Mancozeb technical<br>Purity 88.2%                      | 0 & 1,000 mg/kg bw, oral (gavage) dose.<br>Bone marrow sampled at 24, 48 & 72 hours.               | <b>Negative</b><br>No increase in the incidence of micronuclei.<br>1000 polychromatic erythrocytes evaluated per animal.<br>Positive control group included.  |
| Micronucleus test in bone marrow of mice.<br>OECD 474<br>GLP<br>Anonymous, 2008a    | Mice, Swiss albino, males & females<br>5/sex     | Mancozeb<br>Purity not reported<br>Vehicle: corn oil    | 0 or 2000 mg/kg bw, oral (gavage) dose on two consecutive days.                                    | <b>Negative</b><br>No clinical signs of toxicity observed & no signs of toxicity to the bone marrow.<br>No increase in the incidence of micronuclei<br>Positive control included.   |
| Micronucleus test in bone marrow of mice.<br>OECD 474<br>GLP<br>Anonymous, 1999     | Mice, Swiss albino, 5 sex/group                  | Mancozeb technical<br>Purity 85%<br>Vehicle: peanut oil | 500, 1000 & 2000 mg/kg bw, oral dose for two consecutive days.<br>Bone marrow sampled at 24 hours. | <b>Negative</b><br>Clinical signs of toxicity noted (reduced bw and lethargy).<br>PCE/NCE ratio was similar between treated and control groups.<br>No increase in the incidence of micronuclei.<br>Positive control included.                       |
| Chromosome aberration study in mice.<br>475<br>GLP<br>Anonymous, 1999               | Mice, Swiss albino, males & females, 5/sex/group | Mancozeb technical<br>Purity 85%<br>Vehicle: peanut oil | 1, 500, 1000 & 2000 mg/kg bw, oral dose  | <b>Negative</b><br>Clinical signs of toxicity noted (diarrhoea & lethargy).<br>No increase in chromosomal aberrations in males.<br>Slight increase in chromatid & chromosomal breaks & fragments in females in high dose group.<br>Positive control |

| Method, guideline, deviations if any | Species, strain, sex, No/group | Test substance | Concentrations tested | Result    |
|--------------------------------------|--------------------------------|----------------|-----------------------|-----------|
|                                      |                                |                |                       | included. |

The genotoxic potential of mancozeb has been examined in four reliable and well conducted guideline bone marrow micronucleus assays in mice. Mancozeb did not induce an increase in micronuclei in any of these tests up to limit doses of 2000 mg/kg bw. Previous toxicokinetic studies have confirmed the bioavailability of mancozeb in the blood after oral administration, and due to the highly perfused nature of the bone marrow tissue it is likely that the bone marrow had been exposed to mancozeb or its metabolites.

Two *in vivo* chromosome aberration studies were carried out in mice. A well conducted study (Anonymous, 1984) observed no increase in the incidence of chromosome aberrations in the high dose group. Clinical signs of toxicity (including lethargy, piloerection and dyspnoea) observed at the high dose of 4400 mg/kg bw confirmed that adequate doses had been administered. Although the study by Anonymous (1999) observed a slight increase in chromosome and chromatid breaks in females only, in the high dose group (1.4% compared with 0.6% in the control group), these were not considered to be biologically significant owing to the marginal nature of the increase and the sex specificity of the response. No increase in aberrant cells was observed in males up to doses of 2000 mg/kg bw. Overall it was concluded that no signs of clastogenicity were observed in any of the *in vivo* tests performed on mancozeb.

### 10.6.3 Short summary and overall relevance of the provided information on germ cell mutagenicity

Mancozeb has been tested in a series of *in vitro* and *in vivo* genotoxicity assays. Mancozeb is not mutagenic in bacterial and host mediated bacterial gene mutation assays, or in gene mutation assays in mammalian cells in culture. An equivocal response was observed *in vitro* in a mouse lymphoma mutation assay. However, mancozeb tested negative in a mammalian cell unscheduled DNA synthesis study. Chromosomal aberrations were induced *in vitro*, but only in the presence of DMSO and therefore this result is considered invalid. A recently and well conducted *in vitro* micronucleus study gave negative results for clastogenicity and aneugenicity (Gilby, 2017). A weakly positive response in sister chromatid exchange tests *in vitro* may be explained by manganese and/or zinc ion interference with enzymes involved in DNA repair and replication. Tight metabolic regulation of these essential nutrients prevents this effect from occurring *in vivo*.

Mancozeb was tested for photomutagenicity in a bacterial reverse mutation test in the presence of UV light. Under the conditions of the test, mancozeb was found to be non-mutagenic (Schreib, 2014).

Mancozeb was shown not to increase the number of polychromatic erythrocytes containing micronuclei in mice, or to induce chromosome aberrations or cytogenetic abnormalities in mice or rats.

Based on the available data set, mancozeb is concluded not to be a mutagen in somatic cells. As there was no indication of mutagenicity in somatic cells arising from the data set, investigations into the effects of mancozeb in germ cells was not required.

### 10.6.4 Comparison with the CLP criteria

Mancozeb was not mutagenic in valid *in vivo* somatic cell mutagenicity tests and so according to the guidance on the application of the CLP criteria no classification is warranted. The overall body of toxicological data from a number of *in vitro* and *in vivo* assays indicates that mancozeb is of no genotoxic concern. Therefore no classification for mutagenicity under the CLP regulation is required.

### 10.6.5 Conclusion on classification and labelling for germ cell mutagenicity

**Not classified (conclusive but not sufficient for classification)**

## 10.7 Carcinogenicity

The long-term toxicity and carcinogenic potential of mancozeb has been investigated in two combined chronic toxicity/carcinogenicity studies in rats, a carcinogenicity study in rats and two carcinogenicity studies in mice. In addition, the findings from two 2-generation reproduction toxicity studies were considered relevant to the assessment of the carcinogenic potential of mancozeb. Three investigative studies from the open literature have also been considered. A number of epidemiological studies are also available.

**Table 14: Summary table of animal studies on carcinogenicity**

| Method, guideline, deviations if any, species, strain, sex, no/group   | Species, strain, sex, no/group                                       | Dose levels duration of exposure   | Results<br>(Effects statistically significantly different unless stated otherwise)  |
|--|--|--|---|
| Two-year combined chronic toxicity/carcinogenicity<br>Oral (dietary)<br>OECD 453<br>GLP<br>Mancozeb<br>83.8%<br>Anonymous, 1990a | Rat, Crl: CD BR<br><br>10/sex/dose (1-yr)<br><br>62/sex /dose (2-yr) | 0, 20, 60, 125, 750 ppm<br><br>Equivalent to:<br>Males: 0.769, 2.33, 4.83, 30.9 mg/kg/day<br><br>Females: 1.06, 3.06, 6.72, 40.2 mg/kg/day | No treatment-related effects on mortality.<br>No treatment-related overt clinical signs of toxicity.<br><b><u>Non-neoplastic findings</u></b><br><b><u>750 ppm (males 30.9 mg/kg bw/day, females 40.2 mg/kg bw/day):</u></b><br>↓ <i>Body weight</i> : 10% females days 0-91<br>↓ <i>Body weight gain</i> : 7.4% males day 364<br>↓ <i>Incidence of diarrhoea</i> : 14/62 males (control 36); 4/62 females (control 12)<br>↓ <i>T3</i> : 30.0% males 3 months<br>↑ <i>T3</i> : 23.3% and 42.6% males at 6 and 24 months<br>↓ <i>T4</i> : 18.4%, 35.5% males at 6 and 18 months; 50.0%, 22.2%, 21.4% females at 3, 18 and 24 months<br>↑ <i>TSH</i> : 33.3%, 52.8% males at 12 and 18 months; 76.5% and 113.3% females at 6 and 18 months<br>↑ <i>Absolute thyroid weight</i> : 59.6% males; 43.2% females at 24 months<br>↑ <i>Relative thyroid weight</i> : 61.6% males; 47.4% females at 24 months<br>↑ <i>Eye bilateral retinopathy incidence and severity</i> : 19/61 males (4/60 control); 49/60 females (21/62 control)<br>↑ <i>Thyroid follicular cell hypertrophy/hyperplasia</i> : 34/61 males (1/60 control); 24/61 females (1/62 control)<br><b><u>125 ppm (males 4.83 mg/kg bw/day, females 6.72 mg/kg bw/day):</u></b><br>No toxicologically significant treatment-related effects.<br><b><u>60 ppm (males 2.33 mg/kg bw/day, females 3.03 mg/kg bw/day):</u></b><br>No toxicologically significant treatment-related effects.<br><b><u>20 ppm (males 0.769 mg/kg bw/day, females 1.06 mg/kg bw/day):</u></b><br>No toxicologically significant treatment-related effects. |

| Method, guideline, deviations if any, species, strain, sex, no/group  | Species, strain, sex, no/group   | Dose levels duration of exposure  | Results<br>(Effects statistically significantly different unless stated otherwise)  |           |                             |  |  |  |  |   |    |    |     |     |              |  |  |  |  |  |                            |           |           |           |           |           |                            |   |   |   |   |     |                          |   |   |   |   |     |                |  |  |  |  |  |                             |           |           |           |           |           |                            |   |   |   |   |    |                          |   |   |   |   |    |
|---|--|---|---|-----------|-----------------------------|--|--|--|--|---|----|----|-----|-----|--------------|--|--|--|--|--|----------------------------|-----------|-----------|-----------|-----------|-----------|----------------------------|---|---|---|---|-----|--------------------------|---|---|---|---|-----|----------------|--|--|--|--|--|-----------------------------|-----------|-----------|-----------|-----------|-----------|----------------------------|---|---|---|---|----|--------------------------|---|---|---|---|----|
|   |  |   | <p><b>Neoplastic findings</b></p> <p>Increased incidence of thyroid follicular cell tumours in both sexes at 750 ppm.</p> <table border="1" data-bbox="695 707 1449 1043"> <thead> <tr> <th rowspan="2">Tumours</th> <th colspan="5">Dietary concentration (ppm)</th> </tr> <tr> <th>0</th> <th>20</th> <th>60</th> <th>125</th> <th>750</th> </tr> </thead> <tbody> <tr> <td colspan="6" style="text-align: center;"><b>Males</b></td> </tr> <tr> <td><b>Thyroid No examined</b></td> <td><b>60</b></td> <td><b>62</b></td> <td><b>60</b></td> <td><b>58</b></td> <td><b>61</b></td> </tr> <tr> <td>Follicular cell carcinomas</td> <td>0</td> <td>0</td> <td>2</td> <td>2</td> <td>14*</td> </tr> <tr> <td>Follicular cell adenomas</td> <td>0</td> <td>1</td> <td>1</td> <td>0</td> <td>20*</td> </tr> <tr> <td colspan="6" style="text-align: center;"><b>Females</b></td> </tr> <tr> <td><b>Thyroid No. examined</b></td> <td><b>62</b></td> <td><b>60</b></td> <td><b>62</b></td> <td><b>61</b></td> <td><b>61</b></td> </tr> <tr> <td>Follicular cell carcinomas</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> <td>4*</td> </tr> <tr> <td>Follicular cell adenomas</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>6*</td> </tr> </tbody> </table> <p>* statistically significantly different (P ≤ 0.05)</p>   | Tumours   | Dietary concentration (ppm) |  |  |  |  | 0 | 20 | 60 | 125 | 750 | <b>Males</b> |  |  |  |  |  | <b>Thyroid No examined</b> | <b>60</b> | <b>62</b> | <b>60</b> | <b>58</b> | <b>61</b> | Follicular cell carcinomas | 0 | 0 | 2 | 2 | 14* | Follicular cell adenomas | 0 | 1 | 1 | 0 | 20* | <b>Females</b> |  |  |  |  |  | <b>Thyroid No. examined</b> | <b>62</b> | <b>60</b> | <b>62</b> | <b>61</b> | <b>61</b> | Follicular cell carcinomas | 0 | 0 | 0 | 1 | 4* | Follicular cell adenomas | 1 | 1 | 1 | 1 | 6* |
| Tumours   | Dietary concentration (ppm)  |   |   |           |                             |  |  |  |  |   |    |    |     |     |              |  |  |  |  |  |                            |           |           |           |           |           |                            |   |   |   |   |     |                          |   |   |   |   |     |                |  |  |  |  |  |                             |           |           |           |           |           |                            |   |   |   |   |    |                          |   |   |   |   |    |
|   | 0  | 20  | 60  | 125       | 750                         |  |  |  |  |   |    |    |     |     |              |  |  |  |  |  |                            |           |           |           |           |           |                            |   |   |   |   |     |                          |   |   |   |   |     |                |  |  |  |  |  |                             |           |           |           |           |           |                            |   |   |   |   |    |                          |   |   |   |   |    |
| <b>Males</b>  |  |   |   |           |                             |  |  |  |  |   |    |    |     |     |              |  |  |  |  |  |                            |           |           |           |           |           |                            |   |   |   |   |     |                          |   |   |   |   |     |                |  |  |  |  |  |                             |           |           |           |           |           |                            |   |   |   |   |    |                          |   |   |   |   |    |
| <b>Thyroid No examined</b>  | <b>60</b>  | <b>62</b>   | <b>60</b>   | <b>58</b> | <b>61</b>                   |  |  |  |  |   |    |    |     |     |              |  |  |  |  |  |                            |           |           |           |           |           |                            |   |   |   |   |     |                          |   |   |   |   |     |                |  |  |  |  |  |                             |           |           |           |           |           |                            |   |   |   |   |    |                          |   |   |   |   |    |
| Follicular cell carcinomas  | 0  | 0   | 2   | 2         | 14*                         |  |  |  |  |   |    |    |     |     |              |  |  |  |  |  |                            |           |           |           |           |           |                            |   |   |   |   |     |                          |   |   |   |   |     |                |  |  |  |  |  |                             |           |           |           |           |           |                            |   |   |   |   |    |                          |   |   |   |   |    |
| Follicular cell adenomas  | 0  | 1   | 1   | 0         | 20*                         |  |  |  |  |   |    |    |     |     |              |  |  |  |  |  |                            |           |           |           |           |           |                            |   |   |   |   |     |                          |   |   |   |   |     |                |  |  |  |  |  |                             |           |           |           |           |           |                            |   |   |   |   |    |                          |   |   |   |   |    |
| <b>Females</b>  |  |   |   |           |                             |  |  |  |  |   |    |    |     |     |              |  |  |  |  |  |                            |           |           |           |           |           |                            |   |   |   |   |     |                          |   |   |   |   |     |                |  |  |  |  |  |                             |           |           |           |           |           |                            |   |   |   |   |    |                          |   |   |   |   |    |
| <b>Thyroid No. examined</b>   | <b>62</b>  | <b>60</b>   | <b>62</b>   | <b>61</b> | <b>61</b>                   |  |  |  |  |   |    |    |     |     |              |  |  |  |  |  |                            |           |           |           |           |           |                            |   |   |   |   |     |                          |   |   |   |   |     |                |  |  |  |  |  |                             |           |           |           |           |           |                            |   |   |   |   |    |                          |   |   |   |   |    |
| Follicular cell carcinomas  | 0  | 0   | 0   | 1         | 4*                          |  |  |  |  |   |    |    |     |     |              |  |  |  |  |  |                            |           |           |           |           |           |                            |   |   |   |   |     |                          |   |   |   |   |     |                |  |  |  |  |  |                             |           |           |           |           |           |                            |   |   |   |   |    |                          |   |   |   |   |    |
| Follicular cell adenomas  | 1  | 1   | 1   | 1         | 6*                          |  |  |  |  |   |    |    |     |     |              |  |  |  |  |  |                            |           |           |           |           |           |                            |   |   |   |   |     |                          |   |   |   |   |     |                |  |  |  |  |  |                             |           |           |           |           |           |                            |   |   |   |   |    |                          |   |   |   |   |    |
| <p>Two-year combined toxicity/carcinogenicity</p> <p>Oral (dietary)</p> <p>OECD 453, (1988)</p> <p>GLP</p> <p>Mancozeb 88.2 and 88.5%</p> <p>Anonymous, 1992a</p> | <p>Rats, Crl: CD SD</p> <p>10/sex/dose (1-yr)</p> <p>50/sex /dose (2-yr)</p> <p>10/sex/dose (blood sampling)</p> | <p>0, 28, 113, 454 ppm</p> <p>Equivalent to:</p> <p>Males: 1.0, 4.0 and 16.8 mg/kg bw/day</p> <p>Females: 1.3, 5.1, 20.8 mg/kg bw/day</p> | <p>No treatment-related effects on mortality.</p> <p>No treatment-related overt clinical signs of toxicity.</p> <p><b>Non-neoplastic findings</b></p> <p><u>454 ppm (males 16.8 mg/kg bw/day, females 20.8 mg/kg bw/day):</u></p> <p>↓ <i>Body weight</i>: 4.4, 5.5% week 13 in males and females respectively</p> <p>↓ <i>Body weight gain</i>: 6.8%, 11.4% weeks 0-13 in males and females respectively; 7.4% weeks 0-26 males</p> <p>↓ <i>Thyroxin T4</i>: 15.6%, 19.2% males at 26 and 52 weeks; 20.0%, 22.7% and 38.7% females at 26, 52 and 78 weeks</p> <p>↑ <i>Thyroid increased height of follicular epithelium</i>: 8/50 males (3/50 control); 5/50 females (1/50 control). The statistical significance of these findings is unclear.</p> <p><i>Thyroid prominent micro follicles</i>: 5/50 males (0/50 control); 1/50 males (0/50 control)</p> <p><u>113 ppm (males 4.0 mg/kg bw/day, females 5.1 mg/kg bw/day):</u></p> <p>No toxicologically significant treatment-related effects.</p> <p><u>28 ppm (males 1.0 mg/kg bw/day, females 1.3 mg/kg bw/day):</u></p> <p>No toxicologically significant treatment-related effects.</p> <p>NOAEL for non-neoplastic changes 113 ppm (equivalent to 4.0 and 5.1 mg/kg bw/day in males and females respectively) based on effects on body weight and functional and morphological thyroid effects at 454 ppm.</p> |           |                             |  |  |  |  |   |    |    |     |     |              |  |  |  |  |  |                            |           |           |           |           |           |                            |   |   |   |   |     |                          |   |   |   |   |     |                |  |  |  |  |  |                             |           |           |           |           |           |                            |   |   |   |   |    |                          |   |   |   |   |    |

| Method, guideline, deviations if any, species, strain, sex, no/group | Species, strain, sex, no/group | Dose levels duration of exposure | Results<br>(Effects statistically significantly different unless stated otherwise)                              |
|--|--------------------------------|----------------------------------|---|
|  |                                |                                  | <p><b>Neoplastic findings</b></p> <p>No treatment-related changes in neoplastic findings at any dose level.</p> |

| <p>104 week Carcinogenicity study</p> <p>Oral (dietary)</p> <p>Non guideline</p> <p>Not GLP</p> <p>Mancozeb</p> <p>Belpoggi <i>et al</i> 2002 (from the open literature)</p> | <p>Rat: Sprague-Dawley</p> <p>75/sex/group</p>                           | <p>0, 10, 100, 500, 1000 ppm</p> <p>Equivalent to: 0.5, 5, 25 &amp; 50 mg/kg bw/day. (based on default assumptions)</p> <p>Treated for 104 weeks but observed until spontaneous death.</p> | <p>No treatment-related effects on mortality.</p> <p>No treatment-related overt clinical signs of toxicity</p> <p><b>Non-neoplastic findings</b></p> <p>No toxicologically significant treatment-related effects at any dose level.</p> <p><b>Neoplastic findings</b></p> <p>Statistically significant increase in thyroid follicular cell carcinomas at both sexes at 1000ppm.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="2">Thyroid gland tumours</th> <th colspan="5">Dietary concentration (ppm)</th> </tr> <tr> <th>0</th> <th>10</th> <th>100</th> <th>500</th> <th>1000</th> </tr> </thead> <tbody> <tr> <td colspan="6" style="text-align: center;"><b>Males</b></td> </tr> <tr> <td>Follicular cell carcinomas</td> <td>0</td> <td>0</td> <td>0</td> <td>2.7</td> <td>8*</td> </tr> <tr> <td>C-cell carcinomas</td> <td>0</td> <td>0</td> <td>1.3</td> <td>0</td> <td>2.7</td> </tr> <tr> <td colspan="6" style="text-align: center;"><b>Females</b></td> </tr> <tr> <td>Follicular cell carcinomas</td> <td>0</td> <td>1.3</td> <td>0</td> <td>0</td> <td>16**</td> </tr> <tr> <td>C-cell carcinomas</td> <td>0</td> <td>0</td> <td>1.3</td> <td>1.3</td> <td>2.7</td> </tr> </tbody> </table> <p>* p&lt;0.05 and **p&lt;0.01</p> <p>Increased occurrence of benign and malignant tumours in a number of organs at all doses.</p> | Thyroid gland tumours | Dietary concentration (ppm) |  |  |  |  | 0 | 10 | 100 | 500 | 1000 | <b>Males</b> |  |  |  |  |  | Follicular cell carcinomas | 0 | 0 | 0 | 2.7 | 8* | C-cell carcinomas | 0 | 0 | 1.3 | 0 | 2.7 | <b>Females</b> |  |  |  |  |  | Follicular cell carcinomas | 0 | 1.3 | 0 | 0 | 16** | C-cell carcinomas | 0 | 0 | 1.3 | 1.3 | 2.7 |
|--|--|--|---|-----------------------|-----------------------------|--|--|--|--|---|----|-----|-----|------|--------------|--|--|--|--|--|----------------------------|---|---|---|-----|----|-------------------|---|---|-----|---|-----|----------------|--|--|--|--|--|----------------------------|---|-----|---|---|------|-------------------|---|---|-----|-----|-----|
| Thyroid gland tumours  | Dietary concentration (ppm)  |  |   |                       |                             |  |  |  |  |   |    |     |     |      |              |  |  |  |  |  |                            |   |   |   |     |    |                   |   |   |     |   |     |                |  |  |  |  |  |                            |   |     |   |   |      |                   |   |   |     |     |     |
|  | 0  | 10   | 100   | 500                   | 1000                        |  |  |  |  |   |    |     |     |      |              |  |  |  |  |  |                            |   |   |   |     |    |                   |   |   |     |   |     |                |  |  |  |  |  |                            |   |     |   |   |      |                   |   |   |     |     |     |
| <b>Males</b>   |  |  |   |                       |                             |  |  |  |  |   |    |     |     |      |              |  |  |  |  |  |                            |   |   |   |     |    |                   |   |   |     |   |     |                |  |  |  |  |  |                            |   |     |   |   |      |                   |   |   |     |     |     |
| Follicular cell carcinomas   | 0  | 0  | 0   | 2.7                   | 8*                          |  |  |  |  |   |    |     |     |      |              |  |  |  |  |  |                            |   |   |   |     |    |                   |   |   |     |   |     |                |  |  |  |  |  |                            |   |     |   |   |      |                   |   |   |     |     |     |
| C-cell carcinomas  | 0  | 0  | 1.3   | 0                     | 2.7                         |  |  |  |  |   |    |     |     |      |              |  |  |  |  |  |                            |   |   |   |     |    |                   |   |   |     |   |     |                |  |  |  |  |  |                            |   |     |   |   |      |                   |   |   |     |     |     |
| <b>Females</b>   |  |  |   |                       |                             |  |  |  |  |   |    |     |     |      |              |  |  |  |  |  |                            |   |   |   |     |    |                   |   |   |     |   |     |                |  |  |  |  |  |                            |   |     |   |   |      |                   |   |   |     |     |     |
| Follicular cell carcinomas   | 0  | 1.3  | 0   | 0                     | 16**                        |  |  |  |  |   |    |     |     |      |              |  |  |  |  |  |                            |   |   |   |     |    |                   |   |   |     |   |     |                |  |  |  |  |  |                            |   |     |   |   |      |                   |   |   |     |     |     |
| C-cell carcinomas  | 0  | 0  | 1.3   | 1.3                   | 2.7                         |  |  |  |  |   |    |     |     |      |              |  |  |  |  |  |                            |   |   |   |     |    |                   |   |   |     |   |     |                |  |  |  |  |  |                            |   |     |   |   |      |                   |   |   |     |     |     |
| <p>18 month carcinogenicity</p> <p>Oral (dietary)</p> <p>OECD 451</p> <p>87/302/EEC B.32 (1988)</p> <p>GLP</p> <p>Mancozeb</p> <p>82.8%</p> <p>Anonymous, 1991a</p>          | <p>Mice, CD-1</p> <p>20/sex/dose (1-yr)</p> <p>70/sex/dose (1.5-yrs)</p> | <p>0, 30, 100, 1000 ppm</p> <p>Equivalent to:</p> <p>Males: 3.75, 12.52, 130.60 mg/kg bw/day</p> <p>Females: 5.18, 17.81, 179.74 mg/kg bw/day</p>  | <p>No treatment-related effects on mortality.</p> <p>No treatment-related overt clinical signs of toxicity</p> <p><b>Non-neoplastic findings</b></p> <p><u>1000 ppm (males 130.60 mg/kg bw/day, females 179.74 mg/kg bw/day):</u></p> <p>↓ <i>Body weight gain</i>: 13% males, 10% females at 18 months</p> <p>↓ T4: 56% and 24.9% in males at 12 and 18 months respectively.</p> <p>↓ T4: 76.3% and 61.5% in females at 12 and 18 months respectively.</p> <p>↑ T3: 45.0% males 18 months</p> <p>↓ T3: 31.3% females 18 months</p> <p><i>Pathology</i>: no treatment-related changes in any of the tissues examined</p> <p><u>100 ppm (males 12.52 mg/kg bw/day, females 17.81 mg/kg bw/day):</u></p> <p>No toxicologically significant treatment-related effects.</p> <p><u>30 ppm (males 3.75 mg/kg bw/day, females 5.18 mg/kg bw/day):</u></p> <p>No toxicologically significant treatment-related effects.</p> <p><b>Neoplastic findings</b></p>   |                       |                             |  |  |  |  |   |    |     |     |      |              |  |  |  |  |  |                            |   |   |   |     |    |                   |   |   |     |   |     |                |  |  |  |  |  |                            |   |     |   |   |      |                   |   |   |     |     |     |

---

|  |  |  |  |
|--|--|--|--|
|  |  |  | No treatment-related changes in neoplastic findings at any dose level. |
|--|--|--|--|

|   |                                  |   |  |  |       |        |         |                      |       |      |       |          |      |      |       |            |      |      |      |
|---|----------------------------------|---|--|--|-------|--------|---------|----------------------|-------|------|-------|----------|------|------|-------|------------|------|------|------|
| <p>78 week carcinogenicity<br/>Oral (dietary)<br/>Mancozeb<br/>88.6%<br/>Anonymous,<br/>1992b</p> | <p>Mice, CD1<br/>60/sex/dose</p> | <p>0,25,100,100<br/>0 ppm<br/>Equivalent to<br/>4.25, 17 &amp;<br/>170 mg/kg<br/>bw/day</p> | <p>No treatment-related effects on mortality.<br/>No treatment-related overt clinical signs of toxicity</p> <p><b><u>Non-neoplastic findings</u></b><br/><u>1000ppm</u><br/>↓ <i>Body weight gain</i>: 6% males &amp; 10% females at 52 weeks, 8% males &amp; 14% females at 78 weeks.<br/><u>100ppm</u><br/>No toxicologically significant treatment-related effects.<br/><u>25ppm</u><br/>No toxicologically significant treatment-related effects.</p> <p><b><u>Neoplastic findings</u></b></p> <table border="1" data-bbox="692 685 1445 864"> <tr> <td></td> <td>0 ppm</td> <td>100ppm</td> <td>1000ppm</td> </tr> <tr> <td><b>Liver tumours</b></td> <td>10/50</td> <td>7/50</td> <td>17/50</td> </tr> <tr> <td>Adenomas</td> <td>8/50</td> <td>5/50</td> <td>17/50</td> </tr> <tr> <td>Carcinomas</td> <td>2/50</td> <td>2/50</td> <td>0/50</td> </tr> </table> <p>No statistically significant differences or trends</p> |  | 0 ppm | 100ppm | 1000ppm | <b>Liver tumours</b> | 10/50 | 7/50 | 17/50 | Adenomas | 8/50 | 5/50 | 17/50 | Carcinomas | 2/50 | 2/50 | 0/50 |
|   | 0 ppm                            | 100ppm  | 1000ppm  |  |       |        |         |                      |       |      |       |          |      |      |       |            |      |      |      |
| <b>Liver tumours</b>  | 10/50                            | 7/50  | 17/50  |  |       |        |         |                      |       |      |       |          |      |      |       |            |      |      |      |
| Adenomas  | 8/50                             | 5/50  | 17/50  |  |       |        |         |                      |       |      |       |          |      |      |       |            |      |      |      |
| Carcinomas  | 2/50                             | 2/50  | 0/50   |  |       |        |         |                      |       |      |       |          |      |      |       |            |      |      |      |

**Table 15: Summary table of human data on carcinogenicity**

| Type of data/report   | Test substance        | Relevant information about the study (as applicable)   | Observations  |
|---|-----------------------|--|---|
| <p>Mortality study of workers exposed to Dithane from 1948 to 1975<br/><br/>Anonymous, 1976b</p>              | <p>Mancozeb</p>       | <p>Mortality from workers exposed to mancozeb (1948 to 1975) at the Rohm and Haas Philadelphia Plant were compared to comparable mortality data from the city of Philadelphia. The exposed cohort was divided into three groups according to exposure and an evaluation system to rank relative exposure was used.</p> | <p>The incidences of total deaths and deaths due to cancers among Rohm and Haas workers involved in the production of mancozeb were similar to those of the control group. No thyroid cancer was found in this study.</p>   |
| <p>Retrospective study of women who were employed at a rubber manufacturer using ETU.<br/><br/>Smith 1976</p> | <p>ETU</p>            | <p>A total of 1929 workers engaged in the production or manufacture of ETU were surveyed retrospectively for thyroid cancer, and compared with the thyroid cancer list of the Birmingham (England) Cancer Registry from 1957-1971.</p>   | <p>Exposure to ETU was not associated with thyroid cancer</p>   |
| <p>Epidemiology study<br/><br/>Dennis <i>et al</i> 2010</p>   | <p>Maneb/mancozeb</p> | <p>The study examined cutaneous melanoma incidence and dose–response relationships for 50 agricultural pesticides</p>  | <p>A significant association between cutaneous melanoma and maneb/mancozeb (≥ 63 exposure days) was found. It was noted that the possibility that pesticide-specific results were driven by sun exposure could not be ruled out. It was noted that no other studies have reported an association between maneb/mancozeb and melanoma.</p> |

| Type of data/report   | Test substance   | Relevant information about the study (as applicable)   | Observations  |
|---|--|--|---|
| Case control study (Agricultural Health Study)<br><i>Lee et al 2007</i>     | Mancozeb   | The relationship between agricultural pesticides and colorectal cancer incidence was analysed in 56,813 pesticide applicators with no prior history of colorectal cancer. Self-administered questionnaires were used to collect detailed pesticide exposure and other information. | No evidence that mancozeb exposure is associated with colorectal cancer incidence.  |
| Case-control study<br><i>Mills et al 2005</i><br>Anonymous, 2007b           | Mancozeb   | The study examined leukaemia and stomach cancers incidence in farm workers in California.  | No association was found between occupational exposure to mancozeb and stomach cancer. An increased risk was reported for leukaemia. The significance of this association is questionable, especially considering that such findings are not supported by the animal data or by any other epidemiology study and can be explained by confounding. |
| Case-Control study<br><i>Band et al 2011</i>                                | Mancozeb   | Occupational risk factors were investigated among 1,516 prostate cancer patients and 4,994 age-matched internal controls consisting of all other cancer sites excluding lung cancer and cancers of unknown primary site  | No association between mancozeb exposure and prostate cancer.   |
| Case control study (Agricultural Health Study)<br><i>Koutros et al 2011</i> | Mancozeb (life-time exposure days)   | The study investigated the relationship between pesticide use and single nucleotide polymorphisms (SNPs) in xenobiotic metabolic enzyme (XME) genes and risk of prostate cancer  | There was no evidence of an association between maneb/mancozeb and prostate cancer.   |
| Epidemiology study<br><i>Nordby et al 2005</i>                              | Mancozeb (estimated from agricultural censuses, and meteorologically based fungal forecasts) | Farm holders and their spouses and children, were cross-linked with national agricultural censuses, and the national population register. Thyroid cancer (319 cases) was identified in the national cancer register.   | There is no evidence that mancozeb exposure is associated with thyroid cancer in this population.   |

**Table 16: Summary table of other studies relevant for carcinogenicity**

| Type of study/data   | Test substance  | Relevant information about the study (as applicable)   | Observations<br>(Effects statistically significantly different unless stated otherwise)   |
|--|---|--|---|
| <p>Two Generation (two litter)</p> <p>Oral (dietary)</p> <p>OECD 416 (1983)</p> <p>GLP</p> <p>Rat, CRI:CD(SD)BR</p> <p>25/sex/group</p> <p>Anonymous, 1988</p> | <p>Mancozeb</p> <p>Purity 84.0%</p> <p>0, 30, 120 or 1200 ppm</p> | <p>Study provides additional information relevant for carcinogenicity. Relevant effects for carcinogenicity in F0 and F1 parents shown only. These groups were treated for approximately 25 weeks.</p> | <p><i>Parental toxicity</i></p> <p><u>1200 ppm (68.9 mg/kg bw/day)</u></p> <p>F0 generation: <b>thyroid effects</b></p> <p>↑ thyroid weight (39% males, 36% females); ↑ thyroid follicular hyperplasia (25/25 males, 22/25 females, none in controls); ↑ <b>follicular adenoma</b> (3/25 males, 0/25 females, none in controls);</p> <p>F0 generation: Other effects</p> <p>↑ relative liver weight (16.5% males, 12.5% females); ↑ relative kidney weight (14% females); ↑ pigment in lumen of proximal renal tubules (9/9 males, 25/25 females, none in controls); ↑ moderate hypertrophy/vacuolation pituitary adenohypophysis (3/25 males, only minimal/mild severity)</p> <p>F<sub>1</sub> generation: <b>thyroid effects</b></p> <p>↑ thyroid weight (48% males, 35% females); ↑ thyroid follicular hyperplasia (24/24 males, 24/24 females, 2/25 in control males, none in control females); ↑ <b>follicular adenoma</b> (4/24 males, 0/25 females, none in controls);</p> <p>F<sub>1</sub> generation: Other effects</p> <p>↑ relative liver weight (14% males, 15.5% females); ↑ relative kidney weight (11% females); ↑ pigment in lumen of proximal renal tubules (24/24 males, 25/25 females, none in controls); ↑ hypertrophy / vacuolation pituitary adenohypophysis (minimal/moderate in males)</p> <p><u>120 ppm (6.95 mg/kg bw/day)</u></p> <p>No effects relevant for carcinogenicity.</p> <p><u>30 ppm (1.73 mg/kg bw/day)</u></p> <p>No effects</p> |

|   |   |   |  |
|---|---|---|--|
| <p>Two Generation (one litter)<br/>Oral (Dietary)<br/>OECD 416 (1983)<br/>Limited endpoints compared to current OECD guideline.<br/>GLP<br/>Rat, CRI:CD(SD)BR<br/>25/sex/group<br/>Anonymous, 1992c</p>     | <p>Penncozeb (mancozeb technical)<br/>Purity 88.4%<br/>0, 25, 150 or 1100 ppm</p>   | <p>Study provides additional information relevant for carcinogenicity. Relevant effects for carcinogenicity in F0 and F1 parents shown only. These groups were treated for approximately 25 weeks. Mean dosages were not provided therefore values were estimated for combined sexes.</p> | <p><i>Parental toxicity</i><br/><u>1100 ppm (74 mg/kg bw/day)</u><br/>F0 parents <b>thyroid effects</b>:<br/>↑ Thyroid weight (61% males, 25% females); ↑ thyroid follicular hypertrophy &amp; hyperplasia (25/25 males, 24/25 females, none in controls); <b>follicular adenoma</b> (5/25 males, 1/25 females, none in controls).<br/>F1 parents <b>thyroid effects</b>:<br/>↑ Thyroid weight (34% males &amp; females); ↑ thyroid follicular hypertrophy &amp; hyperplasia (23/25 males, 25/25 females, none in controls); <b>follicular adenoma</b> (11/25 males, 0/25 females, none in controls).<br/><u>150 ppm (10 mg/kg bw/day) and 25 ppm (1.7 mg/kg bw/day) (F0 and F1)</u><br/>No effects relevant for carcinogenicity. No histopathology of thyroid undertaken.</p> |
| <p>Investigative study<br/>(From literature review)<br/>Non guideline<br/>Not GLP<br/>Rat: F344<br/>5-9 males/group<br/>Perez-Carreón <i>et al</i> 2009</p>   | <p>Mancozeb (analytical standard of “high” purity”) dosed in a pesticide mixture of 12 pesticides.<br/>Mancozeb included at 0.02 and 0.10 mg/mL<br/>Gavage 5 times/week for 8 weeks<br/>Vehicle: dissolved in DMSO and then suspended in 1% CMC</p> | <p>The study used four protocols to investigate co-carcinogenic effects and tumour promoting activity using various doses of DEN and 2AAF.</p>  | <p>Mancozeb (in a pesticide mixture) does not have tumour promoting properties or co-carcinogenic activity in rat medium term liver carcinogenesis. However, the validity of these findings is questioned by the use of DMSO as vehicle.</p>   |
| <p>Investigative study<br/>(From literature review)<br/>Non-guideline<br/>Oral (dietary)<br/>Not GLP<br/>Rat: Wistar<br/>19 pregnant females; male and female offspring<br/>Valentich <i>et al</i> 2006</p> | <p>Mancozeb<br/>100 ppm<br/>Duration: dams: GD 10 – LD 3;<br/>Offspring: 8 weeks from day 30<br/>Purity 80%</p>   | <p>The study investigated the effect of co-administration of mancozeb and phenobarbital on nitrosomethylurea-induced pancreatic tumours in rats.</p>  | <p>No clear effects of mancozeb and phenobarbital were seen.</p>   |

|   |   |   |  |
|---|---|---|--|
| Neoplastic alterations in mouse skin<br>(From literature review)<br>Non-guideline<br>Not GLP<br>Mice<br>4 (sex not specified)<br>Shilpa <i>et al</i> 2011 | Mancozeb<br>200 mg/kg bw in DMSO<br>Purity not reported | This study aimed to establish the early proteomic signature of mancozeb exposure in a short-term assay in mouse skin and <i>in vitro</i> models using human skin cell line. | Two proteins, S100A6 (Calcyclin) and S100A9 (Calgranulin-B) were significantly up-regulated. These proteins are markers of keratinocyte differentiation and proliferation and the authors suggested that they may play a role in mancozeb-induced neoplastic alterations. However the small group size and the fact that DMSO was used as a vehicle question the validity of these findings. |
|---|---|---|--|

### 10.7.1 Chronic/carcinogenicity studies in rats

The chronic toxicity/carcinogenicity of mancozeb was investigated in three life time feeding studies in rats.

#### Anonymous (1990)

In a combined chronic toxicity study/carcinogenicity study there were no treatment related effects on mortality. A low incidence of diarrhoea among male rats fed the dose of 750 ppm mancozeb was the only clinical sign attributed to compound intake in rats in this study. The initial lower mean body weight gain of males (9%) and females (16%) in the 750 ppm group was thought to be compound related. There were no treatment-related effects on ophthalmoscopic examinations, haematology, clinical-chemistry or urinalysis parameters. In the 750 ppm males and females, T4 levels were lower (up to 52%) compared to controls and TSH levels were higher (up to 113%).

There were no compound-related effects at 12 months on any organ weight. At 24-months, male and female rats fed 750 ppm mancozeb had elevated mean absolute (up to 60%) and relative (up to 62%) thyroid/parathyroid weights.

Gross changes observed at necropsy during the second year of the study included enlarged thyroids in both males and females fed 750 ppm diets and thyroid masses in the male rats in this dietary group. Male and female rats fed 750 ppm diets had increased incidences of thyroid nodular hyperplasia and hypertrophy/hyperplasia. Increased incidences and severity of bilateral retinopathy were also noted for both male and female rats fed 750 ppm diets.

#### **Intergroup comparison of microscopic non-neoplastic findings day 366 to 737**

| Finding                      | Males                   |    |    |     |     | Females |    |    |     |     |     |
|------------------------------|-------------------------|----|----|-----|-----|---------|----|----|-----|-----|-----|
|                              | 0                       | 20 | 60 | 125 | 750 | 0       | 20 | 60 | 125 | 750 |     |
| Dietary concentrations (ppm) | 0                       | 20 | 60 | 125 | 750 | 0       | 20 | 60 | 125 | 750 |     |
| Number examined              | 60                      | 62 | 61 | 58  | 61  | 62      | 60 | 62 | 61  | 61  |     |
| Thyroid follicular cell      | Hyperplasia nodular     | 0  | 1  | 3   | 2   | 15*     | 1  | 2  | 2   | 0   | 11* |
|                              | Hyperplasia/hypertrophy | 1  | 1  | 2   | 1   | 34*     | 1  | 0  | 1   | 0   | 24* |
| Eye                          | Bilateral retinopathy   | 4  | 2  | 1   | 3   | 19*     | 21 | 28 | 24  | 31* | 49* |

\* Statistically significant difference from control group mean, p<0.05 Fischer's

Male and female rats fed 750 ppm diets had increased incidences of thyroid follicular cell carcinomas (14/61 vs 0/60 in males and 4/61 vs 0/62 in females) and adenomas (20/61 vs 0/60 in males and 6/61 vs 1/61 in females). The incidences of rats with carcinomas or adenomas were higher for males than for females.

**Intergroup comparison of microscopic neoplastic findings day 366 to 737**

| Finding                            | Males     |           |           |            |            | Females   |           |           |            |            |   |
|------------------------------------|-----------|-----------|-----------|------------|------------|-----------|-----------|-----------|------------|------------|---|
|                                    | 0         | 20        | 60        | 125        | 750        | 0         | 20        | 60        | 125        | 750        |   |
| <b>Dietary concentration (ppm)</b> | <b>0</b>  | <b>20</b> | <b>60</b> | <b>125</b> | <b>750</b> | <b>0</b>  | <b>20</b> | <b>60</b> | <b>125</b> | <b>750</b> |   |
| <b>Number examined</b>             | <b>60</b> | <b>62</b> | <b>61</b> | <b>58</b>  | <b>61</b>  | <b>62</b> | <b>60</b> | <b>62</b> | <b>61</b>  | <b>61</b>  |   |
| <b>Thyroid follicular cell</b>     | Adenoma   | 0         | 1         | 1          | 0          | 20*       | 1         | 1         | 1          | 1          | 6 |
|                                    | Carcinoma | 0         | 0         | 2          | 2          | 14*       | 0         | 0         | 0          | 1          | 4 |

\* Statistically significant difference from control group mean,  $p < 0.05$  Fischer's

The thyroid changes observed in this study were considered to be related to mancozeb's main metabolite, ethylene thiourea (ETU), a substance which causes thyroid tumours in rats and mice. ETU belongs to a class of compounds that inhibits synthesis of thyroid hormone and induces release of high levels of TSH by the pituitary.

Anonymous (1992)a

In another combined chronic toxicity study/carcinogenicity study there were no treatment related effects on mortality or clinical signs of toxicity up to the top dose of 454 ppm. Statistically lower absolute body weights (up to 5% of control) and statistically lower body weight gains (up to 7% of control) were observed in both sexes in the top dose group. There were no treatment-related effects on ophthalmoscopic examinations, organ weights, haematology, clinical-chemistry and urinalysis parameters. Statistically significantly slightly lower thyroxine (T4) concentrations were evident in the high dosage groups at weeks 26 and 52, and in the high dosage females at weeks 63 and 78.

Treatment-related non-neoplastic findings were confined to the thyroid of males and females receiving 454 ppm, and consisted of a marginally higher incidence of increased height of follicular epithelium, generally with prominent microfollicles.

A higher incidence of pituitary tumours, particularly adenomas, was observed in males receiving 113 or 454 ppm. However, statistical significance was not demonstrated and the incidence was considered comparable with the upper limit of the laboratory historical control range. Therefore, this finding was considered unlikely to be related to treatment. No treatment-related effect was seen in the incidence of follicular cell tumours of the thyroid in male or female rats. There was a higher incidence of parafollicular cell carcinoma of the thyroid in all treated males. As this incidence fell within the laboratory historical control range, this tumour was not considered to be treatment-related.

**Intergroup comparison of microscopic neoplastic findings**

| Finding                             | Dietary Concentration (ppm) |            |            |           |           |           |           |           |    |
|-------------------------------------|-----------------------------|------------|------------|-----------|-----------|-----------|-----------|-----------|----|
|                                     | Males                       |            |            |           | Females   |           |           |           |    |
|                                     | 0                           | 28         | 113        | 454       | 0         | 28        | 113       | 454       |    |
| <b>Number examined</b>              | <b>50</b>                   | <b>50a</b> | <b>50b</b> | <b>50</b> | <b>50</b> | <b>50</b> | <b>50</b> | <b>50</b> |    |
| <b>Pituitary pars anterior</b>      | Adenoma                     | 18         | 22         | 28        | 27        | 31        | 31        | 28        | 34 |
|                                     | Adenocarcinoma              | 3          | 2          | 2         | 1         | 7         | 5         | 4         | 6  |
| <b>Thyroid follicular cells</b>     | Adenoma                     | 6          | 2          | 2         | 6         | 0         | 0         | 2         | 2  |
|                                     | Adenocarcinoma              | 2          | 0          | 1         | 3         | 0         | 0         | 0         | 1  |
| <b>Thyroid parafollicular cells</b> | Adenoma                     | 0          | 0          | 0         | 1         | 0         | 0         | 0         | 0  |
|                                     | Carcinoma                   | 1          | 6          | 6         | 6         | 3         | 3         | 3         | 3  |

Belpoggi *et al* (1992)

A publication of a long-term study of mancozeb conducted at the Cancer Research Center of the Ramazzini Foundation is available (Belpoggi *et al.*, 2002). Groups of 75 male and female Sprague-Dawley rats, 8 weeks old at the start of the treatment, were administered mancozeb at the concentration of 1000, 500, 100, 10, and 0 ppm in feed supplied *ad libitum* for 104 weeks. At the end of the treatment, animals were kept under controlled conditions until spontaneous death. There were no differences between treated groups and controls in food or water consumption, body weight, survival or behaviour up to the top dose of 1000 ppm. At post mortem, there were no treatment related effects in non-neoplastic histopathological findings. Increases in the occurrence of benign and malignant tumours compared to controls were observed in a

number of organs. Total malignant mammary tumours were increased in all mancozeb treated females; zymbals gland and ear duct carcinomas were increased at 1000 ppm in males and overall, the incidence of head and neck carcinomas was increased in a dose-related manner in males and in females of all treated groups. Hepatocellular carcinomas were increased for males at 1000 ppm and the incidence of pancreatic malignant tumours was increased in males and females treated with 100, 500 or 1000 ppm mancozeb. Malignant thyroid gland tumours were increased in males at 500 and 1000 ppm, and in females at 10, 100 and 1000 ppm mancozeb. Increases in haemolympho-reticular neoplasia were also observed in treated groups.

#### Incidence of Animals with Neoplasms (%) – Males

|   | 0 ppm | 10 ppm           | 100 ppm          | 500 ppm              | 1000 ppm             |
|---|-------|------------------|------------------|----------------------|----------------------|
| Zymbal gland carcinomas                   | 1.3   | 1.3              | 5.3              | 8.0                  | 16.0**               |
| Ear duct carcinoma                        | 2.7   | 10.7             | 6.7              | 9.3                  | 13.3*                |
| Overall total carcinomas of head and neck | 6.7   | 16 <sup>##</sup> | 16 <sup>##</sup> | 25.3 <sup>**##</sup> | 33.3 <sup>**##</sup> |
| Hepatocarcinomas                          | 0     | 0                | 1.3              | 1.3                  | 5.3                  |
| Pancreas – exocrine adenocarcinoma        | 0     | 0                | 0                | 0                    | 1.3                  |
| - Islet cell carcinoma                    | 0     | 0                | 1.3              | 2.7                  | 4.0                  |
| Thyroid gland – follicular carcinoma      | 0     | 0                | 0                | 2.7                  | 8.0*                 |
| - C-cell carcinoma                        | 0     | 0                | 1.3              | 0                    | 2.7                  |
| Osteosarcoma in bones of the head         | 2.7   | 0                | 0                | 1.3                  | 1.3                  |
| Haemolympho-reticular neoplasia           | 21.3  | 29.3             | 42.7**           | 46.7**               | 40.0*                |

\* p<0.05 and \*\*p<0.01 using  $\chi^2$  test. ## p<0.01 using Cochran-Armitage test for dose response relationship

#### Incidence of Animals with Neoplasms (%) – Females

|   | 0 ppm | 10 ppm | 100 ppm | 500 ppm | 1000 ppm |
|---|-------|--------|---------|---------|----------|
| Mammary tumours                           |       |        |         |         |          |
| - Fibroma and fibroadenoma                | 46.7  | 54.7   | 40.0    | 42.7    | 57.3     |
| - Adenocarcinoma                          | 4.0   | 6.7    | 12.0    | 10.7    | 6.7      |
| - Fibrosarcoma                            | 0     | 0      | 0       | 0       | 2.7      |
| - Liposarcoma                             | 0     | 0      | 0       | 0       | 2.7      |
| Overall total carcinomas of head and neck | 9.3   | 32.0** | 17.3    | 25.3*   | 28.0**   |
| Pancreas – exocrine adenocarcinoma        | 0     | 0      | 0       | 0       | 1.3      |
| - Islet cell carcinoma                    | 0     | 1.3    | 4.0     | 2.7     | 0        |
| Thyroid gland – follicular carcinoma      | 0     | 1.3    | 0       | 0       | 16.0**   |
| - C-cell carcinoma                        | 0     | 0      | 1.3     | 1.3     | 2.7      |
| Osteosarcoma in bones of the head         | 0     | 1.3    | 0       | 0       | 1.3      |
| Haemolympho-reticular neoplasia           | 14.7  | 26.7   | 36.0**  | 28.0    | 21.3     |

\* p<0.05 and \*\*p<0.01 using  $\chi^2$  test

Overall, rats treated with mancozeb for 104 weeks and then fed control diets until spontaneous death showed a significant increase in the total tumours and in certain specific tissue/tumour types compared to controls, in some cases even from the lowest dose of 10 ppm. The paper concludes that mancozeb should be considered as a multi-potent carcinogenic agent capable of producing tumours of many types in various sites in treated animals. Most of the tumours in this study arose after 112 weeks of age (animals were 8 weeks old at the start of dosing) and the authors state it is unlikely they would have observed the multi-potent carcinogenic activity of mancozeb if the study had ceased after 104 weeks of treatment. Therefore, the unusual design of the study and absence of any historical control data mean that it is not possible to interpret the dose response and hence the biological significance of these tumours. The conclusion of the authors that mancozeb should be considered as a multi-potent carcinogen is inconsistent with the findings from the available regulatory carcinogenicity studies on mancozeb. In addition, it is noted that no information on the purity of the test material was reported, further reducing the validity and reliability of the findings from this publication. This

study was available at the time of the first review of mancozeb under Dir 91/414 and did not lead to classification for carcinogenicity.

### **10.7.2 Carcinogenicity studies in mice**

The carcinogenicity of mancozeb was investigated in two 18 month carcinogenicity studies in mice.

#### Anonymous (1991)

In an 18 month carcinogenicity study in mice there were no abnormal clinical signs throughout the study up to the top dose of 1000 ppm. Survival of all mancozeb-treated groups was comparable to that of controls, except for a higher survival observed in the mid-dose males (100 ppm). Mean weekly body weights for males and females of the 1,000 ppm dose group were consistently lower and statistically different from controls. Food consumption was not affected by treatment at any concentration levels. Some light, but statistically significant differences in red blood cell parameters at 12 months were not apparent at 18 months, and were therefore not considered to be associated with treatment. Thyroid function assays showed significant decreases in mean T4 levels in the high dose males and females at 12 months and in females at 18 months. Mean T3 levels in the high dose males were significantly increased at 18 months and significantly decreased in females at 18 months. The depression in T4 values was considered to be related to mancozeb treatment. Changes in T3 values could not be unequivocally related to treatment. TSH levels were not affected. Necropsy revealed no consistent gross lesions that could be attributed to the test substance, and no consistent differences were demonstrated in organ weights. Microscopic examination of the tissues revealed no treatment-related lesions. There were no statistically significant differences in the incidences of tumours lesions between treated and control animals.

#### Anonymous (1992b)

In another 18 month carcinogenicity study, there were no compound-related mortality or clinical signs up to the top dose of 1000 ppm. Reduced body weights and lower body weight gains in males and females of the high dose group were not statistically significant. Food consumption and differential blood counts were comparable between treated and control groups. There were no remarkable intergroup differences for organ weights. There were no macroscopic or microscopic findings that could be attributed to compound administration. Under the conditions of this study, dietary administration of 1000 ppm mancozeb (88.6% pure) to Charles River CD-1 mice for 78 weeks resulted in minimal signs of systemic toxicity and no mortality or evidence of carcinogenicity.

### **10.7.3 Other studies relevant to carcinogenicity**

Two 2-generational studies were carried out. These provide additional information on the carcinogenic potential of mancozeb. Further details of these studies are available in the RAR (renewal assessment report), section B6 produced by the UK for the purposes of renewal under Regulation 844/2012.

#### Anonymous (1988b)

In a two-generation study in rats, there were no treatment-related clinical signs or deaths in the adults of either generation. At the top dose of 1200 ppm, mean body weights for male and female parental rats of both generations were significantly below controls throughout the pre-mating period, and body weights remained depressed among first and second-generation females throughout the gestation and lactation periods. Mean food consumption at this level was also significantly decreased throughout the pre-mating period in male and female parents of the first but not the second generation. Thyroid follicular adenomas were seen in the top dose males of both generations.

#### Anonymous (1992c)

In a two-generation study in rats there were no compound-related deaths or clinical signs of toxicity evident for either generation up to the top dose of 1100 ppm. Body weights and body weight gains were significantly reduced in males and females of the high-dose group. Food consumption was significantly decreased for both sexes during the pre-mating period of both generations at the high dose. Food consumption for F<sub>1</sub> females was also significantly decreased at the high dose during the period of gestation and lactation. At

1100 ppm mean thyroid weight was markedly increased in the males of both generation and moderately increased in females of both generations. Histopathology, however, revealed thyroid hyperplasia and hypertrophy in nearly all parental animals of the F<sub>0</sub> and F<sub>1</sub> generation at the high dose. Thyroid follicular cell adenomas were also found in five males of the F<sub>0</sub> generation and in 11 males of the F<sub>1</sub> generation at the high dose. Overall thyroid follicular adenomas were seen in the top dose males of both generations.

#### Additional investigative studies from the literature review

A long term study into the effects of a mixture of pesticides was carried out by Isael Perez-Carreón *et al* 2009. Mancozeb in a mixture of 12 pesticides were administered by oral gavage at a dose of 25 mg/kg bw, on three consecutive days. Four protocols were followed:

- A) gavage five times a week during 8 weeks with 0.5 ml of pesticide or control suspensions, week 4 single dose DEN, week 5 days 1 to 3 three daily doses 2AAF, week 5 day 4 partial hepatectomy;
- B) gavage five times a week during 8 weeks with 0.5 ml of pesticide or control suspensions, week 4 single dose DEN, week 5 day 4 partial hepatectomy;
- C) gavage five times a week during 8 weeks with 0.5 ml of pesticide or control suspensions, week 5 days 1 to 3 three daily doses 2AAF, week 5 day 4 partial hepatectomy;
- D) gavage five times a week during 8 weeks with 0.5 ml of pesticide or control suspensions, week 5 day 4 partial hepatectomy.

No significant differences in tumour promoting activity between animals treated with the pesticide mixture (including mancozeb) and controls were identified, as evaluated using gamma-glutamyl transpeptidase (GGT) positive altered hepatocyte foci, as well, protein and mRNA levels of glutathione S-transferase P (GSTP) in liver extracts. Overall, the pesticide mixture (including mancozeb) evaluated in this report did not have tumour promoting activity in this rat medium-term liver carcinogenesis assay.

A study by Valentich *et al* 2006 investigated the effect of co-administration of mancozeb and phenobarbital on nitrosomethylurea-induced pancreatic tumours in rats. No clear effects of mancozeb and phenobarbital were seen; however the findings were inconclusive and no information on systemic toxicity was reported.

A study by Shilpa *et al* 2011 aimed to establish the early proteomic signature of mancozeb exposure in a short-term assay in mouse skin and *in vitro* models using human skin cell line. In skin samples taken from mice exposed to acetone (control) or mancozeb (200 mg/kg bw) the authors found that two proteins, namely, S100A6 (Calcyclin) and S100A9 (Calgranulin-B) were significantly up-regulated. These proteins are markers of keratinocyte differentiation and proliferation and the authors suggested that they may play a role in mancozeb-induced neoplastic alterations. It is noted that the group size for this study was small i.e. only 4 mice. The *in vitro* part of this study used HaCaT cells as a model for human skin keratinocyte carcinogenesis but was considered inappropriate due to the use of DMSO as a vehicle.

#### **10.7.4 Short summary and overall relevance of the provided information on carcinogenicity**

The carcinogenicity of mancozeb has been investigated in five life-time feeding studies, three in rats and two in mice. The majority of these studies are adequate to assess the carcinogenic potential of mancozeb in rodents. At the top doses administered (up to 31/40 (M/F) mg/kg bw/day in rats and 130/180 (M/F) mg/kg bw/day in mice), systemic toxicity was demonstrated with decreases in body weights and body weight gains.

**Table 17: Thyroid follicular tumour incidences in rats administered mancozeb**

| Study/<br>Reference                  | Dose mancozeb<br>ppm (mg/kg bw/day;<br>males/females) | Tumour incidence (% tumour bearing animals at study termination) |                      |
|--------------------------------------|---|--|----------------------|
|                                      |   | Males  | Females              |
| Carcinogenicity<br>Anonymous (1990)  | 0   | 0A, 0C <sup>a</sup>  | 1.6A, 0C             |
|                                      | 20 (0.7/1.1)  | 1.6A, 0C   | 1.7A, 0C             |
|                                      | 60 (2.3/3.1)  | 1.7A, 3.3C   | 1.6A, 0C             |
|                                      | 125 (4.8/6.7)   | 0A, 3.4C   | 1.6A, 1.6C           |
|                                      | 750 (30.9/40.2)                                       | 32.8A*, 23.0C*   | 9.8C*, 6.6C*         |
| Carcinogenicity<br>Anonymous (1992a) | 0 to 454<br>(0-16.8/20.8)                             | No tumours observed at any doses                                 |                      |
| 2-Generation<br>Anonymous (1988b)    | 0   | No tumours (F0 & F1)   | No tumours (F0 & F1) |
|                                      | 30 (1.73-2.49)  | No tumours (F0 & F1)   | No tumours (F0 & F1) |
|                                      | 120 (6.95-10.52)                                      | No tumours (F0 & F1)   | No tumours (F0 & F1) |
|                                      | 1200 (68.9-114.26)                                    | 12.0A (F0), 16.6A (F1)   | No tumours (F0 & F1) |
| 2-Generation<br>Anonymous (1992c)    | 0   | No tumours (F0 & F1)   | No tumours (F0 & F1) |
|                                      | 1100 (74)   | 20.0A (F0), 44.0A (F1)   | 4.0A (F0), 0A (F1)   |

<sup>a</sup>A=adenomas, C=carcinomas

\*Statistically significant ( $P \leq 0.05$  as described in the study report). Note that the statistical significance of histopathological findings was not reported in Anonymous (1992c).

Three literature studies have also investigated the carcinogenicity or co-carcinogenicity of mancozeb (Belpoggi *et al*, 2002; Perez-Carreón *et al*, 2009; Valentich *et al*, 2006). However, the poor reporting and the lack of information on the purity and stability of mancozeb and the lack of historical control data means that no clear conclusions can be drawn from these studies.

Overall, the main effect of mancozeb chronic exposure in rats and mice was thyroid toxicity. Rats appeared to be more sensitive to these effects than mice. Thyroid effects were observed from a dose of 16.8/20.8 mg/kg bw/d in rats and from a dose of 130/180 mg/kg bw/d in mice. Thyroid follicular tumours (carcinomas and adenomas) were also seen in male and female rats at the top dose of 31/40 mg/kg bw/d (Anonymous, 1990), but not in mice up to doses (130/180 mg/kg bw/d) causing generalised and thyroid toxicity (decreases in T4). The tumorigenic effect of mancozeb in rats is attributable to the metabolite ETU, a well-established thyroid toxicant. ETU inhibits the synthesis of thyroid hormones in the thyroid follicular cells, reducing blood levels of T4 and thereby stimulating the release of increased TSH levels by the pituitary as part of the endogenous feedback-control mechanism. Thyroid tumours occur in the rat when the threshold for pituitary-thyroid feedback is exceeded on a chronic basis resulting in an over-stimulation of the thyroid and subsequent development of proliferative lesions.

The association between exposure to mancozeb and endocrine-related outcomes has been investigated both in medical and epidemiology studies of workers handling mancozeb and of the general public who may be exposed to it. Many studies have not distinguished between EBDC pesticides in general and mancozeb. ETU in urine or blood has also been used as a biomarker of EBDC exposure. The DAR (2000) under Directive 91/414 contains five medical studies where data from workers in mancozeb/EBDC manufacturing plants were analysed to determine whether there was any evidence of thyroid dysfunction. None of these studies found any such evidence. More recent epidemiology studies have also examined the possible association between mancozeb (EBDC) exposure and effects on the thyroid. The quality of these studies varies widely and several are contradictory. The overall conclusion from these epidemiology and medical studies is that environmental or workplace exposure to mancozeb does not disrupt the thyroid hormonal system in humans and is not associated with thyroid tumours in humans.

Two studies have examined the association between prostate cancer and exposure to mancozeb and found no increased risk. This is in concordance with the absence of effects on the androgen hormonal system in experimental animals and *in vitro*.

The possible association of mancozeb exposure with various types of cancer (melanoma, colorectal, leukaemia and gastric) has also been investigated in humans. Overall, no association was found between occupational exposure to mancozeb and colorectal or gastric cancer. An increased risk was reported for melanoma and leukaemia. The significance of this association is questionable, especially considering that such findings are not supported by the animal data or by any other epidemiology study and can be explained by confounding.

### 10.7.5 Comparison with the CLP criteria

Overall, thyroid follicular tumours (carcinomas and adenomas) were seen in male and female rats at the top dose of 31/40 mg/kg bw/d (Anonymous, 1990), but not in mice up to doses (130/180 mg/kg bw/d) causing generalised and thyroid toxicity (decreases in T4). Male rats appeared to be more sensitive than female rats, with carcinomas being seen in 23% of the males (vs 0% in controls) and in 7% of the females (vs 0% in controls) and with adenomas being seen in 33% of the males (vs 0% in controls) and in 10% of the females (vs 1.6% in controls). Thyroid tumours in rats were associated with thyroid toxicity (effects on thyroid hormones, thyroid hypertrophy and hyperplasia) also occurring at the top dose of 31/40 mg/kg bw/d. Thyroid follicular adenomas were also seen in two rat multi-generation studies mainly in adult males of the F0 and F1 generations.

Evidence from mutagenicity studies indicates that a genotoxic mode of action can be excluded for these thyroid tumours in rats. Also, there is no evidence from human medical surveillance or epidemiology studies that mancozeb exposure causes cancer in humans, although exposure levels in human epidemiology studies are intrinsically lower than those in experimental animals.

A clear mode of action (MoA) involving the disturbance of the HPT (hypothalamus-pituitary-thyroid) axis via the metabolite ETU has been identified for these tumours (for further details of studies supporting this MoA, refer to the RAR, section B6, produced by the UK for the purposes of renewal under Regulation 844/2012). Mancozeb is metabolised to ETU in all mammals by approximately 7% by weight. ETU inhibits the peroxidase activity of TPO (thyroid peroxidase), preventing iodide oxidation and thus reducing the formation of thyroid hormone pre-cursors. The resulting reduction in circulating T4 (and T3) is detected by the hypothalamus which reacts by increasing TSH levels via the pituitary in an attempt to increase the production of T4. The action of TSH on the thyroid follicular cells leads to hypertrophy (with associated increased thyroid gland weight). Prolonged exposure can eventually result in thyroid follicular cell hyperplasia and development of tumours of the thyroid gland (adenomas and carcinomas).

The HTP axis operates in a similar way in both humans and experimental animals, so a similar mode of action would occur in humans. Accordingly, the relevance to humans of the postulated MoA cannot be excluded according to qualitative differences between species. However, there are important quantitative differences between the physiology of the thyroid and the biochemical response to TSH between rats and humans. The rodent thyroid is far more dynamic than that of humans. The follicular cells appear to be in active synthesis compared to humans where they appear to be quiescent. T4 has a much shorter half-life than in humans (12 h compared to 5–9 days), and constitutive levels of TSH are about 25-fold higher in rats compared to humans. The shorter half-life of T4 is thought to be related to the absence of thyroid binding globulin (TBG) in adult rats, which leads to a higher turnover rate of thyroid hormones. In adult humans, thyroid hormones are tightly bound to TBG in blood. In humans, follicular cell hypertrophy, which may allow the release of hormone from thyroglobulin, has been observed, but hyperplasia is rare (Hill et al, 1998; McClain and Rice, 1999). Vickers et al (2012) compared the effect of PTU (an irreversible TPO inhibitor used to treat hyperthyroidism in humans) on rat and human thyroid slices/lobes *in vitro*. TPO was inhibited in both species with similar IC50s (approximately 5 µM). However, gene expression in the thyroids, following exposure to PTU was different between rats and humans. The expression of many thyroid-specific genes was significantly altered in rats whilst in humans very few thyroid-specific genes were altered. The consequence of these differences is that the thyroid of rats is more responsive than that of humans.

The potency of ETU to the thyroid of experimental animals and humans also depends upon absorption, distribution, metabolism and excretion in those species. The metabolism of ETU seems to be least efficient in rats and more efficient in higher mammals including dogs and humans. Ruddick et al (1977) showed that

pregnant rats were less able to metabolise ETU than pregnant mice (approximately 2- fold difference). *In vitro* metabolism studies in several species show that the metabolism of ETU in hepatocytes increases in the following order: rats < mice < humans, with rabbits and dogs being similar to humans (Daston, 1990; Saghir et al, 2005; Zhu, 2015).

Thyroid tumours are a relatively common finding in rat long-term studies, whilst the only known human thyroid carcinogen is ionizing radiation. In addition, there is no clear evidence that hypothyroidism (goitre) in humans progresses to neoplasia and whilst thyroid hypertrophy has been observed in humans, thyroid hyperplasia is rare. Several medical and epidemiology studies have investigated whether there is any association between EBDC exposure and thyroid cancer but have found none (Anonymous, 1976b; Anonymous, 1985a; Anonymous, 1990b; Nordby et al, 2005). In addition, kinetic differences in the metabolism of ETU between rodents and humans strongly indicate that humans are more effective at metabolising ETU than rodents. The company's analysis of this MoA according to the WHO MoA and human relevance framework is presented in Annex 1.

Overall, therefore, the thyroid follicular tumours seen in rats with mancozeb could in theory occur in humans; the question is whether the quantitative differences between rats and humans in critical dynamic and kinetic elements underpinning the thyroid carcinogenic response to mancozeb are so large that the thyroid tumours induced by mancozeb in rats would occur in humans only at very high, unrealistic dose levels, irrelevant for classification. This depends on the carcinogenic potency of mancozeb in rats. Carcinogenic potency is evaluated in the EU by estimating the T25 (the chronic daily dose which will give 25% of the animals tumours at a specific site, after correction for spontaneous incidence, within the standard life-span of that species). There is also a C&L guidance document on thyroid tumours (EC, 1999, ECBI49/99-Add1.Rev2) which proposes that carcinogens are subdivided into three potency groups of high, medium and low potency according to the criteria described below and that substances producing thyroid tumours in rodents with low or medium potency by a clearly established perturbation of the thyroid hormone axis, in general, do not need to be classified for carcinogenicity under the CLP Regulation:

High potency carcinogen -  $T25 \leq 1$  mg/kg bw/d;

Medium potency carcinogen -  $1$  mg/kg bw/d <  $T25 \leq 100$  mg/kg bw/d,

Low potency carcinogen -  $T25 > 100$  mg/kg bw/d.

The T25 value for the thyroid follicular tumours seen in rats with mancozeb can be calculated from the study by Anonymous (1990a). The lowest dose of mancozeb producing the highest tumour incidence is the top dose in males, where 31 mg/kg bw/d produced adenomas in 33% of rats and carcinomas in 23% of rats. No adjustment for dosing duration is required because dosing was continuous for the lifetime of the rats (104 weeks) and started at 37 days of age. No subtraction for spontaneous tumour incidence is required because the control tumour incidence in males was 0 and no laboratory historical control tumour data are available. Accordingly, the T25 value for mancozeb and adenomas is 23 mg/kg bw/d whilst that for mancozeb and carcinomas is 34 mg/kg bw/d. In both cases, the T25 value places mancozeb clearly into the medium potency carcinogen group. Therefore, mancozeb is a medium potency rat thyroid carcinogen with a clearly established non-genotoxic MoA. As such, the thyroid tumours induced by mancozeb in rats would in theory occur in humans only at very high, unrealistic dose levels, irrelevant for classification. It is actually most likely that these tumours would never develop in humans as there is no clear evidence that hypothyroidism (goitre) in humans progresses to neoplasia and because whilst thyroid hypertrophy has been observed in humans, thyroid hyperplasia is rare. Therefore, mancozeb does not meet the criteria for classification even in the lowest category. Hence, classification for carcinogenicity is not required. This is consistent with the current harmonised classification of mancozeb. It should be also noted that ETU causes thyroid tumours in rats and mice, but it is not classified for carcinogenicity in its harmonised entry.

#### 10.7.6 Conclusion on classification and labelling for carcinogenicity

**Not classified (conclusive but not sufficient for classification)**

## 10.8 Reproductive toxicity

### 10.8.1 Adverse effects on sexual function and fertility

Not addressed in this dossier.

### 10.8.2 Adverse effects on development

The developmental toxicity of mancozeb has been investigated in developmental toxicity studies in rats and rabbits. Five developmental toxicity studies (3 in the rat and 2 in the rabbit) were described in the original DAR (2000) under Directive 91/414/EEC. These studies were conducted in the 1980s and those performed in the rat used severely maternally toxic maximum dose levels (360 - 512 mg/kg bw/d). These rat studies resulted in malformations (mainly of head and neck) at high doses causing severe maternal toxicity. Mancozeb was classified as Reprotox category 2 (H361d) as a result of these studies. The evidence suggested that the malformations seen in the rat with mancozeb were due to its main metabolite, ETU. ETU is an established developmental toxicant (harmonised classification with Repr Cat 1b; H360DD) which causes malformations (mainly of head – skull, brain and spinal cord; neck – cleft plate; tail; and vertebrae) in the rat in the absence of maternal toxicity. Approximately 7% of mancozeb by weight is converted/metabolised to ETU in experimental animals. New regulatory guideline developmental toxicity studies on mancozeb (and ETU – Anonymous, 2015) have been conducted to provide data on additional endpoints and to clarify the developmental effects attributed to mancozeb. In addition, 3 developmental toxicity investigations in the rat from the open literature review are available. The availability of these new studies justifies a re-consideration of the classification of mancozeb for this endpoint.

A developmental neurotoxicity study (OECD TG 426) is also available. This study was conducted to address the concern about the potential relationship between thyroid effects and brain development. An additional open literature publication investigating the developmental neurotoxicity of mancozeb in rats has also been identified.

**Table 18: Summary table of animal studies on adverse effects on development**

| Study, species (strain)   | Dose levels and dosing period   | Critical effects<br>(Effects statistically significantly different unless stated otherwise)  |
|---|---|--|
| <b>Developmental toxicity studies in rats</b>   |   |  |
| <b>Developmental toxicity</b><br>Oral (gavage)<br>EPA OPPTS 870.3700 (predates current version issued 1998); reporting deficiencies<br>Non GLP<br>Rat, BLU (SD)BR<br>26 mated females/group<br>Vehicle: corn oil<br>purity 83.0%<br>Anonymous, 1980 | Mancozeb: 0, 2, 8, 32, 128 or 512 mg/kg bw/day on gestation days 6-15<br><br>ETU (positive control): 50 mg/kg bw/day on gestation days 6-15 | <b>Maternal toxicity</b><br><br><u>512 mg/kg bw/day:</u><br>3/22 pregnant terminated prematurely and killed in extremis, , 13/22 with litters at term. Clinical signs of lethargy, scruffy coat, diarrhoea, soft faeces, bloody vaginal discharge, hunched, dehydrated;<br>↓ body weight gain 95%, days 6-20;<br>↓ food consumption (2 g, days 10-15 cf. 16 g controls)<br><br><u>128 mg/kg bw/day:</u><br>↓ body weight gain 39%, days 6-20;<br>↓ food consumption (12 g, days 10-15 cf. 16 g controls)<br><br><u>32 mg/kg bw/day:</u><br>No effects<br><br><u>ETU 50 mg/kg bw/day:</u> |

| Study, species (strain) | Dose levels and dosing period | Critical effects<br>(Effects statistically significantly different unless stated otherwise) |
|-------------------------|-------------------------------|---|
|                         |                               | No effects  |

|  |   |   |
|--|---|---|
|  |   | <p><b>Developmental toxicity</b></p> <p><u>512 mg/kg bw/day:</u></p> <p>6/19 total resorption<br/>           ↑ number of resorptions (3.77 cf. 0.81 controls);<br/>           ↓ number live foetuses (7.05 cf. 10.77 controls);<br/>           ↓ mean foetal weight 27% (2.80g cf. 3.82g controls);<br/>           ↑ incidence malformation e.g. meningoencephalocele /exencephaly, dilated brain ventricles, cleft palate, kinked/shortened tail</p> <p><u>128 mg/kg bw/day:</u></p> <p>No effects</p> <p><u>32 mg/kg bw/day:</u></p> <p>No effects</p> <p><u>ETU 50 mg/kg bw/day:</u></p> <p>↓ mean foetal weight<br/>           ↑ incidence malformation e.g. meningoencephalocele /exencephaly, dilated brain ventricles, cleft palate, kinked/shortened tail</p> <p>Developmental NOAEL 128 mg/kg bw/day<br/>           Maternal NOAEL 32 mg/kg bw/day</p> |
| <p><b>Developmental toxicity</b></p> <p>Oral (gavage)</p> <p>OECD 414 (1981)</p> <p>GLP</p> <p>Rat, CD</p> <p>25 mated females/group</p> <p>Vehicle: 1% MC<br/>           purity 88.6%</p> <p>Anonymous, 1988c</p> | <p>0, 10, 60 or 360 mg/kg bw/day on gestation days 6-15</p> | <p><b>Maternal toxicity</b></p> <p><u>360 mg/kg bw/day:</u></p> <p>1/25 treatment-related death (killed in extremis) preceded by clinical signs;<br/>           ↑ incidence of reeling gait, partial use or slight paralysis of hind limbs (5/25 cf. 0 incidence in controls);<br/>           ↓ body weight gain (25.4% days 6-20);<br/>           ↓ food consumption during dosing (16.7% days 6-8, 20.8% days 9-11)</p> <p><u>60 mg/kg bw/day:</u></p> <p>No effects</p> <p><b>Developmental toxicity</b></p> <p><u>360 mg/kg bw/day:</u></p> <p>↑ incidence incomplete ossification of interparietal bone (90% foetuses cf. 75.8% controls);</p>   |

|  |  |   |
|--|--|---|
|  |  | <p>↑ incidence incomplete ossification of thoracic vertebral centra (51.3% fetuses cf. 28.0% controls)</p> <p>↑ incidence large anterior fontanelle (11.9% fetuses cf. 2.2% controls)</p> <p><u>60 mg/kg bw/day:</u></p> <p>No effects</p> <p>Developmental NOAEL 60 mg/kg bw/day</p> <p>Maternal NOAEL 60 mg/kg bw/day</p> |
|--|--|---|

|  |   |  |
|--|---|--|
| <p><b>Developmental toxicity</b><br/> Oral (gavage)<br/> OECD 414 (1981)<br/> GLP<br/> Rat, Wistar<br/> 24 mated females/group<br/> Vehicle: peanut oil<br/> purity 86.2%<br/> Anonymous, 1999b</p>                | <p>0, 100, 225 or 500 mg/kg<br/> bw/day on gestation days<br/> 6-15</p> | <p><b>Maternal toxicity</b><br/> <u>500 mg/kg bw/day:</u><br/> No effects<br/> <u>225 mg/kg bw/day:</u><br/> No effects<br/> <br/> <u>100 mg/kg bw/day:</u><br/> No effects<br/> <b>Developmental toxicity</b><br/> <u>500 mg/kg bw/day:</u><br/> ↑ macroscopic pathology in lungs, liver, kidney:<br/> ↑ lung congestion/hyperaemia; liver<br/> congestion/mottling ; kidney patchy<br/> congestion/congestion<br/> ↑ dumbbell shaped thoracic centra (15<br/> foetuses/6 litters cf. 0 incidence in controls)<br/> <u>225 mg/kg bw/day:</u><br/> ↑ macroscopic pathology in lungs, liver, kidney:<br/> ↑ lung congestion/hyperaemia; liver<br/> congestion/mottling kidney patchy<br/> congestion/congestion)<br/> ↑ dumbbell shaped thoracic centra (16<br/> foetuses/6 litters cf. 0 incidence in controls)<br/> <u>100 mg/kg bw/day:</u><br/> No effects<br/> Developmental NOAEL 100 mg/kg bw/day<br/> Maternal NOAEL 500 mg/kg bw/day</p> |
| <p><b>14 day tolerability study in non-pregnant SD rats</b><br/> Oral (gavage)<br/> Guideline N/A<br/> Non GLP<br/> Rat, SD<br/> 3 females/group<br/> Vehicle: 1% MC<br/> Mancozeb (86%)<br/> Anonymous, 2015b</p> | <p>0, 60, 120, 180, 240 or<br/> 300 mg/kg bw/day for 14<br/> days</p>   | <p><b>General toxicity in non-pregnant females</b><br/> <u>300mg/kg bw/day</u><br/> ↓ body weight (9.8% day14);<br/> <u>240 mg/kg bw/day:</u><br/> ↓ body weight (6% day14);<br/> <u>180 mg/kg bw/day:</u><br/> ↓ body weight (8.3% day14);<br/> <u>120 mg/kg bw/day:</u><br/> No effects<br/> <u>60 mg/kg bw/day:</u><br/> No effects</p>   |

|   |  |  |
|---|--|--|
| <p><b>Preliminary range finding &amp; TK study</b></p> <p>Oral (gavage)</p> <p>Non-guideline</p> <p>GLP</p> <p>Rat, CrI:CD(SD)</p> <p>23 mated females/group including TK: 8 mated females/group at term</p> <p>Vehicle: 1% MC</p> <p>Mancozeb 86.0%</p> <p>Anonymous, 2015c</p>  | <p>0, 80, 120 or 160 mg/kg bw/day on gestation days 6-19</p>   | <p><b>Maternal toxicity</b></p> <p><u>160 mg/kg bw/day:</u></p> <p>↓ body weight gain (36.8% days 9-12, 21.6% days 6-20);</p> <p>↓ food consumption (10% days 6-20)</p> <p><u>120 mg/kg bw/day:</u></p> <p>↓ body weight gain (31.2% days 9-12, 7.8% days 6-20)</p> <p><u>80 mg/kg bw/day:</u></p> <p>↓ body weight gain (31.2% days 9-12, 6.9% days 6-20)</p> <p><b>Developmental toxicity – limited foetal evaluation</b></p> <p><u>160 mg/kg bw/day:</u></p> <p>No effects</p> <p><b>Toxicokinetics</b></p> <p>The presence of ETU in all mancozeb-treated litters demonstrated that they were exposed to mancozeb and ETU.</p> |
| <p><b>Developmental toxicity</b></p> <p>Oral (gavage)</p> <p>OECD 414 (2001)</p> <p>GLP</p> <p>Rat, CrI:CD(SD)</p> <p>25 mated females/group</p> <p>Vehicle: 1% MC</p> <p>Purity 86.0%</p> <p>Anonymous, 2015d</p>  | <p>0, 10, 40 or 160 mg/kg bw/day on gestation days 6-19.</p>   | <p><b>Maternal toxicity</b></p> <p><u>160 mg/kg bw/day:</u></p> <p>↓ body weight gain (14.2% days 6-20);</p> <p>↓ food consumption (7.7% days 6-20)</p> <p><u>40 mg/kg bw/day:</u></p> <p>No effects</p> <p><b>Developmental toxicity</b></p> <p><u>160 mg/kg bw/day:</u></p> <p>No effects</p> <p>Developmental NOAEL 160 mg/kg bw/day</p> <p>Maternal NOAEL 40 mg/kg bw/day</p>  |
| <p><b>Investigation into possible effects on sexual development</b></p> <p>Oral (gavage)</p> <p>Non guideline</p> <p>Non GLP</p> <p>Rats, Han-Tac:WH</p> <p>10-12 dams/group</p> <p>Vehicle: corn oil</p> <p>Mancozeb (in mixture of 5 pesticides)</p> <p>Purity 76%</p> <p>Hass <i>et al</i> 2012 (from open literature)</p> | <p>6.25 &amp; 25 mg/kg bw/day</p> <p>Pre-natal &amp; perinatal exposure</p> <p><i>In vitro</i> androgen receptor reporter gene assay, steroidogenesis assay and T-screen assay performed</p> | <p>No significant effects on body weight and no clinical signs of toxicity</p> <p>No effects on gestation length and pup body weights</p> <p>No effects on sexual development parameters in offspring</p> <p>No AR antagonism <i>in vitro</i> and no effect on synthesis of oestradiol, progesterone or testosterone <i>in vitro</i>.</p> <p>No effects on T-screen assay.</p> <p>Sexual development NOAEL &gt; 25 mg/kg bw/day</p>  |

|   |  |   |
|---|--|---|
| <p><b>Developmental toxicity in the rat</b></p> <p>Oral</p> <p>Non guideline</p> <p>Non GLP</p> <p>Rats</p> <p>10-22/group</p> <p>Vehicle: corn oil</p> <p>Mancozeb tested individually along with 4 other pesticides</p> <p>Purity not reported</p> <p>Jacobsen <i>et al</i> 2012 (from open literature)</p>       | <p>6.25 &amp; 25 mg/kg bw/day</p> <p>From gestation day 7 to post natal day 16</p>   | <p>No treatment related effects on body weight gain, litter size or pup mortality.</p> <p>No effects on hormone levels, sexual maturity, organ weights, sperm motility, mammary glands, behaviour or histopathology.</p> <p>No thyroid effects</p> <p>Post-natal development NOAEL &gt; 25 mg/kg bw/day</p>   |
| <p><b>Investigative developmental study</b></p> <p>Oral (gavage)</p> <p>Non guideline</p> <p>Non GLP</p> <p>Rat: Wistar</p> <p>10-12 pregnant females/group</p> <p>Vehicle: corn oil</p> <p>Mancozeb (in a mixture of 5 pesticides)</p> <p>Purity 76%</p> <p>Overgaard <i>et al</i> 2013 (from open literature)</p> | <p>0, 6.25, 25 mg/kg bw/day</p> <p>From gestation day 7 to gestation day 21 and from post natal day 1 to post natal day 16</p> | <p>No effect on juvenile body weight</p> <p>No effect on puberty onset</p> <p>No treatment related effects on Kiss 1 mRNA expression in the AVPC or ARC of the hypothalamus in female offspring</p> <p>Puberty onset NOAEL &gt; 25 mg/kg bw/day</p>   |
| <p><b>Developmental toxicity studies in rabbits</b></p>   |  |   |
| <p><b>Developmental toxicity</b></p> <p>Oral (gavage)</p> <p>OECD 414 (1981)</p> <p>GLP</p> <p>Rabbit, NZW</p> <p>20 inseminated females/group</p> <p>Vehicle: 0.5% MC</p> <p>purity 83%</p> <p>Anonymous, 1987b</p>  | <p>0, 10, 30 or 80 mg/kg bw/day on gestation days 7-19</p>   | <p><b>Maternal toxicity</b></p> <p><u>80 mg/kg bw/day:</u></p> <p>2/20 treatment-related deaths due to weight loss; ↑ clinical signs (anorexia, scant faeces, alopecia); weight loss &amp; minimal food intake in these animals but not survivors.</p> <p><u>30 mg/kg bw/day:</u></p> <p>No effects</p> <p><b>Developmental toxicity</b></p> <p><u>80 mg/kg bw/day:</u></p> <p>5/20 abortion (0 in controls), 2/20 total resorption (2 in controls);</p> <p>Developmental NOAEL 30 mg/kg bw/day</p> <p>Maternal NOAEL 30 mg/kg bw/day</p> |

|  |  |  |
|--|--|--|
| <p><b>Developmental toxicity</b></p> <p>Oral (gavage)</p> <p>OECD 414 (1981)</p> <p>GLP</p> <p>Rabbit, NZW</p> <p>18 inseminated females/group</p> <p>Vehicle: 1% MC</p> <p>Purity 88.4%</p> <p>Anonymous, 1991b</p> | <p>0, 5, 30, 55 or 100 mg/kg bw/day on gestation days 6-18</p>   | <p><b>Maternal toxicity</b></p> <p><u>100 mg/kg bw/day:</u></p> <p>↓ body weight gain (62% days 6-19);<br/>↓ food consumption (37% days 6-19).</p> <p><u>55 mg/kg bw/day:</u></p> <p>No effects</p> <p><b>Developmental toxicity</b></p> <p><u>100 mg/kg bw/day:</u></p> <p>5/16 abortion (2/13 in controls);<br/>↑ post-implantation loss (26.8% cf. 21.6% controls)</p> <p><u>55 mg/kg bw/day:</u></p> <p>No effects</p> <p>Developmental NOAEL 55 mg/kg bw/day</p> <p>Maternal NOAEL 55 mg/kg bw/day</p>  |
| <p><b>Developmental neurotoxicity studies in rats</b></p>  |  |  |
| <p><b>Preliminary range finding &amp; TK study</b></p> <p>Oral (dietary)</p> <p>OECD 426 (2007)</p> <p>GLP</p> <p>Rat, CrI:CD(SD)BR</p> <p>15 mated females/group</p> <p>Purity 81.0%</p> <p>Anonymous, 2008b</p>    | <p>Target doses 5, 30 and 60 mg/kg bw/day.</p> <p>From gestation day 6 to termination on post-partum day 21-28</p> | <p><b>Maternal toxicity</b></p> <p><u>60 mg/kg bw/day:</u></p> <p>↓ body weight gain (37% GD6-20);<br/>↓ food consumption (16% GD6-20);<br/>↑ serum TSH (25% GD 20, 38% PND21); ↓ serum T4 (23% GD20, 44% PND21); ↑ thyroid weight (12% GD20 ); ↑ thyroid follicular cell hypertrophy (6/15 cf. 3/15 controls)</p> <p><u>30 mg/kg bw/day:</u></p> <p>↓ body weight gain (14% GD6-20);<br/>↓ food consumption (12% GD6-20);<br/>↑ serum TSH (17% GD20); ↓ serum T4 (55% GD20, 24% PND21); ↑ thyroid weight (9% GD20); ↑ thyroid follicular cell hypertrophy (5/14 cf. 3/15 controls)</p> <p><u>5 mg/kg bw/day:</u></p> <p>No effects</p> <p><b>Developmental neurotoxicity</b></p> <p>No developmental neurotoxicity effects seen</p> <p><u>60 mg/kg bw/day:</u></p> <p>↓ body weight PND 7 (males 17%, females 16%), PND 21 (males 12%, females 12.5%)</p> <p><u>30 mg/kg bw/day:</u></p> <p>↓ body weight PND 7 (males 22%, females 19%), PND 21 (males 13%, females 12%)</p> <p><u>5 mg/kg bw/day:</u></p> <p>No effects</p> |

|  |  |   |
|--|--|---|
| <p><b>Developmental neurotoxicity</b></p> <p>Oral (dietary)</p> <p>Non-guideline</p> <p>GLP</p> <p>Rat, CrI:CD(SD)BR</p> <p>25 mated females/group</p> <p>Purity 81.0%</p> <p>Anonymous, 2008c</p>                                     | <p>Target doses 5, 15 and 30 mg/kg bw/day</p> <p>From gestation day (GD) 6 to GD20 or to post-natal day (PND) 21</p> | <p><b>Maternal toxicity</b></p> <p><u>30 mg/kg bw/day:</u></p> <p>↓ body weight gain (26% gestation days 6-12, 5% gestation days 6-20);</p> <p>↑ thyroid follicular hypertrophy (11/25 cf. 6/24 controls)</p> <p><u>15 mg/kg bw/day:</u></p> <p>No effects</p> <p><b>Developmental neurotoxicity</b></p> <p><u>30 mg/kg bw/day:</u></p> <p>No effects</p> <p>DNT NOAEL 30 mg/kg bw/day</p> <p>Maternal NOAEL 15 mg/kg bw/day</p>  |
| <p><b>Investigative developmental neurotoxicity study</b></p> <p>Oral (gavage)</p> <p>Non guideline</p> <p>Non-GLP</p> <p>Rat: Wistar</p> <p>9-21 time-mated females/group</p> <p>Axelstad <i>et al</i> 2011(from open literature)</p> | <p><b>Mancozeb</b></p> <p>0, 50, 100 or 150/100 mg/kg bw/day</p> <p>GD 7 – PND 16</p> <p>Vehicle: corn oil</p>       | <p><b>Maternal toxicity</b></p> <p><u>150 mg/kg bw/day:</u></p> <p>Severe weight loss, mild hind limb paralysis. Dose reduced to 100 mg/kg bw/day at different timepoints.</p> <p>↓ T<sub>4</sub> GD 15 (37%)</p> <p><u>100 mg/kg bw/day:</u></p> <p>↓ body weight gain (27% days 7-21);</p> <p>↓ T<sub>4</sub> GD 15 (27%)</p> <p><u>50 mg/kg bw/day:</u></p> <p>↓ body weight gain (20% days 7-21);</p> <p>↓ T<sub>4</sub> GD 15 (21%)</p> <p><b>Developmental neurotoxicity</b></p> <p>No effects seen</p> <p>DNT NOAEL &gt;100/150 mg/kg bw/day</p> <p>Maternal LOAEL 50 mg/kg bw/day</p> |

**Table 19: Summary table of recent/key developmental toxicity study conducted with ETU**

| Type of study/data  | Test substance/dose levels  | Relevant information about the study (as applicable)  | Observations<br>(Effects statistically significantly different unless stated otherwise)   |
|---|---|---|---|
| <b>Developmental toxicity</b><br>Oral (gavage)<br>OECD 414 (2001)<br>GLP<br>Rat, Crl:CD(SD)<br>24 mated females/group<br>Anonymous, 2015a | ETU (>98% pure),<br>0, 2.5, 5, 15 or 30 mg/kg bw/day on gestation days 6-19<br>Vehicle: water | Study conducted to determine no effect and effect levels for the known teratogen, ETU and for direct comparison with the study on mancozeb (Anonymous, 2015d). ETU is a primary metabolite of mancozeb. | <b>Maternal toxicity</b><br><u>30, 15, 5 and 2.5 mg/kg bw/day:</u><br>No effects<br><b>Developmental toxicity</b><br><u>30 mg/kg bw/day:</u><br>↓ mean foetal weight 13.5% (3.3g cf. 3.8g controls),<br>↑ incidence malformation and developmental variations including malformed tail, meningocele, hydrocephaly, malrotated limb, limb hyperextension, rib and vertebral anomalies, 27 presacral vertebrae and 14th rudimentary ribs, reduced ossification or unossified bones<br><u>15 mg/kg bw/day:</u><br>↑ incidence malformation (hydrocephaly in 2 litters)<br><u>5 mg/kg bw/day:</u><br>no effects<br>Developmental NOAEL 5 mg/kg bw/day<br>Maternal NOAEL 30 mg/kg bw/day |

### 10.8.3 Developmental toxicity in rats

The developmental toxicity of mancozeb has been investigated in four studies in rats.

#### Anonymous (1980)

In the study by Anonymous (1980), groups of 26 pregnant SD rats were given mancozeb by gavage from day 6 to 15 of gestation at doses of 0, 2, 8, 32, 128 or 512 mg/kg bw/day. Food consumption and body weights were decreased at 128 mg/kg bw/d and above in mancozeb treated dams. Body weights for all other mancozeb-treated groups were comparable to the control groups. Litter data indicated significant decreases in the average number of live foetuses, mean foetal weight and mean gravid uteri and increased resorptions only at 512 mg/kg bw/d.

At 512 mg/kg bw/d 6/19 litters were total resorptions. The remaining 13 litters had live foetuses of significantly lower body weight compared to the control. Adverse compound-related effects were clearly manifested at 512 mg/kg bw/d for gross abnormalities (agnathia, cleft palate, meningoencephalocele), soft tissue effects (dilated ventricles, compressed spinal cord), and skeletal tissue effects (incomplete ossification of the skull, clavicle, scapula). The effects observed at 128 mg/kg bw/d were not biologically or statistically significant.

#### **Summary of significant foetal anomalies - external**

|                              | Corn oil<br>(10 mL/kg/day) | Dithane M-45 (mg/kg bw/day) |        |        |        |        | ETU (mg/kg<br>bw/day) |
|------------------------------|----------------------------|-----------------------------|--------|--------|--------|--------|-----------------------|
|                              | Control                    | 2                           | 8      | 32     | 128    | 512    | 50                    |
| Number of foetuses/litters   | 278/23                     | 248/22                      | 245/23 | 248/23 | 212/20 | 155/13 | 232/21                |
| Agnathia                     | 0                          | 0                           | 0      | 0      | 0      | 15/1   | 8/1                   |
| Cleft palate                 | 0                          | 0                           | 0      | 0      | 0      | 24/3   | 8/1                   |
| Cleft lip                    | 0                          | 0                           | 0      | 0      | 0      | 15/1   | 8/1                   |
| Meningoencephalocele         | 0                          | 0                           | 0      | 0      | 0      | 27/4   | 181/20                |
| Ablepharia                   | 0                          | 0                           | 0      | 0      | 0      | 1/1    | 0                     |
| Urogenital cleft             | 0                          | 0                           | 0      | 0      | 0      | 3/1    | 0                     |
| No anal opening              | 0                          | 0                           | 0      | 0      | 0      | 0      | 2/2                   |
| Kinked tail                  | 1/1                        | 0                           | 0      | 0      | 0      | 58/8   | 114/16                |
| Short tail                   | 0                          | 0                           | 0      | 0      | 0      | 15/3   | 141/19                |
| Tail agenesis                | 0                          | 0                           | 0      | 0      | 0      | 0      | 59/11                 |
| Hemimelia                    | 0                          | 0                           | 0      | 0      | 0      | 0      | 2/1                   |
| Clubbed limb                 | 0                          | 0                           | 0      | 0      | 0      | 15/1   | 2/1                   |
| Forelimb flexure             | 0                          | 0                           | 0      | 0      | 1/1    | 4/2    | 104/15                |
| Abnormal pelvic limb posture | 0                          | 0                           | 0      | 0      | 1/1    | 0      | 75/15                 |
| Oligodactyly                 | 0                          | 0                           | 0      | 0      | 0      | 0      | 6/2                   |
| Syndactyly                   | 0                          | 0                           | 0      | 0      | 0      | 0      | 6/1                   |
| Webbed digits                | 0                          | 0                           | 0      | 0      | 0      | 0      | 8/3                   |

**Summary of significant foetal anomalies - visceral**

|  | Corn oil<br>(10 mL/kg/day) | Dithane M-45 (mg/kg bw/day) |       |       |       |       | ETU (mg/kg<br>bw/day) |
|--|----------------------------|-----------------------------|-------|-------|-------|-------|-----------------------|
|  | Control                    | 2                           | 8     | 32    | 128   | 512   | 50                    |
| Number of foetuses/litters             | 90/23                      | 80/22                       | 83/23 | 84/23 | 73/20 | 52/13 | 81/21                 |
| Nasal cavity haemorrhage               | 0                          | 0                           | 0     | 0     | 0     | 1/1   | 0                     |
| Olfactory bulbs deformed               | 0                          | 0                           | 0     | 0     | 0     | 7/3   | 78/21                 |
| Eyes deformed                          | 0                          | 0                           | 0     | 0     | 0     | 0     | 2/1                   |
| Exencephaly                            | 0                          | 0                           | 0     | 0     | 0     | 5/1   | 5/3                   |
| Dilated brain ventricles               | 0                          | 0                           | 2/2   | 0     | 1/1   | 28/9  | 75/20                 |
| Deficiency of tissue in olfactory bulb | 0                          | 0                           | 0     | 0     | 0     | 7/3   | 78/21                 |
| Brain tissue atrophy                   | 0                          | 0                           | 0     | 0     | 0     | 9/2   | 42/13                 |
| Spinal cord haemorrhage                | 0                          | 0                           | 1/1   | 2/1   | 1/1   | 0     | 0                     |
| Spinal cord compressed                 | 0                          | 0                           | 0     | 0     | 0     | 13/4  | 64/18                 |
| Fluid filled pericardial sac           | 9/4                        | 3/2                         | 11/6  | 9/6   | 9/6   | 10/6  | 14/7                  |
| Stomach reduced, thick walled          | 0                          | 0                           | 0     | 0     | 0     | 5/1   | 46/13                 |
| Adrenal agenesis                       | 0                          | 0                           | 0     | 0     | 0     | 0     | 2/1                   |
| Hydroureter                            | 23/15                      | 35/18                       | 28/16 | 20/12 | 27/14 | 18/8  | 76/21                 |
| Hydronephrosis                         | 7/4                        | 13/7                        | 14/8  | 10/7  | 5/5   | 9/6   | 53/18                 |
| Hypoplastic kidney                     | 0                          | 0                           | 2/1   | 0     | 0     | 0     | 0                     |
| Kidney pelvis haemorrhage              | 0                          | 1/1                         | 0     | 0     | 0     | 0     | 0                     |
| Ectopic kidney                         | 0                          | 0                           | 0     | 0     | 0     | 0     | 6/3                   |
| Kidney agenesis                        | 0                          | 0                           | 0     | 0     | 0     | 0     | 9/4                   |
| Ovary agenesis                         | 0                          | 0                           | 0     | 0     | 0     | 0     | 2/1                   |
| Testis agenesis                        | 0                          | 0                           | 0     | 0     | 0     | 0     | 2/1                   |
| Cryptorchidism                         | 0                          | 0                           | 0     | 0     | 0     | 2/2   | 14/8                  |
| Fat pad oedema                         | 0                          | 0                           | 0     | 0     | 0     | 0     | 44/13                 |
| Body oedema                            | 0                          | 0                           | 0     | 0     | 0     | 8/2   | 2/2                   |

**Summary of significant foetal anomalies - skeletal**

|   | Corn oil<br>(10 mL/kg) | Dithane M-45 (mg/kg bw/day) |        |        |        |        | ETU (mg/kg<br>bw/day) |
|---|------------------------|-----------------------------|--------|--------|--------|--------|-----------------------|
|   | Control                | 2                           | 8      | 32     | 128    | 512    | 50                    |
| Number of foetuses/litters                                | 187/23                 | 168/22                      | 162/23 | 165/23 | 139/20 | 103/13 | 151/21                |
| Skull incomplete ossification                             | 0                      | 0                           | 3/2    | 2/2    | 6/2    | 36/5   | 111/19                |
| Skull wide cranial suture                                 | 1/1                    | 0                           | 0      | 0      | 0      | 34/6   | 127/19                |
| Clavicle incomplete ossification                          | 0                      | 0                           | 0      | 0      | 0      | 6/1    | 0                     |
| Clavicle curved   | 0                      | 0                           | 0      | 0      | 0      | 5/1    | 24/6                  |
| Scapula incomplete ossification                           | 0                      | 0                           | 0      | 0      | 0      | 16/2   | 0                     |
| Scapula misshapen   | 0                      | 0                           | 0      | 0      | 0      | 0      | 6/2                   |
| Sternebrae fused  | 0                      | 0                           | 0      | 0      | 0      | 9/1    | 6/2                   |
| Ribs incomplete ossification                              | 0                      | 1/1                         | 3/2    | 2/1    | 6/2    | 6/1    | 13/6                  |
| Ribs fused and/or thickened                               | 0                      | 0                           | 0      | 0      | 0      | 10/1   | 31/10                 |
| Ribs wavy   | 0                      | 0                           | 0      | 0      | 0      | 6/1    | 24/4                  |
| More than 13 ribs   | 11/8                   | 8/6                         | 6/4    | 11/9   | 9/5    | 12/6   | 7/7                   |
| Less than 13 ribs   | 0                      | 0                           | 0      | 0      | 0      | 0      | 3/2                   |
| Cervical vertebrae fused                                  | 0                      | 0                           | 0      | 0      | 0      | 0      | 1/1                   |
| Thoracic vertebrae fused                                  | 0                      | 0                           | 0      | 0      | 0      | 0      | 1/1                   |
| Lumbar vertebrae fused                                    | 0                      | 0                           | 0      | 0      | 0      | 0      | 6/3                   |
| Lumbar vertebrae absent                                   | 0                      | 0                           | 0      | 0      | 0      | 1/1    | 0                     |
| Sacral vertebrae fused                                    | 0                      | 0                           | 0      | 0      | 0      | 0      | 2/2                   |
| Sacral vertebrae absent                                   | 0                      | 0                           | 0      | 0      | 0      | 13/2   | 1/1                   |
| Caudal vertebrae fused                                    | 0                      | 0                           | 0      | 0      | 0      | 0      | 4/3                   |
| Caudal vertebrae absent                                   | 0                      | 0                           | 0      | 1/1    | 0      | 19/4   | 32/9                  |
| Kyphosis  | 0                      | 0                           | 0      | 0      | 0      | 3/2    | 20/6                  |
| Pelvic bone incomplete ossification                       | 0                      | 0                           | 0      | 0      | 0      | 7/7    | 5/3                   |
| Pelvic bone misshapen                                     | 0                      | 0                           | 0      | 0      | 0      |        | 1/1                   |
| Pubis absent  | 0                      | 0                           | 0      | 0      | 0      | 10/1   | 1/1                   |
| Hindlimb long bones incomplete ossification/<br>misshapen | 0                      | 0                           | 0      | 0      | 0      | 6/1    | 5/2                   |
| Hindlimb long bones absent                                | 0                      | 0                           | 0      | 0      | 0      | 10/1   | 1/1                   |

Anonymous, 1988c

In another developmental toxicity study (Anonymous, 1988c), mancozeb was administered by gavage to groups of 25 time-mated SD rats on days 6-15 of gestation at doses of 0, 10, 60 and 360 mg/kg bw/day. One female at 360 mg/kg/day was killed in extremis after showing marked loss of body weight, hind limb paralysis and a general loss of condition. A further four females at 360 mg/kg/day showed a reeling gait during the last days of treatment which developed into slight, transient, hind limb paralysis after dosing had been completed. Hind limb paralysis was therefore seen in 5 animals out of 25 animals at the top dose. Body weight gain of females receiving 360 mg/kg/day was reduced (by 25%) during the treatment period and, although after treatment ceased, the rate of weight gain improved to control values, the initial deficit was not recouped. Females at 10 or 60 mg/kg/day were unaffected. At 360 mg/kg/d, food intake was reduced during the treatment period. Females receiving 10 or 60 mg/kg/d were unaffected.

Litter parameters showed no treatment-related intergroup differences. Skeletal evaluation revealed a slight reduction in ossification of the interparietal bone and thoracic vertebral centra in all treated groups, which was statistically significant at 360 mg/kg/day. Morphological development was otherwise unaffected by treatment with the exception of an increased incidence of large anterior fontanelle (11.9% fetuses cf. 2.2% controls; not statistically significant). No other adverse effects upon foetal survival, growth and development in utero were observed.

**Summary of significant foetal anomalies (% foetal incidence/number of litters affected)**

|   | Mancozeb (mg/kg bw/day) |          |          |           |
|---|-------------------------|----------|----------|-----------|
|   | 0                       | 10       | 60       | 360       |
| Number of foetuses/litters examined for external anomalies<br>No significant findings | 358/25                  | 345/25   | 347/25   | 322/23    |
| Number of foetuses/litters examined for internal anomalies<br>No significant findings | 182/25                  | 175/25   | 176/25   | 160/23    |
| Number of foetuses/litters examined for visceral <sup>a</sup> anomalies               | 176/25                  | 170/25   | 171/25   | 162/23    |
| Increased dilatation of brain ventricles  | 1.1%/1                  | 0.6%/1   | 0.6%/1   | 0         |
| Moderate internal hydrocephaly  | 0                       | 0        | 0        | 0.6%/1    |
| Haemorrhage cerebro-spinal fluid and brain ventricles                                 | 0                       | 1.2%/2   | 0.6%/1   | 1.2%/2    |
| Unilateral hydronephrosis   | 1.7%/6                  | 1.2%/2   | 0        | 0         |
| Bilateral hydronephrosis  | 1.1%/2                  | 0        | 0        | 0.6%/1    |
| Unilateral hydroureter  | 5.1%/6                  | 5.9%/8   | 5.3%/8   | 3.7%/5    |
| Bilateral hydroureter   | 1.1%/2                  | 1.8%/3   | 0.6%/1   | 1.9%/2    |
| Number of foetuses/litters examined for skeletal anomalies                            | 182/25                  | 175/25   | 176/25   | 160/23    |
| Medium anterior fontanelle  | 97.8%/25                | 99.4%/25 | 96.0%/25 | 88.1%/23  |
| Large anterior fontanelle   | 2.2%/3                  | 0.6%/1   | 4.0%/4   | 11.9%/10  |
| Incomplete ossification of supra-occipital bone                                       | 18.1%/14                | 16.0%/14 | 19.3%/14 | 20.6%/18  |
| Incomplete ossification of interparietal bone   | 75.8%/25                | 80.0%/25 | 86.9%/25 | 90.0%*/23 |
| Ribs 13/14  | 0.5%/1                  | 1.7%/2   | 1.7%/2   | 2.5%/3    |
| Ribs 14/14  | 1.1%/2                  | 0.6%/1   | 1.1%/2   | 0         |
| Ribs short and/or wavy  | 0                       | 0        | 0        | 1.3%/1    |
| Ribs thickened  | 0                       | 0        | 0        | 1.3%/1    |
| Incomplete ossification of thoracic vertebral centra                                  | 28.0%/20                | 39.4%/22 | 39.2%/23 | 51.3%/21  |

<sup>a</sup> After freehand serial sectioning

\*Statistically different from control (p<0.05)

Overall, mancozeb administered at a dose level of 360 mg/kg/day to pregnant rats during organogenesis was associated with maternal toxicity, as evidenced by reduced body weight gain and food intake. In addition, transient slight paralysis of the hind limbs was recorded in 5 out of the 25 females, and one severely affected

animal was killed in extremis. With the exception of slight reductions in the degree of ossification of the interparietal bone and thoracic vertebral centra, there were no adverse effects upon survival, growth and development in utero.

#### Anonymous, 1999b

A study by Anonymous (1999b) looked at the teratogenicity of mancozeb in the Wistar rat. Groups of 24 pregnant females were administered mancozeb by gavage from day 6 to 15 of gestation at doses of 0, 100, 225 or 500 mg/kg bw/day. No mortality occurred during the course of the study. No treatment-related clinical signs were observed whatever the dose level. The pregnancy rate was 83.33% for all the dose groups without any variation among this parameter between treated and control groups. The body weight and body weight gain of the dams was unaffected by treatment. The food consumption remained normal during the study. With the exception of an incidental decrease in mean number of *corpora lutea* in the low dose group and a significant difference in sex ratio at the high dose group (incidental and not treatment-related), the reproductive parameters did not show any variations from normal. The overall incidence of major malformation, minor external, visceral and skeletal anomalies were unaffected by treatment up to a dose level of 100 mg/kg bw/day. The incidence of lung emphysema, kidney congestion and dumbbell shaped thoracic centre were significantly higher in mid dose level (225 mg/kg bw/day) and high dose level (500 mg/kg bw/day) groups. In conclusion, in this study in rats, no maternal toxicity was observed up to the highest tested dose of 500 mg/kg bw/day. Developmental toxicity (lung emphysema, kidney congestion and dumbbell shaped thoracic centre) was observed from a dose of 225 mg/kg bw/day. It is noted that the findings of this study are inconsistent with those of the previous two studies.

#### Anonymous, 2015b; Anonymous, 2015c; Anonymous, 2015d

In order to address the issues identified with the developmental toxicity of mancozeb in the rat, 3 new developmental toxicity studies have been conducted.

The first study (Anonymous, 2015b) was a range finding study in non-pregnant females to determine dose levels of the test substance for subsequent studies in pregnant rats. In addition, an assessment of plasma levels of mancozeb and its metabolite ethylenethiourea (ETU) was performed. Mancozeb was administered orally by gavage to 5 groups of 3 non-pregnant female SD rats once daily from study days 0 through 13. Dosage levels were 60, 120, 180, 240, and 300 mg/kg bw/d. A concurrent control group composed of 3 non-pregnant females received the vehicle on a comparable regimen. All females survived to the scheduled necropsy on study day 14. Noteworthy clinical findings observed during the study were limited to the post-dosing observations, and consisted of a single occurrence of salivation for 1 female in the 300 mg/kg bw/d group approximately 48 minutes following dose administration on study day 8. Body weight losses were noted for all 3 females in the 300 mg/kg bw/d group sporadically throughout the treatment period, which resulted in a mean body weight loss of 15 g when the overall dosing period (study days 0-14) was evaluated and a mean body weight on study day 14 that was 9.8% lower than the control group value. Slight body weight losses were also noted for 2 of the 3 females in the 180 and 240 mg/kg bw/d groups when the overall dosing period was evaluated, which resulted in lower (8.3% and 6.0%) mean body weights in these groups, respectively, compared to the control group. There were no consistent trends in body weight changes in the 60 or 120 mg/kg bw/d dose groups and body weights were similar to the control group. Food consumption in the 60, 120, 180, 240, and 300 mg/kg bw/d groups was similar to that noted in the control group throughout the dosing period. At necropsy, no remarkable internal findings were noted at any dose level. Rat plasma concentrations of mancozeb ranged from below the limit of quantification (<10.0) to 213 ng/mL and plasma concentrations of ETU ranged from below the limit of quantification (<10.0) to 1950 ng/mL, 6 hours after the final dose administration. Overall, plasma mancozeb concentrations were significantly lower than those for ETU; this was the consequence of the rapid metabolism of mancozeb to ETU. A clear dose response between administered mancozeb and plasma ETU levels was seen. Doses of 60 and 120 mg/kg bw/d were considered to be well tolerated, based on the lack of toxicologically significant effects. Based on these results, dose levels of 80, 120, and 160 mg/kg bw/d were selected for a preliminary oral (gavage) study of mancozeb in pregnant SD rats.

In the subsequent study (Anonymous, 2015c), mancozeb was administered orally by gavage to groups of 23 pregnant female SD rats once daily from GD 6 through to GD 19. Dose levels were 0, 80, 120 and

160 mg/kg bw/d. No mancozeb-related clinical findings were noted. Lower mean body weight gains with corresponding reduced mean food consumption were noted in the 160 mg/kg bw/d group compared to the control group during GD 9-12 and 15-20, as well as when the overall treatment period (GD 6-20) was evaluated, resulting in a slightly lower (4.9%) mean body weight in this group on GD 20. A lower (approximately 40%) mean net body weight gain was also noted in the 160 mg/kg bw/d group, resulting in a mean net body weight that was 6.5% lower than the control group; gravid uterine weight in this group was similar to the control group. Food consumption was also consistently reduced at 160 mg/kg bw/d. Intrauterine growth and survival in the 80, 120, and 160 mg/kg bw/d groups were similar to the control group and no external foetal malformations or developmental variations were observed at any dosage level. Mean thyroxine (T<sub>4</sub>) levels in the 120 and 160 mg/kg bw/d groups were 23.3% to 30.5% lower than in the control group at the 4-hour post-dosing time points. Mean T<sub>4</sub> levels at the 2- and 6-hour post-dosing time points were either similar to the control or lower in the test substance-treated groups; however, there was no consistent dose response relationship for the decreases in mean T<sub>4</sub> at these time points.

All pregnant rats dosed orally with mancozeb at 80, 120, or 160 mg/kg bw/d were systemically exposed to mancozeb and its metabolite, ETU. Concentrations of mancozeb in both maternal and foetal plasma samples were much lower than those of ETU. On GD 19, exposure to mancozeb and ETU, in terms of AUC<sub>last</sub>, increased as dosage increased from 80 to 160 mg/kg bw/d. Systemic exposure to mancozeb and ETU increased nearly dose-proportionally over the 80 to 160 mg/kg bw/d range. Exposure to the metabolite ETU, in terms of AUC<sub>last</sub>, was 56-, 71-, and 55-fold higher than exposure to mancozeb at 80, 120, and 160 mg/kg bw/d, respectively, in maternal animals. Peak plasma mancozeb concentrations were reached at 2 or 4 hours post-dosing, indicating rapid absorption. Peak plasma ETU concentrations were reached at 6 hours post-dosing at all mancozeb dosage levels, indicating that once absorbed, mancozeb is rapidly metabolised to ETU. Oral administration of mancozeb at 80, 120, and 160 mg/kg bw/d to pregnant rats resulted in exposure of the foetuses to ETU. Similarly to maternal animals, exposure to ETU in foetuses increased nearly dose-proportionally with increasing mancozeb dose. Exposure to ETU was similar in maternal animals and foetuses, with foetal/dam ratios of approximately 0.92. Overall, in this preliminary developmental toxicity study, maternal toxicity was observed at a dosage level of 160 mg/kg bw/d as evidenced by lower mean body weight gains and corresponding reduced mean food consumption compared to the control group, which resulted in a slightly lower mean body weight on gestation day 20. There were no test substance-related effects on intrauterine growth, survival, and external foetal morphology at any dosage level. Based on these results, dosage levels of 10, 40, and 160 mg/kg/d were selected for a definitive prenatal development toxicity study of mancozeb.

In the definitive study (Anonymous, 2015d), mancozeb was administered orally by gavage to groups of 25 pregnant female SD rats once daily from GD 6 through to GD 19. Dose levels were 0, 10, 40 and 160 mg/kg bw/d. No mancozeb-related clinical findings were noted. Lower mean body weight gains were noted in the 160 mg/kg bw/d group near the end of the treatment period resulting in a lower overall mean body weight gain (14.2% for GD 6-20) and lower mean body weights at the end of the treatment period (GD 19 and 20). Mean food consumption in this group was generally lower throughout the treatment period. Intrauterine growth and survival were not affected by mancozeb at any dose level. There were no test substance-related foetal malformations or developmental variations in the 10, 40, or 160 mg/kg bw/d groups.

#### Incidence of foetal malformations

|   | Dose level of Mancozeb (mg/kg bw/day) |        |        |        |
|---|---------------------------------------|--------|--------|--------|
|   | 0                                     | 10     | 40     | 160    |
| No. foetuses/litters examined – external    | 358/23                                | 379/25 | 356/24 | 383/25 |
| Microphthalmia/anophthalmia                 | 0                                     | 1/1    | 0      | 0      |
| Omphalocele                                 | 0                                     | 0      | 0      | 1/1    |
| Localised foetal oedema                     | 0                                     | 1/1    | 0      | 0      |
| No. foetuses/litters examined - soft tissue | 358/23                                | 379/25 | 356/24 | 383/25 |
| Hydrocephaly                                | 0                                     | 1/1    | 0      | 0      |
| Situs inversus                              | 0                                     | 0      | 1/1    | 0      |
| No. foetuses/litters examined – skeletal    | 358/23                                | 379/25 | 356/24 | 383/25 |
| Costal cartilage anomaly                    | 0                                     | 1/1    | 0      | 0      |

**Incidence of foetal variations**

|   | Dose level of Mancozeb (mg/kg bw/day) |        |        |        |
|---|---------------------------------------|--------|--------|--------|
|   | 0                                     | 10     | 40     | 160    |
| No. foetuses/litters examined – external                  | 358/23                                | 379/25 | 356/24 | 383/25 |
| Findings - none   | 0                                     | 0      | 0      | 0      |
| No. foetuses/litters examined - soft tissue               | 358/23                                | 379/25 | 356/24 | 383/25 |
| Major blood vessel variation                              | 0                                     | 0      | 1/1    | 1/1    |
| Spleen small  | 0                                     | 1/1    | 0      | 0      |
| Renal papilla(e) not developed and/or distended ureter(s) | 10/4                                  | 1/1    | 0      | 0      |
| No. foetuses/litters examined – skeletal                  | 358/23                                | 379/25 | 356/24 | 383/25 |
| Reduced ossification of the skull                         | 1/1                                   | 0      | 4/4    | 3/3    |
| Hyoid unossified  | 1/1                                   | 2/1    | 5/3    | 5/4    |
| Reduced ossification of the vertebral arches              | 4/4                                   | 0      | 2/2    | 1/1    |
| Unco-ossified vertebral centra                            | 0                                     | 0      | 0      | 1/1    |
| Cervical centrum 1 ossified                               | 53/17                                 | 41/17  | 45/17  | 41/14  |
| Extra site of ossification ventral to cervical centrum 2  | 0                                     | 0      | 1/1    | 0      |
| 7 <sup>th</sup> cervical rib(s)                           | 2/2                                   | 1/1    | 3/3    | 2/1    |
| Bent rib(s)   | 2/1                                   | 0      | 1/1    | 0      |
| Reduced ossification of the 13 <sup>th</sup> ribs         | 2/1                                   | 2/2    | 2/2    | 0      |
| 14 <sup>th</sup> rudimentary rib(s)                       | 25/11                                 | 40/15  | 20/10  | 35/18  |
| 27 presacral vertebrae                                    | 0                                     | 1/1    | 0      | 0      |

**Incidence of foetal skeletal variations**

|  | Dose level of Mancozeb (mg/kg bw/day) |        |        |        |
|--|---------------------------------------|--------|--------|--------|
|  | 0                                     | 10     | 40     | 160    |
| No. foetuses/litters examined – skeletal     | 358/23                                | 379/25 | 356/24 | 383/25 |
| Sternebra(e) 1, 2, 3 and/or 4 unossified     | 4/3                                   | 0      | 1/1    | 1/1    |
| Sternebra(e) 5 and/or 6 unossified           | 58/15                                 | 45/19  | 68/19  | 56/17  |
| Sternebra(e) malaligned (slight or moderate) | 4/4                                   | 3/2    | 1/1    | 5/4    |
| Pubis unossified                             | 2/2                                   | 0      | 0      | 0      |

Overall, in this modern guideline-compliant developmental toxicity study in rats, no developmental toxicity was seen up to the top dose of 160 mg/kg bw/d at which a moderate level of maternal toxicity (decreased mean body weight gain and food consumption) occurred. No kinetic measurements for mancozeb or ETU were performed in this study; however, estimates obtained from the data available in the preliminary study (Anonymous, 2015c) indicate that doses of mancozeb up to that causing maternal toxicity (160 mg/kg bw/d) in this investigation result in peak plasma concentrations of ETU lower than those seen following administration of ETU at the NOAEL (5 mg/kg bw/d), LOAEL (15 mg/kg bw/d) and effect level (30 mg/kg bw/d) for developmental toxicity in Anonymous (2015a).

Studies identified from the open literature

A study by Hass *et al* (2012) was conducted to determine whether a mixture of low doses of five environmentally relevant endocrine disrupting pesticides with dissimilar modes of action would cause adverse effects on sexual development. The five pesticides used were mancozeb (technical grade, purity 76%), epoxiconazole, prochloraz, tebuconazole and procymidone. Dams were dosed orally by gavage, from GD7 to 21 and from the day after birth to PD16. Mancozeb was administered to 10-12 dams/group at 6.25 and 25 mg/kg bw/d. Controls (22 dams) were given corn oil. The pesticides were also investigated in the androgen receptor reporter gene assay *in vitro* to determine their ability to activate the androgen receptor and to inhibit androgen-induced activation of the androgen receptor. The T-screen assay was used for *in vitro* detection of the agonistic and antagonistic properties of the pesticides at the level of the thyroid hormone receptor. The potential for effects on the synthesis of estradiol, progesterone and testosterone *in vitro* in the human adrenocortical carcinoma cell line H295R was also investigated.

There were no statistically significant effects on maternal body weight during gestation and no clinical signs of toxicity. There were no effects on gestation length and pup body weights. Nipple retention in male offspring was significantly increased at the high dose of mancozeb ( $P < 0.05$ ) however, it is most likely this was a chance finding as no anti-androgenic activity was demonstrated for mancozeb (it did not exhibit androgen receptor antagonism *in vitro* nor did it affect the synthesis of estradiol, progesterone or testosterone in the H295R steroid synthesis assay). In the male offspring, there was no effect of treatment on ano-genital

distance. One male in each of the mancozeb-treated groups showed malformation of the seminal vesicle which was not significant in comparison with the controls. Mancozeb did not exhibit androgen receptor antagonism *in vitro*. Neither did it affect the synthesis of estradiol, progesterone or testosterone in the H295R steroid synthesis assay. Triiodothyronine (T<sub>3</sub>) induced dose-dependent proliferation of GH3 cells in the T-screen assay but no data were reported in the publication to support this conclusion.

In conclusion, in this study in rats involving pre-natal and perinatal exposure to mancozeb up to 25 mg/kg bw/d, no treatment-related effects on sexual development parameters were seen. Nipple retention was increased in male offspring at the top dose; however, it is most likely this was a chance finding as no anti-androgenic activity was demonstrated for mancozeb (it did not exhibit androgen receptor antagonism *in vitro* nor did it affect the synthesis of estradiol, progesterone or testosterone in the H295R steroid synthesis assay).

A similar study was conducted in the same laboratory in order to determine whether a mixture of low doses of five environmentally relevant endocrine disrupting pesticides with dissimilar modes of action would cause effects on male and female development (Jacobsen *et al* 2012). Fourteen groups of 10-22 rats were administered individual pesticides (mancozeb 6.25 or 25 mg/kg bw/day) or mixtures of all 5 pesticides in corn oil, from gestation day (GD) 7 to post natal day (PD) 16. There were no treatment related effects on dam body weight gain, litter size or pup mortality in any of the dose groups. When dosed alone none of the individual pesticides had any effects on hormone levels, sexual maturity, organ weights, sperm motility, mammary glands, behaviour or histopathology. In conclusion mancozeb at doses of 6.25 or 25 mg/kg bw/d administered orally to females during pregnancy and lactation (GD 7 to PD16) had no effect on the development of the offspring (in particular thyroid, reproductive organs and behavioural endpoints) both before and after puberty.

Another similar study was conducted in the same laboratory to determine whether a mixture of low doses of five environmentally relevant endocrine disrupting pesticides with dissimilar modes of action would cause effects on sexual development and expression of kisspeptin in the hypothalamus (Overgaard *et al.*, 2013). Groups of 10-12 pregnant female Wistar rats were dosed by gavage from gestation day (GD) 7 to GD 21 and from the day after delivery until postnatal day (PD) 16 with 0, 6.25 or 25 mg mancozeb/kg bw/d in corn oil. There were no effects on juvenile body weight but adult body weight was higher than control in the mancozeb 25 mg/kg bw/d group. There were no treatment related effects on puberty onset. There were no treatment related effects on Kiss 1 mRNA expression in the AVPV (anteroventral periventricular nucleus) or ARC (arctuate nucleus) of the hypothalamus. In conclusion, gestational (GD 7 to GD 21) and lactational (PD 1-PD 16) exposure of rats to mancozeb at 6.25 or 25 mg/kg bw/d had no effect on puberty onset or on Kiss1 mRNA expression in the hypothalamus in female offspring.

#### 10.8.4 Developmental toxicity in rabbits

The developmental toxicity of mancozeb has been investigated in 2 studies in rabbits.

In the first rabbit study by Anonymous (1987b), groups of 20 NZW pregnant rabbits were administered mancozeb by gavage from day 7 to 19 of gestation at doses of 0, 10, 30 or 80 mg/kg bw/d. No treatment-related deaths occurred in the control or in the 10 and 30 mg/kg bw/d dose groups. One animal died in the 30 mg/kg bw/d group but this was attributed to mis-dosing. Two does were sacrificed in a moribund condition at the high dose and the deaths considered treatment-related (one of these does was pregnant and did not abort). Clinical signs were comparable between controls and animals receiving 10 and 30 mg/kg bw/d. Animals receiving 80 mg/kg bw/day manifested significant increases in clinical signs. Alopecia, anorexia, ataxia, scant faeces and abortions were all observed at the highest dose tested. Body-weight gain and food consumption were not significantly different between controls and groups receiving 10 or 30 mg/kg bw/d. At 80 mg/kg bw/d, body-weight and food consumption were significantly decreased in does that aborted and those sacrificed moribund. Does producing at least one viable foetus had body-weight gains and food consumption values similar to controls. No treatment-related changes were evident in the incidence of gross post-mortem findings between does in the control and treated group. Reproductive parameters between controls and does receiving 10 or 30 mg/kg bw/d were comparable as measured by the number of abortions, litters produced, and the mean number per litter or corpora lutea, implantations, resorptions, dead and live

foetuses or sex ratio. At 80 mg/kg bw/d, a significant increase in does aborting (5/15) and 2 total resorptions out of 20 litters were reported with a corresponding decrease in the number of litters produced. All other parameters were comparable to the control group. Mean foetal body weight was similar between the control and treated groups. There were no significant increases in the types or incidence of malformations or developmental variations between control or treated groups. Overall, developmental toxicity (abortions and resorptions) was seen in this study at the top dose of 80 mg/kg bw/d in the presence of maternal toxicity.

In the second rabbit study by Anonymous (1991b), mancozeb was administered by gavage to groups of 18 NZW pregnant rabbits from day 6 to 18 of gestation at doses of 0, 5, 30, 55 and 100 mg/kg bw/d. No treatment-related clinical effects or treatment-related necropsy findings were detected. Two dams in the control group and five in the 100 mg/kg bw/d dose group aborted. A clear and substantial body-weight loss was observed in does at 100 mg/kg bw/d for days 6-9 post-coitum (*i.e.* days 1-3 of compound administration). Body-weight gain during days 9-15 was also substantially depressed compared to controls at the top dose. Food consumption was also markedly decreased between days 6-19 at 100 mg/kg bw/d. A slight post-implantation loss (5%) was also observed at the top dose, but given its magnitude it was not considered adverse. Overall, no developmental toxicity was seen in this study up to a dose (100 mg/kg bw/d) causing maternal toxicity.

### 10.8.5 Developmental neurotoxicity in rats

A developmental neurotoxicity (DNT) study in rats (OECD TG 426) is also available. This study (Anonymous, 2008b – a dose range finding study; Anonymous, 2008c – the main DNT study) was conducted to address the concern about a potential relationship between thyroid effects and brain development.

In the dose range finding study (Anonymous, 2008b), mancozeb was given on a continuous basis in the diet to groups of 15 pregnant female SD rats from gestation day 6 until euthanasia (post partum day 21). The target test substance doses were 5, 30 and 60 mg/kg bw/d. No test substance-related clinical findings were observed in parent females. At 60 mg/kg/d, body weight, body weight gain and food consumption were significantly decreased during the gestation treatment period (by 10.5%, 37% and 16%, respectively;  $p < 0.01$ ). Significant reductions in gestation body weight gain and food consumption were also evident at 30 mg/kg/d (by 14% and 12%, respectively;  $p < 0.01$ ). Subsequently, mean body weights in the 60 mg/kg/d group females remained lower during lactation, but there were no test substance-related effects on mean body weight gain or food consumption. No test substance-related effects on mean body weights, body weight gains or food consumption were noted during gestation in the 5 mg/kg/d group or during lactation in the 5 and 30 mg/kg/d groups.

An increased incidence of thyroid gland follicular cell hypertrophy was noted in the 30 and 60 mg/kg/d groups on LD 21 and was associated with a statistically significant reduction in serum T<sub>4</sub>; increased TSH at 60 mg/kg/d did not achieve statistical significance. Relative thyroid weights were increased in some of the 60 mg/kg/d group dams and associated with follicular cell hypertrophy.

#### Summary of thyroid effects

|  | Dose level of Mancozeb (mg/kg bw/day) |        |        |        |
|--|---------------------------------------|--------|--------|--------|
|  | 0                                     | 5      | 30     | 60     |
| Total T <sub>4</sub> (µG/dL) GD 20                   | 1.32                                  | 0.82   | 0.59*  | 1.02   |
| TSH (ng/mL) GD 20                                    | 9.58                                  | 12.46  | 11.20  | 11.98  |
| Total T <sub>4</sub> (µG/dL) LD 21                   | 3.94                                  | 4.36   | 2.98*  | 2.22** |
| TSH (ng/mL) LD 21                                    | 10.82                                 | 10.19  | 10.75  | 14.91  |
| Absolute thyroid weight (g) GD 20                    | 0.0233                                | 0.0213 | 0.0254 | 0.0260 |
| Absolute thyroid weight (g) LD 21                    | 0.0240                                | 0.0223 | 0.0216 | 0.0232 |
| Thyroid cyst, ultimobranchial, present GD 20         | 2/5                                   | 1/5    | 0/5    | 1/5    |
| Thyroid hypertrophy, follicular cell - minimal GD 20 | 0/5                                   | 0/5    | 1/5    | 1/5    |
| Thyroid cyst, ultimobranchial, present LD 21         | 5/10                                  | 2/10   | 5/9    | 2/10   |
| Thyroid hypertrophy, follicular cell - minimal LD 21 | 2/10                                  | 0/10   | 4/9    | 5/10   |

Statistically significant difference from control \* $P < 0.05$

Statistically significant difference from control \*\* $P < 0.01$

Mean gestation length and parturition were unaffected by mancozeb. The mean number of pups born, the percentage of males at birth, live litter size on PND 0, postnatal survival and general physical condition were unaffected by maternal exposure to mancozeb. Lower mean body weight gains were observed in the male and female pups in the 30 and 60 mg/kg/d groups during PND 4-7, 7-11 and 17-21, resulting in mean body weights that were 10.9% to 21.6% lower than the control group values during PND 7-21. These body weight decreases were most marked on PND 7 and 11, but were not dose-related.

There were no macroscopic findings in the pups that were found dead, euthanized in extremis or at the scheduled necropsy that could be attributed to maternal exposure to mancozeb. Plasma and milk analyses in the high dose animals (60 mg/kg/d) showed that the pups were exposed to residues of both mancozeb and ETU. The mean concentrations in plasma for GD 20 dams and foetuses were 0.356 ppm and 0.278 ppm, respectively. For LD 4 dam and PND 4 pup plasma, the mean concentrations were 1.18 ppm and 0.037 ppm, respectively. The mean concentration in milk was 0.426 ppm in the LD 4 samples and 0.440 ppm in the LD 10. ETU residues were found in plasma and milk from all dose groups. The ETU residue levels increased with increasing dietary concentration of mancozeb. In this DNT range-finding study, dams given 30 or 60 mg/kg/d mancozeb had lower mean body weights, body weight gains and food consumption, higher mean serum concentrations of TSH, lower mean serum concentrations of total T<sub>4</sub> and a higher incidence of thyroid gland follicular cell hypertrophy which generally corresponded with increased relative thyroid weight at the highest dose. The offspring in the 30 and 60 mg/kg/d groups had decreased body weights and body weight gains. There were no treatment-related effects at 5 mg/kg/d. Therefore, dietary doses of 5, 15 and 30 mg/kg/d were selected for the definitive DNT study.

In the definitive DNT study (Anonymous, 2008c), mancozeb was given on a continuous basis in the diet to groups of 25 pregnant female SD rats from gestation day 6 until euthanasia (post partum days 21-28). The target test substance doses of 5, 15 and 30 mg/kg bw/d were achieved. One group of animals received the basal diet alone and served as the control group. Clinical observations including FOB, body weight and food consumption were monitored for the females during the study. Dams were allowed to litter and rear their offspring to day 21 post partum. At necropsy, thyroid weights were collected and the thyroids processed for histopathological examination. Pre-weaning developmental landmarks (pinna detachment, eye opening and surface righting response) were evaluated in offspring. On postnatal day (PND) 4, litters were culled to 8 pups/litter (4 pups/sex, when possible). If a litter failed to meet the sex ratio criteria (at least 3 pups/sex), the litter was not used for neurobehavioral or neuropathological evaluation. Following culling, a subset (Subset A) of 20 pups/sex/group was assigned to FOB (PND 4, 11, 21, 35, 45 and 60), acoustic startle response (PND 20 and 60), locomotor activity (PND 13, 17, 21 and 61) and learning and memory (PND 62). From this subset, 15 pups/sex/group were selected for brain weight evaluations on PND 72; of these, 10 pups/sex/group were selected for neuropathological and morphometric evaluations on PND 72. A second subset (Subset B) of 20 pups/sex/group was selected for learning and memory tests (PND 22). A third subset (Subset C) of 15 pups/sex/group was selected for brain weight evaluations on PND 21; of these, 10 pups/sex/group were selected for neuropathological and morphometric evaluations on PND 21. Indicators of physical development (balanopreputial separation and vaginal patency) were evaluated for all F1 animals in Subset A. All F1 animals not selected for behavioural evaluations were euthanized and necropsied on PND 21. F1 animals selected for learning and memory assessment on PND 22 were necropsied following completion of these assessments.

Dietary exposure to mancozeb from gestation day 6 through to weaning produced no test substance-related effects on clinical findings, FOB parameters, food consumption, gestation length, parturition or macroscopic findings at necropsy. Test substance-related effects were evident for maternal body weight gain, thyroid weight and thyroid histopathology at 30 mg/kg bw/d. Maternal body weight gain was reduced following the onset of treatment. The effect was statistically significant for gestation days 6-9 and 6-12. For gestation days 6-20, the decrease in body weight gain was 4.6%. However, the effect on body weight gain was influenced by an incidentally higher litter size in the 30 mg/kg bw/d group compared to the concurrent control group (16.0 vs. 14.7 pups/litter). When litter size was used as a covariate in the statistical analysis of body weight gain, the reduction at 30 mg/kg bw/d was highly significant. In addition, when the body weight gain data were normalized for litter size and gestation day 20 conceptus weights, the decrease in gain during gestation

days 6-20 was 9.4%. Therefore, 30 mg/kg bw/day was shown to be an ideal high-exposure level based on the OECD test guideline criteria.

A 30 mg/kg bw/d, absolute and relative mean thyroid weights were increased by 7.5% and 9.1%, respectively, and corresponded with an increased incidence of thyroid follicular cell hypertrophy; these changes were considered to be test substance-related.

### Summary of thyroid effects

|  | Dose level of Mancozeb (mg/kg bw/day) |        |        |         |
|--|---------------------------------------|--------|--------|---------|
|  | 0                                     | 5      | 15     | 30      |
| Absolute thyroid weight (g)                            | 0.0187                                | 0.0192 | 0.0185 | 0.0201  |
| Thyroid weight (g/100g final body weight) <sup>b</sup> | 0.00638                               | 0.007  | 0.006  | 0.00696 |
| Thyroid hypertrophy, follicular cell - minimal         | 6/24                                  | -      | -      | 11/25   |

<sup>b</sup> Values for the 5 and 15 mg/kg bw/day groups expressed only to 3 decimal places.

There were no test substance-related effects on any of the F1 litter parameters including survival, clinical signs, FOB, growth, development, motor activity, startle response, learning and memory, brain morphometry and histopathology of the central and peripheral nervous systems. Based on these findings and on the presence of ETU in pup plasma and in milk (investigated in the preliminary study), it can be concluded that mancozeb has been adequately tested for DNT and the results show that mancozeb has no developmental neurotoxicity.

A DNT study from the open literature (Alexstad 2011) is also available. This study was conducted to investigate if perinatal mancozeb exposure would cause developmental neurotoxicity in rats. Two separate studies were conducted, a preliminary dose range-finder (6 dams/group) and a large dose response study (22 dams/group). Time-mated Wistar rats were gavaged once daily from GD7 to PND16. Dose levels for the preliminary study were 0, 200, 350 or 500 mg/kg bw/d. In the main study, dose levels were 0, 50, 100 or 150 mg/kg bw/d.

Doses of 150 mg/kg bw/d and above caused toxic effects in the dams. In the preliminary study, severe weight loss and hind limb paralysis occurred in all groups after a few days and doses were halved on GD12. All animals in the two highest dose groups and two in the low dose group were killed on GD14 due to continued toxic signs. In the main study, two high-dose dams were killed on GD16 and the high dose was lowered to 100 mg/kg bw/d. Maternal body weight and body weight gain was significantly lower than control in all dose groups throughout gestation. Body weight gain was generally higher than control in all groups throughout lactation but terminal body weight was significantly lower than control in the high-dose group.

There were no effects on gestation length, litter size, post implantation loss, neonatal death, gender distribution, AGD (ano-genital distance) or nipple retention. Offspring body weight was lower compared to controls in the high dose group at birth and on PND6, and remained slightly (but not significantly) lower than control until PND45. In dams, T<sub>4</sub> was dose-dependently reduced in all treated groups on GD15. There was no effect on PND 24 and thyroid weights were also unaffected. In offspring no treatment-related effects on T<sub>4</sub>, thyroid gland weight or histopathology were seen.

### Effects of Mancozeb on T<sub>4</sub> and testosterone in dams and offspring

| Hormone measurement (nM)    | Dose Mancozeb (mg/kg bw/day) |       |        |         |
|-----------------------------|------------------------------|-------|--------|---------|
|                             | Control                      | 50    | 100    | 150/100 |
| No. of samples              | 14-15                        | 15-20 | 17-22  | 8-10    |
| T <sub>4</sub> – dams GD15  | 41.4                         | 32.7* | 30.15* | 26.26*  |
| T <sub>4</sub> – dams PND24 | 24.8                         | 21.2  | 19.6   | 23.14   |
| T <sub>4</sub> – pups PND16 | 32.5                         | 35.8  | 34.6   | 33.1    |
| T <sub>4</sub> – pups PND24 | 18.5                         | 19.8  | 22.1   | 24.3    |
| Testosterone PND16          | 1.05                         | 1.58  | 1.54   | 1.65    |

\* Significantly different from control p< 0.0001

There were no effects on offspring organ weights on PND16 (testes, epididymis, prostate, ovaries, liver), PND24 (testes) or in young adults (ovaries) and no histopathological effects in ovaries and testes (other organ not examined). None of the behavioural tests showed any effect of mancozeb exposure.

In conclusion, mancozeb at 150 mg/kg bw/d and above induced toxic effects in dams characterised by severe bodyweight loss and hind limb paralysis. The severity of the maternal toxicity was such that the dose had to be reduced to 100 mg/kg bw/d and some animals had to be terminated prematurely. Increased maternal T<sub>4</sub> levels at 50 mg/kg bw/d and above did not affect offspring T<sub>4</sub> levels, thyroid weights or histopathology on PND 16 and no effects on reproductive organ weights or behaviour in adult offspring. Overall, no developmental toxicity was seen in this study up to a dose of 100/150 mg/kg bw/d. Thyroid toxicity (increased T<sub>4</sub> levels) was observed in the maternal animals from the lowest dose of 50 mg/kg bw/d. These results indicate that in rats, maternal hypothyroxinemia during gestation does not necessarily lead to hyperactivity or reduced learning abilities in the offspring. It is noted that the maternal toxicity reported in this study was not consistent with that observed in other developmental toxicity studies. In regulatory guideline studies, pregnant rats have been shown to tolerate 160 mg/kg bw/d (Anonymous, 2015d) with only a transient effect on body weight. Only the high dose level of 360 mg/kg bw/d (Anonymous, 1988c) induced significant maternal toxicity, including transient, hindlimb paralysis.

#### 10.8.6 Recent/key developmental toxicity study on ETU in rats

ETU is an established developmental toxicant (harmonised classification with Repr Cat 1B; H360D) which causes malformations (mainly of head and neck) in the rat in the absence of maternal toxicity. Approximately 7% of mancozeb is converted to ETU in experimental animals. The evidence suggests that the malformations (mainly of head and neck) seen in the rat with mancozeb are due to its main metabolite, ETU. A new regulatory guideline rat developmental toxicity study on ETU, including measurements of plasma levels of ETU has been conducted to demonstrate that the foetal malformations caused by mancozeb in the rat are due to the production of a teratogenic dose of ETU.

In a prenatal developmental toxicity study of ETU, the test substance was administered orally by gavage to 4 groups of 24 pregnant female SD rats once daily from GD 6 to 19 (Anonymous, 2015a). Dose levels were 2.5, 5, 15, and 30 mg/kg bw/d. No treatment-related clinical findings were noted. Mean body weight losses or lower mean body weight gains were noted in all ETU-treated groups following the initiation of dose administration (GD 6-7). Corresponding lower mean food consumption was noted during this same period in the 15 and 30 mg/kg bw/d groups. Lower mean food consumption was also noted in the 30 mg/kg bw/d group at the end of the dosing period (GD 18-20). As the effects on body weight and food consumption were minor and tended to be limited to the first days of treatment, they were not considered adverse. Mean foetal body weights in the 30 mg/kg bw/d group were up to 13.5% lower than the control group.

Higher incidences of the following foetal malformations were noted at 30 mg/kg bw/d: external (short, bent, curly, constricted, or bifurcated tail, meningocele, malrotated limb, limb hyperextension, and domed head), visceral (hydrocephaly, subcutaneous haemorrhage, and meningocele) and skeletal (skull anomaly, rib anomaly, interrupted ossification of the rib[s], vertebral anomaly with or without associated rib anomaly, vertebral centra anomaly, costal cartilage anomaly, only 12 pairs of ribs present, and small, interrupted, detached, or thin rib[s]). ETU-related increased incidences of visceral and skeletal developmental variations were also noted at 30 mg/kg bw/d. Skeletal developmental variations in this group included 27 presacral vertebrae and 14th rudimentary ribs. Skeletal developmental variations consisting of reduced ossification or unossified bones (reduced ossification of the skull, hyoid unossified, sternbra[e] nos. 1, 2, 3, and/or 4 unossified, reduced ossification of the rib[s], unco-ossified vertebral centra, pubis unossified, and reduced ossification of the vertebral arches) and visceral developmental variations (renal papilla[e] not fully developed and/or distended ureter[s]) noted at 30 mg/kg bw/d were indicative of developmental delay and considered secondary to the reduced foetal weights noted at this dosage level. At 15 mg/kg bw/d, foetal test substance-related effects were limited to an increased incidence of the malformation hydrocephaly. No ETU-related foetal malformations or developmental variations were noted in the 2.5 and 5 mg/kg bw/d groups.

**Incidence of foetal malformations**

|   | Dose level of ETU (mg/kg bw/day) |        |        |        |        |
|---|----------------------------------|--------|--------|--------|--------|
|   | 0                                | 2.5    | 5      | 15     | 30     |
| No. foetuses/litters examined – external    | 330/24                           | 320/23 | 322/23 | 332/23 | 363/24 |
| Meningocele                                 | 0                                | 0      | 0      | 0      | 183/22 |
| Domed head                                  | 0                                | 0      | 0      | 0      | 192/22 |
| Limb malrotated                             | 0                                | 0      | 0      | 0      | 46/11  |
| Limb hyperextension                         | 0                                | 0      | 0      | 0      | 4/1    |
| Tail constricted                            | 0                                | 0      | 0      | 0      | 1/1    |
| Bifurcated tail                             | 0                                | 0      | 0      | 0      | 1/1    |
| Short tail                                  | 0                                | 0      | 0      | 0      | 61/12  |
| Bent tail                                   | 0                                | 0      | 0      | 0      | 200/24 |
| Curly tail                                  | 0                                | 0      | 0      | 0      | 1/1    |
| Localised foetal oedema                     | 0                                | 0      | 0      | 1/1    | 0      |
|   | Dose level of ETU (mg/kg bw/day) |        |        |        |        |
|   | 0                                | 2.5    | 5      | 15     | 30     |
| No. foetuses/litters examined - soft tissue | 330/24                           | 320/23 | 322/23 | 332/23 | 363/24 |
| Meningocele                                 | 0                                | 0      | 0      | 0      | 4/3    |
| Hydrocephaly                                | 0                                | 0      | 0      | 7/2    | 304/24 |
| Subcutaneous haemorrhage                    | 0                                | 0      | 0      | 0      | 61/21  |
| Right-sided aortic arch                     | 0                                | 0      | 1/1    | 0      | 0      |
| Interrupted aortic arch                     | 0                                | 0      | 0      | 1/1    | 0      |
| Retrosophageal aortic arch                  | 0                                | 0      | 0      | 1/1    | 0      |
| Lungs lobular dysgenesis                    | 0                                | 0      | 1/1    | 1/1    | 0      |
| Situs inversus                              | 0                                | 0      | 0      | 1/1    | 0      |
| No. foetuses/litters examined – skeletal    | 330/24                           | 320/23 | 322/23 | 332/23 | 363/24 |
| Skull anomaly                               | 0                                | 1/1    | 0      | 0      | 28/17  |
| Bent limb bone(s)                           | 0                                | 1/1    | 0      | 0      | 0      |
| Bent scapula(e)                             | 0                                | 1/1    | 0      | 0      | 0      |
| Rib anomaly                                 | 0                                | 0      | 0      | 0      | 55/18  |
| Interrupted rib(s)                          | 0                                | 0      | 0      | 0      | 23/10  |
| Interrupted ossification of the rib(s)      | 0                                | 0      | 0      | 0      | 4/4    |
| Only 12 pairs of ribs                       | 0                                | 0      | 0      | 0      | 1/1    |
| Rib(s) small                                | 0                                | 0      | 0      | 0      | 5/4    |
| Rib(s) detached                             | 0                                | 0      | 0      | 0      | 5/3    |
| Rib(s) thin                                 | 0                                | 0      | 0      | 0      | 1/1    |
| Costal cartilage anomaly                    | 0                                | 0      | 0      | 1/1    | 13/9   |
| Vertebral anomaly with/without rib anomaly  | 0                                | 0      | 0      | 0      | 45/19  |
| Vertebral centra anomaly                    | 0                                | 0      | 0      | 0      | 3/2    |

**Incidence of foetal variations**

|   | Dose level of ETU (mg/kg bw/day) |        |        |        |        |
|---|----------------------------------|--------|--------|--------|--------|
|   | 0                                | 2.5    | 5      | 15     | 30     |
| No. fetuses/litters examined – external                   | 330/24                           | 320/23 | 322/23 | 332/23 | 363/24 |
| Findings  | 0                                | 0      | 0      | 0      | 0      |
| No. fetuses/litters examined - soft tissue                | 330/24                           | 320/23 | 322/23 | 332/23 | 363/24 |
| Haemorrhagic ring around the iris                         | 1/1                              | 1/1    | 0      | 0      | 0      |
| Major blood vessel variation                              | 0                                | 1/1    | 2/2    | 1/1    | 0      |
| Liver accessory lobule(s)                                 | 4/3                              | 1/1    | 1/1    | 1/1    | 0      |
| Renal papilla(e) not developed and/or distended ureter(s) | 0                                | 4/2    | 0      | 8/5    | 28/7   |
|   | Dose level of ETU (mg/kg bw/day) |        |        |        |        |
|   | 0                                | 2.5    | 5      | 15     | 30     |
| No. fetuses/litters examined – skeletal                   | 330/24                           | 320/23 | 322/23 | 332/23 | 363/24 |
| Reduced ossification of the skull                         | 4/3                              | 14/4   | 10/8   | 5/5    | 116/24 |
| Hyoid unossified  | 4/3                              | 6/4    | 3/3    | 2/2    | 40/16  |
| Reduced ossification of the vertebral arches              | 0                                | 0      | 0      | 0      | 5/2    |
| Unco-ossified vertebral centra                            | 0                                | 0      | 0      | 0      | 11/8   |
| Cervical centrum 1 ossified                               | 55/16                            | 52/18  | 81/20  | 110/21 | 82/17  |
| 7 <sup>th</sup> cervical rib(s)                           | 1/1                              | 1/1    | 2/2    | 4/2    | 0      |
| Bent rib(s)   | 4/4                              | 12/4   | 6/4    | 7/5    | 9/6    |
| Reduced ossification of the rib(s)                        | 0                                | 0      | 1/1    | 0      | 6/3    |
| Reduced ossification of the 13 <sup>th</sup> ribs         | 3/1                              | 0      | 0      | 2/1    | 3/2    |
| 14 <sup>th</sup> rudimentary rib(s)                       | 13/9                             | 32/13  | 48/13  | 63/15  | 87/23  |
| 14 <sup>th</sup> full ribs                                | 0                                | 1/1    | 2/1    | 1/1    | 2/2    |
| 27 presacral vertebrae                                    | 0                                | 0      | 6/3    | 2/1    | 23/8   |
| Sternebra(e) 1, 2, 3 and/or 4 unossified                  | 0                                | 0      | 0      | 2/2    | 5/33   |
| Sternebra(e) 5 and/or 6 unossified                        | 56/14                            | 19/7   | 28/12  | 37/11  | 67/19  |
| Sternebra(e) malaligned (slight or moderate)              | 3/3                              | 3/3    | 3/3    | 7/5    | 6/5    |
| Pubis unossified  | 0                                | 0      | 0      | 0      | 8/2    |

The mean concentrations of ETU in the blood of maternal and foetal rats on GD 20 were 124, 355, 1280, and 2940 ng/mL in the maternal animals, and 113, 299, 1170, and 2790 ng/mL in foetuses at 2.5, 5, 15, and 30 mg/kg bw/d, respectively. The concentration responses for blood ETU with dose level appeared visually to be linear and exposure in the foetuses was similar to the maternal animals, with mean maternal/foetal ratios of 1 at all dose levels.

In conclusion, in a recent guideline developmental toxicity study in rats, no maternal toxicity was seen up to the top dose of 30 mg/kg bw/d ETU. Developmental effects were noted at 30 mg/kg bw/d, as evidenced by lower mean foetal weights, foetal malformations and developmental variations. Developmental effects were also noted at 15 mg/kg bw/d, but were limited to hydrocephaly in 2 litters.

**Other developmental studies on ETU**

The developmental toxicity of ETU in mammals has been investigated in numerous studies in rats, mice, hamsters, rabbits, cats and guinea pigs. These are described in more details in the RAR (2017).

Overall, on the basis of these studies, it can be concluded that ETU is unequivocally teratogenic in the rat (producing malformations predominantly of the central nervous system and head) at doses that do not induce maternal toxicity. The hamster has also been shown to be sensitive to the teratogenic potential of ETU at high doses approaching the maternotoxic range. The mouse is less sensitive to the teratogenic effects of ETU than the rat and hamster. In the guinea pig, rabbit and cat, ETU does not produce clear evidence of teratogenic potential. An overall NOAEL for developmental effects of ETU has been demonstrated in the rat, the most sensitive species, at 5 mg/kg bw/d. These data support classification of ETU with Repr Cat 1B (H360D) under the CLP Regulation. This is consistent with the current harmonised classification of ETU.

### 10.8.7 Other relevant information to the assessment of developmental toxicity

Two guideline 2-generation studies in the rat are available. These have been described in detail in the RAR (2017). In the first study (Anonymous et al 1988), mancozeb (84%) at dietary levels up to 1200 ppm (70 mg/kg bw/d) produced no adverse effects on reproductive capability or on the health and survival of offspring. In the second study (Anonymous, 1992), mancozeb (88.4%) at dietary levels up to 1100 ppm (65 mg/kg bw/d) produced no adverse effects on fertility and reproductive performance. However, a slight delay in eye opening, a 9% decrease in pup weights on days 14 and 21 and a 19% reduction in pup viability on day 4 were seen at the top dose of 1100 ppm. These effects were associated with parental toxicity (decreased body weight gains (by 10-24%), reduced food consumption and thyroid toxicity in males and females).

### 10.8.8 Short summary and overall relevance of the provided information on adverse effects on development

Five developmental toxicity studies (3 in the rat and 2 in the rabbit) were described in the original DAR (2000) under Directive 91/414. These studies were conducted in the 1980s and those performed in the rat used severely maternally toxic maximum dose levels (360 - 512 mg/kg bw/d); these maternally toxic doses resulted in malformations (mainly of head and neck) in the rat. Mancozeb was classified as Reprotox category 2 (H361d) as a result of these studies. The evidence suggested that the malformations seen in the rat with mancozeb were due to its main metabolite, ETU. ETU is an established developmental toxicant (harmonised classification with Repr Cat 1B; H360D) which causes malformations (mainly of head – skull, brain and spinal cord; neck – cleft palate; tail; and vertebrae) in the rat in the absence of maternal toxicity. Approximately 7% of mancozeb is converted to ETU in experimental animals.

The teratogenicity study by Anonymous (1980) was central to the decision to classify mancozeb. This study showed that mancozeb caused total litter loss and malformations, mainly of the head and neck, at the high dose of 512 mg/kg bw/d, at which severe maternal toxicity occurred. More recent investigations of the developmental toxicity of mancozeb and ETU in the rat (Anonymous, 2015d & a) have demonstrated that the foetal malformations observed by Anonymous (1980) were totally attributable to the production of a teratogenic dose of ETU and that this was only produced at mancozeb exposures which caused excessive maternal toxicity (death/killing in extremis, paralysis, body weight and food consumption decreases and suffering).

No developmental neurotoxicity was seen in a regulatory study in the rat up to a dose (30 mg/kg bw/d) which caused maternal toxicity (decreases in body weight gain and thyroid histopathology). Additional investigations of the developmental toxicity of mancozeb in the rat from the open literature did not identify effects on neurological endpoints, sexual behaviour, post-natal development and puberty onset. No developmental toxicity was observed in rabbits up to doses (80-100 mg/kg bw/d) causing severe maternal toxicity. The company (Mancozeb Task Force)'s assessment of developmental toxicity is provided in Annex 2. The DS agrees with the applicant assessment, which is provided mainly for completeness and further details.

### 10.8.9 Comparison with the CLP criteria

Five developmental toxicity studies (3 in the rat and 2 in the rabbit) were described in the original DAR (2000) under Directive 91/414. Malformations (mainly of head and neck) were seen in the rat at severely maternally toxic dose levels. Mancozeb was classified as Reprotox category 2 (H361d) as a result of these studies. The evidence suggested that the malformations seen in the rat with mancozeb were due to its main metabolite, ETU. ETU is an established developmental toxicant (harmonised classification with Repr Cat 1B; H360D) which causes malformations (mainly of head and neck) in the rat in the absence of maternal toxicity. Approximately 7% of mancozeb is converted to ETU in rats.

The rat teratogenicity study by Anonymous (1980) was central to the decision to classify mancozeb. This study showed that mancozeb caused total litter loss and malformations, mainly of the head and neck, at the high dose of 512 mg/kg bw/d, at which severe maternal toxicity occurred.

On the basis of this study, the C&L Specialised Expert Group agreed in 1993 that classification for developmental toxicity was not appropriate because the foetal malformations seen in the rat with mancozeb were attributed to the formation of ETU, a teratogenic metabolite of mancozeb classified with Repr. Cat 1B; H360D, but that the levels of ETU produced by mancozeb would not reach the threshold for teratogenic effects. However, the same Group concluded in 2005 that classification of mancozeb with Reprotox category 2 (H361d) was warranted. The Group noted that although the malformations occurred in the presence of severe maternal toxicity (death/killing in extremis, paralysis, body weight and food consumption decreases, and suffering), they could not be considered the secondary, unspecific consequence of the observed maternal toxicity.

More recent investigations of the developmental toxicity of mancozeb and ETU in the rat, including measurements of plasma levels of ETU (Anonymous, 2015a & d) have demonstrated that the foetal malformations observed by Anonymous (1980) were totally attributable to the production of a teratogenic dose of ETU. The developmental toxicity study of ETU in the rat (Anonymous, 2015a) clearly identified 5 mg/kg bw/d as a non-teratogenic dose (NOAEL). Anonymous (2015a) also identified 15 mg/kg bw/d as a LOAEL, causing a minimal teratogenic response, whilst 30 mg/kg bw/d was well within the teratogenic dose range. The mean doses of mancozeb calculated to produce blood levels of ETU equivalent to those generated by doses of ETU of 5, 15 and 30 mg/kg bw/d were 143 (range 130-166), 429 (range 390-499) and 859 (range 780-998) mg/kg bw/d respectively. Consequently, when mancozeb was administered to rats at a dose (160 mg/kg bw/d) that was maternally toxic (decreases in body weight and food consumption) but did not cause excessive maternal toxicity (Anonymous, 2015d), insufficient ETU was generated to produce teratogenicity as ETU-driven teratogenic effects would start to appear from a dose of mancozeb of ~429 mg/kg bw/d (range 390-499 mg/kg bw/d). These dose conversions are explained more clearly below.

The doses of mancozeb required to generate equivalent ETU blood levels to those seen after oral administration of ETU at 5, 15 and 30 mg/kg bw/day in pregnant rats (Anonymous, 2015a) were calculated as follows. A developmental toxicity study in rats (Anonymous, 2015a) was conducted with ETU (at doses of 0, 2.5, 5, 15 and 30 mg/kg bw/d). This study identified the NOAEL (5 mg/kg bw/d), LOAEL (15 mg/kg bw/d) and clear-effect-level (30 mg/kg bw/d) for the teratogenicity of ETU in rats. Satellite animals for toxicokinetic analysis were also dosed in this study, such that the AUC and C<sub>max</sub> for ETU in maternal plasma were determined. Plasma levels of ETU (in dams) peaked at 6h after dosing and there was a linear relationship between dose of ETU and plasma ETU levels. The maternal blood levels of ETU (estimated at 24 hours after the final dose) at the ETU NOAEL, LOAEL and clear-effect-level were thus determined.

A similar study (Anonymous, 2015d) was conducted with mancozeb (at doses of 0, 80, 120 and 160 mg/kg bw/d) where AUC and C<sub>max</sub> for the metabolite ETU in maternal plasma were determined. Plasma levels of ETU (in dams) also peaked at 6h after dosing mancozeb, indicating that once absorbed, mancozeb is rapidly metabolised to ETU. There was also a linear relationship between dose of mancozeb and plasma ETU levels. Plasma concentration versus time data for ETU following administration of mancozeb was used to calculate the rate constants (k) for the decline in ETU plasma concentrations. At each dose level of mancozeb, the mean, minimum and maximum maternal plasma levels of ETU were determined. The maternal plasma concentrations of ETU estimated at 24 hours after the final dose of ETU to pregnant rats were used, along with the rate constants (k) for the decline in ETU concentrations after dosing of mancozeb, to estimate the maximum ETU concentrations at 6 hours after dosing with mancozeb (T<sub>max</sub>). Linear regression lines were fitted through the 6-hour ETU concentrations versus dose of mancozeb data to calculate the mean dose of mancozeb required to give concentrations of ETU equal to those at the ETU NOAEL (5mg/kg bw/d), LOAEL (15 mg/kg bw/d) and clear-effect-level (30 mg/kg bw/d). An estimate of the uncertainty of the value was made by estimating the maximum and minimum mancozeb dose values.

The dossier submitter is of the view that these recent investigations have demonstrated that teratogenic levels of ETU will only be generated at mancozeb doses (360-521 mg/kg bw/day) which cause excessive maternal toxicity. This is because only a small amount (approximately 7%) of mancozeb is converted to ETU in animals; in addition, the rate of this conversion is likely to be slow, such that systemic peaks of ETU are only generated at very high doses of mancozeb. The relevance to hazard identification and classification of such teratogenic effects seen only in the presence of excessive maternal toxicity (death/killing in extremis,

paralysis, body weight and food consumption decreases, suffering) is questionable. On this basis, classification of mancozeb for developmental toxicity is not warranted and R2 (H361d) should be removed.

#### **10.8.10 Adverse effects on or via lactation**

Not addressed in this dossier.

#### **10.8.11 Conclusion on classification and labelling for reproductive toxicity**

|  |
|--|
| <b>Not classified (conclusive but not sufficient for classification)</b> |
|--|

### 10.9 Specific target organ toxicity-single exposure

Not addressed in this dossier.

### 10.10 Specific target organ toxicity-repeated exposure

The specific target organ toxicity of mancozeb upon repeated exposure has been investigated in regulatory 28 day, 90 day and 1 year studies in rats, mice and dogs, 28 and 90 day inhalation studies in rats and 28 and 90 day dermal studies in rats. There are also numerous human and animal studies from the open literature.

**Table 20: Summary table of animal studies on STOT RE**

| Method, guideline, deviation(s) from the guideline (if any)  | Species, strain, sex, number/group   | Dose levels, duration of exposure    | CLP Guideline value for classification (mg/kg bw/d or mg/l 6h/d rat study) | Results<br>(Effects statistically significantly different unless stated otherwise)   |
|--|--|--------------------------------------|--|--|
| <b>Oral studies in rats (28 days)</b>  |  |                                      |  |  |
| <b>28 day oral</b><br>(gavage)<br>OECD 407<br>(1981)<br>Deviations:<br>control and test<br>animals were<br>not age<br>matched, no<br>statistics, not all<br>groups reported.<br>GLP<br>Vehicle:<br>distilled water.<br>Mancozeb<br>Purity: 89.83%<br>Anonymous,<br>1994b | Rat, Sprague<br>Dawley (SD)<br>6/sex/group<br><br>(8/sex/group<br>for 200 mg/kg<br>bw/day) | 0, 50, 200 or<br>500 mg/kg<br>bw/day | Cat 1 = 30<br><br>Cat 2 = 300  | <u>500 mg/kg bw/day</u><br>1/6 females killed for humane reasons on day 21;<br>5/6 females ataxia, 2/6 females hind limb<br>paralysis day 28<br>↓ Body weight gain males, females overall loss<br>week 1-5<br>Clinical chemistry: ↓ 11.3% glucose, 31.6%<br>creatinine, 23.1% potassium in females<br>Haematology: ↑ 34.7% lymphocytes in females<br>Histopathology: no effects reported.  |
|  |  |                                      |  | <u>200 mg/kg bw/day</u><br>1/8 females killed for humane reasons on day 13;<br>2/8 females ataxia.<br>↓ Body weight gain, males and females week 1-5<br>Clinical chemistry: ↑ 59.7% ALT males, 14.7%<br>creatinine males, 38.6%/35.0% glucose<br>males/females; ↓ 54.0% bilirubin males,<br>42.5%/43.6% phosphorus males/females, 37.4%<br>AST in females, 18.1% potassium in females<br>Haematology: ↑ 31.2% lymphocytes in males,<br>39.8% WBC in females; ↓ 40.7% segmented<br>cells in males<br>Histopathology: Liver degeneration: 8/8 males<br>mild to severe; 4/6 females mild to moderate –<br>effect considered incidental as not observed at<br>the higher dose of 500 mg/kg bw/day. |
|  |  |                                      |  | <u>50 mg/kg bw/day</u><br>No treatment related findings  |

| Oral studies in rats (90 days)  |                                     |   |             |   |
|---|-------------------------------------|---|-------------|---|
| <b>Sub chronic 12 week oral</b><br>(dietary)<br><br>Non guideline<br><br>Non GLP<br><br>Purity 80%<br><br>Szepvolgyi <i>et al</i><br>(1989)<br><br>(from literature review) | Rat, H-Wistar<br><br>12/males/group | 1, 10, 50, 75, 113, 169, 253 and 379 mg/kg bw/day | Cat 1 = 10  | <u>379 mg/kg bw/day</u><br><br>Mortality: 4/12 died week 1-6<br><br>Clinical observations: prostration, weakness and posterior distal paralysis, resolved in survivors by end of study.<br><br>Body weight: ↓ (34.7% week 4) and body weight gain (83.4% weeks 1-12)<br><br>Food consumption: ↓ 34.8% weeks 1-12<br><br>Clinical chemistry: cholinesterase ↑ 77.3%; AST ↓ 20.0%; serum protein ↓ 15.9%;<br><br>Liver enzymes: APDM ↓ 37.7%; AHO ↓ 37.2%;<br><br>Iodine: Thyroid ↓ 91%, protein bound ↓ 63.2%<br><br>Relative organ weights: ↑ thyroid (~ 3-fold), liver (48.9%), kidneys (36.4%), testes (59.4%), adrenals (46.8%)<br><br>Histopathology: Thyroid enlarged and proliferating epithelial cells (incidences not reported) |
|   |                                     |   | Cat 2 = 100 | <u>253 mg/kg bw/day</u><br><br>Body weight: ↓ (20.3% week 4) and body weight gain (52.9% weeks 1-12)<br><br>Food consumption: ↓ 21.9% weeks 1-12<br><br>Clinical chemistry: Cholinesterase ↑ 50.1%; serum protein ↓ 10.1%;<br><br>Liver enzymes: APDM ↓ 20.5%, liver triglycerides ↑ 51.1%<br><br>Iodine: Thyroid ↓ 90%, protein ↓ 52%<br><br>Relative organ weight: ↑ thyroid (~1.5-fold), liver (41.9%), kidneys (27.3%), testes (31.7%), adrenals (35.7%)<br><br>Histopathology: Thyroid enlarged and proliferating epithelial cells (incidences not reported)   |
|   |                                     |   |             | <u>169 mg/kg bw/day</u><br><br>Body weight: ↓ (13.3% week 4) and body weight gain (24.2% weeks 1-12)<br><br>Food consumption: ↓ 17.7% weeks 1-12<br><br>Clinical chemistry: cholinesterase ↑ 56.5%;<br><br>Liver enzymes: triglycerides ↑ 47.6%<br><br>Iodine: Thyroid ↓ 81%, protein bound ↓ 48.6%<br><br>Relative organ weight: ↑ thyroid (77.3%), liver (22.5%)<br><br>Histopathology: thyroid follicular cells columnar, some lumens proliferation (incidences not reported)  |

|   |   |  |                                      |  |
|---|---|--|--------------------------------------|--|
|   |   |  |                                      | <p><u>113 mg/kg bw/day</u></p> <p>Liver enzymes: ↑ triglycerides 44.7%</p> <p>Iodine: Thyroid ↓ 80%, protein bound ↓ 48.6%</p> <p>Relative organ weight: ↑ thyroid (55.4%), liver (14.5%)</p> <p>Histopathology: thyroid follicular cells columnar, some lumens proliferation (incidences not reported)</p> <p><u>75 mg/kg bw/day</u></p> <p>Iodine: ↓ 83% in thyroid</p> <p>Relative organ weight: ↑ thyroid (50.2%), liver (14.5%)</p> <p><u>50 mg/kg/bw/day</u></p> <p>Iodine: ↓ 83% in thyroid</p> <p><u>10 mg/kg/bw/day</u></p> <p>Iodine: ↓ 21% in thyroid</p>   |
| <p><b>Subchronic 90 day oral</b></p> <p>(dietary)</p> <p>OECD 408</p> <p>GLP</p> <p>Mancozeb technical Purity 88.2% (Batch BL.I.850.930)</p> <p>Anonymous, 1989</p> | <p>Rat, CrI (SD) BR</p> <p>10/sex/group</p> <p>10/sex/group control &amp; high dose to investigate recovery</p> | <p>0, 28; 113 and 454 ppm</p> <p>Equivalent to:</p> <p>Males 0, 1.7, 7.0 and 29.2 mg/kg bw/day;</p> <p>Females 0, 2.1, 8.4 and 33.4 mg/kg bw/day</p> <p>90 days with 4-week recovery period for 454 ppm group.</p> | <p>Cat 1 = 10</p> <p>Cat 2 = 100</p> | <p><u>454 ppm (29.2 and 33.4 mg/kg bw/day in males and females respectively)</u></p> <p>↓ Body weight gain: 14.9% females weeks 0-13</p> <p>↓ Haematology: 40.2% neutrophils females</p> <p>↓ T4: 18.6 and 15.2% in males and females respectively</p> <p>↑ T3: 22.2% in females</p> <p>Pathology: no treatment related findings</p> <p>All effects recovered after 28 days without treatment</p> <p><u>113 ppm (7.0 and 8.4 mg/kg bw/day in males and females respectively)</u></p> <p>↓ T4: 15.2% in females (not statistically significant)</p> <p><u>28 ppm (1.7 and 2.1 mg/kg bw/day in males and females respectively)</u></p> <p>No effects</p> |
| <p><b>Three-month oral</b></p> <p>(dietary)</p> <p>OECD 408</p> <p>GLP</p> <p>Mancozeb Purity 84%</p> <p>Anonymous, 1986b</p>                                       | <p>Rat, CRL-CD (SD)</p> <p>14/sex/group</p>   | <p>0 (control), 30, 60, 125, 250 and 1000 ppm</p> <p>Equivalent to:</p> <p>Males: 0, 1.8, 3.5, 7.4, 15.0 and 57.3 mg/kg bw/day</p> <p>Females: 0, 2.2, 4.4, 9.2, 17.8 and 74.6 mg/kg bw/day</p>                    | <p>Cat 1 = 10</p> <p>Cat 2 = 100</p> | <p><u>1000 ppm (57.3 and 74.6 mg/kg bw/day in males and females respectively)</u></p> <p>↓ Body weight: 3-8% males weeks 3 to 13, 3-14% females weeks 2 to 13 (females statistically significant weeks 7-10)</p> <p>Organ weights: thyroid (absolute ↑ 32.0% males; relative ↑ 49.2% and 33.1% in males and females respectively; liver (relative ↑ 10.7 and 23.8% in males and females); testes (↑ absolute 10.6% and relative 4.8%); spleen (↑ relative 21.9% females)</p> <p>↓ T4: 33.8 and 42.9% in males and females respectively</p>   |

|  |   |  |                                   |  |
|--|---|--|-----------------------------------|--|
|  |   |  |                                   | <p>↑ <i>TSH</i>: 3.6-fold and 2.7 fold in males and females respectively</p> <p>↓ Hepatic mixed function oxidase activity: 31-35% males and 34-40% females</p> <p>Histopathology: Thyroid follicular cell hyperplasia: 9/10 males, 9/10 females (0/10 controls both sexes); adrenal hypertrophy zona glomerulosa 6/10 males, 3/10 females (1/10 control both sexes); liver hypertrophy of the centrilobular hepatocytes 2/10 males</p> <p><u>250 ppm (15.0 and 17.8 mg/kg bw/day in males and females respectively)</u></p> <p>↓ T4: 28.3% in females;</p> <p>↑TSH: 56.7 and 93.9% in males and females respectively (not statistically significant)</p> <p><u>125 ppm (7.4 and 9.2 mg/kg bw/day in males and females respectively)</u></p> <p>No treatment related effects</p> <p><u>60 ppm (3.5 and 4.4 mg/kg bw/d in males and females respectively)</u></p> <p>No treatment related effects</p> <p><u>30 ppm (1.78 and 2.2 mg/kg bw/day in males and females respectively)</u></p> <p>No treatment related effects</p> |
| <p><b>Sub chronic 90 day toxicity oral</b><br/>(gavage)<br/>OECD 408 (1981)<br/>Minor deviations<br/>THs were not investigated<br/>GLP<br/>Vehicle distilled water<br/>Sanachem Mancozeb technical Purity 89.1%<br/>Anonymous, 1997c</p> | <p>Rats Sprague Dawley<br/>12/sex/group</p> | <p>0, 15, 25, 40 or 50 mg/kg bw/day<br/>Dosed 5 days/week, 90 days</p> | <p>Cat 1 = 10<br/>Cat 2 = 100</p> | <p><u>50 mg/kg bw/day</u><br/>No treatment-related effects<br/><u>40 mg/kg bw/day</u><br/>No treatment-related effects<br/><u>25 mg/kg bw/day</u><br/>No treatment-related effects<br/><u>15 mg/kg bw/day</u><br/>No treatment-related effects</p>   |

|   |   |  |                                   |  |
|---|---|--|-----------------------------------|--|
| <p><b>Sub chronic toxicity oral (90 days)</b><br/>(Gavage)<br/>OECD 408 (1981)<br/>Minor deviations<br/>THs were not investigated<br/>GLP<br/>Vehicle peanut oil<br/>Mancozeb Purity 85%<br/>Anonymous, 1999c</p> | <p>Rat Wistar<br/>12/sex/group<br/>12/sex/group<br/>control and high dose<br/>recovery groups</p> | <p>0, 64, 160, 400 mg/kg bw<br/>Daily for 90 days<br/>Recovery after 28 days</p> | <p>Cat 1 = 10<br/>Cat 2 = 100</p> | <p><u>400 mg/kg bw/day</u><br/>Mortality: 1/24 males (day 14), 1/24 females (day 86, values include main study and recovery animals)<br/>Haematology: neutrophils: ↑ (23.2% females); ↓ lymphocytes (6.1% females)<br/>Organ weights: adrenals ↑ (60% absolute and 33.3% relative in females); liver ↑ (18-21% relative weight recovery group both sexes and absolute weight recovery males)<br/>Histopathology: hepatocellular degeneration/necrosis 11/11 males; 2/12 recovery; inflammatory changes 9/12 females; 0/12 recovery<br/><u>160 mg/kg bw/day</u><br/>Organ weights: ↑ adrenals (80% absolute and 33.3% relative in females) females<br/><u>64 mg/kg bw/day</u><br/>No treatment related effects.</p> |
|---|---|--|-----------------------------------|--|

| Method, guideline, deviation(s) from the guideline (if any)   | Species, strain, sex, number/group                       | Dose levels, duration of exposure  | CLP Guideline value for classification (mg/kg bw/d or mg/l 6h/d rat study) | Results<br>(Effects statistically significantly different unless stated otherwise)   |
|---|--|--|--|--|
| <b>Oral studies in mice (28 days)</b>   |  |  |  |  |
| <p><b>Four week range finding dietary study in mice.</b></p> <p>Non guideline Deviations, weight and pathology of liver and thyroid only, limited clinical pathology parameters</p> <p>Dose mg/kg bw not reported.</p> <p>Non GLP</p> <p>Mancozeb: purity 83%</p> <p>Anonymous, 1985b</p> | <p>Mouse, Charles River COBS-CD-1</p> <p>5/sex/group</p> | <p>0, 1, 10, 100, 1000 or 10000 ppm (mancozeb)</p> <p>Equivalent to 0, 0.2, 2, 20, 200 and 2000 mg/kg bw/day</p> | <p>Cat 1 = 30</p> <p>Cat 2 = 300</p>                                       | <p>No treatment-related effects on mortality.</p> <p>No treatment-related overt clinical signs of toxicity.</p> <p><u>10000 ppm (2000 mg/kg bw/day)</u></p> <p>↓ Body weight: 9.2% males, 11.7% females day 28</p> <p>↑ Organ weights: ↑ absolute thyroid and liver weight (66.7% and 20.2% respectively females); ↑ relative thyroid weight: (25.8% males, 57.9% females); ↑ relative liver weight (9.6% males, 19.7% females)</p> <p>Thyroid hyperplasia: 4/5 males, 5/5 females</p> <p><u>1000 ppm (200 mg/kg bw/day)</u></p> <p>↓ Body weight: 18.6% males day 14 9.5% females day 21</p> <p>↑ Organ weights: absolute thyroid and liver weight (33.3% and 15.1% respectively females)</p> <p>Thyroid hyperplasia: 1/5 females</p> <p><u>100 ppm (20 mg/kg bw/day DAR)</u></p> <p>No treatment-related findings.</p> |

| Oral studies in mice (90 days)  |   |  |                           |  |
|---|---|--|---------------------------|--|
| <b>Sub chronic toxicity oral.</b><br>(dietary)<br>OECD 408<br>Few minor deviations<br>GLP<br>Purity 83.1%<br>Anonymous, 1985c | Mouse<br>Charles River<br>COBS-CD-1<br>15/sex/group | 0 (control), 10, 100, 1000 or 10000 ppm<br>Equivalent to:<br>0, 1.8, 18, 167 and 1663 mg/kg bw/day in males;<br>0, 2.3, 22, 234 and 2160 mg/kg bw/day in females<br>3 months | Cat 1 = 10<br>Cat 2 = 100 | No treatment-related effects on mortality.<br>No treatment-related overt clinical signs of toxicity.<br><u>10000 ppm (1663 and 2160 mg/kg bw/day in males and females respectively)</u><br>↓ Body weight: 8.9% males, 6.8% females (day 28 values). Difference from control less marked at end of study.<br>Food consumption: ↓ 12.9% males, 19.9% females (day 28 values)<br>Liver enzymes: ↓ aniline hydroxylase activity (55% males, 48% females); ↓ aminopyrine-demethylase activity (34% males)<br>Organ weights: ↑ absolute thyroid (76.3% and 62.2% in males and females); ↑ relative liver (12.3% and 10.5% in males and females); ↑ relative kidney (22.9% and 10.5% in males and females)<br>Histopathology: Thyroid follicular cell hyperplasia, vacuolation of epithelium, congestion and decreased colloid density in 11-15/15 males and females (control 0-5/30); liver possible hepatocytic nuclear pleomorphism 10/15 females (4/30 controls)<br><u>1000 ppm (167 and 234 mg/kg bw/day in males and females respectively)</u><br>Body weight: ↓ 5% males only (day 28 value)<br>Liver enzymes: ↓ aminopyrine-demethylase activity (38% males)<br><u>100 ppm (18 and 22 mg/kg bw/day in males and females respectively)</u><br>No treatment-related findings<br><u>10 ppm (1.8 and 2.3 mg/kg bw/day in males and females respectively)</u><br>No treatment-related findings |

| Method, guideline, deviation(s) from the guideline (if any)   | Species, strain, sex, number/group    | Dose levels, duration of exposure  | CLP Guideline value for classification (mg/kg bw/d or mg/l 6h/d rat study) | Results (Effects statistically significantly different unless stated otherwise)  |
|---|---------------------------------------|--|--|--|
| <b>Oral studies in dogs (90 days)</b>   |                                       |  |  |  |
| <p><b>Three month dietary toxicity study in dogs</b></p> <p>OECD 409</p> <p>GLP</p> <p>Purity 83.35%)</p> <p>Anonymous, 1986c</p> | <p>Dog: Beagle</p> <p>6/sex/group</p> | <p>0, 10, 100, 1000 or 5000 ppm adjusted to give 100% a.i.</p> <p>Equivalent to:</p> <p>Males: 0, 0.29, 2.98, 28.62 &amp; 101.53 mg/kg bw/day</p> <p>Females: 0, 0.32, 3.35, 28.91 &amp; 108.67 mg/kg bw/day</p> <p>3 months</p> | <p>Cat 1 = 10</p> <p>Cat 2 = 100</p>                                       | <p><u>5000 ppm (101.53 and 108.67 mg/kg bw/day in males and females respectively)</u></p> <p>Mortality: Two males and one female dog killed weeks 8 - 10 due to poor health</p> <p>Clinical observations: dehydration all animals, thinness 2/6 males 6/6 females, few no faeces 6/6 males 5/6 females</p> <p>Body weight: ↓ 21.3% and 23.3% males and females week 13; lost weight over course of study.</p> <p>Food consumption: ↓ ~ 40% both sexes (overall).</p> <p>Haematology: ↓ RBC (25%), Hb (21.6%), Hct (22.4%) females week 5; Hb (15.9%) and RBC (17.7%) males week 5</p> <p>T3: ↓ 58.3% and 40.0% in males and females week 5</p> <p>T4: ↓ 7% and 81% in males and females week 5</p> <p>ALT: ↓ ~ 40% week 5 both sexes</p> <p>Histopathology: thyroid follicular cell hyperplasia 6/6 males and 6/6 females; thymic cortical lymphoid depletion 6/6 males and 5/5 females; Reproductive organs hypoplastic changes: aspermatogenesis testis 3/6; hypogenesis of the epididymis (2/6), prostate (6/6), ovaries (4/6) and uteri (4/6)</p> <p><u>1000 ppm (28.62 and 28.91 mg/kg bw/day in males and females respectively)</u></p> <p>Clinical observations: Occasional dehydration.</p> <p>Body weight: ↓ 9.6% males and 15.1% females week 13; loss or lack of gain during course of study</p> <p>Food consumption: ↓ 10.2% males, 18.7% females (overall value)</p> <p>Haematology: ↓ RBC (15.9%), Hb (15.0%), Hct (18.2%) females week 5</p> <p><u>100 ppm (2.98 and 3.35 mg/kg bw/d in males and females respectively)</u></p> <p>No treatment-related changes</p> <p><u>10 ppm (0.29 and 0.32 mg/kg bw/day in males and females respectively)</u></p> <p>No treatment-related changes</p> |

|  |   |   |                                      |  |
|--|---|---|--------------------------------------|--|
| <p><b>13 weeks oral toxicity study in dogs.</b></p> <p>(gavage in gelatine capsules)</p> <p>OECD 409</p> <p>GLP</p> <p>Mancozeb Purity 88.2%</p> <p>Anonymous, 1987c</p> | <p>Dog: Beagle</p> <p>4/sex/group, plus</p> <p>2/sex/group (high dose and control) for recovery (6 weeks)</p> | <p>0, 5.7, 34.0 and 340/204 mg/kg bw/day</p> <p>Equivalent to 5, 30 and 300/180 mg ai/kg bw/day</p> <p>13 weeks followed by 6 week recovery for the 340/204 mg/kg bw/day group.</p> <p>High dose reduced from day 17.</p> | <p>Cat 1 = 10</p> <p>Cat 2 = 100</p> | <p><u>340/204 mg/kg bw/day</u></p> <p><i>Clinical signs:</i> emesis, yellow faeces, pale mucous membranes, emaciation, subdued behaviour and isolated occurrence of convulsion or collapse</p> <p><i>Body weight and body gain:</i> ↓ 16% weight week 13, 60% gain week 1-13 full recovery during the reversibility period</p> <p><i>Food consumption:</i> ↓ 21% males, 24% females (weeks 1-13); full recovery during the reversibility period</p> <p><i>Haematology:</i> ↓ PCV, Hb and Hct (~ 25% in males and 30% in females after 12 weeks)</p> <p><i>Clinical chemistry:</i> ↓ glucose (13.3% males, 14.5% females after 12 weeks); ↑ ALP activity (31.3% after 6 weeks, 58.6% after 12 weeks females only); ↑ cholesterol (81.8% males after 12 weeks); ↑ bilirubin (200% males, 50% females after 12 weeks)</p> <p><i>T4:</i> ↓ 30.0% males and 35.0% female after 6 weeks and 55.6% females after 12 weeks</p> <p><i>T3:</i> ↓ 33.3% females after 12 weeks</p> <p><i>Organ weights:</i> ↑ thyroid (~ 120% absolute and 170% relative); ↑ relative liver weights (39.0% males, 47.1% females); ↑ relative adrenal weights (42.2% females only)</p> <p><i>Histopathology:</i> ↑ thyroid follicular hyperplasia (4/4 males and 3/4 females), colloid pallor and accumulation of colloid in the thyroid; mesenteric lymph node: ↑ hypoplasia 2/4 males 1/ 4 females; ↑ testes immaturity 2/4</p> <p>All effects recovered after 6 week recovery period</p> <p><u>34 mg/kg bw/day</u></p> <p><i>Clinical chemistry:</i> ↑ ALP activity (38.6% females after 12 weeks)</p> <p><i>T4:</i> ↓ 40% females after 6 weeks;</p> <p><i>Histopathology:</i> ↑ thyroid follicular hyperplasia (2/4 males and 2/4 females), colloid pallor in thyroid (3/4 males 2/4 females); mesenteric lymph node: ↑ hypoplasia 3/4 males 2/4 females; ↑ testes immaturity 2/4</p> <p><u>5.7 mg/kg bw/day</u></p> <p><i>Histopathology:</i> ↑ Thyroid follicular hyperplasia (3/4 males and 2/ 4 females), colloid pallor in thyroid 3/4 males 3/4 females</p> |
|--|---|---|--------------------------------------|--|

| Oral studies in dogs (1 year)  |                                       |  |                                      |   |
|--|---------------------------------------|--|--------------------------------------|---|
| <p><b>52 week oral toxicity study in the dog</b></p> <p>(dietary)</p> <p>OECD 452</p> <p>GLP</p> <p>Mancozeb</p> <p>Purity 84.5%</p> <p>Anonymous, 1990c</p> | <p>Dog: Beagle</p> <p>4/sex/group</p> | <p>0 (control), 50, 200, 800 or 1600 ppm</p> <p>Equivalent to:</p> <p>Males: 0, 1.8, 7.6, 28.4 &amp; 53.0 mg/kg bw/day</p> <p>Females: 1.9, 7.8, 29.2 &amp; 59.7 mg/kg bw/day in females</p> <p>52 consecutive weeks</p> | <p>Cat 1 = 2.5</p> <p>Cat 2 = 25</p> | <p><u>1600 ppm (53.0 and 59.7 mg/kg bw/day in males and females respectively)</u></p> <p>Mortality: 2/4 killed <i>in extremis</i> weeks 10 and 11. One acute urogenital tract lesion; other chronic regenerative anaemia.</p> <p>Body weight and body gain: ↓ 11.9% weight week 52, 30.6% gain week 1-53 females, not evident in 2 surviving males</p> <p>Food consumption ↓ (not quantified)</p> <p>Haematology: ↓ Hb (17.8% and 11.5% at 13 and 52 weeks in females), RBC (16.7%), PCV (15.3% at 13 weeks in females); ↑ MCV (7.3-9.3% weeks 13, 26 and 52 in males)</p> <p>Clinical chemistry: ↑ Serum cholesterol (41.1% and 54.4% weeks 13 and 26 in females).</p> <p>T4: ↓ 20-25% males, 20-39.5% females, not statistically significant;</p> <p>Organ weights: ↑ thyroid weights (absolute 47.0% males, 72.1% females; relative 50.0% males and 57.5% females); ↑ liver weights (relative 12.8% males, 27.9% females, not statically significant)</p> <p>Histopathology: ↑ Thyroid follicular distension (2/2 males, 4/4 females)</p> <p><u>800 ppm (28.4 and 29.2 mg/kg bw/day in males and females respectively)</u></p> <p>Body weight and body gain: ↓ ~ 17% both sexes week 52, 80.7% males, 35.4% females gain week 1-52</p> <p>Food consumption: ↓ both sexes</p> <p>Haematology: ↓ Hb (11.0% and 12.1% at 13 and 52 weeks in females), PCV (9.7% at 13 weeks in females)</p> <p><u>200 ppm(7.6 and 7.8 mg/kg bw/day in males and females respectively)</u></p> <p>No treatment-related effects.</p> <p><u>50 ppm (1.8 and 1.9 mg/kg bw/day in males and females respectively)</u></p> <p>No treatment-related effects.</p> |

|  |                                    |  |                                   |   |
|--|------------------------------------|--|-----------------------------------|---|
| <p><b>Oral toxicity study to dogs for 52 weeks.</b><br/>(capsule)</p> <p>EPA 83-1, consistent with OECD 452</p> <p>GLP</p> <p>Mancozeb technical Purity 88.6 %</p> <p>Anonymous, 1991c</p> | <p>Dog: Beagle<br/>4/sex/group</p> | <p>0, 2.3, 22.6 and 113 mg /kg bw/day</p> <p>Daily for 52 weeks except for 113 mg/kg bw/day group which were sacrificed in week 26</p> | <p>Cat 1 = 2.5<br/>Cat 2 = 25</p> | <p><u>113 mg /kg bw/day</u></p> <p>One male died on week 13 with marked anaemia. Rest of group killed week 26 on humane grounds.</p> <p>Clinical signs: Underactivity, thin and pale, emesis, yellow/green faeces</p> <p>Body weight gain: ↓ 47.1% females days 0-90</p> <p>Food consumption: ↓ 3% males, 18% females weeks 1-13</p> <p>Haematology: ↓ 35-39% PCV, Hb, RBC in females after 24 weeks; ↑ MCV 4.8% males after 24 weeks</p> <p>Clinical chemistry: ↑ cholesterol (81.3% males after 24 weeks); ↑ ALP (156.3% males); ↑ inorganic phosphorus (18.5% males); ↑ total protein (7.1% males); ↓ ALT (51.4% females); ↓ AST (32.1% females)</p> <p>T4: ↓ 38.9% males, 41.4% females after 24 weeks (female value not statistically significant).</p> <p><u>22.6 mg/kg bw/day:</u></p> <p>Body weight gain: ↓ 45.2% females days 0-364</p> <p>Food consumption: ↓ 4% males, 13% females weeks 1-52</p> <p>Haematology: ↑ MCV (4.5% males after 50 weeks)</p> <p>Clinical chemistry: ↑ cholesterol (37.0% females after 24 weeks); ↓ AST (25.0% females after 24 weeks); ↓ urea (25.7% males); ↓ creatinine (41.7% males);</p> <p>T4: ↓ 26.3% males after 50 weeks.</p> <p>Organ weights: ↑ relative liver weight (44.6% in females); ↑ relative thyroid weight (35.2% in males (not statistically significant, increased in 2/4 males)).</p> <p><u>2.3 mg /kg bw/day</u></p> <p>No treatment-related findings.</p> |
|--|------------------------------------|--|-----------------------------------|---|

|   |                                    |  |                                   |  |
|---|------------------------------------|--|-----------------------------------|--|
| <p><b>52 week oral</b><br/>(capsule)<br/>toxicity study in dogs.</p> <p>EPA 83-1,<br/>consistent with<br/>OECD 452 but<br/>only 2 groups</p> <p>GLP</p> <p>Mancozeb<br/>Purity 88.6 %</p> <p>Anonymous,<br/>1991d</p> | <p>Dog, Beagle<br/>4/sex/group</p> | <p>Orally by<br/>capsules</p> <p>0 and 40 mg/kg<br/>bw/day</p> <p>Daily for 52<br/>weeks</p> | <p>Cat 1 = 2.5<br/>Cat 2 = 25</p> | <p><u>40 mg/kg bw/day</u></p> <p><i>Clinical observations:</i> 2/4 females thin, 1/4 females hypothermic and of pale appearance from week 21</p> <p><i>Body weight:</i> ↓ 26.7% weight week 52, 82.8% gain weeks 1-13 females</p> <p><i>Food consumption:</i> ↓ 20-26% females</p> <p><i>Clinical chemistry:</i> ↓ ALAT (46.2% and 33.3% in females after 24 and 52 weeks); ↓ ASAT (44.4% in females after 24 weeks); ↑ inorganic phosphorous (25.0% and 20% in females after 24 and 50 weeks); ↑ ALP (73.0-121.6% both sexes after 24 and 50 weeks); ↑ Cholesterol (14.0-37.0% both sexes after 24 and 50 weeks,(only stat. sig. in females after 24 weeks).</p> <p><i>T4:</i> ↓ 36.4%, 42.1% in males and females respectively after 50 weeks;</p> <p><i>T3:</i> ↓ 14.3% females after 50 weeks</p> <p><i>Organ weights:</i> ↑ Thyroid weight (22.2% and 17.1% absolute values in males and females)</p> <p><i>Histopathology:</i> Liver: iron pigment deposition in Kuffer cells (4/4 females), periacinar lipofuscinosis 4/4 males (incidence in controls 1/4 for both findings)</p> |
|---|------------------------------------|--|-----------------------------------|--|

| Method, guideline, deviation(s) from the guideline (if any)  | Species, strain, sex, number/group   | Dose levels, duration of exposure  | CLP Guideline value for classification (mg/kg bw/d or mg/l 6h/d rat study) | Results<br>(Effects statistically significantly different unless stated otherwise)   |
|--|--|--|--|--|
| <b>Inhalation studies in rats (28 days)</b>  |  |  |  |  |
| <b>Subacute inhalation toxicity study in rats</b><br>(nose-only)<br>Mancozeb<br>Purity: 83.35%<br>Anonymous,<br>1986d                    | Rat/ Crl:CD<br>(SD)BR<br>38/sex/group<br>5/sex/group<br>killed after 4 weeks   | 6 hours a day and 5 days per week<br><br>Concentration<br>0, 0.022, 0.086, 0.308 mg/L<br><br>Respirable concentration<br>0, 0.008, 0.04, 0.127 mg/L<br><br>Mass median diameter 3.7-4.4 µm<br><br>GSD 2.1-2.3<br><br>4 weeks | Cat 1 = 0.06<br><br>Cat 2 = 0.6  | <u>0.127 mg/L respirable (0.308 mg/L total aerosol)</u><br><br>Body weights: ↓ 5.5% males weight week 4, 10.9% males gain week 0-4<br><br><u>0.04 mg/L respirable (0.086 mg/L total aerosol)</u><br><br>No treatment related findings<br><br><u>0.008 mg/L respirable (0.022 mg/L total aerosol)</u><br><br>No treatment related findings  |
| <b>Inhalation studies in rats (90 days)</b>  |  |  |  |  |
| <b>Subchronic inhalation toxicity study in rats</b><br>(Nose-only)<br>EPA guidelines 82-4<br>GLP<br>purity 83.35%<br>Anonymous,<br>1986d | Rat/ Crl:CD<br>(SD)BR<br>38/sex/group<br>10/sex/group<br>killed after 13 weeks | 6 hours/day, 5 days/week<br><br>Concentration<br>0, 18, 79, 326 mg/m <sup>3</sup><br><br>Respirable concentration<br>0, 8, 36, 144 mg/m <sup>3</sup><br><br>Mass median diameter 3.8-4.2 µm, GSD 2.1<br><br>13 weeks         | Cat 1 = 0.02<br><br>Cat 2 = 0.2  | <u>144 mg/m<sup>3</sup> respirable (326 mg/m<sup>3</sup> total aerosol)</u><br><br>Body weights: ↓ 6.8% males weight week 13, 10.4% males gain week 0-13<br><br>T4: ↓ 31.2% females<br><br>Triglycerides: ↓ 36.2% males after 13 weeks<br><br>Histopathology: Thyroid follicular epithelium hyperplasia (mild) 3/10 females<br><br><u>36 mg/m<sup>3</sup> respirable (79 mg/m<sup>3</sup> total aerosol)</u><br><br>No treatment related findings<br><br><u>8 mg/m<sup>3</sup> respirable (18 mg/m<sup>3</sup> total aerosol)</u><br><br>No treatment related findings |

| Method, guideline, deviation(s) from the guideline (if any)  | Species, strain, sex, number/group   | Dose levels, duration of exposure  | CLP Guideline value for classification (mg/kg bw/d or mg/l 6h/d rat study) | Results (Effects statistically significantly different unless stated otherwise)  |
|--|--|--|--|--|
| <b>Dermal studies in rats (28 days)</b>  |  |  |  |  |
| <b>4 week repeat dermal toxicity study in rats</b><br>OECD 410<br>GLP<br>Vehicle: distilled water<br>Mancozeb Purity 82.4%<br>Anonymous, 1988d       | Rat, Crl: CDBR, SD<br>10/sex/group   | 0 (control), 10, 100 or 1 000 mg/kg bw/day<br>6 hours/day<br>20 or 21 applications | Cat 1 = 60<br>Cat 2 = 600  | <u>10, 100 or 1000 mg/kg bw/day</u><br>No effects  |
| <b>Dermal 28 day study in rat</b><br>OECD 410<br>GLP<br>Mancozeb, purity of test substance not reported<br>Vehicle: peanut oil<br>Anonymous, (1999d) | Rat: Sprague-Dawley Crl: CD(SD)BR<br>5/sex/group, including recovery groups for control and 750 mg/kg bw/day | 0, 120, 300, 750 mg/kg bw/day<br>6 hours/day, 5 days/week for 4 consecutive weeks  | Cat 1 = 60<br>Cat 2 = 600  | <u>750 mg/kg bw/day</u><br>Clinical signs: lethargy in both sexes.<br>Haematology: ↑ lymphocytes 13.5% males; ↓ 26.7% males<br>Organ weight: relative brain weight ↑ 19.3% females.<br>Macroscopic pathology: liver congestion/hard in consistency: 4/5 females (0/5 controls and 3/5 recovery controls).<br>Microscopic pathology: Liver foci of round cell infiltration: 3/5 females (1/5 main study controls); skin acanthosis and hyperkeratosis 3/5 males (0/5 main study controls)<br><u>300 mg/kg bw/day</u><br>Organ weight: relative brain weight ↑ 12.4% females.<br>Macroscopic pathology: liver congestion/hard in consistency: 4/5 females (0/5 controls and 3/5 recovery controls).<br><u>120 mg/kg bw/day</u><br>No effects |

| Dermal studies in rats (90 days)  |                         |   |                           |  |
|---|-------------------------|---|---------------------------|--|
| <b>90 day dermal toxicity in rats.</b><br>OECD (411)<br>GLP<br>Vehicle distilled water<br>Mancozeb<br>Purity 89.1%<br>Anonymous,<br>1997d | Rat: SD<br>12/sex/group | 0 and 1000<br>mg/kg bw/day<br>at least six<br>hours per day,<br>5 days /week<br>90 days | Cat 1 = 20<br>Cat 2 = 200 | <u>1000 mg/kg bw/day</u><br>No treatment-related effects |

**Table 21 Summary table of human data on STOT RE**

| Type of data/report  | Test substance  | Route of exposure<br>Relevant information about the study (as applicable)  | Observations   |
|--|-----------------|--|--|
| Thyroid function in male workers manufacturing mancozeb, an agricultural fungicide, and in men not exposed to mancozeb.<br>Anonymous (1985a) | Mancozeb        | Thyroid function in men currently or previously exposed to EBDCs for many years at a manufacturing site was compared to 153 men not exposed to EBDC, its products or ETU, who worked at the same plant. Blood was analysed for thyroid hormones, complete blood count and chemistry profile. A 24 hour urine sample was analysed for iodide, creatinine, ETU and EBDC. | Exposure to EBDC manufacture was not associated with an increased prevalence of thyroid abnormalities  |
| Worker exposure data<br>Smith (1984)   | ETU             | Clinical examinations and thyroid function tests were carried out over a period of 3 years in the UK on 8 workers involved in the manufacture of ETU and 5 workers involved in the mixing of ETU with rubber.  | Mixers but not process workers had significantly lower levels of T4 in their blood compared to controls. With the exception of one mixer with elevated TSH levels, who was evaluated as hypothyroid on further testing, no effects were found on TSH or thyroid binding globulin |
| Worker exposure data<br>Anonymous (1990b)  | Mancozeb        | In workers in an EBDC fungicide factory in the Netherlands dermal exposure to mancozeb varied from 290.19 mg to 3305.87 mg outside clothing (including hands and head) and from 7.92 mg to 118.7 mg inside clothing. Respiratory exposure was minor when compared to dermal exposure, resulting in 290.30 to 4818.27 µg. Thyroid hormone levels were determined.       | No biologically significant differences were observed for the concentrations of T3, T4 and TSH in blood samples collected before and after each shift.<br>No effects on thyroid hormones were detected.  |
| Worker exposure data<br>Steenland <i>et al</i> (1997)  | EBDC pesticides | Sprayers using EBDCs (49 men), landowners (lightly exposed, 14 men) and a non-exposed control group (31 men) compared for blood T4 and TSH levels. ETU was determined in urine   | Low levels of ETU were detected in the urine of EBDC workers. Although an apparent increase in age-adjusted TSH occurred, T4 and TSH levels were within normal levels in all groups.   |

| Type of data/report   | Test substance            | Route of exposure<br>Relevant information about the study (as applicable)   | Observations   |
|---|---------------------------|---|--|
| Cross-sectional worker exposure study<br>Baranska <i>et al</i> (2008)   | Pesticides                | Immune function was determined by measurement of antibody titres against two vaccinations of hepatitis B  | Exposure to EBDCs and other pesticides did not affect the ability of the immune system to respond to vaccination, but pesticide exposed workers who were genetically characterized by the 2.2 IL-1 $\alpha$ polymorphism showed a lower antibody response than unexposed controls with the same genotype |
| Cross-sectional study of female spouses of pesticide workers (Agricultural Health Study)<br>Goldner <i>et al</i> (2010) | Organochlorine pesticides | Self-reported history of physician diagnosed thyroid disease and exposure to organochlorines was assessed among 16,529 female spouses of pesticide applicators. The risk of thyroid disease was also assessed in relation to ever use of herbicides, insecticides, fungicides including maneb or mancozeb, and fumigants.   | Ever use of maneb/mancozeb was associated with hypothyroidism and hyperthyroidism but further studies are needed to confirm the findings.  |
| Cross-sectional study of pesticide workers (Agricultural Health Study)<br>Goldner <i>et al</i> (2013)                   | Organochlorine pesticides | Self-reported history of physician diagnosed thyroid disease and exposure to pesticides was investigated in 22,246 male pesticide applicators. The association between ever use of 50 pesticides and the occurrence of any thyroid disease (hypothyroidism, hyperthyroidism, or other disease vs controls with no thyroid disease) was evaluated.   | There was no evidence that exposure to maneb/mancozeb increased the risk of either hypothyroidism or hyperthyroidism as observed previously among the spouses of applicators.  |
| Cross-sectional case-control study<br>Panganiban <i>et al</i> (2004)  | EBDCs                     | The study was a cross-sectional investigation of the incidence of thyroid gland disorders among banana plantation workers exposed to EBDCs and the relation between the incidence of thyroid gland disorders and blood and urinary ETU. The study group included 57 directly exposed workers, 31 indirectly exposed workers randomly selected from four banana plantations and 43 comparison workers from an organic farm. All subjects underwent complete medical examinations and laboratory tests. | There were no statistically significant differences in thyroid function tests of exposed and control groups and no statistically significant differences in the prevalence of abnormal thyroid ultrasound results, or solitary nodules in exposed workers compared to controls.                          |
| Worker exposure study<br>Colosio <i>et al</i> (2007);   | Mancozeb                  | This study investigated immunotoxic effects induced by exposure to the fungicide mancozeb in Italian vineyard workers. The study included 48 vineyard workers intermittently exposed to mancozeb and 45 healthy controls. The subjects were investigated three times: before the seasonal application of pesticides and at 30 and 45 days after the beginning of the application period.  | No relevant adverse immune effects were found in the pesticide exposed workers compared with the non-exposed controls  |

| Type of data/report   | Test substance | Route of exposure<br>Relevant information about the study (as applicable)  | Observations  |
|---|----------------|--|---|
| Worker exposure study<br>Corsini <i>et al</i> (2005)  | Mancozeb       | The study, conducted in Italy, included 26 subjects: 13 vineyard workers (12 male, 1 female) engaged in mancozeb application by tractor, and 13 control subjects (12 male, 1 female) never exposed to mancozeb or to other plant protection products. The potential immunotoxic effects of mancozeb were investigated using several blood cellular and serum parameters.   | Comparisons within exposed workers suggest that low-level exposure to mancozeb may have slight immunomodulatory effects. However, the results are difficult to interpret because of the small sample size. The investigators concluded that the prognostic significance of the slight changes observed in the study is unclear. |
| Worker exposure study (EUROPIT)<br>van Amelsvoort <i>et al</i> (2008)                               | Mancozeb       | This study was conducted in the Netherlands to investigate the short-term and long-term immune effects of occupational exposure to EBDCs, in particular mancozeb. 41 re-entry workers and 40 non-exposed controls were investigated before the seasonal application of pesticides and 30 days after the beginning of the application period. Immune parameters were determined in blood and all participants filled in a questionnaire regarding exposure and outcome parameters, and all subjects underwent a comprehensive medical examination | No relevant adverse immune effects were found in the pesticide exposed workers compared with the non-exposed controls.  |
| Cross-sectional worker exposure study<br>Steerenberg <i>et al</i> 2008                              | EBDCs          | The study involved five field studies in: the Netherlands (flower bulb growers, mainly re-entry workers), Italy (vineyard workers), Finland (potato farmers), and Bulgaria (workers from a zineb factory and greenhouse workers) to evaluate a possible association between occupational exposure to pesticides and haematological parameters and components of the immune defence.  | EBDCs do not influence the immunologic system in a clinically significant fashion, and do not pose a significant health risk to the exposed subjects.   |
| Cross-sectional study of pesticide workers (Agricultural Health Study)<br>Beard <i>et al</i> (2011) | Mancozeb       | The authors identified 110 suicides among 81,998 cohort members. Effects on state of mind, as suicide, were determined   | No association was established between pesticide and subsequent incidence of suicide in pesticide applicators and their spouses in the US Agricultural Health Study   |
| Case-control study<br>Dhillon <i>et al</i> (2008)   | Pesticides     | Associations between self-reported exposure to pesticide products, organic pesticides, and other occupational and environmental exposures were determined. 100 cases of Parkinson's Disease (PD) and 84 controls were evaluated for associations between self-reported exposure to pesticide products, organic pesticides, and other occupational and environmental exposures and PD.  | No relationship between exposure to mancozeb and risk of PD was found   |
| Cross-sectional study of pesticide workers (Agricultural Health Study)<br>Kamel <i>et al</i> (2007) | Mancozeb       | Data from pesticide applicators and spouses participating in the Agricultural Health Study (USA) were evaluated in relation of self-reported PD and pesticide exposure.  | No evidence of an association between incident or prevalent PD and mancozeb exposure  |
| Case control study<br>Tanner <i>et al</i> (2009);<br>Tanner <i>et al</i> (2011)                     | Mancozeb       | 519 PD cases from 8 movement disorder clinics across the US and 511 controls were investigated. In follow-up study lifetime use of pesticides and PD investigated.   | No evidence of association of PD with mancozeb exposure.  |

| Type of data/report   | Test substance | Route of exposure<br>Relevant information about the study (as applicable)  | Observations   |
|---|----------------|--|--|
| Cross-sectional study of pesticide workers (Agricultural Health Study)<br>Mills <i>et al</i> (2009) | Mancozeb       | The study examined myocardial infarction (MI) mortality and nonfatal MI incidence among male pesticide applicators | The study does not provide convincing evidence that maneb/mancozeb, or any individual pesticide or pesticide class, is associated MI mortality or nonfatal MI incidence. The investigators concluded that there was little evidence of increased risk of MI mortality or nonfatal MI associated with the occupational use of pesticides in a population with low risk for MI |

**Table 22: Summary table of other studies relevant for STOT RE**

| Method, guideline, deviation(s) from the guideline (if any)   | Species, strain, sex, number/group   | Dose level, duration of exposure  | CLP Guideline value for classification (mg/kg bw/d or mg/l 6h/d rat study) | Results (Effects statistically significantly different unless stated otherwise)  |
|---|--|---|--|--|
| <p><b>Subchronic oral neurotoxicity</b> (dietary)</p> <p>Non guideline GLP</p> <p>Deviations: no clinical chemistry, organ weights or standard histopathology (neuropathology only)</p> <p>Mancozeb</p> <p>Purity 79.3%</p> <p>Anonymous, 1991e</p> | <p>Rat, Crl:CD BR,</p> <p>10/sex/group; plus 2 groups of 16 females for 14 days only</p> | <p>0, 20, 125, 750 and 5000 ppm for 90 days</p> <p>Equivalent to:<br/>Males: 0, 1.35, 8.21, 49.7 and 339 mg/kg bw/day<br/>Females: 0, 1.67, 10.5 and 63.3 mg/kg bw/day</p> <p>5000 ppm and 5000 ppm for 14 days</p> <p>Due to mortality the initial group of females at 5000 ppm were fed control diet from day 14.</p> | <p>Cat 1 = 10</p> <p>Cat 2 = 100</p>                                       | <p><u>5000 ppm (339 and 413 mg/kg bw/day in males and females, respectively):</u></p> <p>Mortality: 1/10 males and 4/10 females weeks 2-4. 0/16 and 0/16 in females fed diet for 2 weeks.</p> <p>Clinical signs: abnormal gait and/or limited or no use of hindlimbs, muscle wasting, from week 2/3.</p> <p>Body weight: ↓ 44.7% in males day 91; initial females weight loss to day 14; additional females reduced body weight gain (not significant).</p> <p>Food consumption: ↓41% in males; ↓ 74% in females week 2; additional females ~ ↓ 33%.</p> <p>Histopathology: intrasheath ellipsoids, myelin phagocytosis, Schwann cell proliferation; demyelinated nerves, myelin sheath thickening, myelin bubbles, neurofibrillary degeneration of nerve tissues in males and females; 10/16 females had posterior thigh muscle atrophy</p> <p><u>750 ppm (49.7 and 63.3 mg/kg bw/day in males and females, respectively):</u></p> <p>Body weight: ↓9% (not significant) in females</p> <p>Histopathology: myelin phagocytosis, Schwann cell proliferation; demyelinated nerves, myelin sheath thickening, myelin bubbles in males; demyelination and myelin ovoids/debris in females.</p> <p><u>125 ppm (8.21 and 10.5 mg/kg bw/day in males and females, respectively):</u></p> <p>No treatment-related effects.</p> <p><u>20 ppm (1.35 and 1.67 mg/kg bw/day in males and females, respectively):</u></p> <p>No treatment-related effects.</p> |

|   |   |  |            |   |
|---|---|--|------------|---|
| <p><b>Oral Investigation into serum T4 and liver microsomal enzyme activity</b><br/>(gavage)<br/>Non guideline investigative study<br/>Non-GLP<br/>Mancozeb<br/>Purity not reported<br/>Vehicle: corn oil<br/>Flippin <i>et al</i> 2009 (from literature)</p> | <p>Rat: Long Evans female rats<br/>8-16/group</p> | <p>0, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500 and 1000 for 4 days.<br/>Serum T4 and liver microsomal enzyme measured 24h after last dose</p> | <p>N/A</p> | <p>Predictive modelling of a mixture of thyroid hormone disrupting chemicals that affect production and clearance of thyroxine.<br/>Mancozeb produced a dose-dependent decrease in circulating levels of T4 with an ED<sub>50</sub> of 259 mg/kg bw/day<br/>No induction of EROD, PROD or T4-UDPGT was seen.</p>  |
| <p><b>Non guideline oral investigative study</b><br/>Oral (drinking water)<br/>Non-GLP<br/>Mancozeb<br/>Purity 80%<br/>Vehicle: water<br/>Kechrid <i>et al</i> 2011 (from literature)</p>   | <p>Rat: Wistar<br/>8/group</p>                    | <p>0, 2 or 3.5 g/L for 4 weeks</p>   | <p>N/A</p> | <p><u>3.5 g/L:</u><br/>↓ Body weight gain, ↓ blood glucose,<br/>↑ ALT, AST and ALP<br/>↑ cholesterol, serum triglycerides, serum creatinine and serum urea concentrations<br/><u>2g/L</u><br/>No effects</p>  |
| <p><b>Non guideline investigative study</b><br/>Non GLP<br/>Mancozeb<br/>Purity 75%<br/>Vehicle: olive oil<br/>Ksheerasagar <i>et al</i> 2010 (from literature)</p>   | <p>Mice, swiss albino, male<br/>10/group</p>      | <p>200, 400, 600, 800 mg/kg bw/day<br/>Administered for 30 days</p>  | <p>N/A</p> | <p><u>800 mg/kg bw/day</u><br/>↓ kidney, spleen &amp; liver weights<br/>↑ thyroid &amp; thymus weights<br/>↓ testes, prostate &amp; cowper's gland weight<br/>↓ number &amp; diameter of spermatogenic and leydig cells<br/>↓ diameter of spermatogonia &amp; primary spermatocytes<br/>↓ number of small follicles ↑number of medium, large and total follicles in the thyroid<br/>Hypertrophy of &amp; hyperplasia of thyroid follicular cells with loss of colloid<br/>↓ protein (in testes, liver &amp; kidney) &amp; glycogen (liver &amp; kidneys)<br/>↑ lipids in testes</p> |

|   |              |   |     |   |
|---|--------------|---|-----|---|
|   |              |   |     | <p><u>600 mg/kg bw/day</u></p> <p>↓ kidney, spleen &amp; liver weights</p> <p>↑ thyroid &amp; thymus weights</p> <p>↓ testes, prostate &amp; cowper's gland weight</p> <p>↓ number &amp; diameter of spermatogenic and leydig cells</p> <p>↓ number &amp; diameter of spermatogenic and leydig cells</p> <p>↓ number of small follicles ↑ number of medium, large and total follicles in the thyroid</p> <p>Hypertrophy of &amp; hyperplasia of thyroid follicular cells with loss of colloid</p> <p>↓ glycogen (liver &amp; kidney) &amp; lipids (kidney)</p> <p>↑ lipids (liver)</p> <p><u>400 mg/kg bw/day</u></p> <p>↓ testes weight</p> <p>Hypertrophy of &amp; hyperplasia of thyroid follicular cells with loss of colloid</p> <p><u>200 mg/kg day</u></p> <p>No effects</p> |
| <p><b>Non guideline investigative study</b></p> <p>Oral</p> <p>Non guideline</p> <p>Non GLP</p> <p>Mancozeb</p> <p>Purity not reported</p> <p>Sakr 2007 (from literature)</p> | Rats, albino | <p>313.6 mg/kg bw/day</p> <p>3 times a week for 6 weeks</p> | N/A | <p><u>313.6 mg/kg bw/day</u></p> <p>Histopathological changes in the liver</p> <p>↑ ALT &amp; AST, malondialdehyde,</p> <p>↓ superoxide dismutase</p> <p>Treatment with mancozeb &amp; ginger extract (120 mg/kg bw/day) improved effects.</p>  |
| <p><b>Non guideline investigative study</b></p> <p>Oral</p> <p>Non GLP</p> <p>Mancozeb</p> <p>Purity not reported</p> <p>Sakr <i>et al</i> 2009 (from literature)</p>         | Rats, albino | <p>313.6 mg/kg bw/day</p> <p>3 times a week for 6 weeks</p> | N/A | <p><u>313 mg/kg bw/day</u></p> <p>↓ serum testosterone &amp; LH</p> <p>↓ diameters of seminiferous tubules</p> <p>Inhibition of spermatogenesis, degeneration of spermatogenic cells, destruction of leydig cells &amp; congestion of blood vessels</p> <p>Treatment of rats with mancozeb and with ginger led to an amelioration of the observed testicular damage.</p>  |

|   |                    |                  |     |  |
|---|--------------------|------------------|-----|--|
| <b>Non guideline investigative study</b>  | Rats, Wistar, male | 500 mg/kg bw/day | N/A | <u>500 mg/kg bw/day</u>  |
| Oral (gavage)                             |                    |                  |     | No changes in body weight  |
| Non GLP                                   |                    |                  |     | ↓ Testis, epididymis, ventral prostate & seminal vesicle weights |
| Mancozeb                                  |                    |                  |     | ↓ sperm density & motility                                       |
| Purity not reported                       |                    |                  |     | 80% negative fertility   |
| Vehicle: olive oil)                       |                    |                  |     | ↓ sialic acid & glycogen content                                 |
| Joshi <i>et al</i> 2005 (from literature) |                    |                  |     | ↑ testicular protein & cholesterol                               |
|   |                    |                  |     | ↓ reduction in testosterone & ALP                                |
|   |                    |                  |     | ↑ acid phosphatase   |

### 10.10.1 Oral

#### Rats

##### *28-day studies*

Groups of 6 Sprague Dawley (SD) rats/sex were administered mancozeb by gavage for 28 days at 0, 50, 200 or 500 mg/kg bw/day. The top dose of 500 mg/kg bw/day resulted in hind limb ataxia/paralysis in females, leading to the early termination of one female. Abnormal clinical and haematological parameters were observed in this dose group, as were reductions in body weights and body weight gain. Females appeared to be more susceptible to mancozeb than males. Ataxia in females was also noted in the 200 mg/kg bw/day dose group, resulting in the premature termination of another female. Reduced body weight and body weight gain, and increases in liver and kidney weights were also observed at 200 mg/kg bw/day. Abnormalities in clinical chemistry parameters also occurred at this dose. No treatment related effects were observed at 50 mg/kg bw/day (Anonymous, 1994b).

##### *90-day studies*

Five key studies investigating the oral administration of mancozeb over 90 days were available.

In the study by Szepvolgyi *et al* (1989), groups of 12 male Wistar rats were given mancozeb in the diet for 90 days at 0, 1, 10, 50, 75, 113, 169, 253 or 379 mg/kg bw/day. The top dose of 379 mg/kg bw/day resulted in significant toxicity (prostration, weakness and paralysis) and the premature death of 4 males within 6 weeks. Survivors at this dose had enlarged thyroids and showed signs of thyroid toxicity, both biochemical (reduced iodine) and histopathological (proliferating epithelial cells). Liver effects included reductions in liver enzymes and increases in relative organ weight, without accompanying histopathological signs. Similar effects on the thyroid and liver were seen at the 253, 169, 113 and 75 mg/kg bw/day doses. At lower doses decreases in thyroid iodine and increases in liver and thyroid weight were unaccompanied by histopathological change in either organ.

In the study by Anonymous (1989), groups of 10 SD rats/sex were given mancozeb in the diet for 90 days at 0, 28, 113 or 454 ppm. Mancozeb had a minimal effect amongst males and females receiving 454 ppm, characterised by a reduced body weight gain during the treatment period. Other changes from controls included decreases in neutrophils, increases in T3 and suppression of T4. These were unaccompanied by organ weight change and histopathology and so were considered to be equivocal.

In the study by Anonymous (1986b), groups of 14 SD rats/sex were given mancozeb in the diet for 90 days at 0, 30, 60, 125, 250 or 1000 ppm. No treatment related mortality or clinical signs were seen at any dose. No effects on body weight or food consumption were recorded in animals fed concentrations up to and including 250 ppm. At 1000 ppm, male rats showed a statistically significant decrease in body weight from week 3

through week 13, whereas in females the 3 to 14% body weight decrease was significant only between weeks 7 and 10. At 1000 ppm, food consumption was decreased in males during weeks 3 to 13, but not in females. Thyroid follicular cell hyperplasia was seen in 90% of the males and females receiving 1000 ppm. A small, well-defined focus of hyperplastic follicular epithelial cells was seen in one male. There was an increased incidence and severity of hypertrophied vacuolated cells in the pituitary of male rats. The kidneys of males and females administered 125-1000 ppm had minimal to moderate amounts of a yellow-brown pigment in the lumen of the cortical tubules. These pigment deposits were not accompanied by any histopathological effects and were attributed to ethylene-bisithiocyanate sulfide (EBIS), a yellow-coloured metabolite of mancozeb; hence, they were not considered to be adverse. There was also an increased incidence of hypertrophy of the cells of the adrenal zona glomerulosa, and of hypertrophy of the centrilobular hepatocytes in males fed 1000 ppm mancozeb. There was hepatocytic centrilobular hypertrophy in the 1000 ppm male rats. The only clinical sign which was considered to be possibly related to treatment was diarrhoea which was noted sporadically in a few animals from Day 57 onwards. However, this did not appear to be dose-dependent and together with the other observed clinical signs was not reflected in the macroscopic pathology, histopathology, haematology or clinical biochemistry. These signs were therefore considered not to be treatment-related. When fed for 3 months to rats, mancozeb induced thyroid, pituitary and liver alterations, both macroscopic and microscopic at the top dose of 1000 ppm (57 mg/kg bw/day). Effects on thyroid hormones were also present at 250 ppm (15 mg/kg bw/day).

In the study by Anonymous (1999c), groups of 12 Wistar rats/sex were given mancozeb by gavage for 90 days at 0, 64, 160 or 400 mg/kg bw/day. At the top dose, one male and one female were found dead. The treatment-related effects at this dose consisted of changes in haematological parameters, increased liver and adrenal weights and hepatocellular degeneration. Increased adrenal weight was also noted at 160 mg/kg bw/day.

In the study by Anonymous (1997c), groups of 12 SD rats/sex were given mancozeb by gavage 5 days/week for 90 days at 0, 15, 25, 40 or 50 mg/kg bw/day. No treatment-related effects were noted at any dose.

In a subchronic neurotoxicity study (Anonymous, 1991e), groups of 10 SD rats/sex were given mancozeb in the diet for 90 days at 0, 20, 125, 750 or 5000 ppm. One male and 4 females died between the second and fourth week of administration in the 5000 ppm group. These deaths resulted in a cessation of test compound to females of the high dose only and administration of control feed from the 15th day through the remainder of the study. Clinical signs of hindlimb effects were observed in all rats fed 5000 ppm diets. Onset of clinical signs in the second and third week of administration consisted of generalised weakness, abnormal gait or mobility, and limited or no use of the rear legs. Loss of muscle mass was also reported in the males. However, by day 60 some males in the high-dose group appeared clinically normal and females showed improvement after one week on control diets. Females of the satellite group fed mancozeb for two weeks also manifested limited rear limb mobility. No other group of rats had clinically observable signs of toxicity or mortality attributable to the intake of the test compound. Body weight, food consumption and food efficiency were substantially decreased (40-45%) in males by day 90 in the high-dose group. Females receiving 5000 ppm also showed initial decreases in food consumption and weight loss that were reversed after cessation of test compound and their placement on control feed. Body weights were also 9% lower than controls among females at 750 ppm. Both male and female rats of the 5000 ppm groups presented with myelin damage and Schwann cells proliferation in sections of nerve tissue and myelin damage in teased nerve fibres. A lower incidence of these lesions was observed in rats fed the 750 ppm diets. Muscular atrophy was also noted microscopically, but only at the 5000 ppm level. Overall, in this dietary 90-day neurotoxicity study in rats, severe neurotoxic effects (hindlimb, loss of muscle mass, muscular atrophy and myelin damage with Schwann cells proliferation of nerve tissue) were seen at the top dose of 5000 ppm (328/420 mg/kg bw/d in M/F) in the presence of generalised toxicity (large reductions in body weight and food consumption and deaths). Less severe neurotoxicity (myelin damage with Schwann cells proliferation of nerve tissue) was also seen at 750 ppm (49/63 mg/kg bw/d in M/F), in association with small reductions in body weight.

Hind limb paralysis was also noted in maternal animals at 150 mg/kg bw/day in an investigative developmental neurotoxicity study (Axelstad *et al.*, 2011 – summarised in the developmental toxicity section).

*Other studies (from the literature review)*

Weanling Long Evans female rats (8-16 per group) were dosed at 0, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500 and 1000 mg mancozeb/kg bw for 4 days (Flippin *et al.*, 2009). 24 hours after the last dose, serum T<sub>4</sub> was measured by radioimmunoassay and liver microsomal enzyme activity was assayed. Mancozeb produced a dose-dependent decrease in circulating levels of T<sub>4</sub> with an ED<sub>50</sub> of 259 mg/kg bw/d. There were no statistically significant decreases in T<sub>4</sub> levels from 15.6 mg/kg bw/d. No induction of EROD (ethoxyresorufin O-deethylase), PROD (pentoxyresorufin O-deethylase) or T<sub>4</sub>-UDPGT (uridine diphosphate glucuronyl transferase) was seen.

Mancozeb (in olive oil) was administered to 6 male albino Wistar rats orally by gavage at 500 mg/kg bw/d for 30 days (Joshi *et al.*, 2005). Sex organ weight analysis, reproductive, biochemical and enzymatic parameters and testosterone levels were evaluated to determine the toxicity of mancozeb on the male rat. There was no significant difference in body weight at the end of the experimental period. Testis, epididymis, ventral prostate and seminal vesicle weights were decreased. Significant testicular toxicity and a marked reduction in testosterone were observed. Overall, oral gavage administration of 500 mg mancozeb/kg bw/d to male Wistar rats for 30 days did not affect body weight development but was associated with testicular toxicity. However, the reliability of this study is questionable. Despite the use of a high dose of mancozeb, no systemic toxicity, as seen in other studies, was reported. The testicular findings are also questionable as they have not been reported in numerous other studies.

Three groups of eight rats were administered with drinking solutions of 0 (control), 2 g/L and 3.5 g/L mancozeb (Kechrid *et al.*, 2011). The animals were maintained for 4 weeks; body weight gain was recorded regularly. At the end of the study the animals were fasted overnight, killed and serum glucose, serum cholesterol, serum triglycerides, serum creatinine, serum urea concentrations and serum glutamic oxaloacetic transaminase (GOT), serum glutamic pyruvic transaminase (GPT) and serum alkaline phosphatase activities were determined. A treatment level of 3.5 g/L resulted in decreased body weight gain, decreased blood glucose and increased activities of alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP). In addition serum cholesterol, serum triglycerides, serum creatinine and serum urea concentrations were significantly elevated. The authors concluded that a 3.5 g/L dose of mancozeb has a toxic effect on body weight and blood biochemistry parameters. However there were no toxic effects at a dose of 2 g/L dose.

Mancozeb dosed orally at 313.6 mg/kg bw/d, 3 times/week for 6 weeks to 20 albino rats induced histopathological changes in the liver and elevation of liver function enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). There was an increase in the lipid peroxidation marker, malondialdehyde (MDA) and a decrease in the level of the antioxidant enzyme superoxide dismutase (SOD). Treating animals with mancozeb + ginger extract (120 mg/kg bw/d) led to improvement in the histopathological lesions, decreases in ALT, AST and MDA and increases in SOD compared to mancozeb alone (Sakr, 2007).

Groups of 20 albino rats were orally dosed with 1/10 LD<sub>50</sub> (313.6 mg/kg bw) of mancozeb (in water), 3 times per week for 6 weeks (Sakr *et al.*, 2009). A significant decrease in serum testosterone and a decrease in luteinizing hormone (LH) were observed. There was also significant testicular toxicity. Treatment of rats with mancozeb and with ginger led to an amelioration of the observed testicular damage. Overall, oral administration of mancozeb at 313.6 mg/kg bw/d for 6 weeks to rats caused toxic effects in the testes. The reliability of this finding is questionable as it is inconsistent with the observations of numerous other repeated dose studies and multigeneration studies in rats.

## Mice

### *28-day studies*

In a 28 day range finding study by Anonymous (1985b), groups of 5 CD-1 mice/sex were given mancozeb in the diet at 0, 10, 100, 1000 or 10,000 ppm. Administration of 10,000 ppm resulted in decreased body weight and increased thyroid weight of females. Increased liver weights and thyroid hyperplasia were observed in both sexes at 10,000 (2000 mg/kg bw/day) and in females at 1,000 ppm (200 mg/kg bw/day). There were no associated histopathology effects.

### *90-day studies*

In the main 90 day study (Anonymous, 1985c) groups of 15 CD-1 mice/sex were given mancozeb in the diet at 0, 10, 100, 1000 or 10,000 ppm. No treatment related mortality or signs of toxicity were observed at any dose level. Decreased body weight and food consumption were noted in the 10000 ppm group for both sexes, and body weight decrease in the 1000 ppm males only. No treatment related haematological and clinical chemistry effects were seen in any group. Hepatic mixed function oxidase activity (as measured by aniline hydroxylase levels) was decreased in both sexes at 10000 ppm, and aminopyrine-demethylase activity was decreased in males at 1000 and 10000 ppm. Thyroid weights (absolute and relative) were increased in both sexes at the 10000 ppm level; also, at this dose, increased liver and kidney weights were present in both sexes. Histopathology revealed an increased incidence of follicular cell hyperplasia and hypertrophy in both sexes at 10000 and 1000 ppm. In addition, increased vacuolation interstitial congestion and decreased colloid density were observed in both sexes in the high dose group. Histopathologic changes in the liver were limited to a possible increase in hepatocytic nuclear pleomorphism in the females at 10000 ppm. Also noted among the 10000 ppm females only were increased deposits of brownish pigment in the adrenal reticularis. Overall, when orally administered (via the diet) to mice for 3 months, mancozeb produced decreases in body weight and induced thyroid and liver effects at concentrations of 1000 (167/234 mg/kg bw/day in M/F) and 10000 ppm (1663/2160 mg/kg bw/day in M/F).

### *Other studies (from the literature review)*

Mancozeb (in olive oil) was orally administered at doses of 200, 400, 600 or 800 mg/kg bw/d to groups of 10 male Swiss albino mice for 30 days (Ksheerasagar *et al.*, 2010). All treated mice were depressed and adopted abnormal posture with the head held in between the forelegs. They were trying to huddle at the corner of the cage and showed more running activity immediately after the administration of mancozeb. In mice treated with 600 or 800 mg/kg bw/d a significant decrease in the kidney, spleen and liver weights and an increase in thyroid and thymus weights were observed. There was no significant change in body weight. There was a significant decrease in the weight of the testes at  $\geq 400$  mg/kg bw/d and in the weight of the prostate and Cowper's glands at  $\geq 600$  mg/kg bw/dy. There was no significant change in the weight of the epididymides, vasa deferentia, seminal vesicles and coagulating glands. Testicular toxicity was observed at 600 and 800 mg/kg bw/d. In the thyroid, treatment with 600 or 800 mg/kg bw/d caused a decrease in the number of small follicles and an increase in the number of medium, large follicles and total number of follicles. Histological observation of the thyroid revealed hypertrophy and hyperplasia of follicular cells with loss of colloid at 400, 600 and 800 mg/kg bw/d. Liver and kidney toxicity were also observed at 600 and 800 mg/kg bw/d. Overall, oral administration of mancozeb to mice for 30 days caused toxic effects on the testis and thyroid from approximately 400 mg/kg bw/d. No such effects were observed at 200 mg/kg bw/d at which clinical signs of toxicity were reported. Although these behavioural findings observed from the lowest dose of 200 mg/kg bw/d indicate systemic toxicity, changes in body weights were not reported. This questions the reliability of these findings in the mouse.

## Dogs

### *90-day studies*

Two 90 day studies in dogs are available.

In a 90 dietary study in Beagle dogs (Anonymous 1986c), groups of 6 Beagle dogs/sex were given mancozeb at 0, 10, 100, 1000 or 5000 ppm. Three top dose dogs (one female and two males) were sacrificed during Weeks 8-10 due to a severe deterioration in their physical condition. Signs associated with reduced food

consumption and low body weights were dehydration, thinness, and pale mucous membranes. A slight to moderate and moderate to marked decrease in food consumption was noted for the 1000 and 5000 ppm dogs, respectively. This was possibly due to a lack of palatability. There was a marked decrease in body weight for the top dose dogs and a lack of body weight gain, or slight loss of body weight in the 1000 ppm dogs. Evaluation of the clinical pathology data revealed a slight reduction in red cell mass in the top dose dogs as indicated by decreased erythrocyte counts, haematocrit values, and haemoglobin concentrations at Weeks 5 and 13. A reduction in red blood cell mass was also seen in the 1000 ppm females at Week 5 but not at Week 13. Increased values of total bilirubin and total cholesterol and decreased values of T3, T4, alanine aminotransferase (ALT) and calcium were also noted for the top dose dogs. In addition, total cholesterol was increased in the 1000 ppm females at Week 13 and total bilirubin was increased in the 1000 ppm males at Week 5. The clinical pathology findings, in general, are consistent with the syndrome of hypothyroidism in the canine. However, some of the clinical pathology changes seen in this study may be related to malnourishment resulting from decreased food intake. Treatment-related findings at gross necropsy were noted in the 1000 and 5000 ppm dogs and included enlarged and/or dark thyroids and decreased thymus size. Analysis of the organ weights revealed significantly greater mean values of the thyroid/parathyroid weights for the top dose male and female dogs when compared to the respective control values. Treatment-related findings at gross necropsy were noted in the 1000 and 5000 ppm dogs and included enlarged and/or dark thyroids and decreased thymus size. Analysis of the organ weights revealed significantly greater mean values of the thyroid/parathyroid weights for the top dose male and female dogs when compared to the respective control values. Analysis of the urine samples indicated the presence of dose-related levels of EBDC (assayed as CS<sub>2</sub>) and ETU. ETU was detected in the blood in the 1000 and 5000 ppm groups. No EBDC was detected in the thyroid at 5000 ppm, while ETU residues increased in the thyroids of the 1000 and 5000 ppm groups. Overall, when orally administered (via the diet) to dogs for 3 months, mancozeb produced decreased feed consumption and body weight gain, haematology and clinical-chemistry findings and thyroid histopathology from a dose of 1000 ppm (30 mg/kg bw/day) and clinical signs of toxicity and mortality at the top dose of 5000 ppm (101 mg/kg bw/day).

In a 90 day (Anonymous, 1987c) capsule dosing study, groups of 4 Beagle dogs/sex were given mancozeb at 0, 5.7, 34 or 340/204 mg/kg bw/day. Administration of mancozeb at doses of 340/204 mg/kg bw/day for 90 days resulted in marked decreases in food consumption and body weight that were accompanied by clinical chemistry changes (decreases in red cell parameters, lower plasma glucose, increases in ALP, cholesterol, bilirubin and decreases in T3 and T4). Increases in thyroid, liver and adrenal weight were observed with associated thyroid histopathology (increased thyroid follicular hyperplasia, colloid pallor and accumulation of colloid in the thyroid). There were also increases in hypoplasia of the mesenteric lymph node. Similar histopathological findings (without organ weight change) were noted at both 34 and 5.7 mg/kg bw/day.

#### *1-year studies*

In a 1 year dietary study by Anonymous (1990c), groups of 4 Beagle dogs/sex were given mancozeb at 0, 50, 200, 800 or 1600 ppm. Two males given 1600 ppm were killed in extremis in weeks 10 and 11. One animal was found to have an acute urogenital tract lesion and the other a chronic regenerative anaemia. The urogenital tract lesion was probably an incidental event but the probability that the anaemia was an idiosyncratic treatment-related reaction cannot be excluded. All other animals survived and there were no clinical signs or palpable masses related to treatment. There were no apparent neurological or ophthalmic changes related to treatment. Animals in the 800 ppm group gained less weight than controls. There were no other treatment-related effects on body weight gain. Food consumption of males and females given 800 ppm was generally less than controls. Throughout the study females given 800 and 1600 ppm had lower haemoglobin, red blood cell count and packed cell volume values than controls. This was not apparent in males surviving to termination. Other than elevated cholesterol levels in females given 1600 ppm there were no changes in clinical chemistry parameters associated with treatment. There was a reduction in T4 levels in animals given 1600 ppm, but no trends were apparent in T3 levels. The cellular and chemical constituents of urine were unaffected by treatment. Treatment-related thyroid follicular distension (increased amount of colloid) was seen at the terminal kill in all the top dose animals, while increased incidence of Kupffer cell pigment was seen in the liver of the top dose (females only). In conclusion, in this 52-week dietary study in dogs, mortality occurred at the top dose of 1600 ppm. The only consistent treatment-related effects during

the study were a reduction in T4 levels (not statistically significant) with increased thyroid weight and thyroid follicular distension in animals given 1600 ppm and transient reductions in haemoglobin, red blood cell count and packed cell volume and elevation in cholesterol in females given 800 (28 mg/kg bw/day) or 1600 ppm (53 mg/kg bw/day). There were no apparent effects of treatment of up to 200 ppm in mancozeb in the diet.

In another 1-year study (Anonymous, 1991c), groups of 4 Beagle dogs/sex were given capsules containing mancozeb at 0, 2.3, 22.6 or 113 mg/kg bw/day. The top dose of 113 mg/kg bw/day was not tolerated for more than 26 weeks with animals showing changes consistent with severe hypothyroidism, which was probably primarily responsible for all other observed changes such as inappetence, body weight loss and anaemia; this dose clearly exceeded the maximum tolerated dose. Similar but minimal changes were seen in the 22.6 mg/kg bw/d dose group.

In a subsequent 1-year study (Anonymous, 1991d), groups of 4 Beagle dogs/sex were given capsules containing mancozeb at 0, or 40 mg/kg bw/day. Clinical signs of toxicity, effects on body weights and food consumption, changes in clinical-chemistry parameters, decreased thyroid hormones, increased thyroid weight and liver histopathology were seen at the only dose tested.

### **10.10.2 Other routes**

#### Dermal

In a 28 day dermal study (Anonymous, 1988d), groups of 10 SD rats/sex were treated with mancozeb in water at 0, 10, 100 or 1000 mg/kg bw/day. There was no evidence of any treatment related effects.

When mancozeb was administered for 28 days to rats using peanut oil, rather than water as the vehicle (Anonymous, 1999c) the treatment-related effects consisted of sparse variations from normal in haematological parameters, organ weights and histopathological examination in females only at dose levels of 300 and 750 mg/kg bw/day. At 750 mg/kg bw/day 3/5 females were also noted to have liver foci of round cell infiltration.

Dermal application of mancozeb for 90 days (Anonymous, 1997d) to SD rats at 1000 mg/kg bw/day resulted in no treatment-related effects.

#### Inhalation

In a 28-day study (Anonymous 1986d), groups of 5 SD rats/sex were exposed by inhalation nose-only (6 hr/day, 5 day/week) to mancozeb aerosol at respirable concentrations of 0, 8, 40 or 127 mg/m<sup>3</sup>. The only effect noted in this study was a decrease in body weights at the top concentration.

A 90 day inhalation study in the rat (Anonymous, 1986e) is also available. In this study, groups of 10 SD rats/sex were exposed by inhalation nose-only (6 hr/day, 5 day/week) to mancozeb aerosol at respirable concentrations of 0, 8, 36 or 144 mg/m<sup>3</sup>. Treatment-related effects (decreased body weights, effects on the respiratory tract, decreased T4 levels and thyroid follicular hyperplasia) were only seen at the top concentration.

### 10.10.3 Short summary and overall relevance of the provided information on specific target organ toxicity – repeated exposure

The repeated dose toxicity of mancozeb by the oral route has been extensively investigated in studies ranging from 4-days to 90 days in rats and mice. Studies in dogs (90 days and 1 year) are also available. Inhalation studies in rats (28 and 90 days) and three dermal studies (28 and 90 day studies) in rats have also been conducted.

The effects of mancozeb after repeated oral administration are consistent with those of its ETU metabolite, which is responsible for the toxicity of the parent compound. ETU interferes with the production of thyroid hormone by inhibition of the thyroid peroxidase enzyme responsible for iodination and coupling of tyrosine residues into the thyroid hormone precursor, thyroglobulin. This mechanism leads to hypertrophy and hyperplasia of the follicular cells of the thyroid gland, and ultimately tumours of this organ after long term exposure to very high doses.

Thyroid toxicity has been seen in all three species investigated, rats, mice and dogs, representing the most sensitive effect of mancozeb repeated oral dose toxicity. In rats exposed to mancozeb for 3 months, thyroid toxicity tended to appear at lower dose levels (from 15 mg/kg bw/d) than in mice (from 180 mg/kg bw/d). Thyroid toxicity was accompanied at higher dose levels by effects on the liver and adrenal, changes in haematological and clinical-chemistry parameters and reduced food consumption and body weights. In rats, neurotoxicity (neurohistopathology findings) also started to occur from a dose of 49 mg/kg bw/d for 90 days; these neurotoxic effects became more severe (hindlimb, and muscular atrophy) at the high dose of 328 mg/kg bw/d for 90 days. In dogs exposed to mancozeb for 3 months or 1 year, thyroid toxicity started to appear from around 22.6 mg/kg bw/d (for 52 weeks). Thyroid toxicity was accompanied by anaemia, effects on the liver and reductions in food consumption and body weight.

Repeated dermal administration of mancozeb to rats for up to 13 weeks had no effects up to the limit dose of 1000 mg/kg bw/d. Repeated inhalation exposure of rats to mancozeb aerosol for 13 weeks resulted in decreased body weights, effects on the respiratory tract, reduced serum T4 levels and thyroid hyperplasia at the top respirable concentration of 144 mg/m<sup>3</sup>.

Animal data from the literature are either unreliable or confirm that the thyroid is the main target organ of repeated oral dose toxicity of mancozeb.

Epidemiology and medical studies indicated that, in reliable studies, mancozeb does not affect the thyroid or have adverse endocrine-related effects in humans. The possible appearance of neurological effects in populations exposed to pesticides has been investigated in several studies. Effects on state of mind, as suicide, were determined by Beard *et al* (2011). No association was established between pesticide and subsequent incidence of suicide in pesticide applicators and their spouses in the US Agricultural Health Study. This finding was consistent for use of any pesticide, including mancozeb.

Possible associations with pesticide use and Parkinson's disease (PD) have been studied. Dhillon *et al* (2008), Kamel *et al* (2007) and Tanner *et al* (2009 & 2011) investigated associations with individual pesticides, including EBDCs. None of these studies found that exposure to mancozeb was associated with increased incidences of PD.

Also, there is no convincing evidence that mancozeb has adverse effects on the immune system in exposed workers.

#### 10.10.4 Comparison with the CLP criteria

Classification into STOT-RE is warranted when significant or severe toxicity is observed after repeated exposure to doses at or below the reference values assigned in the guidance on the application of the CLP criteria. These values are extrapolated from the value for oral administration to the rat in 90 day studies and are given in the table below:

| Route | Duration | Category 1 (mg/kg bw/day) | Category 2 (mg/kg bw/day) |
|-------|----------|---------------------------|---------------------------|
| Oral  | 28 day   | $\leq 30$                 | $> 30 \leq 300$           |
| Oral  | 90 day   | $\leq 10$                 | $> 10 \leq 100$           |
| Oral  | 52 weeks | $\leq 2.5$                | $> 2.5 \leq 25$           |

The values for other routes of administration, also based on 90 day studies in the rat are  $<20 \leq 200$  mg/kg bw/day for dermal exposure and  $< 0.02 \leq 0.2$  mg/l 6h/day for inhalation exposure. STOT-RE is assigned on the basis of either significant or severe toxicity. ‘Significant’ is taken to mean changes which clearly indicate toxicologically relevant functional disturbances or morphological changes. ‘Severe’ refers to profound effects of a considerably more adverse nature which significantly impact on health.

No adverse effects were noted when mancozeb was administered dermally to rats for 28 days or 90 days up to the limit dose (Anonymous, 1988a; Anonymous, 1999c; Anonymous 1997d). Effects on body weights, respiratory tract and thyroid were seen when mancozeb was given to rats via the inhalation route for 90 days (6 hr/day) at the top concentration of 0.3 mg/L total aerosol (i.e. at a concentration above the CLP guidance value of 0.2 mg/L 6h/day for classification) (Anonymous, 1986e). Therefore, no classification of mancozeb for STOT-RE by the dermal or inhalation route is required.

However in repeated dose oral studies in rats, mice and dogs significant effects were observed at doses around or below the CLP guideline values for classification into STOT-RE 2; target organs appeared to be the liver, thyroid, nervous system and adrenals. Mice appeared to be less sensitive (Anonymous, 1985b; Anonymous, 1985c) than rats and dogs to the toxicity of mancozeb, with significant effects occurring at dose levels above the CLP guidance values for classification. Therefore, only the findings in rats and dogs are considered further in this section. It is also noted that Wistar rats (Szepvolgyi et al., 1989; Anonymous, 1999c) appeared to be less sensitive than Sprague-Dawley (SD) rats and that some rat studies were relatively clean because used low dose levels (Anonymous, 1989; Anonymous, 1997c). It is further noted that in dogs, more significant effects tended to appear after 90 days of treatment (Anonymous, 1986c; Anonymous, 1987c) rather than 1 year (Anonymous, 1990c; Anonymous, 1991c and 1991d). No significant effects were seen in studies from the literature review at dose levels below the guidance values for classification.

When adverse effects are observed at or around the guidance values, it should be considered whether the effects are significant enough to warrant classification. According to the guidance on the application of the CLP criteria the following effects might be considered as significant and thus warrant classification for STOT-RE.

- (a) *Morbidity or death resulting from repeated or long term exposure.*
- (b) *Significant functional changes in the central or peripheral nervous system or other organ systems.*
- (c) *Any consistent or adverse change in clinical biochemistry, haematology or urinalysis parameters.*
- (d) *Significant organ damage noted at necropsy.*
- (e) *Multifocal or diffuse necrosis, fibrosis or granular formation in organs with regenerative capacity.*
- (f) *Morphological changes that are reversible but provide clear evidence marked organ dysfunction.*
- (g) *Evidence of cell death in organs incapable of regeneration.*

Conversely the following effects may be observed, but are not considered to be supporting evidence for classification for STOT-RE.

- (a) *Clinical observations or small changes in body weight gain, food consumption or water intake.*
- (b) *Small changes in clinical biochemistry, haematology or urinalysis parameters.*
- (c) *Changes in organ weights with no evidence of organ dysfunction.*
- (d) *Adaptive responses that are not considered toxicologically relevant.*
- (e) *Substance induced species specific mechanisms of toxicity.*

The findings of the oral studies in rats and dogs that are specific to each target organ are compared with these criteria below.

#### Liver

Liver hypertrophy of the centrilobular hepatocytes was observed in 2/10 males when 57 mg/kg bw/day of mancozeb (a dose below the guidance value of 100 mg/kg bw/d for classification with STOT-RE 2) were administered to SD rats for 90 days (Anonymous, 1986b). This effect is not severe enough to warrant classification. Clinical-chemistry findings, indicative of liver toxicity, were seen at 34 mg/kg bw/day (a dose below the guidance value of 100 mg/kg bw/d for classification with STOT-RE 2) in a 90-day study in dogs (Anonymous, 1986c). However, in the absence of liver histopathology, these effects are also considered insufficient for classification.

Therefore, classification of mancozeb with STOT-RE 2 for effects on the liver is not justified.

#### Thyroid

Thyroid follicular cell hyperplasia was observed in 9/10 males and 9/10 females at 57/74 (M/F) mg/kg bw/day (i.e. below the guidance value of 100 mg/kg bw/d for classification with STOT-RE 2) in a 90-day study in SD rats (Anonymous, 1986b). These effects were accompanied by changes in thyroid hormones. Thyroid follicular cell hyperplasia was also noted in a 90 day dog study (Anonymous, 1986c) in 6/6 males and 6/6 females at 101/108 (M/F) mg/kg bw/day, i.e. just above the guidance value of 100 mg/kg bw/day for classification. Changes in thyroid hormones were also seen at this dose. In another 90 day dog study (Anonymous, 1987c), thyroid follicular hyperplasia was observed in 2/4 males and 2/4 females at 34 mg/kg bw/day. This effect also occurred at the lower dose of 5.7 mg/kg bw/day where thyroid follicular hyperplasia was observed in 3/4 males and 2/4 females.

Therefore, significant thyroid toxicity occurred in rats and dogs at dose levels below the guidance values for classification with STOT-RE 2. Although there is evidence that rats are more sensitive than humans to perturbation of thyroid homeostasis, this evidence is less clear for the dog. In addition, it is noted that in a 6-month study in monkeys with ETU (Leber et al., 1978 – see RAR, section B6 for further details), thyroid toxicity was observed from the relatively low dose of 2.5 mg/kg bw/day.

Overall, therefore, it is concluded that mancozeb could induce thyroid toxicity in humans at dose levels relevant for classification. Hence, classification of mancozeb with STOT-RE 2 for effects on the thyroid is justified. This conclusion may appear in conflict with the conclusion that mancozeb-induced thyroid tumours in rats (and not mice) are unlikely to occur in humans and therefore that classification of mancozeb for carcinogenicity is not appropriate (see section 10.7). The dossier submitter considers that there is no inconsistency as although it is plausible that mancozeb would induce thyroid toxicity in humans at dose levels relevant for classification, it is highly unlikely that mancozeb would cause thyroid hyperplasia and tumours in humans since there is no clear evidence that hypothyroidism (goitre) in humans progresses to neoplasia and because whilst thyroid hypertrophy has been observed in humans, thyroid hyperplasia is rare.

Nervous system

In a 28 day oral study in SD rats (Anonymous, 1994b), 2/8 females displayed hind limb ataxia after administration of mancozeb at doses of 200 mg/kg bw/day (below the guidance value of 300 mg/kg bw/day for classification with STOT-RE 2). Hind limb paralysis was noted in 2/6 females at the same dose.

In addition, in a 90 day oral neurotoxicity study in SD rats (Anonymous, 1991e), myelin phagocytosis, Schwann cell proliferation, demyelinated nerves, myelin sheath thickening and myelin bubbles were observed in males and demyelination and myelin ovoids and debris were noted in females at 750 ppm (49/63 mg/kg bw/day; M/F) (below the guidance value of 100 mg/kg bw/day for classification with STOT-RE 2). Detailed incidences (information on severity not available in the study report) of these neurohistopathological findings seen at 750 ppm in this 90 day oral neurotoxicity study are shown in the table below. None of the findings were seen in control animals apart from myelin bubbles in the lumbar, dorsal root ganglion sections (indicated with \* in the table) which were also observed in one control female.

| Pathological findings                    | Males 750 ppm<br>(Group VII)<br>Incidence (no. animals<br>affected) | Females 750 ppm<br>(Group VIII)<br>Incidence (no. animals<br>affected) |
|--|---|--|
| Number animals examined                  | 10  | 10   |
| Cervical, dorsal root ganglion sections: |   |  |
| Myelin bubbles                           | 1   | 1  |
| Myelin phagocytosis                      | 1   |  |
| Schwann cell proliferation               | 1   |  |
| Lumbar, dorsal root sections:            |   |  |
| Myelin bubbles                           | 1   |  |
| Myelin phagocytosis                      | 1   |  |
| Schwann cell proliferation               | 1   |  |
| Lumbar, dorsal root ganglion sections:   |   |  |
| Myelin bubbles*                          | 2   |  |
| Myelin phagocytosis                      | 1   |  |
| Schwann cell proliferation               | 1   |  |
| Lumbar, ventral root sections:           |   |  |
| Myelin bubbles                           | 3   | 1  |
| Myelin phagocytosis                      | 1   |  |
| Schwann cell proliferation               | 1   |  |
| Tibial nerve, lower:                     |   |  |
| Myelin bubbles                           | 2   |  |
| Myelin phagocytosis                      | 2   |  |
| Schwann cell proliferation               |   |  |

Therefore, based on these findings, mancozeb should be classified for STOT-RE category 2 for effects on the nervous system.

Adrenals

Adrenal hypertrophy of the zona glomerulosa was observed in 6/10 males and 3/10 females when mancozeb was administered at doses of 57 and 74 mg/kg bw/day (below the guidance value of 100 mg/kg bw/day for classification with STOT-RE 2) to SD male and female rats respectively in a 90-day study (Anonymous, 1986b). However, these effects were not replicated in numerous other studies; therefore, classification of mancozeb with STOT-RE 2 for effects on the adrenals is not appropriate.

Other effects

In addition, deaths were seen at 200 mg/kg bw/day (below the guidance value of 300 mg/kg bw/day) in a 28-day study in SD rats (Anonymous, 1994b) and at 101/108 (M/F) mg/kg bw/day (just above the guidance value of 100 mg/kg bw/day) in a 90-day study in dogs (Anonymous, 1986c). In dogs, mortality was also accompanied by severe clinical signs of toxicity and anaemia.

### Overall

Significant effects were seen with mancozeb at oral dose levels below the guidance values for classification with STOT-RE 2 in the thyroid (rats and dogs) and nervous system (rats). In addition, deaths in rats and dogs and severe clinical signs of toxicity in dogs were seen at oral doses below or marginally above the STOT-RE 2 guidance values. Therefore, classification of mancozeb with STOT-RE 2 (H373) for the oral route is justified. No adverse effects were noted when mancozeb was administered dermally to rats for 28 days or 90 days up to the limit dose (Anonymous, 1988a; Anonymous, 1999c; Anonymous 1997d). Effects on body weights, respiratory tract and thyroid were seen when mancozeb was given to rats via the inhalation route for 90 days (6 hr/day) at the top concentration of 0.3 mg/L total aerosol (i.e. at a concentration above the CLP guidance value of 0.2 mg/L 6h/day for classification) (Anonymous, 1986e). Therefore, no classification of mancozeb for STOT-RE by the dermal or inhalation route is required.

#### **10.10.5 Conclusion on classification and labelling for STOT RE**

**STOT-RE 2; H373: May cause damage to organs (thyroid, nervous system) through prolonged exposure (oral route)**

#### **10.11 Aspiration hazard**

Not addressed in this dossier.

## 11 EVALUATION OF ENVIRONMENTAL HAZARDS

### 11.1 Rapid degradability of organic substances

Note that in all cases, DT50 values refer to Single First Order (SFO) kinetics; the terms ‘half-lives’ and SFO DT50 values are used interchangeably as they relate to the same value. Where DT50 values are quoted for mancozeb, these relate to primary degradation, not dissipation or ultimate degradation. Degradation rates for ultimate degradation have not been submitted or calculated.

Where studies were conducted at temperatures other than 12°C, half-lives have been normalised to 12°C as necessary using equation 25 in Guidance on the BPR: Volume IV, Part B Risk Assessment (active substances) Version 1.0 April 2015, i.e.  $DT50(X^{\circ}C) = DT50(t) \cdot e^{(0.08(T-X))}$ .

**Table 23: Summary of relevant information on rapid degradability**

| Method  | Results   | Remarks  | Reference  |
|---|---|--|--|
| <b>Hydrolysis</b>   |   |  |  |
| US EPA Subdivision N, 161-1, similar to OECD 111, predates GLP  | 25°C<br>pH 5: half-life 2.8 hours (7.9 hours at 12°C)<br>pH 7: half-life 5.5 hours (15.5 hours at 12°C)<br>pH 9: half-life 12.9 hours (36.5 hours at 12°C)<br><br>main degradates:<br>ETU – pH dependent, up to 100%<br>EU – pH dependent, up to 11.5%  | Variable mass balance attributed to inhomogeneity of dosing solution (test substance of low solubility). Biphasic degradation at pH 5 & 7, half-life expressed as DT90/3.32. | Lawrence <i>et al</i> 1988; kinetic calculations in Hardy 2015 |
| US EPA Subdivision N, 161-1, similar to OECD 111, GLP compliant | 25°C<br>pH 5: half-life 34.8 hours (98.4 hours at 12°C)<br>pH 7: half-life 51.2 hours (144.9 hours at 12°C)<br>pH 9: half-life 22.9 hours (64.8 hours at 12°C)<br><br>main degradates:<br>ETU – pH dependent, up to 94.5%<br>EU – pH dependent, up to 25.6%<br>2 unidentified degradants >10% | Variable mass balance attributed to inhomogeneity of dosing solution (test substance of low solubility).   | Wang 1995; kinetic calculations in Hardy 2015                  |

|                                    |   |   |  |
|------------------------------------|---|---|--|
| OECD 111, GLP compliant            | <p>20°C</p> <p>pH 4: half-life 0.39 hours (0.7 hours at 12°C)</p> <p>pH 7: half-life 0.53 hours (1.0 hours at 12°C)</p> <p>pH 9: half-life 0.34 hours (0.6 hours at 12°C)</p> <p>35°C</p> <p>pH 4: half-life 0.15 hours</p> <p>pH 7: half-life 0.52 hours</p> <p>pH 9: half-life 0.30 hours</p> <p>main degradates at 20°C:</p> <p>EBIS – pH dependent, up to 41.3%</p> <p>ETU – pH dependent, up to 90.7%</p> <p>EU – pH dependent, up to 31.2%</p> <p>Seven unknown degradants &gt;10%</p>  | Study reliable  | Völkel 2001b;<br>kinetic calculations<br>in Hardy 2015 |
| OECD 111, GLP compliant            | <p>25°C</p> <p>pH 4: half-life 0.7 hours (2.0 hours at 12°C)</p> <p>pH 7: half-life 3.0 hours (8.5 hours at 12°C)</p> <p>pH 9: half-life 5.5 hours (15.6 hours at 12°C)</p> <p>35°C</p> <p>pH 4: half-life 0.4 hours</p> <p>pH 7: half-life 1.5 hours</p> <p>pH 9: half-life 2.4 hours</p> <p>50°C</p> <p>pH 4: half-life 0.3 hours</p> <p>pH 7: half-life 0.5 hours</p> <p>pH 9: half-life 0.4 hours</p> <p>main degradates at 25°C:</p> <p>ETU – pH dependent, up to 94.8%</p> <p>EU – pH dependent, up to 55.1%</p> <p>CPII – pH dependent, up to 11.1%</p> <p>CPIII – pH dependent, up to 24.5%</p> | Study reliable for mancozeb, some concerns regarding degradant identification, particularly CPII and CPIII.   | Cardinali 2007<br>(corrections submitted 2016)         |
| <b>Photolysis</b>                  |   |   |  |
| No stated guideline, pre-dates GLP | Mancozeb hydrolysed rapidly in dark control at 25°C, little difference between levels in exposed and dark control. Degradate EBIS degradation is enhanced by light exposure.  | Reliability questionable due to use of mercury vapour lamp. However, practical influence of light exposure on mancozeb likely to be limited given rapid hydrolysis. | Yeh 1985   |

| Ready biodegradability                          |  |  |  |
|---|--|--|--|
| OECD 301B, GLP compliant                        | Test item 5-6% biodegradation in 36 days.<br>Aniline reference 94% biodegradation (by % of theoretical CO <sub>2</sub> ).  | Study performed with a formulated product. Study outcome classifies test substance as 'not readily biodegradable'.   | Ectors 1995  |
| Biodegradation                                  |  |  |  |
| OECD 309, GLP compliant                         | Carsington pelagic fresh water system, 20°C. Mancozeb DT90 < 3 days (< 5.7 days at 12°C).<br><br>Degradants:<br>M1 (max 11.15% AR at 60 days); M4 (ethanolamine; max 15.4% AR at 14 days); M8 (glycolic acid; 15.46% AR at 28 days); EU (41.22% AR at 60 days); M13 (ethylene glycol; 24.69% AR at 49 days); ETU (35.00% AR at 3 days).  | More than 90% disappearance of mancozeb between dosing and second sampling time at 3 days after treatment. Mineralisation up to 16.8% at 60 days after treatment.                                    | Dobson 2015  |
| German BBA, US EPA 162-3 & 162-4, GLP compliant | Two water/sediment simulation study, four systems, 20°C.<br>Mancozeb whole system DT50 0.05 – 0.28 days (0.09 – 0.53 days at 12°C).<br>No partitioning of mancozeb to sediment detected.<br>Degradants:<br>EBIS – up to 30.9% AR total system<br>ETU – up to 51.6% AR total system<br>EU – up to 43.5% AR total system<br>Hydantoin – up to 11.7% AR total system<br>Unknown 2 - up to 15.2% AR total system | Two separate studies but very similar. Rapid primary degradation of mancozeb with significant degradant formation. Up to 57.8% AR mineralisation at 106 DAT, up to 36.7% AR unextracted at 106 days. | Müller-Kallert 1994<br>Völkel 1995<br>Kinetic calculations in Hardy 2015 |

All DT50 values in the table above are calculated at stated study temperature; DT50 values in parentheses have been normalised to 12°C using  $(DT50 \text{ at } T) \cdot e^{(0.08 \cdot (T-12))}$  as recommended by ECHA. In hydrolysis studies where incubations at multiple temperatures were run, only the DT50 from the lowest temperature incubations have been normalised to 12°C.

### 11.1.1 Ready biodegradability

Ectors 1995; an OECD 301B, GLP-compliant study was conducted on a commercial formulation of mancozeb containing 80% w/w mancozeb; no details of the constituents of the remaining 20% w/w in the formulation were given. Mancozeb is of low solubility and the formulation was considered to be dispersible in water. For the study, the formulation was added directly to the activated sewage sludge/nutrient solution with additional water and stirred with magnetic stirrers to keep the test substance dispersed. No other solvents were used. The organic carbon content of the test item was 0.13 mg C/mg active substance and ThCO<sub>2</sub> was calculated as 0.47 mg CO<sub>2</sub>/mg active substance. The test systems were 5L brown glass bottles

containing activated sewage sludge as the inoculum in high quality water and nutrient solution; these bottles were connected to CO<sub>2</sub> absorber bottles containing 0.0125 M Ba(OH)<sub>2</sub>. At the start of the incubation period, the mancozeb test item was added to the sewage sludge/nutrient solution and constantly stirred. The study author stated that the study was conducted at 'room temperature' and records of temperature indicated that the temperature varied between 20 - 25°C over the study duration. CO<sub>2</sub> liberated by biodegradation of the test item reacts with Ba(OH)<sub>2</sub> in the absorber bottles to form insoluble BaCO<sub>3</sub> which precipitates. CO<sub>2</sub> production was thus determined by titration of remaining Ba(OH)<sub>2</sub> with 0.05 M HCl and using phenolphthalein as an indicator. The mancozeb test item was tested alongside aniline as a reference substance. Due to the physical nature of the test item, % DOC removal could not be measured. There was 96% DOC removal from the aniline reference and 94% biodegradation (% of theoretical CO<sub>2</sub>). The biodegradation of the mancozeb test item as a % of ThCO<sub>2</sub> was 5 and 6% in the two test vessels. An intense smell of H<sub>2</sub>S came free during the titration of the absorber solutions of the mancozeb test system (mancozeb contains S). It was concluded that the mancozeb test item was not readily biodegradable. The study is considered to be reliable.

### 11.1.2 BOD<sub>5</sub>/COD

For the purpose of classification, data generated by the ready biodegradability study supersede direct BOD<sub>5</sub> and COD measurements.

### 11.1.3 Hydrolysis

Lawrence *et al.*, 1988; the hydrolysis of <sup>14</sup>C-mancozeb was investigated at 25.4 °C in sterile aqueous buffer solutions of pH 5, 7 and 9; the study was conducted to the US EPA Subdivision N, 161-1 guideline, which is similar to OECD 111, and predated GLP. At 25 °C mancozeb underwent rapid degradation at all three pH. Degradation was pH related, ranging from 2.8 hours at pH 5 to 1.9 hours at pH 9; normalisation to 12°C results in DT50 7.9 hours at pH 5 – 36.5 hours at pH 9. The main hydrolysis product was ETU with up to 100% observed. A further major degradant was EU at a maximum of 11.5%. Validity of the study is limited due to variability of recovery but gives a reasonable understanding of hydrolytic behaviour.

Wang, 1995; the hydrolysis of <sup>14</sup>C-mancozeb was investigated at 25 °C in sterile aqueous buffer solutions of pH 5, 7 and 9; the study was conducted to the US EPA Subdivision N, 161-1 guideline, which is similar to OECD 111, and was GLP compliant. At 25 °C mancozeb underwent relatively rapid degradation at all three pH. The pH dependent degradation observed in Lawrence *et al.*, 1988 was not demonstrated, but degradation still varied dependent on pH. Results normalised to 12°C were as follows: pH 5 – 4.1 days; pH 7 – 6.0 days; pH 9 – 2.7 days. The main hydrolysis product was ETU with up to 94.5% observed. A further major degradant was EU at a maximum of 25.6%. Two unidentified degradants also exceeded 10%. Validity of the study is limited due to variability of recovery.

Völkel 2001b; the hydrolysis of <sup>14</sup>C-mancozeb was investigated at 20 and 35 °C in sterile aqueous buffer solutions of pH 5, 7 and 9; the study was conducted to the OECD 111 guideline, and was GLP compliant. At 20 °C mancozeb underwent rapid degradation at all three pH. DT50s varied dependent on pH. Results at 20°C normalised to 12°C were as follows: pH 4 – 0.7 hours; pH 7 – 1.0 hour; pH 9 – 0.6 hours. The main hydrolysis products were EBIS up to 41.3%, ETU with up to 90.7% and EU with up to 31.2% observed. Seven unidentified degradants also exceeded 10%. The study is considered reliable.

Cardinali 2007 (update 2016): the hydrolysis of <sup>14</sup>C-mancozeb was investigated at 25, 35 and 50 °C in sterile aqueous buffer solutions of pH 5, 7 and 9; the study was conducted to the OECD 111 guideline, and was GLP compliant. At 20 °C mancozeb underwent rapid degradation at all three pH. DT50s varied dependent on pH, similar to seen in the study of Lawrence *et al.* 1988. Results at 20°C normalised to 12°C ranged from 2.0 hours at pH 4 to 15.6 hours at pH 9. The main hydrolysis products were ETU with up to 94.8% and EU with up to 55.1% observed. Two additional degradants were also seen at 11.1% and 24.5%, however the reliability of the degradant identification is uncertain as these degradants were not seen in any other mancozeb study, let alone in hydrolysis studies. The study is considered reliable with respect to data on mancozeb, but of suspect reliability with respect to degradant identification.

**11.1.4 Other convincing scientific evidence**

No information.

**11.1.4.1 Field investigations and monitoring data (if relevant for C&L)**

No information.


**11.1.4.2 Inherent and enhanced ready biodegradability tests**

No information.

**11.1.4.3 Water, water-sediment and soil degradation data (including simulation studies)****Aerobic mineralisation in surface water**

Dobson 2015; conducted on a fresh water pelagic water system at 20°C in the dark using two dose rates of <sup>14</sup>C-mancozeb as recommended in OECD 309. The water had a pH of 8.81, was non-turbid and colourless and had a dissolved organic carbon content of 4.2 mg/l. Study duration was 60 days. Sampling regime designed to consider degradant behaviour rather than to accurately quantify mancozeb decline as rapid decline of mancozeb was expected. Mancozeb was not detected by 3DAT and thus had declined by >90% of applied at 3 DAT (only previous sample event was at 0 DAT). Thus it is only possible to state that the DT90 of mancozeb at 20°C was <3 days, i.e. DT90 <5.7 days at 12°C. 16.8% mineralisation was seen at study termination in low dose incubation, 8.1% mineralisation in high dose incubation. A large number of degradants were generated. Unidentified M1 (max 11.15% AR at 60 days); ethanolamine (max 15.4% AR at 14 days); glycolic acid (15.46% AR at 28 days); EU (41.22% AR at 60 days); ethylene glycol (24.69% AR at 49 days); ETU (35.00% AR at 3 days). Study is reliable. A proposed metabolic pathway of mancozeb in surface water from the Dobson 2015 study is shown below.

Figure 6.1: Proposed metabolic pathway of mancozeb in surface water



### Water/sediment study

Müller-Kallert 1994; conducted to US EPA 162-3 & 162-4 guidelines, similar to OECD 308, and GLP compliant. Conducted on two fresh water water/sediment systems incubated at 20°C in the dark, study duration 106 days. Properties of the water/sediment systems are given below.

| <i>Sediment</i>                             | <i>River</i> | <i>Pond</i> |
|---|--------------|-------------|
| <b>pH (KCl)</b>                             | 7.6          | 7.3         |
| <b>Redox potential (mV)</b>                 | -174         | -156        |
| <b>OC (g C/100g dry sediment)</b>           | 1.06         | 1.59        |
| <b>Biomass (mg microb. C/100g dry sed.)</b> | 43.1         | 90.1        |
| <b>CEC (mVal N/100g dry sed)</b>            | 4.6          | 17.8        |
| <b>USDA nomenclature</b>                    | sand         | loam        |
| <b>Clay (% &lt; 2µm)</b>                    | 12.1         | 43.1        |
| <b>Silt (% 2-50 µm)</b>                     | 4.9          | 31.3        |
| <b>Sand (% &gt;50 µm)</b>                   | 83.0         | 25.6        |
| <i>Water phase</i>                          |              |             |
| <b>Oxygen concentration (mg/l)</b>          | 10.2         | 7.7         |
| <b>pH</b>                                   | 7.72         | 7.31        |
| <b>Total organic carbon (mg C/l)</b>        | 6.5          | 12.1        |
| <b>redox potential (mV)</b>                 | +230         | +210        |

<sup>14</sup>C-mancozeb was dosed. Mancozeb declined rapidly in the whole systems. Analysis for mancozeb was performed after complexing extract with EDTA. Degradation of mancozeb can be expressed either as the degradation of the main complexed fraction (i.e. sodium salt of ethylenebisdithiocarbamate, nabam) or as the sum of the complexed fractions. DT50 of the main complexed fraction whole system normalised to 12°C = 0.17 – 0.23 days. DT50 of sum of complexed fractions in whole system normalised to 12°C = 3.17 – 3.41 days. No partitioning of mancozeb to either sediment. Mineralisation 57.7 – 57.8% AR at 106 days. Unextracted residues 35.4 – 36.7% AR at 106 days. Significant formation of degradants: EBIS – up to 30.9% AR total system; ETU – up to 47.6% AR total system; EU – up to 29.5% AR total system. Study is reliable.

Völkel 1995; virtually a repeat of Müller-Kallert 1994 with similar water/sediment systems and study methodology. Properties of the water/sediment systems are given below.

| <i>Sediment</i>                             | <i>River</i> | <i>Pond</i> |
|---|--------------|-------------|
| <b>pH (KCl)</b>                             | 6.85         | 6.61        |
| <b>Redox potential (mV)</b>                 | -105         | -112        |
| <b>OC (g C/100g dry sediment)</b>           | 1.35         | 5.03        |
| <b>Biomass (mg microb. C/100g dry sed.)</b> | 109.7        | 330.3       |
| <b>CEC (mVal N/100g dry sed)</b>            | 2.77         | 7.05        |
| <b>USDA nomenclature</b>                    | sand         | loam        |
| <b>Clay (% &lt; 2µm)</b>                    | 7.0          | 5.0         |
| <b>Silt (% 2-50 µm)</b>                     | 11.6         | 35.8        |
| <b>Sand (% &gt;50 µm)</b>                   | 81.4         | 59.2        |
| <i>Water phase</i>                          |              |             |
| <b>Oxygen concentration (mg/l)</b>          | 2.5 - 7.2    | 4.5 - 7.8   |
| <b>pH</b>                                   | 8.02         | 7.37        |
| <b>Total organic carbon (mg C/l)</b>        | 2.6          | 1.1         |
| <b>redox potential (mV)</b>                 | +142         | +129        |

Study duration was 105 days. Mancozeb declined rapidly in the whole systems; DT50 of the main complexed fraction whole system normalised to 12°C = 0.55 – 1.14 days. DT50 of sum of complexed fractions in whole system normalised to 12°C = 0.59 – 0.97 days. No partitioning of mancozeb to either sediment. Mineralisation 17.6 – 47.1% AR at 105 days. Unextracted residues 39.5 – 43.6% AR at 105 days. Significant formation of degradants: EBIS – up to 12.7% AR total system; ETU – up to 51.6% AR total

system; EU – up to 43.5% AR total system; hydantoin – up to 11.7% AR total system; unknown degradant 2 - up to 15.2% AR total system. Study is reliable.

#### 11.1.4.4 Photochemical degradation

Yeh 1985; the study was not conducted to a specified guideline and predates GLP. <sup>14</sup>C-mancozeb declined rapidly in the dark at 25°C as might be expected from hydrolysis data; at time zero sample time, mancozeb concentrations had already declined to 6.8% AR in light exposed samples and 8.7% AR in dark control. There was very little effect of light exposure on the degradation of mancozeb, however, the lamp was a mercury vapour lamp which may not have a spectral distribution sufficiently similar to sunlight. The degradation of the major degradant EBIS appeared to be enhanced by light exposure. The use of a mercury vapour lamp makes the study of questionable reliability, however the rapidity of hydrolysis suggests that aqueous photolysis will be of limited relevance to mancozeb.

#### Summary and discussion of degradation

Mancozeb degrades rapidly in hydrolysis studies; three of four studies show DT50 values normalised to 12°C of 0.6 hours – 1.5 days. One hydrolysis study gave longer DT50 values normalised to 12°C of 2.7 – 6.0 days. Degradation varied with pH, although a clear pH tendency was not clear across the four studies. Two of the studies indicated that degradation was faster under acid conditions and slower under alkaline conditions. Degradant occurrence in the hydrolysis studies was pH related. ETU was formed at high levels in all pH tested with >90% at pH 4-5, 57 – 87% at pH 7 and 57-90% at pH 9. EU was found up to 6% at pH 4, 13% AR at pH 7 and 11-55% at pH 9. EBIS was potentially less affected by pH with maximum 33% at pH 4, 41% at pH 7 and 30% at pH 9.

A single aqueous photolysis study using mancozeb was available. This old study dating to 1985 was conducted using a mercury vapour lamp. The RMS is of the understanding that such lamps are not recommended for use in sunlight simulation tests. However, it was noted that decline of mancozeb in the dark control was very rapid due to hydrolysis and that there was no influence of illumination on rate of decline.

A single ready biodegradability study was submitted using a simple dispersion in water formulation containing 80% w/w mancozeb. This study indicated that the mancozeb formulation was not classified as readily biodegradable.

A study on aerobic mineralisation of mancozeb in surface water was submitted. A pelagic system from a natural fresh water body was chosen for this study. Given the expected rapid degradation of mancozeb, the study authors decided to concentrate attention on degradant behaviour rather than mancozeb and therefore the second sample time was three days after application rather than attempting to sample more frequently within the first three days. As expected, degradation of mancozeb was rapid with no mancozeb detected at 3 DAT. No kinetic parameters could be calculated, thus it can be concluded that mancozeb in this study had a DT90 <3 days at 20°C (DT90 <5.7 days normalised to 12°C). There was maximum of 16.8% AR as CO<sub>2</sub> at 60 days (study end) suggesting relatively little mineralisation in this study. Given the frequency of initial sampling, it is possible that peak formation of the rapidly formed and degraded degradant EBIS (as seen in the aerobic water/sediment studies) may have been missed. However, other degradants were also found to be major in this study. ETU was found at a maximum of 35% AR at 3 DAT and EU at 41% AR at 60 DAT (study end). Four other major degradants were also found which in some cases were tentatively identified. These were M1 (unidentified, 11% at 60 DAT), ethanolamine (15.4% at 14 DAT), glycolic acid (15.2% at 14 DAT), ethylene glycol (24.7% at 49 DAT).

Two water/sediment studies were submitted; the studies were very similar to each other, having been conducted by the same laboratory and using nominally the same two water/sediment systems and methodology, but separated in time. As in other water studies, mancozeb degraded rapidly. DT50 values expressed as the main complexed fraction (i.e. nabam, the sodium salt of EBDC) were in the range 0.17 – 1.14 days (normalised to 12°C) for the whole water/sediment systems. When expressed as the sum of

complexed fractions, the DT50 range (at 12°C) was 0.59 – 3.41 days. Mancozeb was not detected in sediment. There were three major identified degradants:

EBIS - maximum in total system 8.9 – 30.9% AR after 0 – 0.25 d.

ETU - maximum in total system 33.6 – 51.6 % AR after 2 days.

EU - maximum in total system 30.7 – 43.5% AR after 7 - 59 days.

A number of other degradants were also found at >10% AR. Mineralisation ranged from 17.6 – 57.8% AR at study termination, i.e. 105 – 106 days after treatment. Unextracted residues were at significant levels at study termination, ranging from 35.4 – 43.6% AR.

Overall, the range of degradation studies indicate that mancozeb undergoes rapid primary degradation in water. A range of degradants are formed at high levels. However, ultimate degradation in biologically active water systems is relatively slow with 16.8% AR as CO<sub>2</sub> at 60 days in the aerobic mineralization in surface water study and 17.6 – 57.8% AR at 105 – 106 days after treatment in water/sediment studies. This suggests that mancozeb would not meet the criteria to be classified as rapidly degradable.

## 11.2 Environmental transformation of metals or inorganic metals compounds

Not applicable.

## 11.3 Environmental fate and other relevant information

### 11.3.1 Adsorption/Desorption

A single adsorption/desorption study on mancozeb in four soils (pH range 5.7 – 7.4, organic carbon range 0.5 – 2.0) is available performed to US EPA guideline 163-1 (similar to OECD 106). However, the study was unable to reliably determine soil adsorption coefficients as mancozeb was unstable during the 24 hour equilibrium period. As a result, the calculated adsorption coefficients represent mancozeb and a range of its degradation products. Koc values ranged from 363 – 2334 ml/g, 1/n 0.686 – 0.777. Whilst not ideal, it would be very difficult to obtain an accurate and reliable estimate of soil adsorption for mancozeb using the OECD 106 test method due to its very rapid degradation in soil.

Whilst not directly indicative of adsorption/desorption or distribution coefficients, in the two water/sediment studies performed with mancozeb (Müller-Kallert 1994 and Völkel 1995), mancozeb degraded rapidly and no mancozeb was detected in sediment. This suggests that if mancozeb were to reach natural water surface water systems, partitioning to sediment would be unlikely to take place to a significant extent, most probably due to rapid degradation. In addition, rapid degradation of mancozeb was also seen in the aerobic mineralisation in surface water study (Dobson 2015). This further suggests that mancozeb would typically exist transiently in water with little or no partitioning to sediment.

### 11.3.2 Volatilisation

Mancozeb has a vapour pressure of  $<5.6 \times 10^{-5}$  Pa at 25°C and Henry's Law constant calculated from vapour pressure and solubility of  $< 6.17 \times 10^{-2}$  Pa.m<sup>3</sup>.mol<sup>-1</sup>. This suggests that mancozeb is of low volatilisation potential and is unlikely to partition from water to the air.

## 11.4 Bioaccumulation

A study to assess the bioaccumulation of mancozeb in fish has not been performed as the log Kow was concluded to be 2.3 (at 20-25°C and pH 6-10) from new chemistry data submitted for the renewal of mancozeb. This is below the EFSA aquatic guidance (2013) trigger of 3 above which a BCF study must be performed for pesticide assessment. It is also below the cut-off value of 4 given in the CLP Regulation and discussed in the ECHA Guidance on the Application of the CLP Criteria (2015) and it indicates a low

potential for bioaccumulation of mancozeb. Information on the aquatic bioaccumulation of the degradant ETU is presented in Annex 1.

**Table 24: Summary of relevant information on bioaccumulation**

| Method  | Test Substance                          | Results  | Remarks  | Reference                           |
|---|---|--|--|-------------------------------------|
| OECD 107 (shake flask method, concentration of test item in layer by CIPAC MT 165)<br><br>GLP | Mancozeb pure, 92.3%<br>Lot FL13-068-6E | At 20 – 25 °C:<br>Log Kow = 2.3 (pH 6 – 8)<br>Log Kow = 2.3 (pH 9 - 10)<br>Log Kow = ∞ (pH 4 - 5)<br>Mancozeb has very low solubility in water and at a low pH mancozeb does not tend to migrate into the water layer. | Acceptable.<br>This indicates that the substance is unlikely to bioaccumulate.               | Bos MWS, 2014<br>Study DL 14-006    |
| Predicted value (ACD Labs version 12.01)<br><br>Non-GLP                                       | Ethylenethiourea (ETU)                  | Log Kow = -0.66 (pH 5.5)<br>Log Kow = -0.66 (pH 7.0)<br>Log Kow = -0.66 (pH 9.0)   | Acceptable.<br>ETU is included in the residue definition, therefore these data are required. | Anonymous (2014) Study 2014/1321435 |

#### 11.4.1 Estimated bioaccumulation

Not estimated as  $\log Kow < 4$ .

#### 11.4.2 Measured partition coefficient and bioaccumulation test data

No data are available as  $\log Kow < 3$ .

#### Summary and discussion of aquatic bioaccumulation

The low  $\log Kow$  of 2.3 indicates no significant potential for bioaccumulation of mancozeb in the aquatic environment, as it falls below the CLP value for concern ( $\log Kow \geq 4$ ). It is considered to have a low potential for bioaccumulation.

## 11.5 Acute aquatic hazard

### Background

Mancozeb was first included in Annex I of Dir. 91/414/EEC on 1<sup>st</sup> July 2006. The UK is the RMS for the AIR 3 renewal of the active under the latest pesticide legislation (EC Reg. no. 1107/2009) and Greece is the Co-RMS. Italy is the RMS for the active metiram, and has evaluated the data on the common degradants of the two actives (see Annex III). Aquatic data were submitted and assessed for the original authorisation. These data have been used for the renewal (for the most part without additional assessment), along with newly submitted aquatic data which have been assessed and summarised for the renewal. Where old endpoints were reported as nominal values, studies were briefly re-assessed to determine if these endpoints are valid in the light of current guidance. Where this could not be confirmed, the studies were considered not acceptable for use in the risk assessment and the classification. This is with the exception of endpoints which are the lowest of the respective taxonomic/trophic group, which have been included in the hazard assessment as a conservative approach. Some of the old studies submitted for the DAR were deemed not valid in additional addenda to the DAR. The endpoints of these studies have not been considered for classification and labelling purposes. This is with the exception of the algal study Forbis (1990) which was considered not valid in addendum 1 to the original DAR. However, as no valid algal studies were available at the time, the endpoint from this study was used in the risk assessment for the DAR. The RMS requested of the applicant that reviewed, mean-measured endpoints be calculated for this and the *Lemna* study. These were provided and have been presented in the summaries below, as well as in table 25. In addition, the applicant later submitted a new algal study on the species *P. subcapitata* which has been evaluated and the results presented in table 25.

Both active and formulation study endpoints have been included in this assessment, as valid mancozeb technical studies were not available to determine the chronic hazard and risk to aquatic invertebrates and aquatic macrophytes. However, this is justified in the case of mancozeb due to the simplicity of the formulations and the high percentage of active substance in the formulations (formulations contain roughly 80% mancozeb w/w with inert/less toxic co-formulants). A confidential Annex has been provided as a separate document which provides details of those formulations used in studies which were critical for the classification of mancozeb. The lowest acute endpoint was from a formulation study, and there is no technical substance study available for chronic invertebrates (the surrogate method was required). Therefore, the acute and chronic classifications using both the lowest endpoints for technical mancozeb and for the formulations have been presented, which result in the same outcome. The identical classifications support the assertion that low levels of co-formulants present in mancozeb formulations that have been tested are unlikely to have an effect on the resulting endpoint, and therefore on the environmental classification. Regardless of whether individual studies were performed with the active or a formulation, all endpoints have been reported in terms of active substance. The degradants of mancozeb for which toxicity data are available are not relevant to the classification of the active substance. Therefore these endpoints have not been presented in the classification assessment, but are summarised in Annex III to the report for completeness. The degradant endpoints were assessed by Italy. . Finally, all the studies summarised in this document are first tier studies on standard species. Higher tier studies are not considered for classification purposes. In cases where sediment-dwelling species have been used, the study endpoints have only been considered if they are available in the form of mg/L (i.e. measurements of test substance were made in the water phase).

**Table 25: Summary of relevant information on acute aquatic toxicity**

| Guideline and GLP status | Substance (purity in % w/w)         | Species                              | Endpoint Effect | Exposure     |          | Results          |                      | Reference                    | Submitted for original approval (O) or renewal (N) |
|--------------------------|-------------------------------------|--------------------------------------|-----------------|--------------|----------|------------------|----------------------|------------------------------|--|
|                          |                                     |                                      |                 | Design       | Duration | Endpoint         | Toxicity (mg a.s./L) |                              |  |
| <b>Fish</b>              |                                     |                                      |                 |              |          |                  |                      |                              |  |
| OECD 203 GLP             | Mancozeb Tech. (purity > 90%)       | <i>Oncorhynchus mykiss</i>           | Mortality       | Semi-static  | 96h      | LC <sub>50</sub> | 0.074 (mm)           | Anonymous, 1987              | O  |
| OECD 203 GLP             | Mancozeb Tech. (purity > 90%)       | <i>Lepomis macrochirus</i>           | Mortality       | Semi-static  | 96h      | LC <sub>50</sub> | 0.083 (mm)           | Anonymous, 1987e             | O  |
| OECD 203 GLP             | Mancozeb Tech. (purity > 90%)       | <i>Oncorhynchus mykiss</i>           | Mortality       | Semi-static  | 96h      | LC <sub>50</sub> | 0.088 (mm)           | Anonymous, 1997e             | O  |
| OECD 203 GLP             | Pencozeb 80 WP (Mancozeb: 82.0%)    | <i>Oncorhynchus mykiss</i>           | Mortality       | Flow-through | 96h      | LC <sub>50</sub> | 0.15 (mm)            | Anonymous, 1993a             | O  |
| OECD 203 GLP             | Dithane M-45 (Mancozeb: 81.3%)      | <i>Oncorhynchus mykiss</i>           | Mortality       | Flow-through | 96h      | LC <sub>50</sub> | 1.0 (nom)            | Anonymous, 2000a             | O  |
| OECD 203 GLP             | Pencozeb 80 WP (Mancozeb: 82.0%)    | <i>Cyprinus carpio</i> (Mirror carp) | Mortality       | Flow-through | 96h      | LC <sub>50</sub> | 1.84 (nom)           | Anonymous, 1993b             | O  |
| OECD 203 GLP             | Dithane M-45 (Mancozeb: Not stated) | <i>Lepomis macrochirus</i>           | Mortality       | Flow-through | 96h      | LC <sub>50</sub> | > 3.6 (mm)           | Anonymous, 2000b             | O  |
| <b>Invertebrates</b>     |                                     |                                      |                 |              |          |                  |                      |                              |  |
| OECD 202 GLP             | Mancozeb Tech. (purity > 90%)       | <i>Daphnia magna</i>                 | Immobilisation  | Static       | 48h      | EC <sub>50</sub> | 0.073 (mm)           | Douglas <i>et al.</i> , 1988 | O  |

| Guideline and GLP status | Substance (purity in % w/w)             | Species                                  | Endpoint Effect       | Exposure      |            | Results  |   | Reference                    | Submitted for original approval (O) or renewal (N) |
|--------------------------|---|--|-----------------------|---------------|------------|--|---|------------------------------|--|
|                          |   |  |                       | Design        | Duration   | Endpoint   | Toxicity (mg a.s./L)  |                              |  |
| OECD 202 GLP             | Sancozeb 800 WP (Mancozeb: 80%)         | <i>Daphnia magna</i>                     | Immobilisation        | Static        | 48h        | EC <sub>50</sub>   | 0.9 (nom)   | Brouwers, 1995               | O  |
| <b>OECD 202 GLP</b>      | <b>Mancozeb 80% WDP (Mancozeb: 80%)</b> | <i>Daphnia magna</i>                     | <b>Immobilisation</b> | <b>Static</b> | <b>24h</b> | <b>EC<sub>50</sub></b>   | <b>0.0112 (nom)</b>   | <b>Rakesh M. Patel, 1998</b> | <b>O</b>   |
| OECD 202 GLP             | Penncozeb 80 WP (Mancozeb: 82.0%)       | <i>Daphnia magna</i>                     | Immobilisation        | Static        | 48h        | EC <sub>50</sub>   | 0.39 (nom)  | Wüthrich, 1993b              | O  |
| OECD 202 GLP             | Fortuna 80 WP (Mancozeb: 79.4%)         | <i>Daphnia magna</i>                     | Immobilisation        | Static        | 48h        | EC <sub>50</sub>   | 1.10 (nom)  | Sesso, J.N. 2007a            | N  |
| OECD 202 GLP             | Dithane M-45 (Mancozeb: 81.3%)          | <i>Daphnia magna</i>                     | Immobilisation        | Flow-through  | 48h        | EC <sub>50</sub>   | 3.8 (mm)  | Rhodes, 2000b.               | O  |
| <b>Algae</b>             |   |  |                       |               |            |  |   |                              |  |
| OECD 201 GLP             | Mancozeb Tech. (purity: 86.1%)          | <i>Pseudokirchneriella subcapitata**</i> | Growth rate           | Static        | 72h        | E <sub>r</sub> C <sub>50</sub><br><br>E <sub>r</sub> C <sub>10</sub><br><br>NOEC | 0.0509 (Geomean-measured)<br><br>0.016 (Geomean-measured)<br><br>0.00201 (Geomean-measured) | Börschig, & Sonntag, 2017    | N  |

| Guideline and GLP status | Substance (purity in % w/w)    | Species                             | Endpoint Effect | Exposure |          | Results  |  | Reference      | Submitted for original approval (O) or renewal (N) |
|--------------------------|--------------------------------|-------------------------------------|-----------------|----------|----------|--|--|----------------|--|
|                          |                                |                                     |                 | Design   | Duration | Endpoint   | Toxicity (mg a.s./L)   |                |  |
| Similar to OECD 201 GLP  | Dithane M-45 (Mancozeb: 82.4%) | <i>Selenastrum capricornutum</i> ** | Growth rate     | Static   | 120h     | E <sub>r</sub> C <sub>50</sub><br><br>E <sub>r</sub> C <sub>10</sub><br><br>NOEC | 0.0322# (Geomean-measured)<br><br>0.00905 (Geomean-measured)<br><br>n.d. | Forbis, 1990## | O  |

Macrophytes

| Guideline and GLP status | Substance (purity in % w/w)      | Species            | Endpoint Effect | Exposure    |          | Results   |                                      | Reference        | Submitted for original approval (O) or renewal (N) |
|--------------------------|----------------------------------|--------------------|-----------------|-------------|----------|---|--------------------------------------|------------------|--|
|                          |                                  |                    |                 | Design      | Duration | Endpoint  | Toxicity (mg a.s./L)                 |                  |  |
| OECD 221 GLP             | Mancozeb 80 WP (Mancozeb: 80.5%) | <i>Lemna minor</i> | Growth rate     | Semi-static | 7d       | <b>E<sub>r</sub>C<sub>50</sub> Frond Number</b> | <b>1.811</b><br>(Geomean-measured)   | Dickinson, 2011d | N  |
|                          |                                  |                    |                 |             |          | <b>E<sub>r</sub>C<sub>10</sub> Frond Number</b> | <b>0.0822</b><br>(Geomean-measured)  |                  |  |
|                          |                                  |                    |                 |             |          | <b>E<sub>r</sub>C<sub>50</sub> Biomass</b>      | <b>1.042</b><br>(Geomean-measured)   |                  |  |
|                          |                                  |                    |                 |             |          | <b>E<sub>r</sub>C<sub>10</sub> Biomass</b>      | <b>0.0371</b><br>(Geomean-measured)  |                  |  |
|                          |                                  |                    |                 |             |          | <b>NOEC</b>                                     | <b>0.0246#</b><br>(Geomean-measured) |                  |  |

n.d. Not determinable

\*\*Currently known as *Raphidocelis subcapitata*

# Re-calculated endpoint by the applicant at the request of the RMS.

## Study was considered to be not valid in addendum 1 to the original DAR. However, as no valid studies were available, the endpoint from this study was used in the risk assessment for the DAR. Mean measured values from this study are considered acceptable for the RAR.

The most sensitive, valid acute and chronic classification endpoint for each main taxonomic/trophic group is presented in **bold**.

### 11.5.1 Acute (short-term) toxicity to fish

Short-term fish studies were provided both for the original Annex I approval for mancozeb, and for the AIR 3 renewal of the active. Those considered acceptable at the original approval and those considered acceptable for the current renewal are summarised below.

#### The acute toxicity of Mancozeb Technical to Rainbow trout (*Oncorhynchus mykiss*) Anonymous (1987d)

The acute toxicity of mancozeb (>90% purity) to the rainbow trout (*Oncorhynchus mykiss*) was assessed in a study performed to OECD guideline number 203 and in compliance with GLP principals. Exposure to the test item was for 96h in semi-static conditions at nominal concentrations of 0 (control), 0.1, 0.18, 0.32, 0.56, and 1.0 mg a.s./L. The mean measured 96h LC<sub>50</sub> was 0.074 mg a.s./L. It was not stated in the study report whether measurements of test concentrations were made in the fresh or spent media, therefore there is some question over whether the mean measured values used for the endpoints from this study are valid. However, as this is the critical endpoint for the acute lab studies on fish, not including it may mean the hazard assessment is not protective, the mean measured value was concluded as being acceptable for use in the risk assessment during the AIR 3 renewal of mancozeb as a pesticide and also for hazard classification.

#### The acute toxicity of Mancozeb Technical to Bluegill sunfish (*Lepomis macrochirus*). Anonymous (1987e)

The acute toxicity of mancozeb (>90% purity) to the Bluegill sunfish (*Lepomis macrochirus*) was assessed in a study performed to OECD guideline number 203 and in compliance with GLP principals. Exposure to the test item was for 96h in semi-static conditions at nominal concentrations of 0 (control), 0.056, 0.10, 0.18, 0.32, and 0.56 mg a.s./L. The mean measured 96h LC<sub>50</sub> (of spent media samples) was 0.083 mg a.s./L. Although it was not stated in the study report whether measurements had been made in freshly prepared or spent solutions, actual measured concentrations made after 0h were consistently lower than those made at 0h; implying that measurements made every 24h were made in the spent rather than the fresh media. Considering the data set available, and that it is likely that the endpoint is presented as the mean measured value of spent media samples, the RMS concluded that it is acceptable to include this endpoint in the risk assessment during the AIR 3 renewal of mancozeb as a pesticide and also for hazard classification.

#### Acute toxicity for freshwater fish *Oncorhynchus mykiss*- 96 hours in a semi-static system. Anonymous (1997e).

The acute toxicity of mancozeb (>90% purity) to the rainbow trout (*Oncorhynchus mykiss*) was assessed on a study performed to OECD guideline number 203 and in compliance with GLP principals. Exposure to the test item was for 96h in semi-static conditions at nominal concentrations of 0 (control), 0.2, 0.4, 1.0, 2.1 and 4.7 mg a.s./L. The mean measured LC<sub>50</sub> 96h was 0.088 mg a.s./L. Although the raw analytical results of test substance analysis were not presented in the study report, mean measured values were presented and it was stated that they were calculated as the geometric mean of fresh and 24h spent media at each exposure period. It is not known whether measured values were within  $\pm 20\%$  of the nominal or initial measured values. However, the geometric mean measured concentration of fresh and spent media is acceptable when measurements are outside of these ranges. Therefore the mean measured LC<sub>50</sub> of 0.088 mg a.s./L was considered acceptable for use in the risk assessment during the AIR 3 renewal of mancozeb as a pesticide and also for hazard classification.

#### Penncozeb 80 WP: 96-hours acute toxicity study in the Rainbow Trout under flow-through conditions. Anonymous (1993a).

The acute toxicity of Penncozeb (82% Mancozeb) to the rainbow trout (*Oncorhynchus mykiss*) was assessed in a study performed to OECD guideline number 203 and in compliance with GLP principals. Exposure to the test item was for 96h in flow-through conditions at nominal concentrations of 0 (control), 0.1, 0.17, 0.31, 0.56, and 1.0 mg product/L. The mean measured 96h LC<sub>50</sub> was 0.18 mg product/L, or 0.15 mg a.s./L. The mean measured NOEC was <0.09 mg product/L. The LC<sub>50</sub> endpoint was concluded as being reliable and acceptable during the EU Annex I renewal of mancozeb as a pesticide.

Acute Toxicity of Dithane M-45 to the rainbow trout (*Oncorhynchus mykiss*) Determined under flow-through test conditions. Anonymous (2000a).

The acute toxicity of Dithane M-45 (81.3% purity) to the Rainbow trout (*Oncorhynchus mykiss*) was assessed in a study performed to OECD guideline number 203 and in compliance with GLP principals. Exposure to the test item was for 96h in flow-through conditions at nominal concentrations of 0 (control), 0.13, 0.25, 0.50, 1.0, and 2.0 mg a.s./L. The nominal 96h LC<sub>50</sub> was 1.0 mg a.s./L. The nominal NOEC was 0.27 mg a.s./L. The study report demonstrated that measured test substance concentrations were maintained within ±20% of the nominal. Therefore the nominal LC<sub>50</sub> was considered acceptable for use in the risk assessment during the AIR 3 renewal of mancozeb as a pesticide and also for hazard classification.

Penncozeb 80 WP: 96-hours acute toxicity study in the Mirror Carp under flow-through conditions. Anonymous (1993b)

The acute toxicity of Penncozeb 80 WP (82% Mancozeb) to the Mirror Carp (*Cyprinus carpio*) was assessed in a study performed to OECD guideline number 203 and in compliance with GLP principals. Exposure to the test item was for 96h in flow-through conditions at nominal concentrations of 0 (control), 0.48, 0.86, 1.54, 2.78, and 5.0 mg product/L. The nominal 96h LC<sub>50</sub> was 2.28-4.1 mg/L. The nominal NOEC was 1.26 mg a.s./L. The RMS used the lowest of these values as a conservative approach and calculated the LC<sub>50</sub> in terms of active substance using the percentage concentration of mancozeb in the formulation. The LC<sub>50</sub> in terms of active substance is 1.84 mg a.s./L. The LC<sub>50</sub> endpoint was concluded as being reliable and acceptable during the EU Annex I renewal of mancozeb as a pesticide.

Acute toxicity of Dithane M-45 to the bluegill sunfish (*Lepomis macrochirus*) determined under flow-through test conditions. Anonymous (2000b).

The acute toxicity of Dithane M-45 (mancozeb % not stated) to the bluegill sunfish (*Lepomis macrochirus*) was assessed in a study performed to OECD guideline number 203 and in compliance with GLP principals. Exposure to the test item was for 96h in flow-through conditions at nominal concentrations of 0 (control), 0.25, 0.50, 1.0, 2.0, and 4.0 mg a.s./L. The mean measured 96h LC<sub>50</sub> was >3.6 mg a.s./L and the NOEC was 0.89 mg a.s./L. The study report demonstrated that measurements of test substance made at the start and end of the test were within ±20% of the nominal. Nevertheless, mean measured concentrations were used to report the endpoints. This is a more conservative approach than using nominal values and is therefore considered acceptable by the RMS. The LC<sub>50</sub> endpoint based on mean measured was therefore considered acceptable for use in the risk assessment during the AIR 3 renewal of mancozeb as a pesticide and also for hazard classification.

### 11.5.2 Acute (short-term) toxicity to aquatic invertebrates

Short-term invertebrate studies were provided both for the original Annex I approval for mancozeb, and for the AIR 3 renewal of the active. Those considered acceptable at the original approval and those considered acceptable for the current renewal are summarised below.

The acute toxicity of Mancozeb technical to *Daphnia magna*. Douglas M.T., Handley J.W. and McDonald I.A. (1988)

The acute toxicity of mancozeb (90% purity) to *Daphnia magna* was assessed in a study performed to OECD guideline number 202 and the EPA Pesticide Assessment Guidelines 72-3. The study was performed in compliance with GLP principals. Exposure to the test item was for 48h in static conditions at nominal concentrations of 0 (control), 0.01, 0.018, 0.032, 0.056, 0.1, 0.18, 0.32, 0.56, and 10.0 mg a.s./L. The mean measured 48h EC<sub>50</sub> was 0.073 mg a.s./L. This endpoint was concluded as being reliable and acceptable during the EU Annex I renewal of mancozeb as a pesticide.

Acute Toxicity of Sancozeb 800 WP for *Daphnia magna*. Study Report No. WE-01-165 of Lisec. Brouwers (1995)

The acute toxicity of Sancozeb 800 WP (80% mancozeb) to *Daphnia magna* was assessed in a study performed to OECD guideline number 202 and in compliance with GLP principals. Exposure to the test item

was for 48h at nominal concentrations of 0 (control), 0.1, 0.2, 0.4, 0.8, and 1.6 mg a.s./L. Mean measured concentrations ranged from 89 to 95% of nominal concentrations. The nominal 48h EC<sub>50</sub> was 0.9 mg a.s./L. This endpoint was concluded as being reliable and acceptable during the EU Annex I renewal of mancozeb as a pesticide.

24 h EC 50 Acute Immobilisation Study of MANCOZEB 80% WDP in *Daphnia magna*. Rakesh M. Patel (1998).

The acute toxicity of MANCOZEB 80% WDP (80% mancozeb) to *Daphnia magna* was assessed in a study performed to OECD guideline number 202 and in compliance with GLP principals. Exposure to the test item was for 24h in static conditions at nominal concentrations of 0 (control), 0.003, 0.006, 0.012, 0.024, and 0.048 mg product/L. The endpoint as reported in the study summary was a nominal EC<sub>50</sub> = 0.014 mg test substance/L equivalent to 0.0112 mg a.s./L. As the reported mancozeb content of the formulation used was 80%, this conversion from formulation to active concentration is accurate. The nominal NOEC was 0.024 mg a.s./L. Measurements of test substance at 0 and 24h presented in the study report were below the detectable limit as the detectable limit was greater than the highest concentration of mancozeb tested. However, measurements were also made in a solution with a nominal concentration of 8.0 mg a.s./L which resulted in detected levels of mancozeb of 7.523 mg at 0h (94% of the nominal) and 7.197 at 24h (90% of the nominal). Therefore it may have been possible that the test substance replicates maintained mancozeb concentrations within ±20% of the nominal over the 24 hours. In the absence of any further measurements, the endpoint is therefore reported as a nominal value. It is accepted that there are shortcomings to this study; however it is the lowest endpoint for acute daphnia available. In addition, the study report demonstrated a strong dose-response with mancozeb concentration and immobility. The endpoint is also within a factor of 10 of the next lowest endpoint from an acceptable 48h daphnia study. The RMS has concluded that the endpoint from this study should be considered in the hazard assessment to ensure that the assessment is suitably protective.

48-hour acute toxicity of Penncozeb 80 WP to *Daphnia magna* (OECD-immobilisation test) (Wuthrich V., 1993)

The acute toxicity of Penncozeb 80 WP (82% mancozeb) to *Daphnia magna* was assessed in a study performed to OECD guideline number 202 and in compliance with GLP principals. Exposure to the test item was for 48h in static conditions at nominal concentrations of 0.063, 0.125, 0.25, 0.5, and 1 mg product/L. Mean measured concentrations were above 80% of the nominal concentrations. The nominal EC<sub>50</sub> was 0.39 mg a.s./L. The EC<sub>50</sub> was concluded as being reliable and acceptable during the EU Annex I renewal of mancozeb as a pesticide.

Acute toxicity of FORTUNA 800 WP to *Daphnia magna*. Sponsored by Ameloria Ltd & Zenith Crop Science S.A. Bioagri Report No A0317.206.242.06. Sesso, J.N. (2007a)

The acute toxicity of FORTUNA 800 WP (79.4% mancozeb) to *Daphnia magna* was assessed in a study performed to OECD guideline number 202 and in compliance with GLP principals. Exposure to the test item was for 48h in static conditions at nominal concentrations of 0 (control), 0.65, 1.3, 2.5, 5, and 10 mg product/L. Mean measured concentrations at 48h were 0 (control), 0.55, 1.27, 2.27, 4.63, and 11.82 mg product/L, ranging between 85 and 118% of the nominal concentrations. The nominal 48h EC<sub>50</sub> was 1.1 mg a.s./L and the NOEC was 0.52 mg a.s./L. The EC<sub>50</sub> was concluded as being reliable and acceptable during the AIR 3 renewal of mancozeb as a pesticide.

Acute toxicity of Dithane M-45 to the water flea, *Daphnia magna*, determined under flow-through conditions. Rhodes, J.E. (2000).

The acute toxicity of Dithane M-45 (mancozeb content: 81.3%) to *Daphnia magna* was assessed in a study performed to OECD guideline number 202 and in compliance with GLP principals. Exposure to the test item was for 48h in flow-through conditions at nominal concentrations of 0 (control), 0.25, 0.50, 1.0, 2.0, and 4.0 mg a.s./L. Mean measured concentrations ranged from 90 to 116% of the nominal. Despite this, endpoints were reported as mean measured concentrations. This is considered a conservative approach and is therefore

considered acceptable by the RMS. The mean measured EC<sub>50</sub> of 3.8 mg a.s./L was concluded as being reliable and acceptable during the AIR 3 renewal of mancozeb as a pesticide.

### 11.5.3 Acute (short-term) toxicity to algae or other aquatic plants

The algal study (Forbis, 1990) was considered not valid in addendum 1 to the original DAR, due to a lack of analytical verification (details on this are vague in the DAR). However, as no other valid algal studies were available at the time the endpoint from this study was used in the pesticide risk assessment and also for hazard classification for the DAR. For the current renewal assessment the RMS requested of the applicant that reviewed, mean-measured endpoints be calculated for this and the new *Lemna* study. These were provided and have been presented in the summaries below, as well as in table 25. They are considered appropriate for use in the risk assessment and hazard classification. In addition, the applicant later submitted a new algal study on the species *P. subcapitata* which has been evaluated and considered acceptable for use in the risk assessment and hazard classification. The results presented in table 25.

Mancozeb TK: Toxicity to *Pseudokirchneriella subcapitata* in an Algal Growth Inhibition Test; Ibacon project No. 121001210 Börschig, & Sonntag, 2017.

A study on the toxicity of Mancozeb Technical (purity: 86.1%) to the algal species *Pseudokirchneriella subcapitata* (currently known as *Raphidocelis subcapitata*) was performed to OECD guideline number 201 and in compliance with GLP principals. Exposure to the test item was for 72h in static conditions at nominal concentrations of 100, 320, 100, 32, 10, and 0 (control) µg test item/L. This corresponds to 86.1, 275.5, 86.1, 27.6, and 8.61 µg a.s./L. Measurements of test substance concentration were made at 0h and every 24h throughout the study. Mean measured concentrations (geometric mean) during the study were 262, 71.5, 20.5, 6.32, and 2.01 µg a.s./L., relating to 6-102% of nominal concentrations (based on actual measured concentrations). Based on geometric mean-measured concentrations, the Growth rate E<sub>r</sub>C<sub>50</sub> was 50.9 µg a.s./L, the E<sub>r</sub>C<sub>10</sub> was 16.0 µg a.s./L, and the NOEC was 2.01 µg a.s./L. These values were considered acceptable for use in the risk assessment for the AIR 3 renewal of mancozeb as a pesticide and will also be used for hazard classification.

Acute toxicity of Dithane® M-45 fungicide to *Selenastrum capricornutum* Printz. Forbis, A. (1990)

A study on the toxicity of Dithane M-45 (82.4% mancozeb) to the algal species *Selenastrum capricornutum* (currently known as *Raphidocelis subcapitata*) was performed to 'US.EPA 1984 and ASTM 1984 standard procedures for the acute toxicity testing of freshwater green algae', and in compliance with GLP principals. Exposure to the test item was in static conditions for 120h at nominal formulation concentrations of 0 (control), 0.033, 0.065, 0.13, 0.25, and 0.5 mg a.s./L. Measurements of the test substance were made throughout the study and ranged from 65-75% of the nominal at 0h, and 1.3-7.3% of the nominal at 120h. The initial measured EC<sub>50</sub> used for the risk assessment was 0.044 mg a.s./L. The initial measured NOEC was 0.023 mg a.s./L. Although the study was originally considered not valid during the EU Annex I renewal of mancozeb, the endpoints quoted above were used in the risk assessment in addendum 1 to the DAR. The RMS determined that it was possible to calculate a valid (mean measured) endpoint from this study (according to the current EFSA opinion; EFSA technical Report, 2015. Ch. 3.1). The applicant provided these values which were calculated to be: E<sub>r</sub>C<sub>50</sub> = 32.2 µg a.s./L (mm), E<sub>r</sub>C<sub>10</sub> = 9.05 µg a.s./L (mm), E<sub>y</sub>C<sub>50</sub> = 8.79 µg a.s./L (mm), and E<sub>y</sub>C<sub>10</sub> = 3.54 µg a.s./L (mm). These values were considered acceptable for use in the risk assessment for the AIR 3 renewal of mancozeb as a pesticide and will also be used for hazard classification.

A study for the toxicity of mancozeb on higher aquatic plants (*Lemna minor*) was submitted for the AIR 3 renewal of the active. This study was assessed and considered acceptable after mean measured endpoints were provided by the applicant upon the request of the RMS. A summary is presented below.

Mancozeb 80 WP - Higher plant (*Lemna minor*) growth inhibition test; Huntington Life Sciences project No. ARK0004. Dickinson (2011d).

A 7-day study on the toxicity of Mancozeb 80 WP (purity: 80.5% mancozeb) to the aquatic plant *Lemna minor* was performed to OECD guideline number 221 and in compliance with GLP principals. Exposure to the test item was in semi-static conditions at nominal formulation concentrations of 0 (control), 0.13, 0.43, 1.38, 4.44, 14.2, and 45.5 mg Mancozeb 80 WP/L. Mean measured active concentrations in fresh media samples taken on days 0 and 5 were 0 (control), 0.0828, 0.303, 0.797, 3.00, 9.98, and 31.9 mg a.s./L. These related to 72-88% of nominal concentrations. Mean measured levels in the spent media samples taken on days 3 and 7 were 0 (control), 0, 0, 0.0057, 0.06, 1.16, and 0.52 mg a.s./L, relating to 0-8% of nominal values. The mean measured (fresh media)  $E_rC_{50}$  was 9.56 mg a.s./L. The RMS requested endpoints based on mean measured values of fresh and expired media samples. The applicant provided these values which were calculated to be:  $E_rC_{50}$  (fronds number) = 1811  $\mu\text{g a.s./L (mm)}$ ,  $E_rC_{10}$  (fronds number) = 82.2  $\mu\text{g a.s./L (mm)}$ ,  $E_rC_{50}$  (biomass) = 1042  $\mu\text{g a.s./L (mm)}$ , and  $E_rC_{10}$  (biomass) = 37.1  $\mu\text{g a.s./L (mm)}$ . These values were considered acceptable for use in the risk assessment for the AIR 3 renewal of mancozeb as a pesticide and also for hazard classification.

#### **11.5.4 Acute (short-term) toxicity to other aquatic organisms**

No studies on other organisms were considered valid for use in the hazard assessment.

## 11.6 Long-term aquatic hazard

Table 26: Summary of relevant information on chronic aquatic toxicity

| Guideline and GLP status | Substance (purity in % w/w)    | Species                      | Endpoint Effect                | Exposure     |          | Results                  |                                     | Reference        | Submitted for original approval (O) or renewal (N) |
|--------------------------|--------------------------------|------------------------------|--------------------------------|--------------|----------|--------------------------|-------------------------------------|------------------|--|
|                          |                                |                              |                                | Design       | Duration | Endpoint                 | Toxicity (mg a.s./L)                |                  |  |
| <b>Fish</b>              |                                |                              |                                |              |          |                          |                                     |                  |  |
| OPPTS 850.1500 GLP       | Mancozeb Tech. (purity: 84.7%) | <i>Pimephales promelas</i>   | Reproduction. Life Cycle Study | Flow-through | 215d     | NOEC<br>EC <sub>10</sub> | 0.00135 (mm)<br><b>0.00127 (mm)</b> | Anonymous, 2012  | N  |
| OPPTS 850.1400 GLP       | Dithane M-45 (Mancozeb: 78.8%) | <i>Cyprinodon variegatus</i> | Growth. Early Life Stage.      | Flow-through | 39d      | NOEC<br>EC <sub>10</sub> | 0.000918 (mm)<br>0.002878 (mm)      | Anonymous, 2011a | N  |
| Similar to OECD 210      | Dithane M-45 (Mancozeb: 82.4%) | <i>Pimephales promelas</i>   | Survival. Early Life Stage.    | Flow-through | 33d      | NOEC<br>EC <sub>10</sub> | 0.0052 (mm)<br>0.00531 (mm)         | Anonymous, 1988e | O  |
| Similar to OECD 210 GLP  | Mancozeb Tech. (purity 79.3%)  | <i>Pimephales promelas</i>   | Survival. Early Life Stage.    | Flow-through | 34d      | NOEC<br>EC <sub>10</sub> | 0.00219 (mm)<br>0.002037 (mm)       | Anonymous, 1994c | O  |
| <b>Invertebrates</b>     |                                |                              |                                |              |          |                          |                                     |                  |  |
| Similar to OECD 211 GLP  | Dithane M-45 (Mancozeb: 82.4%) | <i>Daphnia magna</i>         | Reproduction                   | Flow-through | 21d      | NOEC<br>EC <sub>10</sub> | 0.0073 (mm)<br>0.0109 (mm)          | Burgess, 1988    | O  |
| OPPTS 850.1350 GLP       | Dithane M-45 (Mancozeb: 78.8%) | <i>Americamysis bahia</i>    | Survival                       | Flow-through | 39d      | NOEC<br>EC <sub>10</sub> | 0.00164 (mm)<br><b>0.00171 (mm)</b> | Hicks, 2011b     | N  |

| Guideline and GLP status | Substance (purity in % w/w)    | Species                                   | Endpoint Effect | Exposure |          | Results  |   | Reference                 | Submitted for original approval (O) or renewal (N) |
|--------------------------|--------------------------------|---|-----------------|----------|----------|--|---|---------------------------|--|
|                          |                                |   |                 | Design   | Duration | Endpoint   | Toxicity (mg a.s./L)  |                           |  |
| <b>Algae</b>             |                                |   |                 |          |          |  |   |                           |  |
| OECD 201 GLP             | Mancozeb Tech. (purity: 86.1%) | <i>Pseudokirchneriella subcapitata</i> ** | Growth rate     | Static   | 72h      | E <sub>r</sub> C <sub>50</sub><br>E <sub>r</sub> C <sub>10</sub><br>NOEC | 0.0509 (Geomean-measured)<br>0.016 (Geomean-measured)<br>0.00201 (Geomean-measured) | Börschig, & Sonntag, 2017 | N  |
| Similar to OECD 201 GLP  | Dithane M-45 (Mancozeb: 82.4%) | <i>Selenastrum capricornutum</i> **       | Growth rate     | Static   | 120h     | E <sub>r</sub> C <sub>50</sub><br>E <sub>r</sub> C <sub>10</sub><br>NOEC | <b>0.0322#</b> (Geomean-measured)<br><b>0.00905</b> (Geomean-measured)<br>n.d.      | Forbis, 1990##            | O  |

| Guideline and GLP status | Substance (purity in % w/w)      | Species            | Endpoint Effect | Exposure    |          | Results   |                                      | Reference        | Submitted for original approval (O) or renewal (N) |
|--------------------------|----------------------------------|--------------------|-----------------|-------------|----------|---|--------------------------------------|------------------|--|
|                          |                                  |                    |                 | Design      | Duration | Endpoint  | Toxicity (mg a.s./L)                 |                  |  |
| <b>Macrophytes</b>       |                                  |                    |                 |             |          |   |                                      |                  |  |
| OECD 221 GLP             | Mancozeb 80 WP (Mancozeb: 80.5%) | <i>Lemna minor</i> | Growth rate     | Semi-static | 7d       | <b>E<sub>r</sub>C<sub>50</sub> Frond Number</b> | <b>1.811</b><br>(Geomean-measured)   | Dickinson, 2011d | N  |
|                          |                                  |                    |                 |             |          | <b>E<sub>r</sub>C<sub>10</sub> Frond Number</b> | <b>0.0822</b><br>(Geomean-measured)  |                  |  |
|                          |                                  |                    |                 |             |          | <b>E<sub>r</sub>C<sub>50</sub> Biomass</b>      | <b>1.042</b><br>(Geomean-measured)   |                  |  |
|                          |                                  |                    |                 |             |          | <b>E<sub>r</sub>C<sub>10</sub> Biomass</b>      | <b>0.0371</b><br>(Geomean-measured)  |                  |  |
|                          |                                  |                    |                 |             |          | <b>NOEC</b>                                     | <b>0.0246#</b><br>(Geomean-measured) |                  |  |

n.d. Not determinable

\*\*Currently known as *Raphidocelis subcapitata*

# Re-calculated endpoint by the applicant at the request of the RMS.

## Study was considered to be not valid in addendum 1 to the original DAR. However, as no valid studies were available, the endpoint from this study was used in the risk assessment for the DAR. Mean measured values from this study are considered acceptable for the RAR.

The most sensitive, valid acute and chronic classification endpoint for each main taxonomic/trophic group is presented in **bold**.

### 11.6.1 Chronic toxicity to fish

Long-term fish studies were provided both for the original Annex I approval for mancozeb, and for the AIR 3 renewal of the active. Those considered acceptable at the original approval and those considered acceptable for the current renewal are summarised below.

#### Mancozeb: Life-Cycle Toxicity Test with the Fathead Minnow, *Pimephales promelas* under Flow-Through Conditions, Anonymous, (2012)

The chronic toxicity of Mancozeb technical (84.8% purity) to the fathead minnow (*Pimephales promelas*) was assessed in a full life-cycle study performed to US EPA OPPTS guideline 850.1500 and in compliance with GLP principals. The parental and offspring generations were exposed to the test item for a total period of 215 days under flow-through conditions at nominal test concentrations of 0 (control), 0.50, 1.0, 2.0, 4.0, and 8.0 µg a.s./L. Mean measured concentrations throughout the test were <MQL (control), 0.382, 0.694, 1.35, 2.58, and 5.05 µg a.s./L. These were within the range of 63-76% of nominal concentrations. Two hundred F0 embryos were used per treatment group. These embryos were allowed to hatch, grow and spawn in the test-substance treated water. Measurements were made of survival, length, wet weight, sublethal effects compared to the control (incl. spinal curvature, resting on bottom, erratic swimming, haemorrhagic, discoloration, and unusual respiration), days till first spawn, number of spawns, and number of eggs at various points throughout the study. F0 female growth was mostly unaffected by treatment concentration. The mean measured NOEC for spinal curvature was 2.58 µg a.s./L, as was the NOEC for the day 167 spawning group. F0 male weight and length on days 118-119 was negatively affected by mancozeb concentration with a NOEC of 2.58 µg a.s./L. This was also the NOEC of F1 survival. Reproduction-related effects were the most sensitive. The number of spawns and percentage of fertile eggs a female produced were negatively affected by mancozeb concentration with mean measured NOECs of 2.58 µg a.s./L. The most sensitive endpoints were the number of eggs per F0 female per day and the cumulative number of eggs produced by F0 minnows, with NOECs of 1.35 µg a.s./L in both cases. The most sensitive mean measured EC<sub>10</sub> was calculated for reproduction with a value of 1.27 µg a.s./L. The EC<sub>10</sub> was concluded as being reliable and acceptable during the AIR 3 renewal of mancozeb as a pesticide.

#### Mancozeb: Early Life-Stage Toxicity Test with the Sheepshead Minnow, *Cyprinodon variegatus*, Under Flow-Through Conditions; Anonymous, (2011a).

The chronic toxicity of Dithane M-45 (78.8% purity) to the Sheepshead Minnow (*Cyprinodon variegatus*) was assessed in an early life stage study performed to US EPA OPPTS guideline 850.1400 and in compliance with GLP principals. 80 embryos per test treatment were exposed to the test substance for 39 days (29 days post-hatch) in flow-through conditions. The nominal test concentrations were 0 (control), 1.9, 3.8, 7.5, 15, and 30 µg a.s./L. Mean measured concentrations were <MQL (control), 0.918, 2.13, 4.46, 9.04, and 19.5 µg a.s./L. Individual measurements ranged from 20-95% of the nominal. Hatchability, survival, length, and wet weight of fish were measured during the test. The mean measured NOECs for hatchability and survival were both 19.5 µg a.s./L. The most sensitive NOEC was growth with a mean measured NOEC of 0.918 µg a.s./L. The most sensitive mean measured EC<sub>10</sub> was calculated for growth with a value of 2.878 µg a.s./L. This EC<sub>10</sub> was concluded as being reliable and acceptable during the AIR 3 renewal of mancozeb as a pesticide.

#### Early life stage toxicity of Dithane® M-45 to Fathead Minnow (*Pimephales promelas*) in a flow-through system. Anonymous. (1988e)

The chronic toxicity of Dithane M-45 (82.4% mancozeb) to the fathead minnow (*Pimephales promelas*) was assessed in an early life stage study performed to 'ASTM (1983) and the Committee on Methods for Toxicity Testing with Aquatic Organisms (1975) protocol ABC 7809' (similar to OECD 210) and in compliance with GLP principals. 80 eggs per test treatment were exposed to the test substance for 33 days in flow-through conditions. The nominal test concentrations were 0 (control), 3.1, 6.2, 12, 25, and 50 µg a.s./L. Mean measured concentrations were 0 (control), 3.5, 5.3, 10, 20, and 43 µg a.s./L. Survival, length, and wet weight of fish were measured during the test. The most sensitive NOEC was survival with a mean measured NOEC of 5.2 µg a.s./L. The most sensitive EC<sub>10</sub> was calculated for survival with a mean measured value of 5.31 µg

a.s./L. The EC<sub>10</sub> was concluded as being reliable and acceptable during the EU Annex I renewal of mancozeb as a pesticide.

Early Life-stage Toxicity of Mancozeb to the Fathead Minnow (*Pimephales promelas*) Under Flow-Through Conditions. Anonymous (1994c).

The chronic toxicity of mancozeb technical (79.3% purity) to the fathead minnow (*Pimephales promelas*) was assessed in an early life-stage study performed to 'ABC protocol n° FIFRA 72-4 based on that described in the Proposed Recommended Bioassay Procedure for Egg and Fry stages of Freshwater Fish (USEPA 1972) and Standard Guide for Conducting Early Stage Toxicity Tests for Fish (ASTM 1988)', similar to OECD 210, and in compliance with GLP principals. 120 eggs per test treatment were exposed for 34 days (28 days post-hatch) in flow-through conditions. The nominal test concentrations were 0 (control), 0.30, 0.60, 1.3, 2.5, 5.0, 10, and 20 µg a.s./L. Mean measured concentrations were 0.592, 1.07, 2.19, 4.56, and 7.97 µg a.s./L in the 1.3, 2.5, 5.0, 10, and 20 µg a.s./L test treatments as measured by GC analysis. Measurements were not made of the first two levels as they were reportedly below the Limit of Detection for the analysis. Measurements were also made by LSC analysis in all levels and resulted in test concentrations of 0.236, 0.535, 1.08, 2.37, 4.65, 9.57, and 19.0 µg a.s./L in the 0.3-20 µg a.s./L nominal treatments, respectively. Egg hatchability, survival, growth, and morphological and behavioural effects were measured throughout the study. There was no statistically significant effect of mancozeb concentration on growth or egg hatchability. The most sensitive NOEC was fry survival with a with a mean measured (by GC analysis) NOEC of 2.19 µg a.s./L, or 4.65 µg a.s./L by LSC analysis. The most sensitive EC<sub>10</sub> was calculated for survival with a value of 2.037 µg a.s./L (by GC analysis). The EC<sub>10</sub> was concluded as being reliable and acceptable during the AIR 3 renewal of mancozeb as a pesticide.

#### 11.6.2 Chronic toxicity to aquatic invertebrates

Long-term invertebrate studies were provided both for the original Annex I approval for mancozeb, and for the AIR 3 renewal of the active. Those considered acceptable at the original approval and those considered acceptable for the current renewal are summarised below.

Chronic toxicity of Dithane® M-45 to *Daphnia magna* under flow-through conditions. Burgess, D. (1988).

The chronic toxicity of Dithane M-45 (82.4% mancozeb) to *Daphnia magna* was assessed in a study performed to US EPA FIFRA 72.4 (similar to OECD guideline number 202) and in compliance with GLP principals. Exposure to the test item was for 21 days in flow-through conditions at nominal concentrations of 0 (control), 3, 5.9, 12, 25, and 50 µg a.s./L. Mean measured concentrations during the study were 0 (control), 2.9, 7.3, 12, 26, and 53 µg a.s./L. 40 daphnids were used per test concentration. Observations were made of survival, occurrence of first brood, fecundity of adults, and growth (as adult length) throughout the study. The mean measured 21 day EC<sub>50</sub> for survival was >53 µg a.s./L and the NOEC was 26 µg a.s./L. This was also the case for daphnid length. There was no significant effect of test treatment on time to first brood. The most sensitive NOEC was for fecundity as number of young produced per adult per day, at 7.3 µg a.s./L. The most sensitive EC<sub>10</sub> was calculated for reproduction with a mean measured value of 10.9 µg a.s./L. The EC<sub>10</sub> was concluded as being reliable and acceptable during the EU Annex I renewal of mancozeb as a pesticide.

Mancozeb: Life-Cycle Toxicity Test of the Saltwater Mysid, *Americamysis bahia*, Conducted under Flow-Through Conditions, Mancozeb Task Force Study No. 2010-1, ABC Study No. 66201. Hicks, S.L. (2011b).

The chronic toxicity of Dithane M-45 (78.8% mancozeb) to the saltwater mysid crustacean *Americamysis bahia* was assessed in a study performed to U.S. EPA Ecological Effects Testing Guidelines OPPTS 850.1350 and in compliance with GLP principals. Exposure to the test item was for 28 days in flow-through conditions at nominal concentrations of 0 (control), 0.33, 0.65, 1.3, 2.5, and 5.0 µg a.s./L. Mean measured concentrations during the study were 0 (control), 0.217, 0.625, 0.882, 1.64, and 3.25 µg a.s./L, relating to 66-96% of the nominal concentrations. 90 <24h old mysids were used per test concentration. Observations were made of survival, sublethal effects compared to the control, time to first brood, and body length in the F0 generation. Brood were collected from this generation, which was terminated at 28 days. Body length was measured for the F1 generation, which was terminated at 11 days after the termination of the F0. There was no statistical effect of test concentration on F0 mysid survival at 0-21 days. The mean measured NOEC was

3.25 µg a.s./L. This was also the case for male and female mysid length for both the F0 and F1 generations. The most sensitive endpoints were F0 survival at 28 days and F1 survival on all days. The mean measured NOECs based on these effects were 1.64 µg a.s./L. The most sensitive EC<sub>10</sub> was calculated for F0 survival with a mean measured value of 1.71 µg a.s./L. The EC<sub>10</sub> was concluded as being reliable and acceptable during the AIR 3 renewal of mancozeb as a pesticide.

### 11.6.3 Chronic toxicity to algae or other aquatic plants

See study summaries for algae and aquatic plants provided under section 11.5.3.

### 11.6.4 Chronic toxicity to other aquatic organisms

No studies on other organisms were considered valid for use in the hazard assessment.

## 11.7 Comparison with the CLP criteria

Data on the degradability of mancozeb has been considered in section 11.1 and it is proposed that the active is considered 'not rapidly degradable' for classification purposes (See Table 23). It was also concluded that mancozeb has a low bioaccumulation potential.

The most sensitive acute and chronic endpoints for each main taxonomic/trophic group are presented in Table 25 and 26 in bold.

### 11.7.1 Acute aquatic hazard

Acute aquatic toxicity data on technical mancozeb are available for fish, invertebrates, and algae. Using the technical endpoints only, the lowest LC/EC<sub>50</sub> value is the 72h E<sub>r</sub>C<sub>50</sub> of 0.0509 mg a.s./L for *P. subcapitata*. This is > 0.01 but ≤ 0.1 mg/L, and therefore mancozeb should be classified as Aquatic Acute category 1 with an acute M-factor of 10. In addition, acute aquatic toxicity data on ~80% w/w wettable powder formulations with mancozeb are available for fish, invertebrates, algae and aquatic plants. The lowest reliable acute endpoint is the 24h nominal EC<sub>50</sub> of 0.0112 mg a.s./L for *Daphnia magna*. This is > 0.01 but ≤ 0.1 mg/L, and therefore mancozeb should be classified as Aquatic Acute category 1 with an acute M-factor of 10.

### 11.7.2 Long-term aquatic hazard (including bioaccumulation potential and degradation)

#### Bioaccumulation

For pesticide approval under EC Reg. 1107/2009, a Log Kow >3 triggers the requirement for a bioconcentration study. Since the Log Kow of mancozeb is < 3 a bioconcentration study is not required. For classification and labelling purposes a substance with Log Kow < 4 may be considered unlikely to bioaccumulate in aquatic organisms. In conclusion, according to the CLP criteria, mancozeb has a low potential for bioaccumulation.

#### Degradation

Mancozeb does not meet the criteria for 'rapidly degradable' as whilst its primary degradation is very fast, it does not meet the criteria for ultimate degradation, i.e. the formation of CO<sub>2</sub>. It is considered that mancozeb meets the criteria for primary degradation. According to The Guidance on the Application of the CLP Criteria (ECHA, 2015); "Data on primary degradation can only be used where it is demonstrated that the degradation products shall not be classified as hazardous to the aquatic environment, i.e. that they do not fulfil the classification criteria." Experimental toxicity endpoints are only available for the mancozeb degradants ETU and EU. Theoretical QSAR endpoints are available for the degradant EBIS. These are summarised in Annex III, Table A3-2.

The lowest acute endpoint for ETU is the *A. bahia* EC<sub>50</sub> of 11 mg a.s./L which is greater than 1 mg/L, Therefore ETU is not classified as acute category 1 based on this data. The lowest acute endpoint for EU is

*O. mykiss* LC<sub>50</sub> of >122 mg a.s./L which is greater than 1 mg/L. Therefore EU is not classified as acute category 1 based on this data.

For ETU, adequate chronic data are available for three trophic levels. The lowest chronic endpoint for ETU is the *D. magna* NOEC of 2 mg a.s./L which is greater than 1 mg/L. Therefore ETU does not fulfil the criteria for chronic classification. For EU, chronic data is only available for algae. However, the algal ErC50 and all other available acute endpoints are greater than 100 mg/L. Therefore EU does not fulfil the criteria for chronic classification.

For the other relevant degradants, a request was made to the applicant to provide classification information based on any available, relevant data. Harmonised classifications were available for all relevant degradants with the exception of glycolic acid, for which the applicant performed a calculation of classification based on available lab data. The full response from the applicant is provided in Annex III, and the classification of the degradants is summarised in the table below.

**Table 11.7.2: Acute and chronic classification of the relevant degradants of mancozeb**

| Degradant<br>(CAS No.)                         | Study<br>type            | Findings<br>[mg/L] | DT <sub>50</sub> (or<br>DT <sub>90</sub> /3.322 where<br>behaviour is<br>biphasic) | Triggered<br>classification and<br>labelling    | Reference   |
|--|--------------------------|--------------------|--|---|---|
| EBIS<br>(33813-20-6)                           | --                       | --                 | 0.5 – 10.9 days <sup>1</sup>   | <b>Aquatic acute hazard<br/>cat. 1 (H400)</b>   | legal classification of EBIS<br>in Annex VI of<br>(EC) No 1272/2008 (CLP)   |
|  | --                       | --                 |  | <b>Aquatic chronic<br/>hazard cat. 1 (H410)</b> |   |
| EDA<br>(1,2-<br>Ethanediamine)<br>(107-15-3)   | --                       | --                 | Not calculable   | <b>No aquatic acute<br/>hazard cat.</b>         | legal classification of EDA<br>in Annex VI of<br>(EC) No 1272/2008 (CLP),<br>however self classification<br>as Chronic 3 is included in<br>CLP Inventory. |
|  | --                       | --                 |  | <b>No aquatic chronic<br/>hazard cat.</b>       |   |
| Ethanolamine<br>(2-Aminoethanol)<br>(141-43-5) | --                       | --                 | 20.2 days  | <b>No aquatic acute<br/>hazard cat.</b>         | legal classification of<br>ethanolamine in Annex VI<br>of (EC) No 1272/2008<br>(CLP)  |
|  | --                       | --                 |  | <b>No aquatic chronic<br/>hazard cat.</b>       |   |
| Glycolic acid<br>(79-14-1)                     | 48-h<br>EC <sub>50</sub> | 44.0               | 2060 days  | <b>No aquatic acute<br/>hazard cat.</b>         | Japanese Environment<br>Agency (NR), Acute<br>Immobilization Test of<br>Glycolic acid to <i>Daphnia<br/>magna</i> Report Nr. 1998-生<br>22                 |
|  | 21-d<br>NOEC             | 4.38               |  | <b>No aquatic chronic<br/>hazard cat.</b>       | Japanese Environment<br>Agency (NR),<br>Reproduction Inhibition<br>Test of Glycolic acid to<br><i>Daphnia magna</i> Report No:<br>1998-生23                |
| Ethylene glycol<br>(107-21-1)                  | --                       | --                 | 11.9 days <sup>2</sup>   | <b>No aquatic acute<br/>hazard cat.</b>         | legal classification of<br>ethylene glycol in Annex<br>VI of (EC) No 1272/2008<br>(CLP)   |
|  | --                       | --                 |  | <b>No aquatic chronic<br/>hazard cat.</b>       |   |
| Oxalic acid<br>(possibly M1)<br>(144-62-7)     | --                       | --                 | 37.8 days <sup>3</sup>   | <b>No aquatic acute<br/>hazard cat.</b>         | legal classification of<br>oxalic acid in Annex VI of<br>(EC) No 1272/2008 (CLP)  |
|  | --                       | --                 |  | <b>No aquatic chronic<br/>hazard cat.</b>       |   |

<sup>1</sup> = Decline calculated on total amount in water + sediment phase

<sup>2</sup> = DT50 calculated tentatively on 2 sample points

<sup>3</sup> = Study had two incubations; maximum occurred in one incubation at study end, but in the other incubation the substance declined before end to allow tentative DT50 calculation (three sample points from study end)

As demonstrated, the degradant EBIS is classified as hazardous to the aquatic environment, with a classification of Aquatic Acute category 1 and Aquatic Chronic category 1. The applicant provided further case that the classification of EBIS is 'covered by the classification of mancozeb and therefore mancozeb can be assessed as rapidly degradable'. However, the CLP guidance does not provide any information as to whether the degradants have to be classified as more hazardous to the aquatic environment than the parent compound in order to preclude consideration as 'rapidly degradable'. Nor is there guidance to determine if the case provided by the applicant is sufficient to discount the classification of EBIS. Therefore, as a conservative approach, mancozeb will not be classified as 'rapidly degradable' due to the classification of the major metabolite EBIS as hazardous to the aquatic environment. It is also noted that another aquatic degradant, EDA, is self-classified as Chronic 3 according to information on the ECHA dissemination website (349 Notified classifications and labelling according to CLP criteria).

Chronic/long-term toxicity data on technical mancozeb are available for fish and algae. Data on ~80% w/w wettable powder formulations are also available on invertebrates and aquatic plants. The lowest NOEC of all the reliable studies is 0.000918 mg a.s./L from the early life stage study on *Cyprinodon variegates*, however, according to page 490 of ECHA (2015)<sup>1</sup> if EC<sub>10</sub> values are available for chronic data then these should be used preferentially over the NOEC for the purpose of hazard classification. The lowest reliable chronic EC<sub>10</sub> is the Full Life Cycle mean measured growth EC<sub>10</sub> of 0.00127 mg a.s./L for *Pimephales promelas*, using technical mancozeb. This is > 0.001 but ≤ 0.01 mg/L, and therefore since it is considered 'not rapidly degradable', mancozeb should be classified as Aquatic Chronic category 1 with an M-factor of 10.

Chronic data on the technical material are not available on invertebrates or aquatic plants, the lowest formulation endpoint is 39-day EC<sub>10</sub> of 0.00171 mg/L for *Americamysis bahia*. Which would also result in a Chronic 1 classification with a Chronic M-factor of 10. Although this was a relatively simple 80% w/w wettable powder formulation, if the use of formulation data are not appropriate, then using the surrogate approach and the lowest invertebrate active substance EC<sub>50</sub> of 0.073 mg active substance/L for *D. magna*, would also result in a Chronic 1 classification and Chronic M-factor of 10 for a non-rapidly degradable substance.

## 11.8 CONCLUSION ON CLASSIFICATION AND LABELLING FOR ENVIRONMENTAL HAZARDS

**Aquatic Acute 1; H400: Very toxic to aquatic life**

**Acute M-factor = 10**

**Aquatic Chronic 1; H410: Very toxic to aquatic life with long lasting effects**

**Chronic M-factor = 10**

## 12 EVALUATION OF ADDITIONAL HAZARDS

### 12.1 Hazardous to the ozone layer

#### 12.1.1 Short summary and overall relevance of the provided information on ozone layer hazard

Not considered in this report.

**12.1.2 Comparison with the CLP criteria**

Not considered in this report.

**12.1.3 Conclusion on classification and labelling for hazardous to the ozone layer**

**Not evaluated. No classification proposed.**

### **13 ADDITIONAL LABELLING**

Additional labelling is not required.

## 14 REFERENCES

- Van Amelsvoort LGPM *et al* (2008). Immune effects and exposure to ethylenebisdithiocarbamate pesticides in re-entry workers in the Netherlands. *Human & Experimental Toxicology*, **27**: 693-700.
- Aprea C, Betta A, Catenacci G, Colli A, Lotti A, Minoia C, Olivieri P, Passini V, Pavan I, Roggi C, Ruggeri R, Sciarra G, Turci R, Vannini P and Vitalone V (1997). Urinary excretion of ethylenethiourea in five volunteers on a controlled diet (multicentric study). *Sci. Total Environ.* 203(2), 167-179.
- Axelstad M *et al* (2011). Exposure to the widely used fungicide mancozeb causes hormone disruption in rat dams but no behavioural effects in the offspring. *Toxicological Sciences*, 120 (2), 439-446.
- Band PR *et al* (2011). Prostate cancer risk and exposure to pesticides in British Columbia farmers. *The Prostate*, **71**: 168-183.
- Baranska M *et al* (2008). Association of pesticide exposure, vaccination response, and interleukin-1 gene polymorphisms. *Hum Exp Toxicol.* 2008; 27(9):709-13.
- Beard JD *et al* (2011). Suicide and Pesticide Use among Pesticide Applicators and Their Spouses in the Agricultural Health Study. *Environ. Health Perspect.* 119, 1610-1615.
- Belpoggi F, Soffritti M, Guarino M, Lambertini L, Cevolani D and Maltoni C (2002). Results of long-term experimental studies on the carcinogenicity of ethylene-bis-dithiocarbamate (Mancozeb) in rats. *Ann. N. Y. Acad. Sci* 982, 123-136.
- Burgess D (1988). Chronic toxicity of Dithane<sup>®</sup> M-45 to *Daphnia magna* under flow-through test conditions. Generated by ABC. ER Company file No.M45-5-1. Unpublished. IIA, 8.2 8.2.6/01.
- Chism EM (1984). Dithane M-45\*: microbial mutagen assay. Rohm and Haas Company Toxicology Department. Pennsylvania, USA. Unpublished Report No. 84R-0060.
- Colosio C *et al* (2007). Changes in serum markers indicative of health effects in vineyard workers following exposure to the fungicide mancozeb: an Italian study. *Biomarkers*, **12**: 574-588.
- Corsini E *et al* (2005). Immunomodulatory effects of the fungicide Mancozeb in agricultural workers *Toxicology and Applied Pharmacology*, 208 (2), 178-185.
- Corsini E *et al* (2006) Molecular mechanisms underlying mancozeb-induced inhibition of TNF-alpha production *Toxicology and Applied Pharmacology*, 212 (2), 89-98.
- DAR (2000). Draft Assessment Report (DAR) Annex B.6 on the active substance mancozeb prepared by the rapporteur Member State Italy in the framework of Directive 91/414/EEC, September 2000.
- Daston, G.P. (1990) Ethylenethiourea: In vivo/in vitro comparisons of teratogenicity. *Teratology*, **41**, 475–476
- Dennis LK *et al* (2010). Pesticide Use and Cutaneous Melanoma in Pesticide Applicators in the Agricultural Health Study. *Environmental Health Perspectives*, **118**:812–817.
- Dickinson RA (2011a). Mancozeb 80 WP - Toxicity to the sediment-dwelling phase of the midge *Chironomus riparius*. Huntington Life Sciences Ltd. Project No.: ARK0003. KCA 8.2.5.3/01.
- Dickinson RA (2011b). Mancozeb 80 WP - Toxicity to the sediment-dwelling endobenthic aquatic oligochaete *Lumbriculus variegatus*; Huntington Life Sciences study number: ARK0003. KCA 8.2.5.4/01.
- Dickinson RA (2011c). Mancozeb 80 WP: Algal Growth Inhibition Assay – *Anabaena*; Huntington Life Sciences project No. ARK0002. KCA 8.2.6.2/01.
- Dickinson RA (2011d). Mancozeb 80 WP - Higher plant (*Lemna minor*) growth inhibition test; Huntington Life Sciences project No. ARK0004. KCA 8.2.7/01.
- Dhillon AS *et al* (2008). Pesticide/Environmental exposures and Parkinson's Disease in East Texas. *Journal of Agromedicine*, **13**(1): 37-48.

- Dobson R (2015). [<sup>14</sup>C]-Mancozeb: Aerobic mineralisation in surface water (OECD 309). Report DR/13/001. KCA 7.2.2.2/01.
- Douglas MT, Handley JW, McDonald IA(1988). The acute toxicity of Mancozeb technical to *Daphnia magna*. Huntingdon Research Centre Ltd. Huntingdon Cambs PE18 6ES England. Elf Atochem. Agri. Unpublished.
- Ectors A (1995). Biodegradation study of Sancozeb 800 WP CO<sub>2</sub> evolution test. WB-04-071. CA 7.2.2.1/01.
- Ekman *et al* (2013). High-throughput method for the analysis of ethylenethiourea with direct injection of hydrolysed urine using on-column extraction liquid chromatography and triple quadrupole mass spectrometry. Journal of Chromatography B, **934**: 53-59.
- EU (2009). Review report for the active substance mancozeb. Finalised in the Standing Committee on the Food Chain and Animal Health at its meeting on 3 June 2005 in view of the inclusion of mancozeb in Annex I of Council Directive 91/414/EEC. SANCO/4058/2001-rev.4.4 July, 2009.
- Fabian and Landsiedal (2015). <sup>14</sup>C-Reg. No. 146099 (Metabolite of BAS 222 F(Metiram), BF 222-ETU; CAS No. 96-45-7 in aqueous vehicle. Study of penetration through human skin *in vitro*.
- Flippin JL, Hedge JM, DeVito MJ, LeBlanc GA and Crofton KM (2009). Predictive modeling of a mixture of thyroid hormone disrupting chemicals that affect production and clearance of thyroxine. International Journal of Toxicology, 28(5): 368-381.
- FOCUS (2006). EC document reference Sanco/10058/2005, Generic Guidance v1.1 (2014).
- Forbis (1990). Acute toxicity of Dithane<sup>®</sup> M-45 Fungicide to *Selenastrum capricornutum* Printz. Generated by ABC. Submitted by: Rohm and Haas Company. ER Company file No.: 77.12. Unpublished. IIA, 8.2. IIIA, 10.2.1. 8.2.6/02a, 8.2.7/01b.
- Foster JR (2015). Mancozeb: Comparative *In vitro* Metabolism using Mouse, Rat, Rabbit, Dog and Human Hepatocytes. HLS report.
- Foxall S & Byers MJ (1984). Dithane M-45\* CHO/HGPRT gene mutation assay. Rohm and Haas Company Toxicology Department. Pennsylvania, USA. Unpublished Report No. 84R-207.
- Gilby B (2017). Mancozeb TK : In vitro micronucleus test in human lymphocytes. Envigo CRS Limited, Huntingdon, Cambridgeshire, UK. Unpublished report No FF56KP.
- Goldner WS, Sandler DP, Yu F, Hoppin JA, Kamel F and Levan TD (2010). Pesticide use and thyroid disease among women in the Agricultural Health Study. Am. J Epidemiol. 171(4), 455-464.
- Goldner WS, Sandler DP, Yu F, Shostrom V, Hoppin JA, Kamel F and Levan TD (2013). Hypothyroidism and pesticide use among male private pesticide applicators in the agricultural health study. J. Occup. Environ. Med. 55 (10), 1171-1178.
- Hardy IAJ (2015a). Mancozeb: Recalculation of hydrolysis DT<sub>50</sub> values from two studies according to FOCUS Kinetics. DR/14/001Z. KCA 7.2.1.1/03.
- Hardy IAJ (2015b). Mancozeb: Kinetic Modelling Evaluation of Two Water Sediment studies According to FOCUS Degradation Kinetics. DR/14/001E. KCA 7.2.2.3/03.
- Hicks SL (2011b). Mancozeb: Life-Cycle Toxicity Test of the Saltwater Mysid, *Americamysis bahia*, Conducted under Flow-Through Conditions. Mancozeb Task Force Study No. 2010-1, ABC Study No. 66201. Unpublished. KCA 8.2.5.2/01.
- Kamel F *et al* (2007). Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am. J. Epidemiol. 165(4), 364-374.
- Kechrid Z *et al* (2011). Effect of mancozeb on the metabolism and enzymatic activities of transaminases and alkaline phosphatase in albino Wistar rats. 8th African Crop Science Society Conference, El-Minia, Egypt, 27-31 October 2007, p.1709-1711.
- Kocialski A (1989) Establishment of an *in vitro* metabolic conversion factor of 7.5% of all EBDCs when converting EBDCs to ethylenethiourea *in vivo* and recalculations of the previously considered

20% *in vivo* conversion exposure factor for EBDCs to ETU. Memorandum to the Caswell file, Health Effects Division, Office of Pesticides Programs, United States Environmental Protection Agency

Koutros S *et al* (2011). Xenobiotic metabolizing gene variants, pesticide use, and risk of prostate cancer. *Pharmagenet Genomics*, **21(10)**: 615-623.

Lawrence B, Kesterton A, Marsh JD, King DL, Lawrence LJ (1988). Hydrolysis of [<sup>14</sup>C] Mancozeb in aqueous solutions at pH 5, 7, and 9. PTRL report No. 1173, Rohm and Haas Report No. 34-89-06, 31. KCA 7.2.1.1/01.

Leber, AP, Wilkinson, GE, Persing RL and Holzworth, DA (1978) Effects of feeding ethylenethiourea in the Rhesus monkey. Final report submitted to EPA by Battelle Laboratories, Columbus, Ohio, Lee WJ *et al* (2007). Pesticide use and colorectal cancer risk in the Agricultural Health Study. *Int J Cancer*. 121(2): 339–346

Lindh CH, Littorin M, Johannesson G and Jonsson BAG (2008). Analysis of ethylenethiourea as a biomarker in human urine using liquid chromatography/triple quadrupole mass spectrometry. *Rapid Communications in Mass Spectrometry*, **22 (16)**, 2573-2579.

Matshushita Ta, Arimatsu Y and Nomura S (1976) GPMT guinea pig max test. Experimental study in contact dermatitis caused by dithiocarbamates maneb, mancozeb, zineb and their related compounds. *Intern. Arch. Occup. Environ. Health* 37: 169 - 178.

McCarroll NE (1985). Dithane M- 45\*: host mediated assay in mice. Hazleton Biotechnologies Corporation, Virginia, USA. Unpublished Report No. 85P-167.

McGlynn-Kreft & McCarthy (1984). Mancozeb: In-vitro unscheduled DNA synthesis assay in Fischer-344 rat hepatocytes. Rohm and Haas Company Toxicology Department. Pennsylvania, USA. Unpublished Report No. 84R-055.

McLeod PL & Doolittle DJ (1985). Dithane M- 45\* mammalian cell transformation test for promotion. Rohm and Haas Company Toxicology Department. Pennsylvania, USA. Unpublished Report No. 84R-297.

Memmert U (1999). Ecological effects of Penncozeb 80 WP in a freshwater mesocosm study. RCC project 681030.

Mills PK *et al* (2005). Lymphohematopoietic cancers in the United Farm Workers of America (UFW), 1988-2001. *Cancer Causes and Control*, **16**:823-830.

Mills KT *et al* (2009). Pesticides and Myocardial Infarction Incidence and Mortality Among Male Pesticide Applicators in the Agricultural Health Study. *Am J Epidemiol*, **170**:892–900

Müller-Kallert H-M (1994). <sup>14</sup>C-Mancozeb: Degradation and Metabolism in Aquatic Systems. RCC Umweltchemie AG- Switzerland. Report/file No.: ER Ref No. 69.3. KCA 7.2.2.3/01.

Nordby KC, Andersen A, Irgens LM and Kristensen P (2005). Indicators of mancozeb exposure in relation to thyroid cancer and neural tube defects in farmers' families. *Scand. J. Work Environ. Health* 31(2), 89-96.

O'Neil PJ & Frank JP (1988). Mancozeb: In-vitro unscheduled DNA synthesis assay in Fischer-344 rat hepatocytes. Rohm and Haas Company Toxicology Department. Pennsylvania, USA. Unpublished Report No. 84R-079.

Palmer SJ (2001c). Ethylene Urea: A 48-hour static acute toxicity test with the cladoceran (*Daphnia magna*). EBDC/ETU Task Force. BASF RegDoc# 2001/5000988. Unpublished. IIA, 8.2.5/03.

Palmer SJ (2001b). Ethylene Urea: A 96-hour toxicity test with the freshwater alga (*Selenastrum capricornutum*) Wildlife International Ltd., USA. EBDC/ETU Task Force, BASF RegDoc# 2001/5000986. Unpublished. IIA, 8.2.7/02.

Panganiban L, Cortes-Maramba N, Dioquino C, Suplido ML, Ho H, Francisco-Rivera A, and Manglicmot-Yabes A (2004). Correlation between blood ethylenethiourea and thyroid gland disorders among banana plantation workers in the Philippines. *Environ. Health Perspect*. 112(1), 42-45.

Patel RM (1998) 24 h EC 50 Acute Immobilisation Study of MANCOZEB 80% WDP in *Daphnia magna*. Indofil study.

Peither A (2002a). Acute toxicity of Penncozeb 80 WP to the rotifer species *Brachyonus calyciflorus* in a 24-hour immobilization test. RCC, Environmental Chemistry and Pharamanalytics Division, CH-4452 Itingen/Switzerland. Report number 837527. Unpublished.

Peither A (2002b). Acute toxicity of Penncozeb 80 WP to the freshwater snail *Lymnea stagnalis* in a 48-hour immobilization test. RCC, Environmental Chemistry and Pharamanalytics Division, CH-4452 Itingen/Switzerland. Report number 837450. Unpublished.

Peither A (2002c). Acute toxicity of Penncozeb 80 WP to crustacean species *Gammarus sp* in a 48-hour immobilization test. RCC, Environmental Chemistry and Pharamanalytics Division, CH-4452 Itingen/Switzerland. Report number 837483. Unpublished.

Peither A (2002d). Acute toxicity of Penncozeb 80 WP to crustacean species *Asellus sp.* in a 48-hour immobilization test. RCC, Environmental Chemistry and Pharamanalytics Division, CH-4452 Itingen/Switzerland. Report number 837505. Unpublished.

Perez-Carreon JI *et al* (2009). Tumour promoting and co-carcinogenic effects in medium-term rat hepatocarcinogenesis are not modified by co-administration of 12 pesticides in mixture at acceptable daily intake. *Food and Chemical Toxicology*, 47 (3), 540-546. Rull RP *et al* (2006). Neural tube defects and maternal residential proximity to agricultural pesticide applications. *American Journal of Epidemiology*, **163(8)**: 743-753.

Rull RP, Ritz B, and Shaw GM (2006). Neural tube defects and maternal residential proximity to agricultural pesticide applications. *Am. J. Epidemiol.* 163(8), 743-753.

Saghir SA, Hansen SC, Lowe ER, Markham DA (2005). Ethylenethiourea: Interspecies comparison of *in vitro* metabolism by female rat, female mouse and female human liver S9 fractions.

Sallenfait AM, Sabate JP, Langonne I, de Ceaurriz J. (1991). Difference in the developmental toxicity of ethylenethiourea and three *N,N'*-Substituted thiourea derivatives in rats. *Fundamental & Applied Toxicology*, 17, 399-408.

Schreib G (2014). Modified reverse mutation assay using bacteria *Salmonella typhimurium* for evaluation of photogenotoxicity with Mancozeb technical, BSL Bioservice Laboratories GmbH, Germany. Unpublished Report No. 143478.

Slabbert JL (1994). Mutagenicity Evaluation of Sanachem Technical Mancozeb (Sancozeb). Division of water technology, CSIR, South Africa. Unpublished Report No. Not specified.

Smith D (1976). Ethylenethiourea: a study of possible teratogenicity and thyroid carcinogenicity. *Journal of Society of Occupational Medicine* 26: 92 – 94.

Smith D (1984). Ethylenethiourea: Thyroid function in two groups of exposed workers. *British Journal of Industrial Medicine* 41: 362 - 366.

Steenland K, Cedillo L, Tucker J, Hines C, Sorensen K, Deddens J, and Cruz V (1997). Thyroid hormones and cytogenetic outcomes in backpack sprayers using ethylenebis(dithiocarbamate) (EBDC) fungicides in Mexico. *Environ. Health Perspect.* 105(10), 1126-1130.

Steenberg P *et al* (2008). Toxicological evaluation of the immune function of pesticide workers, a European wide assessment *Human & Experimental Toxicology*, **27**: 701-707.

Swaen GM *et al* (2008). Occupational exposure to ethylenebisdithiocarbamates in agriculture and allergy: results from the EUROPIT field study. *Human & Experimental Toxicology*, **27**: 715-720.

Szepvolgyi J, Nagy K, Sajgone Vukan K, Regoly-Merei A, Soos K, Toth K, Pinter A and Antal M (1989). Subacute toxic examination of Dithanes M45. *Fd Chem. Toxic.* Vol 27, No. 8, pp 531-538.

Tanner CM *et al* (2009). Occupation and risk of Parkinsonism: a multicenter case-control study. *Arch. Neurol.* 66 (9), 1106-1113.

Tanner CM *et al* (2011). Rotenone, paraquat, and Parkinson's disease. *Environ. Health Perspect.* 119(6), 866-872.

Valentich MA *et al* (2006). Effect of the co-administration of phenobarbital, quercetin and mancozeb on nitrosomethylurea-induced pancreatic tumors in rats. *Food and Chemical Toxicology*, 44 (12), 2101-2105.

Van Wijngaarden RPA (2013). Re-evaluation of the Report: Ecological effects of Penncozeb 80 WP in a freshwater mesocosm study (Memmert, 1999; RCC project 681030). Alterra project 5210074-01. KCA 8.2.8/03.

Varona-Uribe M *et al* (2015). Exposure to Pesticide Mixtures and DNA Damage among Rice Field Workers. *Archives of environmental & occupational health. Arch. Environ. Occup. Health.*

Vickers AE, Heale J, Sinclair JR, Morris S, Rowe JM and Fisher RL (2012) Thyroid organotypic rat and human cultures used to investigate drug effects on thyroid function, hormone synthesis and release pathways. *Toxicology and Applied Pharmacology*, 260(1):81-8

Völkel W (1995). [<sup>14</sup>C]-Mancozeb: Degradation and metabolism in aquatic systems. RCC Umweltchemie AG- Switzerland. RCC project 361462. KCA 7.2.2.3/02.

Wang WW (1991). Hydrolysis of <sup>14</sup>C-mancozeb in water at pH 5, 7 and 9. XenoBiotic Laboratories Inc. Princeton, NJ. Report RPT0075. KCA 7.2.1.1/02.

Wilmer JWGM (1982) Examination of "Penncozeb technisch" for mutagenic activity in the Ames test. Civo Institute TNO, Netherlands. Unpublished Report No. V82.388/220064.

Yeh SM (1985). Water photolysis study of mancozeb. Biospherics Inc., Rockville, MD. Rohm and Haas report No. 31L-85-13. KCA 7.2.1.2/01.

Yeh SM (1986). Batch Soil Adsorption/Desorption of Mancozeb. Biospherics Inc., Report/file No: ER Ref No. 49.3. US Ref No. 310-86-62. KCA 7.1.3.1.1/01.

Zhu W (2015). Ethylene thiourea (ETU): Comparative In vitro Metabolism using Mouse, Rat, Rabbit, Dog and Human Hepatocytes. HLS report.

**15 ANNEXES**

ANNEX I: MANCOZEB AND THYROID CARCINOGENICITY: MODE OF ACTION ANALYSIS USING THE WHO/IPCS MOA FRAMEWORK

ANNEX II: EVALUATION OF DEVELOPMENTAL TOXICITY, POSSIBLE MODES OF ACTION AND RELEVANCE TO HUMANS

ANNEX III: SUPPLEMENTARY DATA ON THE DEGRADANTS OF MANCOZEB

ANNEX IV: INFORMATION ON THE FORMULATION USED IN STUDIES WHICH WERE CRITICAL TO THE ENVIRONMENTAL CLASSIFICATION (SEPARATE DOCUMENT)

ANNEX V: CONFIDENTIAL REFERENCES (SEPARATE DOCUMENT)

## ANNEX I: MANCOZEB AND THYROID CARCINOGENICITY: MODE OF ACTION ANALYSIS USING THE WHO/IPCS MOA FRAMEWORK

### **Problem formulation**

Administration of mancozeb to rats for 2 years in a carcinogenicity study, resulted in an increased incidence of thyroid follicular tumours (adenomas and carcinomas) at the highest dose of 750 ppm (30 to 40 mg/kg bw/day) (Anonymous, 1990a). Another carcinogenicity study conducted at lower doses (highest dose of 454 ppm; 16 to 20 mg/kg bw/day) did not produce thyroid tumours in rats (Anonymous, 1992a). The tumour incidences are shown in Table A1-1. A carcinogenicity study in mice produced no thyroid tumours (Anonymous, 1991a). The thyroid gland and thyroid hormonal system are the target for mancozeb in short-term and long-term toxicity studies in rats, mice and dogs. The effects on the thyroid hormonal system are caused by the metabolite of mancozeb, ethylenethiourea (ETU). In mammals metabolism of mancozeb to ETU is approximately 7% by weight. Exposure of different species to ETU may differ due to differences in the down-stream metabolism of ETU, although there is some contradictory evidence on this. This leads to quantitative differences in effects on the thyroid across different species, rats being the most sensitive.

Perturbation of the thyroid hormonal system is a common chemically-induced effect and there are several possible mechanisms by which this may occur. The mode of action (MoA) for ETU is via inhibition of the thyroperoxidase enzyme (TPO) in the thyroid gland. TPO is a key enzyme involved in the synthesis of thyroid hormones, thus inhibition results in decreased production of the thyroid hormones T4 (thyroxine) and T3 (triiodothyronine). This in turn, results in disturbance of the hypothalamus-pituitary-thyroid axis (HPT) as the hormonal feedback control mechanisms attempt to adjust thyroid hormone concentrations to normal endogenous levels.

Humans have qualitative and quantitative differences in thyroid physiology and response compared to rodents and therefore the carcinogenic effects of mancozeb on the thyroid gland in rats may have low relevance for humans exposed to mancozeb. In addition, exposure of humans to ETU from mancozeb may be lower than rats because of greater metabolism of ETU to inactive products. This analysis uses the Human Relevance Framework (HRF) to help understand whether mancozeb-induced thyroid tumours seen in rats indicate a risk to humans. The analysis includes evidence for the MoA, qualitative and quantitative differences in thyroid physiology between experimental animals and humans, the role of metabolism and possible alternative MoAs. It will provide an answer to the question “**Are thyroid tumours in rats caused by mancozeb, relevant for humans who may be exposed to mancozeb?**”

**Table A1-1: Thyroid follicular tumour incidences in rats administered mancozeb**

| Reference                  | Dose mancozeb ppm (mg/kg bw/day; males/females) | Tumour incidence (% tumour bearing animals, day 365 -734) |              |
|----------------------------|---|---|--------------|
|                            |   | Males   | Females      |
| Anonymous (1990a)          | 0   | 0A, 0C <sup>a</sup>                                       | 1.6A, 0C     |
|                            | 20 (0.7/1.1)                                    | 1.6A, 0C  | 1.7A, 0C     |
|                            | 60 (2.3/3.1)                                    | 1.7A, 3.3C  | 1.6A, 0C     |
|                            | 125 (4.8/6.7)                                   | 0A, 3.4C  | 1.6A, 1.6C   |
|                            | 750 (30.9/40.2)                                 | 32.8A*, 23.0C*  | 9.8C*, 6.6C* |
| Hooks <i>et al</i> (1992a) | 0 to 454 (0-16.8/20.8)                          | No tumours observed at any doses                          |              |

<sup>a</sup>A=adenomas, C=carcinomas

\*Statistically significant ( $P \leq 0.05$  as described in the study report).

**Hypothesised mode of action for the induction of thyroid follicular tumours in rats by mancozeb**

A large number of chemicals cause disturbance of the thyroid hormonal system in experimental animals via several MoAs including both direct and indirect effects on thyroid hormones (Howdeshell, 2002; Miller *et al*, 2009). The net effect of MoAs that lead to decreased levels of the thyroid hormones T4 and T3 is the following well-characterised sequence of events. The lowered levels of circulating thyroid hormones are sensed by the hypothalamus and pituitary gland and may result in increased release of TRH (thyrotropin releasing hormone) and TSH (thyroid stimulating hormone, also called thyrotropin) from the hypothalamus and pituitary respectively. TSH acts on thyroid follicular cells in an attempt to stimulate the production of new thyroid hormones. This process may cause thyroid follicular cell hypertrophy, changes in cell shape and loss of colloid from the thyroid follicle. This generally results in increased thyroid gland weight. Under conditions of prolonged exposure, thyroid follicular cell hyperplasia may occur, possibly eventually leading to tumours of the thyroid gland (adenomas and carcinomas). This paradigm has been described for many rodent thyroid perturbants (Hill *et al*, 1998; Hurley, 1998; McClain and Rice, 1999).

The postulated MoA for mancozeb, firstly involves metabolism to ETU, formation is approximately 7% by weight in all mammals studied (DAR, 2000). ETU is the proximate metabolite responsible for the actions of mancozeb on the thyroid hormonal system. The effects of ETU on the thyroid hormonal system, in short and long-term studies mirror those of mancozeb, but occur at lower doses, as would be expected from direct administration of the active entity. ETU is carcinogenic in the rat thyroid and (unlike mancozeb) also in the mouse. The species difference in carcinogenicity is likely to be, at least partly, due to differences in the metabolism of ETU between rats and mice (DAR, 2000).

ETU inhibits the peroxidase activity of TPO within the thyroid, preventing the oxidation of iodide and hence the formation of thyroid hormone precursors on the colloidal protein thyroglobulin. The result of this direct mode of action is that production of T4 and T3 are decreased.

The molecular mode of action of ETU has been extensively investigated. Doerge and Takazawa (1990) showed that ETU inhibited the oxidation of iodine to triiodide. Inhibition of TPO occurred only in the presence of iodide and caused concomitant metabolism of ETU. Inhibition ceased when ETU was completely metabolised. This MoA is similar to that of pharmaceutically-used TPO inhibitors such as propyl thiouracil (PTU) and methimazole but differs in that PTU and methimazole are irreversible inhibitors of TPO (Taurog, 1976; Taurog and Dorris, 1989) whilst ETU is a reversible inhibitor. Covalent binding of ETU to TPO was negligible. More recently, Freyberger and Ahr (2006) showed that ETU caused a transient inhibition of iodide oxidation followed by resumption of enzyme activity, similar to control values. ETU was metabolised during the reaction and results were similar to those of Doerge and Takazawa (1990). Results confirmed that inhibition of TPO was reversible, unlike when amitrole (another known irreversible inhibitor of TPO) was used.

**Summary of data for use in Mode of Action Analysis**

Studies that demonstrate that mancozeb causes the events described in the hypothesised mode of action for the induction of thyroid follicular tumours are shown in Table A1-2. These are largely repeated dosing/carcinogenicity studies, but two 2-generation reproduction studies in rats have also been included because parental animals in these studies (dosed for 25 weeks) also developed thyroid tumours and are relevant for consideration of dose-response.

Studies on the metabolism of mancozeb to ETU are not described here but can be found in the DAR (2000) and M-CA Dossier Section 5.1 (2015). The studies used in this MoA analysis were limited to those concerned with oral administration because this provides the most useful database for dose response, temporal effects and species differences. It is acknowledged that human exposure is likely to be via dermal or inhalational routes, however after absorption of mancozeb the end result of systemic exposure will be similar. Only studies that were considered reliable in the DAR (2000) and M-CA Dossier Section 5 (2015) are used. All the studies are described in detail in Sections 10.7 and 10.10 of the CLH Dossier, the DAR (2000) or M-CA Dossier Section 5 (2015).

**Table A1-2: Studies used in the MoA analysis. Studies are presented in decreasing order of duration, via oral administration in rats, mice and dogs.**

| Species/sex             | Route/Dose  | Findings relevant for the thyroid hormonal system  | Comments   | Reference         |
|-------------------------|---|--|--|-------------------|
| <b>Studies in rats</b>  |   |  |  |                   |
| Rat/<br>Male and female | Dietary at 0, 28, 113 or 454 ppm for 104 weeks. The study included interim timepoints at 26, 52 and 78 weeks.<br><br>Achieved intake of a.i. was 1.0/1.3; 4.0/5.1 or 16.8/ 20.8 mg/kg bw/day for males and females receiving 28, 113 or 454 ppm respectively.                           | Serum T4 was reduced at 454 ppm at weeks 26 and 52, and in the high dosage females only at weeks 26, 52 and 78. T3 & TSH were unaffected.<br><br>There were no effects on weight of adrenals, brain, liver, ovaries, testes, thyroid; and no treatment-related histopathological effects on these organs, mammary glands, pituitary or other reproductive organs; with the exception of the thyroid. At 454 ppm there were increases in the height of the thyroid follicular epithelium and prominent micro follicles present in both sexes.<br><br>There were no increased tumour incidences.   | Effects on T4 and the thyroid are consistent with disturbance of the HTP axis at doses $\geq$ 16.8 mg/kg bw/day. It should be noted that increases in thyroid tumours were not seen.<br><br>Thyroid weight was not determined.<br><br>There were no effects on other endocrine-related organs, indicating that other hormonal systems were largely unaffected. | Anonymous (1992a) |
| Rat/<br>Male and female | Dietary at 0, 20, 60, 125 or 750 ppm for 104 weeks. The study included interim time points at 3, 6, 12, 18 and 24 months.<br><br>Achieved intake of a.i. was 0.7/1.1; 2.3/3.1; 4.8/ 6.7 or 30.9/ 40.2 mg/kg bw/day for males and females receiving 20, 60, 125 or 750 ppm respectively. | Serum T4 was reduced and TSH was increased at 750 ppm at intervals, in both sexes through the study. There was no consistent pattern to effects on T3.<br><br>Thyroid weight and thyroid follicular cell hypertrophy/hyperplasia increased at 750 ppm in both sexes.<br><br>Thyroid follicular hypertrophy/hyperplasia was seen at 52 weeks and increased thyroid weight was seen at 104 weeks at this dose. An increased incidence of thyroid follicular cell carcinomas, adenomas, nodular hyperplasia and hypertrophy/hyperplasia occurred at 750 ppm. The incidence of carcinomas and adenomas was higher in males (14/61 and 20/61 respectively) than in females (4/61 and 6/61). In control rats, the incidence of both carcinomas and adenomas was 0 in males and 0 and 1 in females. | Effects on T4, TSH and the thyroid are consistent with disturbance of the HTP axis at doses $\geq$ 30.9 mg/kg bw/day. Thyroid follicular tumours resulted from this disturbance.<br><br>There were no effects on other endocrine-related organs, indicating that other hormonal systems were largely unaffected.   | Anonymous (1990a) |

| Species/sex             | Route/Dose   | Findings relevant for the thyroid hormonal system  | Comments   | Reference         |
|-------------------------|--|--|--|-------------------|
| Rat/<br>Male and female | 2-generation reproduction study: parental animals in F0 and F1 phases.<br>Dietary at 0, 30, 120 or 1200 ppm for approximately 25 weeks.<br>Achieved intake of a.i. was 1.73-2.49, 6.95-10.52 or 68.9-114.26 mg/kg bw/day for males and females receiving 30, 120 or 1200 ppm respectively. | In both F0 and F1 parental males and females at the highest dose, thyroid weight was increased and most rats showed thyroid follicular hypertrophy & hyperplasia. Thyroid follicular adenomas were increased: F0: 3/25 males, none in females or controls; F1: 4/24 males, none in females or controls.<br>A low incidence of hypertrophy/vacuolation of the pituitary adenohypophysis occurred in males.<br>There were no thyroid effects at the lower doses. | Effects on thyroid weight and histopathology are consistent with disturbance of the HTP axis at doses 68 mg/kg bw/day. Thyroid follicular adenomas were seen in male rats. The sex specificity and the doses at which the tumours occurred are consistent with the carcinogenicity studies in rats.  | Anonymous (1988b) |
| Rat/<br>Male and female | 2-generation reproduction study: parental animals in F0 and F1 phases.<br>Dietary at 0, 25, 150 or 1100 ppm for approximately 25 weeks.<br>Achieved intake of a.i. was 1.7, 10 or 74 mg/kg bw/day for males and females receiving 25, 150 or 1100 ppm respectively.                        | In both F0 and F1 parental males and females at the highest dose, thyroid weight was increased and most rats showed thyroid follicular hypertrophy & hyperplasia. Thyroid follicular adenomas were increased: F0: 5/25 males, 1/25 females, none in controls; F1: 11/25 males, none in females or controls.<br>No effects on thyroid weight at 150 or 25 ppm (10 or 1.7 mg/kg/bw/day). Thyroid histopathology was not done.                                    | Effects on thyroid weight and histopathology are consistent with disturbance of the HTP axis at doses 74 mg/kg bw/day. Thyroid follicular adenomas were seen in male rats. The sex specificity and the doses at which the tumours occurred are consistent with the carcinogenicity studies in rats.  | Anonymous (1992c) |
| Rat/<br>Male and female | Dietary at 0, 28, 113 or 454 ppm for 90 days (13 weeks). Rats were killed after 90 days or after a 4 week recovery period.<br>Achieved intake of a.i. was 1.7/2.1; 6.8/8.5 or 27/ 34 mg/kg bw/day for males and females receiving 28, 113 or 454 ppm respectively.                         | After 90 days of treatment Mancozeb reduced plasma T4 levels at 454 ppm (27 mg/kg bw/day) in males and 113 ppm (8.5 mg/kg bw/day) and above in females. Changes in females were not-statistically significant at any dose. Effects on T3 were equivocal.<br>The effects on T4 were reversed after the recovery period.   | Disturbance of the HTP axis was indicated by effects on T4 at 8.5 mg/kg bw/day, although there were no effects on thyroid weight or histopathology. Effects were reversible.<br>TSH was not measured.  | Anonymous (1989)  |
| Rat/<br>Male and female | Dietary at 0, 30, 60, 125, 250 or 1000 ppm for 90 days (13 weeks).<br>Achieved intake of a.i. was 1.7/2.2; 3.5/4.4, 7.4/9.2, 15/18 or 57/75 mg/kg bw/d for males and females receiving 30, 60, 125, 250 or 1000 ppm respectively.  | Mancozeb: Serum T4 was decreased in both sexes at 1000 ppm (57 mg/kg bw/d) and TSH was increased. At 250 ppm (15 mg/kg bw/day), T4 was decreased in females and TSH was increased in males (36%) and females (50%). Thyroid weight and thyroid follicular hyperplasia were increased at 1000 ppm. Relative liver weight was increased and mixed function oxidase (MFO) activity was decreased at 1000 ppm.   | Mancozeb caused disturbance of the HTP axis, indicated by effects on T4 & TSH at 15 mg/kg bw/day. At higher doses further changes were thyroid weight increases and histopathological findings.<br>A similar pattern of changes was caused by ETU (14 mg/kg bw/day) indicating that the effects caused by Mancozeb are attributable to ETU. ETU also affected the pituitary. | Anonymous (1986b) |

| Species/sex               | Route/Dose  | Findings relevant for the thyroid hormonal system   | Comments   | Reference                      |
|---------------------------|---|---|--|--------------------------------|
| Rat/<br>Male              | Dietary at 0, 10, 50, 75, 113, 169, 253 or 379 mg/kg bw/day in the diet for 12 weeks.   | Relative thyroid weight was increased at 75 mg/kg bw/day and above. MFO activity was decreased whilst P450 levels were unchanged). Dose dependent thyroid hyperplasia occurred from 113 mg/kg bw/day.   | Effects on the thyroid are consistent with disturbance of the HTP axis at doses from 75 mg/kg bw/day.<br>Thyroid hormones and TSH were not measured.   | Szepvolgyi <i>et al</i> (1989) |
| Rat/<br>Female            | Dietary at 0, 75, 150, 300, or 600 mg/kg bw/day for 6 weeks.  | Thyroid weight, iodine concentrations in serum and protein bound iodine were increased at all doses.  | Effects on the thyroid and iodine levels, are consistent with disturbance of the HTP axis at doses from 75 mg/kg bw/day.<br>Thyroid hormones, TSH and thyroid histopathology were not determined.  | Horing <i>et al</i> (1990)     |
| Rat/<br>Female            | Oral by gavage at 0, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500 or 1000 mg/kg bw/day for 4 days.   | Mancozeb reduced serum T4 with 31.3 mg/kg bw/day giving a 20% decrease and an ED50 (the dose eliciting a 50% decrease in T4) of 259 mg/kg bw/day.   | Effects on serum T4 are consistent with disturbance of the HTP axis at doses from 31 mg/kg bw/day.<br>TSH, thyroid weight and histopathology were not determined.  | Flippin <i>et al</i> (2009)    |
| <b>Studies in mice</b>    |   |   |  |                                |
| Mouse/<br>Male and female | Dietary at 0, 30, 100 or 1000 ppm for 18 months. The study included an interim timepoint at 12 months.<br>Achieved intake of a.i. was 4/5; 13/18; or 131/180 mg/kg bw/day for males and females receiving 30, 100 or 1000 ppm respectively. | T4 was decreased at 1000 ppm in both sexes at 12 & 18 months. Effects on T3 were equivocal and TSH was unaffected. No other treatment-related findings (including thyroid histopathology) were reported and there was no evidence of carcinogenicity. | Mancozeb caused disturbance of the HTP axis, indicated by effects on T4 at doses of 131 mg/kg bw/day.<br>Thyroid weight was not determined.  | Anonymous (1991a)              |
| Mouse/<br>Male and female | Dietary at 0, 10, 100, 1000 or 10,000 ppm for 90 days (13 weeks).<br>Achieved intake of a.i. was approximately 1.8/2.2; 18/22; 180/220 or 1800/2200 mg/kg bw/day for males and females receiving 10, 100, 1000 or 10,000 ppm respectively.  | Thyroid weight was increased in both sexes at 10,000 ppm. Thyroid hypertrophy/hyperplasia was seen in both sexes from 1000 ppm. Liver weight was increased at 10,000 ppm, some histopathological changes were seen and MFO activity was reduced.      | Mancozeb caused disturbance of the HTP axis, indicated by thyroid weight increases and hypertrophy/hyperplasia at doses $\geq$ 180 mg/kg bw/day. Liver weight increases occurred at 1800 mg/kg bw/day.<br>Thyroid hormones and TSH were not determined.<br>A similar pattern of changes was caused by ETU (from 17 mg/kg bw/day) indicating that the effects caused by Mancozeb are attributable to ETU. | Anonymous (1985c)              |

| Species/sex               | Route/Dose  | Findings relevant for the thyroid hormonal system  | Comments  | Reference         |
|---------------------------|---|--|---|-------------------|
| Mouse/<br>Male and female | Dietary at 0, 1, 10, 100, 1000 or 10,000 ppm for 4 weeks.<br><br>Achieved intake of a.i. was approximately 0.15, 1.5, 15, 150 or 1500 mg/kg bw/day for mice receiving 1, 10, 100, 1000 or 10,000 ppm respectively.  | Mancozeb: Thyroid weight was increased at 10,000 ppm in females only. Thyroid hyperplasia was seen in both sexes at 10,000 ppm and in females at 1000 ppm. Liver weight was increased from 1000 ppm but no histopathological changes were seen.  | Mancozeb caused disturbance of the HTP axis, indicated by thyroid weight increases and histopathological findings at doses from 150 mg/kg bw/day. Liver weight increases occurred at 1500 mg/kg bw/day.<br><br>Thyroid hormones and TSH were not determined.<br><br>A similar pattern of changes was caused by ETU (from 15 mg/kg bw/day) indicating that the effects caused by Mancozeb are attributable to ETU. | Anonymous (1985b) |
| <b>Studies in dogs</b>    |   |  |   |                   |
| Dog/<br>Male and female   | Dietary at 0, 50, 200, 800 or 1600 ppm for 52 weeks.<br><br>Achieved intake of a.i. was 1.8/1.9; 7.6/7.8; 28/29 or 50/56 mg/kg bw/day for males and females receiving 50, 200, 800 or 1600 ppm respectively.        | Serum T4 was reduced, thyroid weight was increased and thyroid histopathological changes were observed at 1600 ppm. Liver weight was increased at 800 ppm and above.   | Mancozeb caused disturbance of the HTP axis, indicated by effects on T4, thyroid weight and histopathology at 50 mg/kg bw/day.<br><br>TSH was not determined.   | Anonymous (1990c) |
| Dog/<br>Male and female   | Oral by capsule, at 0, 2.3, 23 or 113 mg/kg bw/day for 52 weeks. [Dogs receiving 113 mg/kg bw/day were killed after 26 weeks].  | Serum T4 was decreased at 113 mg/kg bw/day in both sexes and at 23 mg/kg bw/day after 52 weeks in males. T3 was unchanged. Relative liver and thyroid weights were increased at 23 mg/kg bw/day and above. No histopathological changes were seen.   | Mancozeb caused disturbance of the HTP axis, indicated by effects on T4 and increased relative thyroid weight at 23 mg/kg bw/day.<br><br>TSH was not determined.  | Anonymous (1991c) |
| Dog/<br>Male and female   | Oral by capsule, at 0 or 40 mg/kg bw/day for 52 weeks.<br><br>[Study was conducted following the loss of the high dose group in Broadmeadow, 1991a].  | Serum T4 and T3 were decreased and thyroid weight was increased in both sexes. No histopathological changes were seen.   | Mancozeb caused disturbance of the HTP axis, indicated by effects on T4, T3 and increased thyroid weight at 40 mg/kg bw/day.<br><br>TSH was not determined.   | Anonymous (1991d) |
| Dog/<br>Male and female   | Oral by capsule, at 0, 5.7, 34.0 and 340/204 mg/kg bw/day for 13 weeks. The study included a 6 week reversibility period.<br><br>[The high dose of 340 mg/kg bw/day was reduced to 204 mg/kg bw/day after 16 days]. | Serum T4 was decreased at 340/204 mg/kg bw/day in both sexes and at 34 mg/kg bw/day in females. Thyroid weight was increased at 340/204 mg/kg bw/day in both sexes. Thyroid follicular hyperplasia and accumulation of colloid in the thyroid were seen in all treated groups.<br><br>Liver weight was increased at 340/204 and 34 mg/kg bw/day. | Mancozeb caused disturbance of the HTP axis, indicated by effects on T4, thyroid weight and thyroid histopathology at doses $\geq$ 34 mg/kg bw/day.<br><br>These changes recovered after 6 weeks without dosing.<br><br>TSH was not determined.   | Anonymous (1987c) |

| Species/sex             | Route/Dose   | Findings relevant for the thyroid hormonal system  | Comments   | Reference         |
|-------------------------|--|--|--|-------------------|
|                         |  | Adrenal weights were increased at 340/204 mg/kg bw/day.<br><br>After the recovery period, thyroid weight and histopathological changes had reversed and T4 levels had largely recovered. |  |                   |
| Dog/<br>Male and female | Dietary at 0, 10, 100, 1000 or 5000 ppm for 3 months.<br><br>Achieved intake of a.i. was 0.3/0.3; 3/3; 29/29 or 102/110 mg/kg bw/day for males and females receiving 10, 100, 1000 or 5000 ppm respectively. | Serum T4 and T3 were decreased at 5000 ppm and enlarged thyroids were noted at 1000 ppm and above. Thyroid follicular cell hyperplasia occurred at 5000 ppm.                             | Mancozeb caused disturbance of the HTP axis, indicated by effects on T4, T3, thyroid weight and histopathology at doses of 29 mg/kg bw/day and above.<br><br>TSH was not determined. | Anonymous (1986c) |

#### **Listing of key events identified for a specific Mode of Action**

The postulated MoA for effects on the thyroid and induction of thyroid follicular tumours in rats by mancozeb can be summarised as follows. Mancozeb is metabolised to ETU (a reversible inhibitor of TPO) resulting in inhibition of thyroid hormone synthesis. The pituitary responds to the decreased blood levels of T4 and T3 by increasing output of TSH. TSH stimulates the thyroid follicular cells in an attempt to increase thyroid hormone production. Stores of thyroid hormone become depleted and prolonged exposure to TSH results in cellular enlargement (hypertrophy) as cellular systems attempt to induce production of thyroid hormones. Continued exposure causes cellular proliferation (hyperplasia) which ultimately progresses to neoplasia if exposure to mancozeb/ETU is chronic.

The initial step of metabolism of mancozeb to ETU is not listed as a Key Event at this stage because the data are not amenable to the dose response and temporal analysis required (see below). Metabolism of mancozeb appears to be linear at a rate of 7% in all species tested (DAR, 2000). However, exposure to ETU also depends upon absorption of mancozeb and metabolism of ETU itself to inactive metabolites. Metabolism of ETU differs across species and is likely to be partly responsible for the differences in lowest effect levels on the thyroid.

The molecular initiating event of TPO inhibition within the thyroid follicular cell is also not amenable to the dose response and temporal analysis required in Section 5a & 5b and therefore is also not listed as a Key Event at this stage. The mechanism of action has been described by Doerge and Takazawa (1990) and Freyberger and Ahr (2006).

The Key Events (shown below) are the onward biological consequences that result from metabolism and the molecular initiating event. These are measurable events that are critical to the induction of the (adverse) effect (Key Event 4: Formation of thyroid follicular tumours). They have been defined by the endpoints measured in the studies in Table A1-2 and are listed in the order in which they occur. Key Events 1 and 2 (Decreased blood T4 levels and Decreased blood TSH levels) have frequently been measured in the studies. Key Event 3 combines increased thyroid follicular cell hypertrophy and hyperplasia as most studies have insufficient time points to distinguish temporally between these, although hypertrophy usually precedes hyperplasia in this MoA. Increased thyroid weight can be viewed as a surrogate for these cellular events, as hypertrophy and hyperplasia contribute to increased thyroid weight. In some studies, thyroid histopathology was not determined whilst thyroid weight was, and therefore Key Event 3 has been described as: Increased thyroid follicular cell hypertrophy and/or hyperplasia (determined as increased thyroid gland weight or histopathologically).

**Key events in the mode of action for mancozeb and thyroid carcinogenicity**

|                                   |  |
|-----------------------------------|--|
| <b>Metabolism</b>                 | Metabolism of mancozeb to ETU (activation) and metabolism of ETU (deactivation).   |
| <b>Molecular Initiating Event</b> | Inhibition of TPO by ETU   |
| <b>Key Event 1</b>                | Decreased blood T4 levels  |
| <b>Key Event 2</b>                | Increased blood TSH levels   |
| <b>Key Event 3</b>                | Increased thyroid follicular cell hypertrophy and/or hyperplasia (determined as increased thyroid gland weight or histopathologically) |
| <b>Key Event 4</b>                | Formation of thyroid follicular tumours  |

**Bradford Hill Considerations for Weight of Evidence Analysis of available data/information for Mode of Action Analysis in experimental species****Dose Response Relationships and Temporal Association**

The dose response and temporal relationships for the Key Events measured in the studies in rats, mice and dogs in Table A1-2 are presented below (Tables A1-3 to A1-5). The responses for the Key Events 1-4 are shown as positive or negative, quantification (degree of change) is not shown in order to keep the tables clearer. Responses among males and females are not distinguished but were generally similar for Key events 1-3 and are also not shown for reasons of clarity. Key Event 4 (Formation of thyroid tumours) is generally not applicable to subchronic studies and therefore is labelled as “not applicable” in the tables, although the histopathological outcome was measured. A sex difference for Key Event 4 was evident (males having a higher tumour incidence than females), but is also not distinguished in the tables for reasons of clarity. Further details on the studies can found in the main document.

**Species: Rat****Table A1-3: Concordance of dose-response and temporal relationships for the Key Events in studies in rats. Data are taken from the studies in Table A1-2.**

| Dose (mg/kg bw/day)                    | Key Event 1<br>Decreased blood T4 levels  | Key Event 2<br>Increased blood TSH levels | Key Event 3<br>Increased thyroid follicular cell hypertrophy and/or hyperplasia (determined as increased thyroid gland weight or histopathologically) | Key Event 4<br>Formation of thyroid tumours | Reference          |
|--|---|---|---|---|--------------------|
| <b>Ordered from low to high dosage</b> | <b>Key events shown in order from earliest event to later (left to right). Results show the time that the event was observed. Quantitative changes in severity are not shown.</b> |   |   |   |                    |
| 0.7/1.1 <sup>a</sup>                   | - <sup>b</sup> (12 to 104 weeks)  | - (12 to 104 weeks)                       | - (12 to 104 weeks)   | - (104 weeks)                               | Anonymous (1990a)  |
| 1.0/1.3                                | - (26 to 104 weeks)   | - (26 to 104 weeks)                       | - (26 to 104 weeks)   | - (104 weeks)                               | Anonymous (1992a)  |
| 1.7/2.2                                | - (13 weeks)  | - (13 weeks)                              | - (13 weeks)  | NA <sup>d</sup>                             | Anonymous (1986b). |
| 1.7/2.1                                | - (13 weeks)  | ND  | - (13 weeks)  | NA  | Anonymous (1989)   |
| 1.7/2.4                                | ND  | ND  | - (25 weeks)  | - (25 weeks)                                | Anonymous (1988b)  |
| 1.7                                    | ND  | ND  | - (25 weeks)  | - (25 weeks)                                | Anonymous (1992c)  |

| <b>Dose (mg/kg bw/day)</b> | <b>Key Event 1<br/>Decreased blood T4 levels</b> | <b>Key Event 2<br/>Increased blood TSH levels</b> | <b>Key Event 3<br/>Increased thyroid follicular cell hypertrophy and/or hyperplasia (determined as increased thyroid gland weight or histopathologically)</b> | <b>Key Event 4<br/>Formation of thyroid tumours</b> | <b>Reference</b>               |
|----------------------------|--|---|---|---|--------------------------------|
| 2.3/3.1                    | - (12 to 104 weeks)                              | - (12 to 104 weeks)                               | - (12 to 104 weeks)   | - (104 weeks)                                       | Anonymous (1990a)              |
| 3.5/4.4                    | - (13 weeks)                                     | - (13 weeks)                                      | - (13 weeks)  | NA  | Anonymous (1986b).             |
| 3.9                        | - (4 days)                                       | ND <sup>c</sup>                                   | ND  | ND  | Flippin <i>et al</i> (2009)    |
| 4.0/5.1                    | - (26 to 104 weeks)                              | - (26 to 104 weeks)                               | - (26 to 104 weeks)   | - (104 weeks)                                       | Anonymous (1992a)              |
| 4.8/ 6.7                   | - (12 to 104 weeks)                              | - (12 to 104 weeks)                               | - (12 to 104 weeks)   | - (104 weeks)                                       | Anonymous (1990a)              |
| 7.8                        | - (4 days)                                       | ND  | ND  | ND  | Flippin <i>et al</i> (2009)    |
| 6.8/8.5                    | - (13 weeks)                                     | ND  | - (13 weeks)  | NA  | Anonymous (1989).              |
| 6.9/10.5                   | ND   | ND  | - (25 weeks)  | - (25 weeks)  | Anonymous (1988b)              |
| 7.4/9.2                    | - (13 weeks)                                     | - (13 weeks)                                      | - (13 weeks)  | NA  | Anonymous (1986b)              |
| 10                         | ND   | ND  | - (12 weeks)  | NA  | Szepvolgyi <i>et al</i> (1989) |
| 10                         | ND   | ND  | - (25 weeks)  | - (25 weeks)  | Anonymous (1992c)              |
| 15.6                       | - (4 days)                                       | ND  | ND  | NA  | Flippin <i>et al</i> (2009)    |
| 15/18                      | + <sup>c</sup> (13 weeks)                        | + (13 weeks)                                      | - (13 weeks)  | NA  | Anonymous (1986b)              |
| 16.8/ 20.8                 | + (26 to 104 weeks)                              | - (26 to 104 weeks)                               | + (26 to 104 weeks)   | - (26 to 104 weeks)                                 | Anonymous (1992a)              |
| 31.3                       | + (4 days)                                       | ND  | ND  | ND  | Flippin <i>et al</i> (2009)    |
| 30.9/ 40.2                 | + (12 to 104 weeks)                              | + (12 to 104 weeks)                               | + (52 & 104 weeks)  | + (104 weeks)                                       | Anonymous (1990a)              |
| 27/ 34                     | + (13 weeks)                                     | ND  | - (13 weeks)  | NA  | Anonymous (1989)               |
| 50                         | ND   | ND  | - (12 weeks)  | NA  | Szepvolgyi <i>et al</i> (1989) |
| 62.5                       | + (4 days)                                       | ND  | ND  | ND  | Flippin <i>et al</i> (2009)    |
| 57/75                      | + (13 weeks)                                     | + (13 weeks)                                      | + (13 weeks)  | - (NA)  | Anonymous (1986b)              |
| 68.9/114.2                 | ND   | ND  | + (25 weeks)  | + (25 weeks)  | Anonymous (1988b)              |

| Dose (mg/kg bw/day) | Key Event 1<br>Decreased blood T4 levels | Key Event 2<br>Increased blood TSH levels | Key Event 3<br>Increased thyroid follicular cell hypertrophy and/or hyperplasia (determined as increased thyroid gland weight or histopathologically) | Key Event 4<br>Formation of thyroid tumours | Reference                      |
|---------------------|--|---|---|---|--------------------------------|
| 74                  | ND                                       | ND  | - (25 weeks)  | + (25 weeks)                                | Anonymous (1992c)              |
| 75                  | ND                                       | ND  | + (6 weeks)   | ND  | Horing <i>et al</i> (1990).    |
| 75                  | ND                                       | ND  | + (12 weeks)  | NA  | Szepvolgyi <i>et al</i> (1989) |
| 113                 | ND                                       | ND  | + (12 weeks)  | NA  | Szepvolgyi <i>et al</i> (1989) |
| 125                 | + (4 days)                               | ND  | ND  | ND  | Flippin <i>et al</i> (2009)    |
| 150                 | ND                                       | ND  | + (6 weeks)   | ND  | Horing <i>et al</i> (1990).    |
| 169                 | ND                                       | ND  | + (12 weeks)  | NA  | Szepvolgyi <i>et al</i> (1989) |
| 250                 | + (4 days)                               | ND  | ND  | ND  | Flippin <i>et al</i> (2009)    |
| 253                 | ND                                       | ND  | + (12 weeks)  | NA  | Szepvolgyi <i>et al</i> (1989) |
| 300                 | ND                                       | ND  | + (6 weeks)   | ND  | Horing <i>et al</i> (1990).    |
| 379                 | ND                                       | ND  | + (12 weeks)  | NA  | Szepvolgyi <i>et al</i> (1989) |
| 500                 | + (4 days)                               | ND  | ND  | ND  | Flippin <i>et al</i> (2009)    |
| 600                 | ND                                       | ND  | + (6 weeks)   | ND  | Horing <i>et al</i> (1990).    |
| 1000                | + (4 days)                               | ND  | ND  | ND  | Flippin <i>et al</i> (2009)    |

<sup>a</sup> Double value indicates the dosage in males and females respectively, where they are different.

<sup>b</sup> - : negative response; <sup>c</sup> ND : Not determined. <sup>d</sup> NA : Not applicable. <sup>e</sup> + : positive response

**Species: Mouse****Table A1-4: Concordance of dose-response and temporal relationships for the Key Events in studies in mice. Data are taken from the studies in Table A1-2.**

| Dose (mg/kg bw/day)                    | Key Event 1<br>Decreased blood T4 levels  | Key Event 2<br>Increased blood TSH levels | Key Event 3<br>Increased thyroid follicular cell hypertrophy and/or hyperplasia (determined as increased thyroid gland weight or histopathologically) | Key Event 4<br>Formation of thyroid tumours | Reference         |
|--|---|---|---|---|-------------------|
| <b>Ordered from low to high dosage</b> | <b>Key events shown in order from earliest event to later (left to right). Results show the time that the event was observed. Quantitative changes in severity are not shown.</b> |   |   |   |                   |
| 0.15                                   | <sup>a</sup> ND   | ND  | - (4 weeks)   | <sup>b</sup> NA                             | Anonymous (1985b) |
| 1.5                                    | ND  | ND  | - (4 weeks)   | NA  | Anonymous (1985b) |
| 1.8/2.2 <sup>c</sup>                   | ND  | ND  | - (13 weeks)  | NA  | Anonymous (1985c) |
| 4/5                                    | - <sup>d</sup> (52 to 78 weeks)   | - (52 to 78 weeks)                        | - (52 to 78 weeks)  | - (52 to 78 weeks)                          | Anonymous (1991a) |
| 15                                     | ND  | ND  | - (4 weeks)   | NA  | Anonymous (1985b) |
| 13/18                                  | - (52 to 78 weeks)  | - (52 to 78 weeks)                        | - (52 to 78 weeks)  | - (52 to 78 weeks)                          | Anonymous (1991a) |
| 18/22                                  | ND  | ND  | - (13 weeks)  | NA  | Anonymous (1985c) |
| 150                                    | ND  | ND  | + <sup>e</sup> (4 weeks)  | NA  | Anonymous (1985b) |
| 131/180                                | + (52 to 78 weeks)  | - (52 to 78 weeks)                        | - (52 to 78 weeks)  | - (52 to 78 weeks)                          | Anonymous (1991a) |
| 180/220                                | ND  | ND  | + (13 weeks)  | NA  | Anonymous (1985c) |
| 1500                                   | ND  | ND  | + (4 weeks)   | NA  | Anonymous (1985b) |
| 1800/2200                              | ND  | ND  | + (13 weeks)  | NA  | Anonymous (1985c) |

<sup>a</sup>- : negative response.      <sup>b</sup> ND : Not determined.      <sup>c</sup> NA : Not applicable.      <sup>d</sup> Double value indicates the dosage in males and females respectively, where they are different;      <sup>e</sup> + : positive response

**Species: Dog****Table A1-5: Concordance of dose-response and temporal relationships for the Key Events in studies in dogs. Data are taken from the studies in Table A1-2.**

| Dose (mg/kg bw/day)                     | Key Event 1. Decreased blood T4 levels   | Key Event 2. Increased blood TSH levels | Key Event 3. Increased thyroid follicular cell hypertrophy and/or hyperplasia (determined as increased thyroid gland weight or histopathologically) | Key Event 4. Formation of thyroid tumours | Reference         |
|---|--|---|---|---|-------------------|
| Ordered from low to high dosage (down). | Key events shown in order from earliest event to later (left to right). Results show the time that the event was observed. Quantitative changes in severity are not shown. |   |   |   |                   |
| 0.3                                     | - <sup>a</sup> (13 weeks)  | ND <sup>b</sup>                         | - (13 weeks)  | NA <sup>c</sup>                           | Anonymous (1986c) |
| 1.8/1.9 <sup>d</sup>                    | - (52 weeks)   | ND                                      | - (52 weeks)  | NA  | Anonymous (1990c) |
| 2.3                                     | - (52 weeks)   | ND                                      | - (52 weeks)  | NA  | Anonymous (1991c) |
| 3                                       | - (13 weeks)   | ND                                      | - (13 weeks)  | NA  | Anonymous (1986c) |
| 5.7                                     | - (13 weeks)   | ND                                      | - (13 weeks)  | NA  | Anonymous (1987c) |
| 7.6/7.8                                 | - (52 weeks)   | ND                                      | - (52 weeks)  | NA  | Anonymous (1990c) |
| 23                                      | + <sup>e</sup> (52 weeks)  | ND                                      | + (52 weeks)  | NA  | Anonymous (1991c) |
| 28/29                                   | - (52 weeks)   | ND                                      | - (52 weeks)  | NA  | Anonymous (1990c) |
| 29                                      | + (13 weeks)   | ND                                      | + (13 weeks)  | NA  | Anonymous (1986c) |
| 34                                      | + (13 weeks)   | ND                                      | - (13 weeks)  | NA  | Anonymous (1987c) |
| 40                                      | + (52 weeks)   | ND                                      | + (52 weeks)  | NA  | Anonymous (1991d) |
| 50/56                                   | + (52 weeks)   | ND                                      | + (52 weeks)  | NA  | Anonymous (1990c) |
| 102/110                                 | + (13 weeks)   | ND                                      | + (13 weeks)  | NA  | Anonymous (1986c) |
| 113                                     | + (26 weeks)   | ND                                      | + (26 weeks)  | NA  | Anonymous (1991c) |
| 340/204                                 | + (13 weeks)   | ND                                      | + (13 weeks)  | NA  | Anonymous (1987c) |

<sup>a</sup> Double value indicates the dosage in males and females respectively, where they are different.

<sup>b</sup> - : negative response; <sup>c</sup> + : positive response ND : Not determined. NA : Not applicable

In general, the dose response and temporal relationship among the Key Events fits the expected pattern for rats, mice and dogs. The temporality of events in subchronic studies proceeds in the expected order. T4 reduction is usually an early event, preceding histopathological changes and weight increases in the thyroid.

Thyroid follicular hypertrophy precedes hyperplasia. Tumours are only observed in rats, and in this species, the appearance of adenomas and carcinomas is always a late event. However, the limited frequency of observations means that in several studies, Key Events 1 to 3 cannot be distinguished temporally because at the time of the first observation all three events had occurred. In rats, the Key Event of T4 reduction occurs at doses below those that induce tumours therefore the dose response supports the MoA.

In rats, the dose at which mancozeb starts to affect the rat thyroid (T4 reduction and TSH increase) is approximately 15 mg/kg bw/day (Table A1-3). The studies of Anonymous (1986b), Anonymous (1992a) provide a lowest effect level (LOEL) at approximately this dose, in spite of being of different durations. The 4 day gavage study of Flippin *et al* (2009) and the 13 week study of Anonymous (1989) gives a slightly higher LOEL of ~30 mg/kg bw/day. The dose responses from the carcinogenicity studies indicate that tumours were observed at doses of approximately 30 mg/kg bw/day (Anonymous, 1990a). No thyroid tumours were noted with mancozeb in the study of Anonymous (1992a) where the highest dose levels only reached 16.8/20.8 mg/kg bw/day. This study was therefore conducted at dose levels below the LOEL for tumours. In the 2-generation studies of Anonymous (1988b) and Anonymous (1992c) parental rats received doses up to approximately 70 mg/kg bw/day for about 25 weeks and thyroid adenomas were seen at this dose but not at the lower doses (approximately 10 mg/kg bw/day and below). These studies therefore support the dose responses seen in the studies mentioned above.

In the mouse, the dose at which mancozeb starts to affect the thyroid is 150 mg/kg bw/day, approximately 10-fold higher than in the rat (Table A1-4). At this dose, T4 was reduced and histopathological changes were seen in the thyroid gland (Anonymous, 1985b; Anonymous, 1985c; Anonymous, 1991a). Mancozeb was not carcinogenic in mice. However the highest dose tested (MTD) was 131 to 180 mg/kg bw/day, the approximate LOEL in this species for thyroid effects. The MoA would predict that a higher dose would be necessary for tumour induction and therefore the absence of tumours also fits the hypothesis.

The sensitivity of the dog is between that of the rat and mouse with a LOEL of approximately 30 mg/kg bw/day for effects on the thyroid (Anonymous, 1986c; Anonymous, 1987c, 1991c, d; Anonymous, 1990c). T4 was reduced and thyroid follicular hyperplasia was reported. TSH levels were not determined in the dog (Table A1-5).

In conclusion, the data on dose response and temporality fit with the proposed MoA for mancozeb in all three species.

### **Consistency & Specificity – Biological Plausibility**

#### **Consistency & Specificity**

The weight of evidence linking the Key Events with the toxicological response is consistent with the observations in many studies in rats, mice and dogs. The same pattern of response among Key Events has been seen in all studies. The incidence of severity (quantitative response) is also consistent; for example, in rats dosed mancozeb in a 4 day study at approximately 30 mg/kg bw/day, 100% of rats had reduced T4 (Key Event 1) (Flippin *et al*, 2009) whilst in a carcinogenicity study, not all rats develop tumours, the incidence of thyroid carcinomas in male and female rats was 23% and 6.6% (Anonymous, 1990a). Thyroid tumours in rats are preceded by hyperplasia that occurs at lower doses, after a shorter duration and at a higher incidence than seen for tumours. These observations also fit with the MoA, where, at similar doses, the incidence/severity of later key events would not be expected to be greater than that of earlier key events.

One study did not show consistent results was a carcinogenicity study on mancozeb in rats conducted by Belpoggi *et al* (2002), where thyroid tumours appear to have been found at doses lower than the LOEL of ~15 mg/kg bw/day described above for thyroid effects in rats. The authors indicate that tumours may have been increased at 0.5 mg/kg bw/day. However, the study had an unusual design where rats were dosed until their natural death and there are very few study details and no historical control data. This makes interpretation of the incidence data at the lower doses difficult. This study is therefore not considered to be reliable for the purposes of this MoA analysis.

Two studies have addressed reversibility. In the 13 week rat study of Anonymous (1989), a recovery phase of 4 weeks was included, after which changes (reduction of plasma T4) were reversed. A recovery phase of

6 weeks was also included in the 13 week dog study of Anonymous (1987c), after which effects (reduction of plasma T4, thyroid weight increases and histopathological changes) were reversed. Reversibility is consistent with the proposed MoA where hormonal changes may be reset by the normal feedback-control systems and non-neoplastic cellular changes may also be reversed. Irreversibility is associated with the later development of thyroid follicular carcinomas.

The evidence is also consistent with ETU being the active metabolite responsible for the effects on the thyroid hormonal system and the tumours in rats. ETU causes an identical spectrum of changes to mancozeb, in rats, mice and dogs, with the Key Events also being the same. The LOELs for ETU in these species are lower than those for mancozeb and ETU causes thyroid follicular tumours in both rats and mice (Table A1-6). These facts are entirely consistent with metabolism of mancozeb to ETU being a requirement for the thyroid effects of mancozeb.

### **Effects of ETU**

The lowest dose at which ETU affects T4 in rats is 1-2 mg/kg bw/day compared to mancozeb where the LOEL is approximately 15 mg/kg bw/day. The most comprehensive study of the endocrine effects of ETU is the extended one generation study of Anonymous (2013). In this study some histopathological effects on the thyroid were described at 0.2 mg/kg bw/day but not all animals were affected and therefore 1-2 mg/kg bw/day is a clear LOEL. This is supported by older studies, although the doses at which effects are seen depends to some extent upon the duration of dosing. After administration for between 28 and 90 days, effects are seen at doses from 11 mg/kg bw/day (Kurtio *et al*, 1986); 12.5 mg/kg bw/day (Freudenthal *et al*, 1978); 15 mg/kg bw/day (Arnold *et al*, 1983), 7.5 mg/kg bw/day (O'Neil and Marshall, 1984); 14 mg/kg bw/d (Anonymous, 1986b) or 6 mg/kg bw/day (NTP, 1992). Dosing for up to 120 days resulted in a slightly lower effect level (5 mg/kg bw/day) (Graham and Hansen, 1972). A recovery period of up to 4 weeks was included in the study of Arnold *et al* (1983) following 7 weeks dosing of ETU. As demonstrated for mancozeb, the effects of ETU on the thyroid were reversible after this period. Effects at exceptionally low doses (0.05 mg/kg bw/day) are described by Nebbia and Fink-Gremmels (1996) after 5 days administration but the changes are small and inconsistent within the paper. As the data are also inconsistent with the data from the other 10 studies, the dose response in this paper is considered unreliable.

Long-term administration of ETU to rats in carcinogenicity studies caused increased incidences of thyroid follicular adenomas and carcinomas (Table A1-6). In an NTP (1992) study where ETU was administered in feed for 2 years, changes in T4 and TSH were seen at doses from 1.25 mg/kg bw/day. Further evidence of disturbance of the HTP axis occurred at higher doses, with histopathological changes and tumours appearing in the thyroid gland at doses from 3.8 mg/kg bw/day. This study included groups exposed as adults only and groups additionally exposed during the perinatal period. The frequency of tumours was increased by additional perinatal exposure to ETU.

Similar results were obtained in a proprietary 2-year carcinogenicity study on ETU. Thyroid follicular adenomas and carcinomas were increased in males but not females at 125 ppm (8.9 mg/kg bw/day) (Table A1-6). T4 was decreased and TSH was increased at this dose level (Anonymous, 1992e). An increased incidence of adenomas of the pituitary were also seen in male rats at 125 ppm in this study (50% incidence at 125 ppm compared with 26.6% incidence in controls). It is likely that these tumours are also a consequence of disruption of the HPT axis. In an earlier 2-year study on ETU, tumours were not noted but disturbance of the HTP axis was indicated by thyroid follicular hyperplasia at doses of 1.25 mg/kg bw/day and above (Graham *et al*, 1975).

In the mouse, the LOEL for effects of ETU on the thyroid is approximately 15 mg/kg bw/day (Anonymous, 1985b; Anonymous, 1985c; NTP, 1992) compared with about 150 mg/kg bw/day for mancozeb. Reliable short-term studies where T4 was measured have not been conducted in mice. Thyroid weight and histopathological findings were seen at doses from 15 mg/kg bw/day after 4 weeks administration (Anonymous, 1985b), histopathological findings were seen at doses from 17 mg/kg bw/day after 4 weeks administration whilst thyroid weight increased at 170 mg/kg bw/day after 3 months (Anonymous, 1985c). Histopathological findings were seen at doses from 19 mg/kg bw/day in both sexes, and thyroid follicular adenomas in males from 75 mg/kg bw/day following administration for 3 months (NTP, 1992).

In 2-year carcinogenicity studies in mice, ETU caused increased incidences of thyroid follicular adenomas and carcinomas, also seen in rats (Table A1-6). In an NTP (1992) study where ETU was administered in

feed for 2 years, changes in T4 and TSH were seen at doses from 17 mg/kg bw/day. Further evidence of disturbance of the HTP axis occurred at higher doses, with histopathological changes and tumours appearing at doses from 50 mg/kg bw/day. This study also included groups exposed as adults only and groups additionally exposed during the perinatal period. The frequency of tumours after additional perinatal exposure to ETU was similar to adult alone. As in rats, an increased incidence of hyperplasia or adenomas of the pituitary was also seen, at 1000 ppm, in both sexes. It is likely that these tumours are also a consequence of disruption of the HPT axis.

In rats and mice therefore, the data are consistent with the proposed MoA where ETU is responsible for thyroid tumour induction, and thyroid tumours are preceded by hyperplasia occurring at lower doses and after shorter durations. Higher doses of ETU for longer durations result in further cellular changes that lead to tumours. The rat is also more sensitive than the mouse to the effects of ETU, the difference in lowest effect levels being about 10-fold. One reason for the difference in sensitivity for rats and mice to ETU is that ETU is more rapidly metabolised and excreted in mice compared in rats. Thus, internal exposure is lower in mice. Further evidence of the sensitivity of the rat HPT axis to the effects of ETU is illustrated by the observation of tumours in other (non-lifetime) study types. In the 2-generation reproductive study of Anonymous (1990d) thyroid adenomas were seen at the highest dose (8-19 mg/kg bw/day) in F0 and F1 generations. In the extended one-generation reproductive toxicity study of Anonymous (2013) a low incidence of thyroid adenomas occurred in the high dose group (10 mg/kg bw/day) in both generations.

The liver is a target organ of ETU in the mouse. Liver weight and MFO activity were increased at doses of 150 mg/kg bw/day after 4 weeks administration (Anonymous, 1985b) and at doses of 170 mg/kg bw/day after 3 months (Anonymous, 1985c). Similar changes were described in NTP (1992) following 3 months administration. Increased incidences of hepatocellular adenoma and carcinoma occurred after 2 years administration at doses of 50 or 150 mg/kg bw/day. However these changes have not been seen with mancozeb.

The dose response data for ETU in the dog is not very consistent. In two studies, the LOEL for effects on the thyroid in the dog ranged from 2 to 66 mg/kg bw/day (Anonymous, 1991f, 1992d). In a 3 month study, effects on T4, T3, thyroid weight and histopathology occurred at doses of 66 mg/kg bw/day but not below (Anonymous, 1991f). After 52 weeks of dosing, similar effects were seen at doses of 2 mg/kg bw/day and above (Anonymous, 1992d). In comparison, the LOEL for effects on the thyroid with mancozeb in dogs was approximately 30 mg/kg bw/day. These data also support the MoA.

**Table A1-6: Thyroid follicular tumour incidences in rats and mice administered ETU**

| Reference        | Dose ppm<br>(mg/kg bw/day; males/females) | Tumour incidence (% tumour bearing animals) |         |
|------------------|---|---|---------|
|                  |   | Males                                       | Females |
| <b>Rat</b>       |   |   |         |
| NTP (1992)       | 0   | 2AC <sup>a</sup>                            | 6AC     |
|                  | 83 (3.8) <sup>b</sup>                     | 26AC*                                       | 16AC*   |
|                  | 250 (12.5) <sup>b</sup>                   | 74AC*                                       | 61AC*   |
| Anonymous (1992) | 0   | 3.3A, 0C                                    | 0A, 0C  |
|                  | 0.5 (0.04/0.05)                           | 0A, 0C                                      | 0A, 0C  |
|                  | 2.5 (0.17/ 0.25)                          | 0A, 0C                                      | 0A, 0C  |
|                  | 5 (0.38/0.49)                             | 0A, 0C                                      | 0A, 0C  |
|                  | 125 (8.9/13.6)                            | 13.3A*, 6.6C*                               | 0A, 0C  |
| <b>Mouse</b>     |   |   |         |
| NTP (1992)       | 0   | 2AC   | 0AC     |
|                  | 330 (50) <sup>b</sup>                     | 2AC   | 4AC*    |
|                  | 1000 (150) <sup>b</sup>                   | 58AC*                                       | 76AC*   |

<sup>a</sup>A=adenomas, C=carcinomas, AC=combined incidence of adenomas and carcinomas.

<sup>b</sup>Exposure estimated according to OECD (2002).

\*Statistically significant (as described in the study report).

### **Biological plausibility**

The proposed MoA is consistent with data from other thyroid toxicants, acting via similar MoAs (TPO inhibition) or other MoAs that also have reduction of blood T4 levels as the first Key Event. Increased secretion of TSH then follows, and the progression of thyroid follicular cells to hypertrophy, hyperplasia and neoplasia (IARC, 1999, 2000; Hard, 1998; McClain 1995; Hurley, 1998). The proliferative response of thyroid follicular cells to TSH has also been shown by Bayer *et al* (1992). The biological changes observed with mancozeb are entirely consistent with the known biology of the thyroid hormonal system and the role of the hypothalamus and pituitary.

The tumour response in the rat caused by mancozeb is also typical of a rodent thyroid carcinogen in that the incidence of thyroid follicular cell tumours is greater in males compared to females. In all studies where tumours were observed, the incidence was markedly greater in males (Anonymous, 1990a; Anonymous, 1988b; Anonymous, 1992c). The same trend can also be seen with ETU in rats. Male rats have generally been found to be more sensitive than female rats, with respect to the proportion of chemicals inducing thyroid tumours (Hurley, 1998). This is supported by TSH levels being typically higher in male rats compared to females and therefore a greater potential for thyroid follicular cell stimulation to hypertrophy and hyperplasia.

### **Consistency across chemicals**

The MoA for ETU is also consistent with that of chemical analogues. Other thioureas, such as the pharmaceuticals PTU (used to control hyperthyroidemia in humans) and TMTU are also inhibitors of TPO. MoA studies have been conducted with several structural analogues and all thioureas studied were inhibitors of TPO although some (e.g. PTU) were irreversible whilst others (e.g. ETU, tetramethylthiourea) were reversible (Doerge and Takazawa; 1990; Freyberger and Ahr, 2006). PTU produces the same Key Events as ETU/mancozeb in rats but PTU is a more potent chemical than ETU. Yamasaki *et al* (2002) dosed male rats with PTU by gavage in a 28 day repeat dose study (OECD TG 407) and a male pubertal assay (dosing from 23 to 53 days of age) at doses of 0.01 and 1 mg/kg bw/day. T4 was reduced at 1 mg/kg bw/day in the pubertal assay and at both 0.01 and 1 mg/kg bw/day in the 28 day repeat dose study.

**Summary**

The evidence for consistency, specificity and biological plausibility is summarised in Table A1-7. Almost all of the studies are consistent in their findings and interpretation, strongly supporting the proposed MoA. Alternative MoAs, such as genotoxicity, have also been considered, but discounted (see section 'Other Potential Modes of Action' below).

**Table A1-7: Comparative weight of evidence for the MoA for mancozeb-induced rat thyroid tumours.**

|                                      | Supporting evidence for Key Events  | Potentially inconsistent evidence   |
|--------------------------------------|---|---|
| <b>Consistency &amp; Specificity</b> | <ul style="list-style-type: none"> <li>- A consistent pattern of response for the Key Events has been seen in rats, mice and dogs administered mancozeb, but with quantitative differences in dose response. An identical pattern (but also with quantitative differences in dose response) is seen with ETU.</li> <li>- The pattern of observations across species/organs/test systems is consistent with what is expected based on the postulated MoA. Inhibition of thyroid hormones by ETU occurs in most species, consistent with the well-conserved nature of TPO. Rat is the most sensitive species to mancozeb, consistent with the biology of the rat HPT axis and less efficient metabolism of ETU compared to other species. Thyroid is the major target organ, consistent with TPO being the key molecular target of ETU. The pituitary gland may also be affected in rats, consistent with the action of ETU on the HTP axis in the most sensitive species.</li> <li>- In studies where mancozeb or ETU have been dosed to rats or dogs (Arnold <i>et al</i>, 1983; Anonymous, 1989; Virgo, 1987) reduction of blood T4 and histopathological changes in the thyroid gland are reversed following a recovery period after cessation of dosing.</li> <li>The dose–response is consistent with the MoA. T4 reduction occurs at doses below those that induce tumours. Doses of mancozeb causing thyroid disturbance and doses of mancozeb causing thyroid tumours are proportionately higher than those of ETU. The carcinogenicity study on mancozeb in rats that did not produce tumours (Anonymous, 1992a) was conducted at dose levels below those established to be the LOEL for tumours.</li> <li>- The incidence of tumours (as % tumour bearing animals) is always lower than earlier effects. For example, all animals in an affected group will show thyroid follicular hyperplasia whilst only a proportion will go on to develop tumours.</li> <li>- ETU also induces thyroid tumours in both rats and mice, consistent with it being the active metabolite. However the dose at which ETU induces tumours is higher in mice than rats, consistent with rat being the more sensitive species.</li> <li>- Other structural analogues produce similar effects to ETU.</li> </ul> | <ul style="list-style-type: none"> <li>- None.</li> <li>- One study with ETU in rats had some inconsistencies (Nebbia and Fink-Gremmels, 1996).</li> <li>- None.</li> <li>- One carcinogenicity study appeared to produce thyroid tumours at doses lower than those causing thyroid effects (Belpoggi <i>et al</i> (2002). However the study design is non-standard and results are not reliable.</li> <li>- None.</li> <li>- None.</li> <li>- None.</li> </ul> |
| <b>Biological</b>                    | <ul style="list-style-type: none"> <li>- The relationship between reduced blood T4 levels, increased TSH and thyroid follicular cell hypertrophy, hyperplasia and</li> </ul>  | <ul style="list-style-type: none"> <li>- None.</li> </ul>   |

|                     | Supporting evidence for Key Events   | Potentially inconsistent evidence |
|---------------------|--|-----------------------------------|
| <b>Plausibility</b> | <p>eventually tumours has been described for many thyroid perturbants (Hill <i>et al</i>, 1989; Hurley <i>et al</i>, 1998; McClain and Rice, 1999). The key initial event in most cases is reduced T4 and the MoA from this to thyroid tumours in rodents is well established. Evidence supporting the role of the pituitary and TSH is also well established.</p> <p>- The tumour incidence in rats, after administration of mancozeb or ETU, is higher in males than females. This is also consistent with other rat thyroid carcinogens and sex differences in TSH levels</p> | - None.                           |

### **Qualitative and Quantitative human concordance**

In this section, concordance for each key event, between and within species will be assessed. This includes species differences in metabolism of mancozeb/ETU, possible species differences in the molecular target (TPO) and species concordance for the key biological events. Qualitative and quantitative human concordance analysis for the key events are summarised in Table A1-9.

### **The metabolism of mancozeb/ETU**

In studies in laboratory animals, mancozeb is partially absorbed (about 50% absorption after oral administration) and rapidly excreted. ETU is the major metabolite. The bioconversion of mancozeb to ETU was 7% on a weight basis, similar to the bioconversion factor for other ethylenebisdithiocarbamates (EBDC). In monkeys, oral doses were very poorly absorbed (Emmerling, 1978). The spectrum of metabolites produced was similar in laboratory and farm animals indicating similar metabolism of mancozeb across species. The pharmacokinetics and metabolism of ETU have been studied in mice, rats, guinea pigs, cats, and monkeys. These studies have shown that ETU is rapidly excreted, primarily in the urine and more quickly in mice than in rats. Half-lives for elimination from maternal blood were 5.5 and 9.4 hours in mice and rats, respectively (Ruddick *et al*, 1977). Literature studies indicate that mancozeb and ETU are also rapidly absorbed and eliminated after oral administration in humans. The elimination half-life of ETU was estimated to be 19-23 hours in humans (Aprea *et al*, 1996; Lindh *et al*, 2008).

The metabolism of ETU across species has been compared in two *in vitro* studies (table A1-8). Saghir *et al* (2005) compared rat, mouse and human using liver S9 as a source of metabolising enzymes. Zhu (2015) compared rat, mouse, dog, rabbit and human using primary hepatocytes as the source of metabolising enzymes. The results of the two studies were similar in that metabolism in the rat was lower than in humans. However, metabolism in mouse hepatocytes in Zhu (2015) was lower than in rat hepatocytes whilst the opposite occurred in Saghir *et al* (2005). The latter result concurs with *in vivo* comparisons of rat and mouse metabolism where metabolism is clearly greater in mice. Metabolism in dog and rabbit appears similar to humans. In these studies, metabolism in humans appears more efficient than rodents, indicating that ETU may be readily removed in humans. These studies were conducted with pools of human S9/hepatocytes and therefore no indication of polymorphisms in metabolism were obtained. Recent literature studies indicate that metabolism of ETU by flavin-dependent monooxygenase (FMO) may be subject to polymorphisms in humans (Krueger *et al*, 2005; Koukouritaki *et al*, 2007). However, the contribution of genetic variants of FMO towards the overall metabolism of ETU in humans is not known. Previous studies (reported in the DAR, 2000) have indicated that ETU is metabolised by both cytochrome P450 isoforms and FMO enzymes. Therefore the impact of genetic variants of FMO in the human population may be low.

The evidence that mancozeb is metabolised to ETU in experimental animals and humans is therefore high. The evidence for species differences in the metabolism of ETU is also high and there is plausible evidence that humans are efficient metabolisers of ETU.

**Table A1-8: Metabolism of ETU in different species**

**Metabolism of ETU in liver S9 after 1 hour (% of total ETU added) (Saghir *et al*, 2005)**

| ETU initial concentration   | Mouse (200) | Rat (105) | Human pool 1 (6) | Human pool 2 (7) | Human pool 3 (7) |
|---|-------------|-----------|------------------|------------------|------------------|
| 100 µM  | 4.98        | 2.11      | 10.76            | 12.81            | 11.72            |
| Metabolism of ETU in hepatocytes after 3 hours (% of total ETU added) (Zhu, 2005) |             |           |                  |                  |                  |
| ETU initial concentration   | Mouse (59)  | Rat (21)  | Rabbit (6)       | Dog (3)          | Human (10)       |
| 2 µM  | ND          | 11.2      | 23.4             | 25.8             | 22.1             |
| 200 µM  | 10.5        | 12.2      | 13.3             | 22.5             | 17.0             |

ND: not detectable

Values in parentheses are the number of individuals in the pools (all females). Note that uninduced S9 was used in the Saghir study.

### **TPO inhibition in different species**

TPO is a well-conserved enzyme and is the key enzyme responsible for thyroid hormone synthesis in many species. ETU has been shown to inhibit TPO in hog and rat TPO (Doerge and Takazawa, 1990; Freyberger and Ahr, 2006; Paul *et al*, 2014). Clear evidence of species differences are lacking because of use of different methods and substrates. Paul *et al* (2013) compared the inhibition of TPO in pigs with that of rats. Although ETU was not used in this paper, the comparison, showed that PTU was a more potent inhibitor of rat TPO than pig TPO. This result indicates that rat TPO may be more responsive to thiourea-type inhibitors than pig TPO.

The evidence that TPO is the molecular target in this MoA is overwhelming, however the evidence for species differences between humans and experimental animals is uncertain.

### **Species concordance for the Key (biological) Events**

There is qualitative concordance between the biological Key Events 1-3 among experimental rats, mice and dogs. The studies in Tables A1-2 and A1-3 present overwhelming evidence that mancozeb caused decreased blood levels of T4, increased TSH blood levels and thyroid follicular hypertrophy/hyperplasia in rats, mice and dogs. There is also overwhelming evidence that these changes are caused by the metabolite, ETU. The quantitative differences in dose response among these species have been discussed previously. The final adverse effect (Key Event 4) of formation of thyroid follicular tumours only occurs in rats and therefore qualitative concordance among experimental species (rats and mice) does not occur. The likely reasons for these (species differences in metabolism) have been discussed previously.

The following discussion focusses on concordance between experimental animals and humans in the response to mancozeb. There are no direct human studies on mancozeb and the thyroid but there are some epidemiology and worker exposure studies. These are referred to in Table A1-9 and described separately below.

Qualitative concordance for Key Event 1 (T4 reduction) between experimental species and humans is plausible because the HPT axis operates in a qualitatively similar manner across species. In an experimental study with 2 phases, monkeys were administered ETU in the diet for 5 months (Leber *et al*, 1978). In Phase I, doses were 2-250 ppm (0.01-12.5 mg/kg bw/day) and in Phase II doses were 50-450 ppm (2.5-22.5 mg/kg bw/day). In Phase I, T4 was marginally decreased at 50 ppm (2.5 mg/kg bw/day) with other thyroid changes occurring at higher doses (e.g. weight increase at 12.5 mg/kg bw/day). In Phase II, T4 was decreased at doses greater than 150 ppm (7.5 mg/kg bw/day). These results indicate that monkeys respond to ETU but the reliability of the dose-response is not uncertain. The monkeys in Phase I suffered with tuberculosis and this phase had to be terminated early. The DAR (2000) questioned the reliability of the study as the NOAEL was derived from both phases, however the monkeys did respond to ETU.

There is no direct data on the thyroid from humans intentionally exposed to mancozeb or ETU, therefore there are no quantitative comparisons available. However, there are fundamental quantitative differences in the function and regulation of the HPT axis between rodents and humans and evidence that humans are less sensitive to thyroid disruption (see below). The more potent structural analogue, PTU, is used pharmaceutically to reduce T4 in human cases of hyperthyroidism. The dosage for humans is approximately 300 mg/day, equating to ~4 mg/kg bw/day for a 70 kg adult. In adult rats, T4 was reduced at PTU doses of 0.01 and 1 mg/kg bw/day in a 28 day study (Yamasaki *et al*, 2002). This indicates that rats are more sensitive than humans to PTU, although both species respond.

Qualitative concordance for Key Event 2 (TSH increase) between experimental species and humans is possible because the HPT axis operates in a qualitatively similar manner across species. In the monkey study described above, TSH was increased at doses of 7.5 mg/kg bw/day (Leber *et al*, 1978). As described for T4 reduction, there are no quantitative comparisons available but the fundamental quantitative differences in the function and regulation of the HPT axis means that humans are less sensitive to thyroid disruption than rats (see Table A1-9).

Qualitative concordance for Key Event 3 (increased thyroid follicular cell hypertrophy and/or hyperplasia) between experimental species and humans is possible because the HPT axis operates in a qualitatively similar manner across species. In the monkey study described above, thyroid follicular hyperplasia was observed. Iodine deficiency in humans leads to goitre. There are no quantitative comparisons available for humans but the fundamental quantitative differences in the function and regulation of the HPT axis means that humans are less sensitive to thyroid disruption than rats (see Table A1-9).

Qualitative concordance for the adverse effect Key Event 4 (Formation of thyroid follicular tumours) between rats and humans is unlikely to occur because humans are resistant to thyroid cancer. Exposure studies and epidemiology studies with mancozeb and ETU in humans have showed no increased incidence of thyroid tumours (see below). The fundamental quantitative differences in the function and regulation of the HPT axis means that humans are less sensitive to thyroid disruption than rats (see Table A1-9).

**Table A1-9: Species concordance analysis of key events in the MoA for induction of thyroid tumours in rats by mancozeb**

| Key Event (name)  | Qualitative Concordance  |  | Quantitative Species Concordance   | Confidence/Uncertainty   |
|---|--|--|--|--|
|   | (Evidence in Experimental Species)   | (Evidence in Humans)   | (Experimental Species and Humans)  | (Experimental Species and Humans)  |
| <b>Metabolism of mancozeb to ETU (activation) and metabolism of ETU (deactivation).</b> | <b>Yes:</b> Metabolism of mancozeb to ETU (7% by weight) shown in all species studied (rats, mice, farm animals, monkeys).<br><br>ETU is metabolised in rats, mice, dogs, guinea pigs, cats, and monkeys | <b>Yes:</b> Metabolism of mancozeb to ETU has been shown in humans. ETU is metabolised in humans.  | <b>Plausible:</b> Metabolism of mancozeb to ETU is likely to be similar in experimental species and humans.<br><br>Metabolism of ETU shows quantitative species differences. The rat shows lowest metabolism whilst human, mouse, dog and rabbit appear to be efficient metabolisers of ETU. | Overwhelming evidence from <i>in vivo</i> and <i>in vitro</i> studies for qualitative similarity.<br><br>High evidence for quantitative species differences in experimental species and humans.<br><br>The <i>in vitro</i> data on mouse in one study is not consistent with <i>in vivo</i> data but other <i>in vitro</i> is. |
| <b>Molecular Initiating Event: Inhibition of TPO by ETU</b>                             | <b>Yes:</b> Inhibition of TPO by ETU has been shown <i>in vitro</i> in rats and pigs. The downstream consequences of TPO inhibition have been shown in rats, mice and dogs administered ETU.             | <b>Likely:</b> Inhibition of human TPO by ETU has not been demonstrated but T4 reduction has been shown in monkeys administered ETU. TPO is a well-conserved enzyme. | <b>Not known:</b> Some species differences in TPO activity have been shown but no data on ETU and human TPO.   | Overwhelming evidence for qualitative similarity and TPO being the molecular target in experimental animals.<br><br>Uncertain evidence for quantitative species differences.<br><br>Data for quantitative species differences is based on chemical analogues not ETU itself.   |
| <b>Key Event 1: Decreased blood T4 levels</b>   | <b>Yes:</b> <i>In vivo</i> studies show that mancozeb reduces blood T4 levels in rats, mice and dogs.  | <b>Plausible:</b> No direct data on mancozeb in humans. Exposure studies and   | There are important differences between the physiology of the thyroid between rats   | Overwhelming evidence for qualitative similarity among laboratory animals.   |

| Key Event (name)   | Qualitative Concordance   |   | Quantitative Species Concordance   | Confidence/Uncertainty   |
|--|---|---|--|--|
|  | (Evidence in Experimental Species)  | (Evidence in Humans)  | (Experimental Species and Humans)  | (Experimental Species and Humans)  |
|  | ETU has a similar qualitative effect.   | epidemiology studies with mancozeb are negative.<br>T4 was reduced in monkeys administered ETU.<br>The ETU structural analogue, PTU, is used pharmaceutically to reduce T4 in human hyperthyroidism.  | (rodents) and humans. Humans may be quantitatively less sensitive than rats to chemicals reducing T4 levels. The biochemical response to TSH between rats (rodents) and humans is also quantitatively different. The rodent thyroid is far more dynamic than that of humans. The follicular cells appear to be in active synthesis compared to humans where they are quiescent. Humans have a greater reserve of thyroid hormone than rats, allowing for a bigger buffering capacity.<br>T4 has a much shorter half-life in rats than in humans (12 hours compared to 5–9 days), and constitutive levels of TSH are about 25-fold higher in rats compared to humans. | Qualitative similarity with humans is plausible but no direct data on mancozeb. The reliability of the monkey study on ETU is uncertain.<br>Strong evidence for quantitative differences in thyroid physiology with humans being less sensitive. The dose of PTU required to reduce T4 in humans is 4–40 fold higher than in rats.               |
| <b>Key Event 2: Increased blood TSH levels</b>   | <b>Yes:</b> In vivo studies show that mancozeb increases blood TSH levels in rats. Direct evidence in mice and dogs is lacking but the later events of increased thyroid follicular cell hypertrophy and/or hyperplasia indicate this occurs.<br>ETU has a similar qualitative effect on TSH. | <b>Possible:</b> No direct data on mancozeb in humans. Exposure studies and epidemiology studies with mancozeb are negative.<br>TSH is part of the thyroid hormonal system in humans. TSH was increased in monkeys administered ETU.                            | The shorter half-life of T4 is thought to be related to the absence of thyroid binding globulin (TBG) in adult rats, which leads to a higher turnover rate of thyroid hormones. In adult humans, thyroid hormones are tightly bound to TBG in blood. The consequence of these differences is that the thyroid of rodents is a much more active organ than that of humans. Thyroid tumours are a relatively common finding in rat long-term studies, whilst the only known human thyroid carcinogen is ionizing radiation. Several analyses have been conducted to investigate the human relevance of rodent thyroid follicular                                       | Overwhelming evidence for qualitative similarity among laboratory animals. Qualitative similarity with humans is plausible but no direct data on mancozeb. The reliability of the monkey study on ETU is uncertain.<br>Strong evidence for quantitative differences in thyroid physiology with humans being less sensitive.                      |
| <b>Key Event 3: Increased thyroid follicular cell hypertrophy and/or hyperplasia (determined as increased thyroid gland weight or histopathologically)</b> | <b>Yes:</b> <i>In vivo</i> studies show that mancozeb increases thyroid follicular cell hypertrophy and/or hyperplasia in rats, mice and dogs.<br>ETU has a similar qualitative effect.   | <b>Uncertain:</b> No direct data on mancozeb in humans. Exposure studies and epidemiology studies with mancozeb are negative.<br>Monkeys administered ETU showed increased thyroid follicular cell hyperplasia.<br>Iodine deficiency in humans leads to goitre. |  | Overwhelming evidence for qualitative similarity among laboratory animals. Qualitative similarity with humans is plausible but no direct data on mancozeb. The reliability of the dose response of the monkey study on ETU is uncertain.<br>Strong evidence for quantitative differences in thyroid physiology with humans being less sensitive. |
| <b>Key Event 4: Formation of thyroid follicular tumours</b>  | <b>No:</b> Carcinogenicity studies show that mancozeb increases thyroid follicular cell adenomas and carcinomas in rats. This did not occur in mice.  | <b>No:</b> Exposure studies and epidemiology studies with mancozeb and ETU in humans have showed no increased incidence of thyroid tumours.   |  | Strong evidence that mancozeb produced thyroid tumours in rats but not mice.<br>Strong evidence for quantitative differences in thyroid physiology with humans being less sensitive  |

| Key Event (name) | Qualitative Concordance            |                      | Quantitative Species Concordance   | Confidence/Uncertainty            |
|------------------|------------------------------------|----------------------|--|-----------------------------------|
|                  | (Evidence in Experimental Species) | (Evidence in Humans) | (Experimental Species and Humans)  | (Experimental Species and Humans) |
|                  |                                    |                      | tumours and have concluded that the relevance is low (Hill <i>et al</i> , 1998; Hurley, 1998; Hard, 1998). |                                   |

### **Evidence for thyroid dysfunction or carcinogenicity in humans**

The association between exposure to mancozeb and endocrine-related outcomes has been investigated both in medical studies and epidemiology studies of workers handling mancozeb and the general public who may be exposed to it. Many studies have not distinguished between EBDC pesticides generally and mancozeb. ETU in urine or blood has also been used as a biomarker of EBDC exposure.

In medical studies where data from workers in mancozeb/EBDC manufacturing plants were analysed to determine whether there was any evidence of thyroid dysfunction, no effects were found. De Fonso (1976) analysed mortality data from workers exposed to mancozeb in a manufacturing plant in the USA (1948-1975) and found that thyroid cancer in exposed workers was not increased. In another study, also in the USA, workers manufacturing mancozeb for many years were given thyroid function tests. Exposure to mancozeb was not associated with increased thyroid abnormalities (Anonymous, 1985a). A similar study in the Netherlands found that factory workers handling mancozeb had normal levels of thyroid hormones (Anonymous, 1990b). Ongoing monitoring of workers at mancozeb manufacturing plants have shown no evidence of thyroid dysfunction.

ETU is also a by-product in rubber manufacture. Two studies of workers at rubber manufacturing plants also monitored thyroid hormone levels (Smith, 1984) and thyroid cancer and foetal abnormalities (Smith, 1976). One group of workers (mixers) was reported to have lowered T4 levels, but not other groups. No increased incidence of thyroid cancer was found.

Epidemiology studies have also examined the possible association between mancozeb (EBDC) exposure and effects on the thyroid. The quality of these studies varies widely and several are contradictory. Details are provided in Dossier M-CA Section 5.9 (2015).

Steenland *et al* (1997) found low levels of ETU in the urine of workers using EBDC fungicides. T4 levels were similar amongst the exposed workers and a non-exposed group whilst TSH adjusted for age appeared slightly elevated. Age was a confounding factor in this study and in fact TSH in all groups was within normal levels. The authors stated that the results were of "borderline significance". Correlation between blood ETU and thyroid disorder was studied in a group of workers in the Philippines (Panganiban *et al*, 2004). There was no difference in thyroid function between directly exposed, indirectly exposed and non-exposed groups. The authors claimed that the exposed workers had a higher incidence of solitary thyroid nodules but the analyses performed in this paper are so poor that the associations and conclusions are considered unreliable. Goldner *et al* (2010) analysed the association between thyroid disease and pesticide use in two papers. The first (2010) investigated female spouses in the Agricultural Health Study in the USA (1993-1997). The second (2013) investigated male applicators in the same Agricultural Health Study. In the first study, the authors claimed a role of maneb/mancozeb in the development of thyroid disease whilst in the second study maneb/ mancozeb was not associated with thyroid effects. Both studies had significant limitations, such as an inability to distinguish between prevalence and incidence of disease and to determine whether exposure preceded disease onset. The results should therefore be interpreted cautiously. A study by Nordby *et al* (2005) investigated the association between mancozeb exposure and thyroid cancer in farmers' families. The study had significant limitations including a lack of adjustment for confounding factors and very crude measures of exposure. The authors concluded that there was no association between mancozeb exposure and thyroid cancer.

The overall conclusion from these epidemiology and medical studies is that environmental or workplace exposure to mancozeb does not disrupt the thyroid hormonal system in humans. Monitoring data shows that exposure levels are generally well within current reference doses and these are protective of human health.

### Summary

Having considered all the evidence, the Human Relevance Framework then addresses the following three questions regarding the human relevance of mancozeb-induced thyroid tumours.

- **Is the weight of evidence sufficient to establish the hypothesised mode of action in experimental species?**

Yes, there is clear evidence that mancozeb causes thyroid cancer in rats via metabolism to ETU, inhibition of TPO, reduction of thyroid hormone synthesis and consequent disruption of thyroid homeostasis.

- **Can human relevance of the specific mode of action be reasonably excluded on the basis of fundamental qualitative differences in key events between experimental species and humans?**

No. TPO is a well-conserved key enzyme involved in the synthesis of thyroid hormones. Drugs such as PTU and methimazole are TPO inhibitors that operate via this MoA to treat hyperthyroidemia in humans. The HPT axis also operates in a similar qualitative way in experimental species and humans, although there are fundamental differences in the physiology of the thyroid system indicating humans are less sensitive than rats to thyroid disrupters.

- **Can human relevance of the specific mode of action be reasonably excluded on the basis of quantitative differences in either kinetic or dynamic factors between experimental animals and humans?**

Yes. The *in vivo* and *in vitro* metabolism data support the rat being the most sensitive species to mancozeb because metabolism of ETU is least efficient in this species. Differences in dose response in rats, mice and dogs administered mancozeb or ETU show that effect levels are lowest in rats and highest in mice, supporting this argument. Thyroid tumours do not develop in mice exposed to mancozeb because at MTD, insufficient ETU is generated to cause tumours.

In addition to kinetic differences there are dynamic differences between rats and humans that indicate that humans are less sensitive to thyroid disruption than rats. Differences in the physiology of the thyroid, a longer half-life for T4, the presence of thyroid binding globulin in blood in humans means that human thyroid has a much greater buffering capacity than the rat thyroid. Many studies in humans have also demonstrated that thyroid cancer is very rare, even in patients with Graves disease or goitre. A study of environmental and heritable causes of cancer in Sweden showed that the environment did not play a principal causative role in thyroid cancer in humans (Czene *et al*, 2002). However, it is a commonly observed finding after chemical exposure in rats.

### Other potential Modes of Action

Other possible MoAs for tumour induction, such as genotoxicity and other non-genotoxic thyroidal modes of action have been excluded. Mancozeb and ETU are not genotoxic and there is no evidence that other thyroidal modes of action contribute to the carcinogenicity of mancozeb (EU, 2009; M-CA Dossier Section 5, 2015).

### Genotoxicity

Mancozeb, ETU and EBDCs as a group of chemicals have been extensively tested for genotoxicity in various bacterial, fungal, and mammalian cell *in vitro* test systems; in assays for structural chromosomal damage in somatic cells *in vivo*; and for heritable effects in *Drosophila* gene mutation assays. The only studies in which positive genotoxic effects have been observed with mancozeb have significant deficiencies, or are flawed in various ways. Overall, neither mancozeb nor ETU is mutagenic when properly tested in higher organism test systems in the two major endpoints used to assess genotoxicity, gene mutation and chromosomal damage. Similarly, ancillary tests have not provided significant evidence of genotoxic damage. The overall body of toxicological data coming from a number of *in vitro* and *in vivo* assays indicates that mancozeb and ETU are not genotoxic (EU, 2009; M-CA Dossier Section 5, 2015).

### **Alternative non-genotoxic thyroidal modes of action**

A common mode of action for chemicals causing thyroid follicular tumours in rats is enhanced metabolism of thyroid hormones by liver enzyme induction leading to reduced T4 levels and disruption of the HPT axis (Dellarco *et al*, 2006; Zoeller, 2007; Miller *et al*, 2009). Chemicals acting via this mechanism induce hepatic xenobiotic metabolising enzymes including T4-uridine diphosphate glucuronosyl transferase (UDPGT), the enzyme responsible for conjugation of thyroid hormones prior to excretion. The potential for a contributory effect of this to the main MoA of TPO inhibition has been examined. However, in several studies in rats, mancozeb appeared to have little effect on the liver. Flippin *et al* (2009) reported that mancozeb did not induce the activity of mixed function oxidase (MFO) enzymes or UDPGT. Szepvolgyi *et al* (1989) and Anonymous (1986b) reported that MFO activity was decreased, whilst Anonymous (1989), Anonymous (1992a), and Anonymous (1990a) reported that the liver was unaffected. This MoA therefore does not appear to have a contributory role for mancozeb.

Another potential contributory MoA is inhibition of iodothyronine deiodinase. Iodothyronine deiodinase is an enzyme present in peripheral tissues that is responsible for the deiodination of T4 to T3, which is a more active ligand than T4 for the thyroid hormone receptor. Inhibition of iodothyronine deiodinase has been demonstrated to be a contributory MoA for PTU. ETU however, did not inhibit this enzyme, demonstrating it is not a contributory MoA for ETU (Freyberger and Ahr, 2006; O'Neil and Marshall, 1984).

Other MoAs, such as interaction with the thyroid hormone receptor have also been excluded (Hass *et al*, 2012; Kjeldsen *et al*, 2013).

### **Uncertainties/Inconsistencies and Identification of Data Gaps**

Inconsistencies and uncertainties have been identified in the previous discussions. However, they are few in number compared to the data supporting the arguments presented.

### **Classification of mancozeb and carcinogenic potency considerations**

In addition to the factors discussed above, the possible classification of mancozeb for carcinogenicity should consider carcinogenic potency using the T25 concept (the chronic daily dose which will give 25% of the animals tumours at a specific site, after correction for spontaneous incidence, within the standard life-span of that species). Carcinogens of high potency have a T25 value of:  $\leq 1$  mg/kg bw/day; those of medium potency a T25 value of 1 to  $\leq 100$  mg/kg bw/day, and those of low potency a T25 value of  $> 100$  mg/kg bw/day. The T25 value for mancozeb as a rat thyroid carcinogen was calculated from the study of Anonymous (1990a) using the method in EC (1999) (see Section 10.7.5 of the main document). The T25 value for mancozeb and rat thyroid adenomas was 23.6 mg/kg bw/day whilst that for mancozeb and rat thyroid carcinomas was 33.5 mg/kg bw/day. In both cases this places mancozeb into the medium potency carcinogen group. According to a TCC&L paper on thyroid tumours (ECBI49/99-Add1.Rev2) non-genotoxic carcinogenic substances producing thyroid tumours in rodents with low or medium potency by a clearly established perturbation of the thyroid hormone axis, in general, do not need to be classified. Mancozeb is a medium potency rat thyroid carcinogen with a clearly established non-genotoxic MoA and therefore does not need to be classified.

### **Conclusions in relation to problem formulation**

There is sufficient evidence to establish the MoA for thyroid disruption caused by mancozeb-induced thyroid tumours in rats. Mancozeb is a medium potency (T25 value of 1 to  $\leq 100$  mg/kg bw/day) rat thyroid carcinogen. There is qualitative evidence that mancozeb, via its metabolite ETU, could potentially cause hypothyroidism in humans as the operation of the HPT axis is qualitatively similar across mammalian species. However there is quantitative evidence that exposure of humans to ETU following mancozeb exposure is lower than rats because of differences in the metabolism of ETU. There are also substantial quantitative dynamic differences in the physiology of the thyroid gland between rats and humans that mean that the human thyroid is less responsive to thyroid disrupters than rats. Thyroid cancer in humans is a rare event whilst thyroid cancer in rats is common. Epidemiology and medical studies also show no increased incidence of hypothyroidism or thyroid cancer in exposed individuals. The question formulated "**Are thyroid tumours in rats caused by mancozeb, relevant for humans who may be exposed to mancozeb?**" can be answered by concluding that the significant quantitative kinetic and dynamic factors means that

relevance is low and the risk to humans is negligible. The clearly established non-genotoxic MoA, the medium potency and low risk to humans means that mancozeb should not be classified as a carcinogen.

### **Additional References**

- Arnold DL, Krewski DR, Junkins DB, McGuire PF, Moodie CA and Munro IC (1983). Reversibility of ethylenethiourea-induced thyroid lesions. *Toxicol Appl. Pharmacol.* 67(2), 264-273.
- Bayer I, Mitmaker B, Gordon PH, Wang E (1992). Modulation of nuclear statin expression in rat thyroid follicle cell following administration of thyroid stimulating hormone. *J. Cell Physiol.* 150, 276-282.
- Czene K, Lichtenstein P and Hemminki K (2002). Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. *Int. J. Cancer* 99(2), 260-266.
- Dellarco VL, McGregor D, Berry SC, Cohen SM and Boobis AR (2006). Thiazopyr and thyroid disruption: case study within the context of the 2006 IPCS Human Relevance Framework for analysis of a cancer mode of action. *Crit Rev. Toxicol.* 36(10), 793-801.
- Doerge DR and Takazawa RS (1990). Mechanism of thyroid peroxidase inhibition by ethylenethiourea. *Chem. Res. Toxicol.* 3(2), 98-101.
- Emmerling (1978). The effects of thyroid hormones on the teratogenic potential of ethylenethiourea in rat. Report from Battelle Laboratories, Columbus, USA
- Freudenthal RI, Kerchner G, Persing R and Baron RL (1978). Dietary subacute toxicity of ethylene thiourea in the laboratory rat. *J Environ Pathol. Toxicol* 1(1), 147-161.
- Freyberger A and Ahr HJ (2006). Studies on the goitrogenic mechanism of action of N,N,N',N'-tetramethylthiourea. *Toxicology* 217(2-3), 169-175.
- Graham and Hansen (1972). Ethylenethiourea evaluation Effects of short term administration of ethylenethiourea upon thyroid function of the rat *Bull. Envir. Contam. Toxicol.* 7 (1) 19-25.
- Graham SL, Davis KJ, Hansen WH, and Graham CH (1975). Effects of prolonged ethylene thiourea ingestion on the thyroid of the rat. *Food Cosmet. Toxicol.* 13(5), 493-499.
- Hard GC (1998). Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. *Environ Health Perspect* 106, 427-436.
- Hass U, Boberg J, Christiansen S, Jacobsen PR, Vinggaard AM, Taxvig C, Poulsen ME, Herrmann SS, Jensen BH, Petersen A, Clemmensen LH and Axelstad M (2012). Adverse effects on sexual development in rat offspring after low dose exposure to a mixture of endocrine disrupting pesticides. *Reprod. Toxicol* 34(2), 261-274.
- Hill RN, Crisp TM, Hurley PM, Rosenthal SL & Singh DV (1998). Risk assessment of thyroid follicular cell tumors. *Environ Health Perspect* 106, 447-457.
- Horing *et al* (1990). Zero threshold for antithyroid effects of mancozeb in rats *Beträge aus toxikologischer forshung* (51-57), Research institute for hygiene and microbiology, Bad Elster, Germany.
- Howdeshell KL (2002). A model of the development of the brain as a construct of the thyroid system. *Environ Health Perspect* 110 Suppl. 3, 337-348.
- Hurley PM (1998). Mode of carcinogenic action of pesticides inducing thyroid follicular cell tumors in rodents. *Environ. Health Perspect.* 106(8), 437-445.
- IARC (1999). International Agency for Research on Cancer. In "Species differences in thyroid, kidney and urinary bladder carcinogenesis. IARC Scientific Publications Vol 147.
- IARC (2001). International Agency for Research on Cancer. In "Some thyrotropic agents. IARC Monograph Eval. Carcinogen. Risks Hum. Vol 79.
- Kjeldsen LS, Ghisari M and Bonefeld-Jorgensen EC (2013). Currently used pesticides and their mixtures affect the function of sex hormone receptors and aromatase enzyme activity. *Toxicol. Appl. Pharmacol.* 272(2), 453-464.

- Koukouritaki SB, Poch MT, Henderson MC, Siddens LK, Krueger SK, VanDyke JE, Williams DE, Pajewski NM, Wang T and Hines RN (2007). Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants. *J. Pharmacol. Exp. Ther.* 320(1), 266-273.
- Krueger SK, Siddens LK, Henderson MC, Andreasen EA, Tanguay RL, Pereira CB, Cabacungan ET, Hines RN, Ardlie KG and Williams DE (2005). Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics. *Pharmacogenet. Genomics* 15(4), 245-256.
- Kurtio P, Savolainen K, Tuominen R, Kosma VM, Naukkarinen A, Mannisto P and Collan Y (1986). Ethylenethiourea and nabam induced alterations of function and morphology of thyroid gland in rats. *Arch. Toxicol. Suppl* 9, 339-344.
- Leber, AP, Wilkinson, GE, Persing RL and Holzworth, DA (1978) Effects of feeding ethylenethiourea in the Rhesus monkey. Final report submitted to EPA by Battelle Laboratories, Columbus, Ohio, McClain RM (1995). Mechanistic considerations for the relevance of animal data on thyroid neoplasia to human risk assessment. *Mutat Res* 333, 131-142.
- McClain RM & Rice JM (1999). A mechanistic relationship between thyroid follicular cell tumours and hepatocellular neoplasms in rodents. *IARC Sci Publ* 61-68.
- Miller MD, Crofton KM, Rice DC and Zoeller RT (2009). Thyroid-disrupting chemicals: interpreting upstream biomarkers of adverse outcomes. *Environ Health Perspect.* 117(7), 1033-1041.
- Nebbia C and Fink-Gremmels J (1996). Acute effects of low doses of zineb and ethylenethiourea on thyroid function in the male rat. *Bull. Environ. Contam Toxicol.* 56(5), 847-852.
- NTP (1992). Toxicology and carcinogenesis studies of ethylenethiourea in F344/N rats and B6C3F1 mice. Report TR 388.
- OECD (2002). Guidance notes for analysis and evaluation of chronic toxicity and carcinogenicity studies. OECD Environment, Health and Safety Publications. Series on Testing and Assessment No. 35 and Series on Pesticides No. 14. Environment Directorate, Joint Meeting of the Chemicals Committee and the Working Party on Chemicals, Pesticides and Biotechnology. ENV/JM/MONO(2002)19.
- O'Neil W & Marshall W (1984). Goitrogenic effects of ethylenethiourea on rat thyroid. *Pesticide Biochemistry and Physiology*, 21,92-101.
- Paul KB, Hedge JM, Macherla C, Filer DL, Burgess E, Simmons SO, Crofton KM, and Hornung MW (2013). Cross-species analysis of thyroperoxidase inhibition by xenobiotics demonstrates conservation of response between pig and rat. *Toxicology* 312C, 97-107.
- Ruddick J A, Newsome WH, and Iverson F (1977). A comparison of the distribution, metabolism and excretion of ethylenethiourea in the pregnant mouse and rat. *Teratology* 16(2), 159-162
- Taurog A (1976). The mechanism of action of the thiourea ethylene antithyroid drugs. *Endocrinology* 98(4), 1031-1046.
- Taurog A, Dorris ML (1989). A reexamination of the proposed inactivation of thyroid peroxidase in the rat thyroid by propylthiouracil. *Endocrinology* 124(6), 3038-3042.
- Yamasaki K, Tago Y, Nagai K, Sawaki M, Noda S, and Takatsuki M (2002). Comparison of toxicity studies based on the draft protocol for the 'Enhanced OECD Test Guideline no. 407' and the research protocol of 'Pubertal Development and Thyroid Function in Immature Male Rats' with 6-n-propyl-2-thiouracil. *Arch. Toxicol* 76(9), 495-501.
- Zoeller RT (2007). Environmental chemicals impacting the thyroid: targets and consequences. *Thyroid* 17, 811-817.

## **ANNEX II: EVALUATION OF DEVELOPMENTAL TOXICITY, POSSIBLE MODES OF ACTION AND RELEVANCE TO HUMANS**

### **Introduction and objectives**

In this annex the developmental toxicity studies on mancozeb are discussed in more detail with respect to toxicokinetic factors controlling levels of its metabolite ETU; possible modes of action (MoA) and the relevance of these for humans. ETU is teratogenic in rats but not in rabbits and therefore this raises questions about human relevance; for example, are humans more similar to rats or to rabbits; how much exposure to mancozeb has to occur to reach the lowest adverse effect level (LOAEL) for ETU in sensitive species? ETU inhibits the formation of thyroid hormones but there is evidence that ETU-induced teratogenicity is not caused by thyroid hormone modulation. The objective of this annex is to provide further detail and discussion in order to help resolve these issues.

### **Mancozeb and developmental toxicity in non-human, mammalian species**

#### **Regulatory background**

Mancozeb has been the subject of several regulatory guideline developmental toxicity studies. In 1980, a rat developmental toxicity reported by Anonymous, investigated a dose level of 512 mg/kg bw/day when given to pregnant rats on gestation days 6-15. This dose level of mancozeb was in excess of the maximum tolerated dose inducing maternal death, severe weight loss, embryo-foetal death and foetal malformations. The malformations were attributed to ETU and not to maternal toxicity because of the consistency of the observations with the ETU positive control group (50 mg/kg bw/day) in the same study. The malformations were also consistent with the earlier studies of ETU reported by Khera (1973)<sup>#</sup>. On the basis of the work of Khera (1973) the no observed effect level of ETU for malformation in the rat was indicated to be 5 mg/kg bw/day. A more recent study (Saillenfait, 1991) indicated that the no observed effect level for malformation in the rat was 15 mg/kg bw/day.

<sup>#</sup>N.B. Although the data reported by Khera in 1973 is relevant in the context of foetal malformation, it should be noted that the studies predate GLP, predate formal test guidelines and the study designs are not consistent with current OECD/EPA test guidelines. For these reasons and also the lack of reported detail, the publication has not been summarised in this document.

In 1993, a Specialised Expert Group reviewed the data from the following studies on the prenatal developmental toxicity of mancozeb in rats and rabbits

- Larsson, 1976 (rat – non-guideline publication, not summarised in this document nor included in the DAR)
- Anonymous, 1980 (rat)
- Anonymous, 1987b (rabbit).

The Specialised Expert Group acknowledged that the foetal malformations present in rats were "...attributed to the formation of ETU", a metabolite of all EBDC fungicides, but as "... ETU levels produced by the parent compound would not reach the threshold for teratogenic effects" classification was not justified.

The Draft Assessment Report of mancozeb was prepared by Italy (2000). The review of developmental toxicity was based on the following studies:

- Anonymous, 1980 (rat)
- Anonymous, 1988c (rat)
- Anonymous, 1999b (rat)
- Anonymous, 1987b (rabbit)
- Anonymous, 1991b (rabbit).

In Addendum 1 to the DAR (Addendum 1 Draft Assessment Report and Proposed Decision of Italy prepared in the context of the possible inclusion of mancozeb in Annex I of Council Directive 91/414/EEC (2002)) it was concluded that "mancozeb is not a teratogenic agent".

*"This evaluation of the mancozeb developmental toxicology database clearly demonstrates that:*

*the maternal NOEL reported in the Anonymous rat development study is not consistent with the toxicity profile of mancozeb and on the basis of the questionable validity, this study should not be incorporated into the developmental hazard evaluation of mancozeb*

- *developmental toxicity associated with mancozeb in the rat is only observed at maternally toxic dosages*
- *the highest reported NOEL for maternal toxicity is 55 mg/kg bw/day for rabbits and 60 mg/kg bw/day for rats (discounting the Anonymous findings)*
- *the highest reported NOEL for embryotoxicity/teratogenicity is 100 mg/kg bw/day for rabbits and 128 mg/kg bw/day for rats*

*As stated in EC Council Directive 67/548/ECC, the classification of a substance as a possible risk of harm to the unborn child (R63) is based on the following criteria:*

- *results in appropriate animal studies which provide sufficient evidence to cause a strong suspicion of developmental toxicity in the absence of signs of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not a secondary non-specific consequence of the other toxic effects, but where the evidence is insufficient place the substance in Category 2 (R61 May cause harm to the unborn child).*

*Findings from the valid, well-conducted developmental studies showed no evidence to cause a suspicion of developmental toxicity in the absence of marked maternal toxicity. Thus, the criteria for R63 are not met.*

*On the basis of the current classification criteria and the results of the developmental toxicity database evaluation, mancozeb should not be classified as a developmental toxicant.”*

Mancozeb was reconsidered for health effects at the Classification and Labelling Working Group Meeting in January 2003. The question of classification for developmental effects (i.e., R63) based on foetal malformations such as cleft palate was discussed briefly and deferred to the next meeting (ECBI/52/03). Industry's position against the need for R63 was presented in ECBI/89/02 Add 11. In the January 2003 Follow-up Period, Greece submitted a position paper (ECBI/89/02 Add. 3) proposing R63 based on teratogenic and foetotoxic potential in rats from the studies of Anonymous (1980) and Anonymous (1988c). At the Working Group meeting in September 2003 the decision was again deferred to allow the meeting to revisit the opinion of the Specialised Experts, who had decided against the need for R63 in 1993. In 2005, the Specialised Experts were asked to evaluate any new studies since the 1993 meeting and to consider whether this additional data would change the conclusion they had reached. It was recognised that a few new studies had been reported and that these supported the recommendation of the Specialised Experts 1993 meeting as no developmental effects were observed as also stated in the 91/414/EEC (DAR) monograph. The Specialised Expert Group was referred to the guidance produced by an expert group on parental toxicity (ECBI/30/04) on how to evaluate maternal toxicity. This guidance clarified how to evaluate developmental effects observed in the presence of maternal toxicity. It was pointed out that a key issue was the highest dose tested because it caused unacceptable maternal toxicity (death, paralysis, suffering, total litter loss). As such toxicity contravened Annex V test guideline requirements, the highest dose (512 mg/kg bw/day) was considered irrelevant for decision-making purposes. Nevertheless, the developmental toxicity studies with mancozeb were considered to provide clear evidence of the mechanistic link to ETU and were therefore relevant to the assessment of classification. The consensus opinion of the Specialised Expert Group was that classification of mancozeb for developmental toxicity was warranted. There was an equal distribution of opinion towards classification for Repr. Cat. 2, R 61 and Repr. Cat. 3, R 63. The Specialised Expert Group advised the evaluation of developmental neurotoxicity (OECD TG 426) for ethylenebis(dithiocarbamates) (EBDC) to address the concern about thyroid effects and brain development (ECBI/58/05).

At the Technical Committee meeting on classification and labelling (2006) the decision was taken that mancozeb should be classified as a Category 3 developmental toxin and given the R63 risk phrase – “Possible risk of harm to the unborn child”.

**Response to the regulatory evaluation of mancozeb**

The issue of developmental toxicity in the rat and the concerns of the Specialised Expert Group (2006) have been readdressed by the EU Mancozeb Task Force.

**Developmental neurotoxicity**

The concern for developmental neurotoxicity (DNT) was addressed by conducting a guideline and GLP compliant developmental neurotoxicity study on mancozeb in rats using the dietary route of exposure. The preliminary to this study confirmed that mancozeb (and ETU) was present in maternal and foetal blood and in milk (Anonymous, 2008b). In the main study, no evidence of developmental neurotoxicity was observed up to the highest dose tested (30 mg/kg bw/day) (Anonymous, 2008c). A lack of behavioural effects in offspring of female rats exposed (by oral gavage) to mancozeb during pregnancy and lactation was also reported in a literature study (Axelstad *et al*, 2011). In this study, rats were exposed to mancozeb at doses up to 150 mg/kg bw/day from gestation day 7 until lactation day 14. Despite significant toxicity in dams characterised by body weight loss and hind limb paralysis, and maternal hypothyroxinemia (resulting in reduction of the highest dose to 100 mg/kg bw/day) no effects were seen in offspring behaviour (spatial learning in a radial arm maze, motor activity measurements and acoustic startle response). In addition, an extended one generation reproduction toxicity study has been conducted on ETU using the dietary route of exposure (Anonymous, 2013). There were no effects on neurobehavioural endpoints or neuropathology at doses up to 10 mg/kg bw/day. A small decrease in brain weight and “size” was noted but was considered to be a consequence of effects on body weight, reflecting reduced growth during late lactation, juvenile and early adult periods and not evidence of specific developmental neurotoxicity.

The detailed results of the following studies to investigate DNT (conducted since the 2006 decision) are provided in the main document (Section 10.8).

- Mancozeb: A dietary exposure and dose range finding developmental neurotoxicity study in rats (Anonymous, 2008b) (reported in Addendum 4 to DAR 2000).
- Mancozeb: An oral (dietary) developmental neurotoxicity study in rats (Anonymous, 2008c) (reported in Addendum 4 to DAR 2000).
- ETU: An F1 Extended One Generation Reproductive Toxicity in Crl:CD(SD) rats (Anonymous, 2013) (required by US EPA).

**Developmental toxicity (morphological)**

The strategy adopted to address the concerns for potential developmental toxicity and morphological effects in rats was to conduct a GLP compliant developmental toxicity study to current OECD test guidelines with dose levels selected to meet test guideline and animal welfare requirements. To better understand the quantitative relationship between mancozeb and ETU production, initial studies were undertaken where mancozeb and ETU levels in maternal and foetal blood samples were analysed as part of dose range finding studies (Anonymous, 2015a & b). To investigate the dose-response of ETU and foetal malformation, a developmental toxicity study of ETU to current OECD test guidelines was undertaken (Anonymous, 2015d). This study also included a satellite group so that blood samples could be taken. ETU concentrations in maternal and foetal blood samples were then determined in order to establish blood levels of ETU at teratogenic and non-teratogenic doses of ETU. In addition, new studies on ETU in the rabbit have been conducted under REACh, legislation.

The detailed results of the following additional studies to investigate developmental toxicity (conducted since the 2006 decision) are provided in the main document (Section 10.8).

- Mancozeb: A 14-day oral (gavage) tolerability study in non-pregnant Sprague Dawley rats (Anonymous, 2015b).
- Mancozeb: A preliminary oral (gavage) study in pregnant Sprague Dawley rats (Anonymous, 2015c).
- Mancozeb: An oral (gavage) prenatal developmental toxicity study in Sprague Dawley rats (Anonymous, 2015d)

- ETU: A 14-day tolerability study in non-pregnant rabbits (Anonymous, 2010d) (required under REACH, legislation).
- ETU: Pilot developmental toxicity study in rabbits (Anonymous, 2010b) (required under REACH, legislation).
- ETU: Developmental toxicity study in rabbits (Anonymous, 2010c) (required under REACH, legislation).
- ETU: An oral (gavage) prenatal developmental toxicity study in Sprague Dawley rats (Anonymous, 2015d).

The key findings in context with the toxicokinetics are presented below.

### **The quantitative relationship between mancozeb and ETU production and its relevance for developmental toxicity**

Early studies established that in rats, mancozeb is rapidly absorbed, metabolised and eliminated, following oral administration. Approximately 50% of mancozeb is absorbed and conversion of mancozeb to ETU is approximately 7% (by weight). ETU has an elimination half-life of 4-8 hours (Anonymous, 1986f; Anonymous, 1986g). The dietary exposure and dose range finding developmental neurotoxicity study in rats (Anonymous, 2008b) demonstrated that maternal dosing with mancozeb results in both maternal and foetal exposure. Neonatal pups are exposed to mancozeb secreted in milk. The toxicokinetics of ETU have also been studied in rats. When administered over a wide range of dose levels, absorption and elimination are rapid. ETU is predominantly eliminated (unchanged) in urine. Maternal dosing with ETU results in foetal exposure to ETU (Kato *et al*, 1976; Ruddick *et al*, 1977; Anonymous, 1987f).

While the early studies provide valuable information regarding the fate of mancozeb and ETU in rats, they rely largely on measurements made using non-specific endpoints i.e. radioactivity or a common moiety method measuring carbon disulphide derived from a range of sulphur containing metabolites and endogenous substances. In the new studies where the toxicokinetics of ETU and mancozeb have been determined as part of the investigation of the developmental toxicity of both substances in rats, a sensitive, specific LC-MS-MS analytical method for the determination of mancozeb and ETU in rat plasma was developed and validated. Use of this method ensured that only the analytes of interest were measured.

The key study details are as follows:

#### **ETU: An oral (gavage) prenatal developmental toxicity study in Sprague Dawley rats (Anonymous, 2015d)**

ETU was administered orally by gavage to groups of 24 bred female Crl:CD(SD) rats once daily from GD 6 through GD 19. Dosage levels were 0, 2.5, 5, 15 and 30 mg/kg bw/day. Clinical observations, body weights, and food consumption were recorded at appropriate intervals. On gestation day 20, a laparohysterectomy was performed and the uteri, placentae, and ovaries were examined. Maternal blood samples for toxicokinetic evaluation were collected from 4 confirmed pregnant females/group and foetal blood samples were collected from their litters on gestation day 20. All foetuses were weighed, sexed, and examined for external, visceral, and skeletal malformations and developmental variations.


Based on the absence of adverse maternal effects, a dosage level of 30 mg/kg bw/day was considered to be the NOAEL for maternal toxicity. Developmental effects were noted at 30 mg/kg bw/day, as evidenced by lower mean foetal weights and foetal malformations and developmental variations. Developmental effects were also noted at 15 mg/kg bw/day, but were limited to hydrocephaly in 2 litters. No test substance-related effects were noted at 2.5 and 5 mg/kg bw/day. Based on these results, a dosage level of 5 mg/kg bw/day was considered to be the NOAEL for embryo/foetal development, with a LOAEL of 15 mg/kg bw/day.

Blood concentrations of ETU on gestation day 20 were similar in maternal and foetal rats. ETU blood concentrations at 15 and 30 mg/kg bw/day were 1280 and 2940 ng/mL, respectively, in maternal rats and 1170 and 2790 ng/mL, respectively, in foetuses. Plasma concentrations of ETU in both maternal and foetal plasma increased approximately linearly with maternal dose; foetal exposure was similar to that of the dams with maternal: foetal concentration ratios of 1.1 to 1.2 (Table A2-1, Figure A2-1).

**Table A2-1: Mean plasma concentrations of ETU in maternal and foetal plasma on GD 20 after oral (gavage) administration of ETU**

| Dose<br>(mg ETU/kg/day) | Maternal concentration<br>(ng/mL) |      | Foetal concentration<br>(ng/mL) |      | Maternal/foetal ratio |
|-------------------------|-----------------------------------|------|---------------------------------|------|-----------------------|
|                         | Mean*                             | SD   | Mean*                           | SD   |                       |
| 0                       | <LOQ                              |      | <LOQ                            |      |                       |
| 2.5                     | 124* <sup>3</sup>                 | 68.7 | 113* <sup>3</sup>               | 59.5 | 1.1                   |
| 5                       | 355                               | 88.1 | 299                             | 66.9 | 1.2                   |
| 15                      | 1280                              | 318  | 1170                            | 221  | 1.1                   |
| 30                      | 2940                              | 742  | 2790                            | 694  | 1.1                   |

\* - N=4 except where designated as \*<sup>N</sup>. <LOQ - concentration below the limit of quantitation (20 ng/mL).

**Figure A2-1: Dose response for ETU in maternal and foetal plasma on GD 20 after oral administration of ETU**

#### **Mancozeb: A 14-day oral (gavage) tolerability study in non pregnant Sprague Dawley rats (Anonymous, 2015b)**


Mancozeb was orally administered to non pregnant rats at doses of 60, 120, 180, 240, and 300 mg/kg bw/day for 14 days. Rat plasma concentrations for mancozeb ranged from BLQ < (10.0) to 213 ng/mL and for ETU ranged from BLQ < (10.0) to 1950 ng/mL, 6 hours after the final dose administration. Sporadic body weight losses occurred throughout the treatment period at dosage levels  $\geq 180$  mg/kg bw/day. The sporadic body weight losses, which occurred in the absence of reduced food consumption, produced lower (8.3%, 6.0%, and 9.8%) mean body weights at 180, 240, and 300 mg/kg bw/day, respectively, on study day 14 compared to the control group value. There were no effects on survival and macroscopic findings at any dosage level. Dosage levels of 60 and 120 mg/kg bw/day were considered to be well tolerated, based on the lack of toxicologically significant effects. Based on these results, dosage levels of 80, 120, and 160 mg/kg bw/day were selected for a preliminary oral (gavage) study of mancozeb in pregnant Crl:CD(SD) rats.

Although group sizes were small and concentrations variable, trend lines through the individual values show a clear dose response for exposure to ETU following administration of mancozeb. Mancozeb concentrations were significantly lower than those for ETU and represent the residue of rapid metabolism of mancozeb to ETU (Table A2-2, Figure A2-2).

**Table A2-2: Plasma concentrations of mancozeb and ETU approximately 6 hours after the final dose of mancozeb**

| Dose<br>(mg mancozeb/kg bw/day) | Mancozeb concentration range<br>(ng/mL) | ETU concentration range<br>(ng/mL) |
|---------------------------------|---|------------------------------------|
| 0                               | <LOQ                                    | <LOQ                               |
| 60                              | <LOQ - 20.9                             | 309 - 813                          |
| 120                             | 46.5 - 100                              | 897 - 975                          |
| 180                             | <LOQ - 87.6                             | 876 - 1100                         |
| 240                             | 107 - 203                               | 1220 - 1950                        |
| 300                             | 85.3 - 144                              | 1550 - 1780                        |

<LOQ - concentration below the limit of quantitation (20 ng/mL).

**Figure A2-2: Dose response for mancozeb and ETU in plasma at approximately 6 hours after the final dose of mancozeb**

**Mancozeb: A preliminary oral (gavage) study in pregnant Sprague Dawley rats (Anonymous, 2015c)**

Mancozeb was administered orally by gavage to groups of 23 bred female Crl:CD(SD) rats once daily from GD 6 through to GD 19. Dosage levels were 0, 80, 120, and 160 mg/kg bw/day. Clinical observations, body weights, and food consumption were recorded at appropriate intervals. Blood samples for toxicokinetic analysis were collected from 3 maternal rats/group at 0 (pre-dose), 2, 4, 6, 12, and 24 hours after dose administration on gestation day 19; foetal blood samples were collected from each viable foetus immediately following maternal blood collection. Plasma samples collected from all maternal animals on gestation day 19 at the 2-, 4-, and 6-hour post-dose time points were also analysed for thyroxine (T<sub>4</sub>) levels. All maternal animals utilized for toxicokinetic blood collection at the 0 (pre-dose), 2-, 4-, 6-, and 12-hour time points were euthanized following blood collection on gestation day 19, and pregnancy status was determined for each female. On gestation day 20, a laparohysterectomy was performed on each female not utilized for toxicokinetic blood collection, as well as the females selected for the 24 hour toxicokinetic blood collection. The uteri, placentae, and ovaries were examined. The foetuses were weighed, sexed, and examined for external malformations and developmental variations.

Maternal toxicity was observed at a dosage level of 160 mg/kg bw/day as evidenced by lower mean body weight gains and corresponding reduced mean food consumption compared to the control group, which resulted in a slightly lower mean body weight on gestation day 20. There were no test substance-related effects on maternal survival, clinical condition, or macroscopic findings, or on intrauterine growth, survival, and external foetal morphology at any dosage level. Based on these results, dosage levels of 10, 40, and 160 mg/kg bw/day were selected for a definitive prenatal development toxicity study of mancozeb administered orally, by gavage, to pregnant CrI:CD(SD) rats.

The results for mancozeb from the 24 hour toxicokinetic blood collection are shown in Table A2-3:

**Table A2-3: Mean plasma concentrations (ng/mL) of mancozeb in maternal and foetal plasma on GD19 after oral (gavage) administration of mancozeb**

| Dose                              | 80 mg mancozeb/kg bw/day |      | 120 mg mancozeb/kg bw/day |    | 160 mg mancozeb/kg bw/day |      |
|-----------------------------------|--------------------------|------|---------------------------|----|---------------------------|------|
|                                   | Mean*                    | SD   | Mean*                     | SD | Mean*                     | SD   |
| <b>Maternal plasma</b>            |                          |      |                           |    |                           |      |
| Time after the final dose (hours) |                          |      |                           |    |                           |      |
| 0                                 | <LOQ                     | NA   | <LOQ                      | NA | <LOQ                      | NA   |
| 2                                 | 61.0                     | 72.0 | 97.9* <sup>2</sup>        | NA | 119                       | 93.2 |
| 4                                 | 74.2                     | 35.4 | 81.6* <sup>2</sup>        | NA | 96.1                      | 35.6 |
| 6                                 | 26.4                     | 24.1 | <LOQ* <sup>2</sup>        | NA | 42.0                      | 10.9 |
| 12                                | <LOQ                     | NA   | <LOQ* <sup>2</sup>        | NA | <LOQ                      | NA   |
| 24                                | <LOQ                     | NA   | <LOQ                      | NA | <LOQ                      | NA   |
| <b>Foetal plasma</b>              |                          |      |                           |    |                           |      |
| 0                                 | <LOQ                     | NA   | <LOQ                      | NA | <LOQ                      | NA   |
| 2                                 | 25.9* <sup>1</sup>       | 44.8 | <LOQ                      | NA | <LOQ                      | NA   |
| 4                                 | <LOQ                     | NA   | <LOQ                      | NA | <LOQ                      | NA   |
| 6                                 | <LOQ                     | NA   | <LOQ                      | NA | <LOQ                      | NA   |
| 12                                | <LOQ                     | NA   | <LOQ                      | NA | <LOQ                      | NA   |
| 24                                | <LOQ                     | NA   | <LOQ                      | NA | <LOQ                      | NA   |

\* - N=3 except where designated as \*<sup>N</sup>. <LOQ - concentration below the limit of quantitation (20 ng/mL). NA - Not applicable.

As observed in the previous study, concentrations of mancozeb in both maternal and foetal samples were low and variable. Peak mean concentrations in maternal plasma were observed between 2 and 4 hours after dosing indicating rapid absorption; concentrations had declined to <LOQ (20 ng/mL) by 12 hours after dosing. Concentrations of mancozeb in foetal plasma were generally <LOQ.


Concentrations of ETU in both maternal and foetal plasma attained peak values by 6 hours after dosing with mancozeb indicating that once absorbed, mancozeb is rapidly metabolised to ETU (Table A2-4, Figure A2-3). Maternal and foetal plasma concentration versus time curves for ETU were very similar; comparison of the dose responses for ETU in maternal and foetal plasma based on AUC<sub>(0-24)</sub> and C<sub>max</sub> values demonstrated that exposure increased approximately in proportion with dose and that there was little difference in exposure between the dams and foetus (Figure A2-4).

**Table A2-4: Mean plasma concentrations (ng/mL) and toxicokinetic parameters for ETU in maternal and foetal plasma on GD 19 after oral (gavage) administration of mancozeb**


| Dose                              | 80 mg mancozeb/kg bw/day |      | 120 mg mancozeb/kg bw/day |      | 160 mg mancozeb/kg bw/day |      |
|-----------------------------------|--------------------------|------|---------------------------|------|---------------------------|------|
| Time after the final dose (hours) | Mean*                    | SD   | Mean*                     | SD   | Mean*                     | SD   |
| <b>Maternal plasma</b>            |                          |      |                           |      |                           |      |
| 0                                 | 147                      | 57.9 | 272                       | 97.3 | 214                       | 83.3 |
| 2                                 | 686                      | 120  | 1030                      | 201  | 1100                      | 101  |
| 4                                 | 761                      | 88.8 | 1020                      | 102  | 1400                      | 126  |
| 6                                 | 973                      | 56.1 | 1470                      | 245  | 1720                      | 156  |
| 12                                | 867                      | 183  | 801                       | 88.6 | 1160                      | 332  |
| 24                                | 315                      | 37.0 | 356                       | 101  | 548                       | 146  |
| C <sub>max</sub> (ng/mL)          | 973                      |      | 1470                      |      | 1720                      |      |
| T <sub>max</sub> (h)              | 6                        |      | 6                         |      | 6                         |      |
| AUC <sub>(0-24)</sub> (ng.h/mL)   | 16600                    |      | 19600                     |      | 25800                     |      |
|                                   |                          |      |                           |      |                           |      |
| Dose                              | 80 mg mancozeb/kg bw/day |      | 120 mg mancozeb/kg bw/day |      | 160 mg mancozeb/kg bw/day |      |
| Time after the final dose (hours) | Mean*                    | SD   | Mean*                     | SD   | Mean*                     | SD   |
| <b>Foetal plasma</b>              |                          |      |                           |      |                           |      |
| 0                                 | 139                      | 90.6 | 266                       | 108  | 163                       | 69.2 |
| 2                                 | 613                      | 90.6 | 938                       | 154  | 963                       | 45.1 |
| 4                                 | 685                      | 104  | 980                       | 157  | 1250                      | 162  |
| 6                                 | 883                      | 20.8 | 1290                      | 304  | 1470                      | 57.5 |
| 12                                | 806                      | 204  | 776                       | 41.4 | 1190                      | 289  |
| 24                                | 304                      | 41.2 | 337                       | 101  | 459                       | 131  |
| C <sub>max</sub> (ng/mL)          | 883                      |      | 1290                      |      | 1470                      |      |
| T <sub>max</sub> (h)              | 6                        |      | 6                         |      | 6                         |      |
| AUC <sub>(0-24)</sub> (ng.h/mL)   | 15300                    |      | 18300                     |      | 23900                     |      |

\* - N=3.

**Figure A2-3: Mean plasma concentrations versus time curves for ETU in maternal and foetal plasma on GD 19 after oral administration of mancozeb**



**Figure A2-4: Dose response (AUC and  $C_{max}$ ) for ETU in maternal and foetal plasma on GD 19 after oral administration of mancozeb**



**Mancozeb: An oral (gavage) prenatal developmental toxicity study in Sprague Dawley rats (Anonymous, 2015d)**

Mancozeb was administered orally by gavage to groups of 25 bred female Crl:CD(SD) rats once daily from GD 6 through to GD 19. Dosage levels were 0, 10, 40, and 160 mg/kg bw/day. Clinical observations, body weights, and food consumption were recorded at appropriate intervals. On gestation day 20, a laparohysterectomy was performed and the uteri, placentae, and ovaries examined. The foetuses were weighed, sexed, and examined for external, visceral, and skeletal malformations and developmental variations.

Based on test substance-related effects on mean body weight gain and food consumption at 160 mg/kg bw/day, a dosage level of 40 mg/kg bw/day was considered to be the no observed adverse effect level (NOAEL) for maternal toxicity. No test substance related effects on intrauterine growth and survival or foetal morphology were noted at any dosage level. Therefore, a dosage level of 160 mg/kg bw/day, the highest dosage level tested, was considered to be the NOAEL for embryo/foetal development when

mancozeb was administered orally by gavage to bred Crl:CD(SD) rats. There was no evidence of teratogenicity due to mancozeb in this study.

Measurements made in the previous studies provided the basis for an estimation of the dose levels of mancozeb necessary to produce peak concentrations of ETU equivalent to those likely to have been achieved following administration of ETU to pregnant rats at the NOEL (5 mg ETU/kg), LOAEL (15 mg ETU/kg) and effect (30 mg ETU/kg) doses.

Plasma concentration versus time data for ETU following administration of mancozeb was available over the range of doses from 80 to 160 mg mancozeb/kg; this was used to calculate the rate constants (k) for the decline in ETU concentrations at each dose levels, the mean, minimum and maximum values were determined.

| Dose (mg mancozeb/kg bw/day) | 80       | 120      | 160      |
|------------------------------|----------|----------|----------|
| k for ETU (h <sup>-1</sup> ) | 0.065684 | 0.077107 | 0.063419 |

|                 |          |
|-----------------|----------|
| Mean k value    | 0.068737 |
| Minimum k value | 0.063419 |
| Maximum k value | 0.077107 |

Measured maternal plasma concentrations of ETU at 24 hours after the final dose of ETU to pregnant rats were used along with the above values for k to estimate the maximum ETU concentrations at 6 hours after dosing (T<sub>max</sub>) using the relationship:

$$C_{6h} = C_{24h} \cdot e^{k \cdot 18}$$

| Dose (mg ETU/kg bw/day)             |           | 2.5 | 5    | 15   | 30    |
|-------------------------------------|-----------|-----|------|------|-------|
| C <sub>24h</sub> (ng ETU/mL)        | measured  | 124 | 355  | 1280 | 2940  |
| C <sub>6h</sub> (ng ETU/mL) mean    | predicted | 427 | 1223 | 4411 | 10131 |
| C <sub>6h</sub> (ng ETU/mL) minimum |           | 388 | 1112 | 4008 | 9207  |
| C <sub>6h</sub> (ng ETU/mL) maximum |           | 497 | 1422 | 5128 | 11779 |

Linear regression lines were fitted through the C<sub>6h</sub> versus dose data and the parameters used to calculate the mean dose of mancozeb required to give concentrations of ETU equal to those at the NOEL (5 mg ETU/kg/day), LOAEL (15 mg ETU/kg/day) and effect (30 mg ETU/kg/day); an estimate of the uncertainty of the value was made by estimating the maximum and minimum values.

|  | NOEL<br>(5mg ETU/kg bw/day) | LOAEL<br>(15 mg ETU/kg bw/day) | Effect<br>(30 mg ETU/kg bw/day) |
|--|-----------------------------|--------------------------------|---------------------------------|
| Mean dose<br>(mg mancozeb/kg/day)      | 143                         | 429                            | 859                             |
| Range of doses<br>(mg mancozeb/kg/day) | 130 - 166                   | 390 - 499                      | 780 - 998                       |

These values indicate that doses of mancozeb up to those that caused maternal toxicity (160 mg/kg bw/day) in the oral (gavage) prenatal developmental toxicity study of mancozeb in Sprague Dawley rats (Anonymous, 2015d) result in peak plasma concentrations of ETU lower than those seen following

administration of ETU at the NOAEL (5 mg/kg), LOAEL (15 mg/kg) and effect level (30 mg/kg) for developmental toxicity.

### **Discussion**

The potential of mancozeb to induce reproductive and developmental toxicity has been thoroughly investigated in regulatory compliant studies.

### **Reproductive toxicity studies**

These comprise:

- A two generation oral (dietary) reproduction toxicity study in rats (Anonymous, 1988b).
- A two generation oral (dietary) reproduction toxicity study in rats (Anonymous, 1992c).
- An oral (dietary) developmental neurotoxicity study in rats (Anonymous, 2008c)

The results of the two reproduction studies are in agreement and confirm that no reproductive or developmental toxicity due to mancozeb was observed at the highest dose level tested, which induced systemic toxicity. These studies clearly demonstrate that mancozeb does not induce reproductive toxicity and therefore requires no classification under CLP.

In addition, the main metabolite of mancozeb, ETU, has been thoroughly evaluated in a recent, regulatory compliant, extended one generation reproductive toxicity study (OECD TG 443) (Anonymous, 2013). The results of this evaluation confirmed that there was no evidence of ETU-related reproductive toxicity or of effects on the estrogen- or androgen-related endocrine pathways at any dose of ETU. No effects on neurobehavioral endpoints were detected at any dose of ETU, despite exposures during critical windows of development.

Neither mancozeb nor ETU induce reproductive toxicity.

### **Developmental toxicity studies**

The main metabolite of mancozeb, ETU is a known teratogenic agent in rats. The relevant, regulatory compliant studies comprise:

- Mancozeb: oral (gavage) teratology study in the rat (Anonymous, 1988c)
- Mancozeb: oral (gavage) prenatal developmental toxicity study in the rat (Anonymous, 2015d)
- Mancozeb: oral (gavage) developmental toxicity study in rabbits (Anonymous, 1987b)
- Mancozeb: oral (gavage) teratogenicity study in the rabbit (Anonymous, 1991b)
- ETU: oral (gavage) prenatal developmental toxicity study in the rat (Anonymous, 2015a)
- ETU: oral (gavage) developmental toxicity study in rabbits (Anonymous, 2010c)

With respect to the evaluations of mancozeb in the rat, it is recognised that the teratogenicity study of Anonymous (1980) has been the focus of regulatory debate and that the results should not be ignored. However, they should be considered in context. It is recognised that this study (Anonymous, 1980) pre-dates GLP, the maternal data are inappropriately presented and most importantly, the highest dose tested exceeded the maximum tolerated dose by causing unacceptable maternal toxicity (death, paralysis, suffering, total litter loss). As the severe toxicity contravened Annex V test guideline requirements, the highest dose (512 mg/kg bw/day) should be regarded as irrelevant for decision-making purposes of the potential of mancozeb to induce developmental toxicity. Nevertheless, the results of this and other studies (Anonymous, 1988c; Anonymous, 2015d & a) demonstrate that the foetal malformations observed by Anonymous (1980) were totally attributable to the production of a teratogenic dose of ETU.

The prenatal developmental toxicity of ETU in the rat (Anonymous, 2015a) clearly identifies 5 mg/kg bw/day as a non-teratogenic dose. This result is entirely consistent with the results of studies published in the literature. Anonymous (2015a) also identified 15 mg/kg bw/day as a LOEL, causing a minimal teratogenic response, whilst 30 mg/kg bw/day was well within the teratogenic dose range. The mean doses of mancozeb calculated to produce blood levels of ETU equivalent to dosing ETU at 5, 15 and 30 mg/kg bw/day were 143 (range 130-166), 429 (range 390-499) and 859 (range 780-998) mg/kg bw/day

respectively. Consequently, when mancozeb is administered to rats at a dose that is maternally toxic but does not exceed the maximum tolerated dose (160 mg/kg bw/day), insufficient ETU is generated to produce teratogenicity. Therefore, administration of mancozeb during organogenesis, at doses of 360 mg/kg bw/day (Anonymous, 1988c), 160 mg/kg bw/day (Anonymous, 2015c) or 128 mg/kg bw/day (Anonymous, 1980) did not induce foetal malformations nor generate a teratogenic dose of ETU. It should be noted that 360 mg/kg bw/day (Anonymous, 1988c) was not in excess of, but was close to, a maximum tolerated dose; slight paralysis of the hind limbs was induced in 5/25 females with one severely affected animal killed in extremis.

The highest dose of 160 mg mancozeb/kg bw/day was selected as an appropriate dose level for administration to the pregnant rat in the definitive, GLP, test guideline compliant, prenatal developmental toxicity study (Anonymous, 2015d). The dose, based on maternal toxicity, was within the range calculated to produce non-teratogenic levels of ETU. This dose of mancozeb did not impair foetal development in the rat. Therefore, 160 mg/kg bw/day, was the NOEL of mancozeb for embryo/foetal development in the rat.

The prenatal developmental toxicity of mancozeb and of ETU have also been evaluated in the rabbit. No teratogenicity was observed for either substance even in the presence of severe maternal toxicity. Mancozeb at  $\geq 80$  mg/kg bw/day was in excess of the maximum dose that could be tolerated by the pregnant dams (Anonymous, 1987b and Anonymous, 1991b). The NOEL of mancozeb for maternal toxicity was 55 mg/kg bw/day (Anonymous, 1991b). The NOEL of mancozeb for developmental toxicity was 100 mg/kg bw/day (Anonymous, 1991).

For ETU, maternal toxicity (reduced body weight gain) was observed at 15 and 50 mg/kg bw/day (Anonymous, 2010c). Mean foetal weight was reduced at 15 and 50 mg/kg bw/day but the 3% difference from control at 15 mg/kg bw/day was within the laboratories historical control range and therefore considered not to be an adverse effect. There were no ETU-related increases in the incidences of foetal malformations or variations at any dose level. The results demonstrate that ETU is not a developmental or teratogenic agent in the rabbit.

The results of three prenatal developmental toxicity studies confirm that mancozeb is not a developmental toxicant in the rabbit and that ETU is not teratogenic in this species.

In conclusion, in well conducted, GLP, test guideline compliant studies, mancozeb has been shown to have no adverse effect on sexual function and fertility in the rat. Similarly, no adverse effects on development of the offspring of rats and of rabbits and no effects on the neurological development of rat offspring were seen. No classification of mancozeb for reproductive toxicity is therefore warranted.

### **ETU-mediated developmental toxicity: Possible modes of action**

#### **A role for thyroid hormones?**

Thyroid hormones are essential for normal development and the maintenance of physiological functions in mammals. In young or foetal mammals, they also are essential for normal brain development and skeletal development. Cretinism, where affected individuals have severely stunted physical and mental growth, has long been known to be associated with severely reduced levels of thyroid hormones (Cranefield, 1962; Boyages and Halpern, 1993; Haddow *et al*, 1999).

Neurological effects in offspring exposed in utero have been described for several thyroid hormone perturbing chemicals including polychlorinated biphenyls (PCBs) (Crofton *et al*, 2000) and the pharmaceuticals, propylthiouracil (PTU) and methimazole (Axelstad *et al*, 2008; Brosvic *et al*, 2002; Shibutani *et al*, 2009; Mallela *et al*, 2014). In the case of PCBs, effects have been described in some human populations exposed via spillages as well as in experimental animal studies (WHO, 2012). However, no such human cases have been described for PTU and methimazole, which are administered to treat hyperthyroidemia. The difference may partly be attributable to different MoAs, or PCBs being sequestered in tissues and only slowly excreted compared to PTU and methimazole, and/or blood levels of these being controlled during treatment. Nevertheless, this example illustrates important differences in human risk for chemicals that have a similar key event of lowered plasma T4.

### **Potential for developmental neurotoxicity**

The two DNT studies conducted on mancozeb in rats (Anonymous, 2008b, c; Axelstad *et al*, 2011) provide valuable information on whether the effects on thyroid hormones result in neurological changes in offspring. Both studies were conducted at dose levels of mancozeb that were above the lowest effect level (LOEL) of 15 mg/kg bw/day, derived in Annex 1, for effects on thyroid hormones. The main study of Anonymous used a maximum dose of 30 mg/kg bw/day (dietary administration) whilst Axelstad used a maximum of 150 mg/kg bw/day (gavage administration). Both studies demonstrated that T4 was reduced in dams at these doses. In pups, Axelstad showed that T4 was unchanged at PND 17 and 24 whilst this was not determined in the study of Anonymous 2008b. In both studies mancozeb had no effect on neurological parameters in offspring including learning, memory and startle response. Brain morphometry and histopathology were also unaffected.

In the extended one generation reproduction toxicity study on ETU in rats (Anonymous, 2013), the maximum dose was 10 mg/kg bw/day (dietary administration) and was therefore conducted at doses of ETU that were above the derived LOEL for effects on thyroid hormones (1-2 mg/kg) (see Annex 1). Effects on T4 were seen in both dams and pups at 2 and 10 mg/kg bw/day. As with mancozeb, there were no effects on neurological parameters in offspring including learning, memory and brain histopathology. These results for ETU contrast with neurological effects seen in rats dosed (via oral gavage) to PTU at 0.8 mg/kg bw/day in a developmental neurotoxicity study (Axelstad *et al*, 2008).

These studies demonstrate that neither mancozeb nor ETU cause neurological damage in offspring, at doses where thyroid hormones are affected in dams. They indicate that at current exposure levels, babies and children exposed to mancozeb are at very low risk for neurotoxicological effects. To date, reviews of epidemiology literature have not indicated that EBDCs may cause neurodevelopmental problems in humans (Ntzani *et al*, 2013; WHO 2012).

### **Potential for developmental toxicity (morphological)**

ETU is developmentally toxic/teratogenic in the rat, causing malformations associated with neural tube development such as hydrocephaly and meningocele. Clear effects are seen at doses of 30 mg/kg bw/day and above with a NOAEL of 5 mg/kg bw/day (Anonymous, 2015d). Other species appear to be more resistant to the teratogenicity of ETU, with mice being largely unaffected at doses up to 800 mg/kg bw/day (Teramoto *et al*, 1978). Rabbits were also largely unaffected at doses up to 80 mg/kg bw/day (Khera, 1973) and no teratogenicity was observed in a recent guideline study of ETU in rabbits (Anonymous, 2010c). Hamsters appear to occupy a middle ground with malformations occurring at doses of 270 mg/kg bw/day. The species difference in response to ETU is due (at least) in part to greater metabolism of ETU in non- (or less) responsive species. This has been reviewed by Khera (1987) and Daston (1997).

Khera (1987) indicated that neuroblasts in the developing nervous system of the rat are the specific target of ETU. Several studies have investigated whether modulation of thyroid hormones are involved in the developmental toxicity of ETU. Initial studies indicated that they may be involved whilst later studies did not support this. The relevant studies are summarised in Table A2-5. The following is taken from the DAR on mancozeb (2000) and is still relevant: "In studies of the mechanism of action, combined treatment of immature rats with thyroxine (T3/T4) and ETU was found to reduce the incidences of hydrocephalus induced by 20 or 40 mg/kg daily doses of ETU (Emmerling, 1978). However, in a second study with ETU administered orally at a 40 mg/kg bw/day dose to hypothyroid (thyroparathyroidectomised), euthyroid (otherwise untreated), or thyroxine-supplemented rats, foetal malformations were unrelated to the alteration in thyroid function in the maternal rat (Lu and Staples, 1978). Combined treatment with ETU and the metabolic inhibitors, SKF-125 or methimazole, increased the incidence and severity of foetal malformations compared to those in groups given ETU only, while combined treatments with the enzyme inducers, phenobarbital or methylcholanthrene failed to influence the teratogenic outcome, thereby indicating that ETU per se may be responsible for the malformations (Khera and Iverson, 1981)."

Support for a direct effect of ETU on the foetus, rather than via thyroid hormones is provided by *in vitro* studies (Table A2-6). In the study of Stannistreet *et al* (1990), the effect of two thyroid hormone antagonists (ETU and methimazole) on rat embryos were compared *in vitro*. In this study, both ETU and methimazole

caused abnormalities at concentrations of 0.5 mM and above but the pattern of changes was different. The authors concluded that ETU and methimazole had a direct effect on embryos rather than via changes in thyroid hormones. Further evidence that ETU has a direct effect on the developing embryo rather than via thyroid hormones is provided by experiments with rat foetal cell cultures (Khera, 1987) and whole embryo cultures (Daston *et al*, 1987). In the studies of Daston (1987, 1997), rat whole embryo cultures exposed directly to ETU developed the same type of malformations as those seen *in vivo*. These studies also lent further support to the species sensitivity to ETU being at least partly due to ability to metabolise ETU. Hepatic S9 prepared from rat (the species most sensitive to ETU) liver was ineffective at reducing the incidence of malformations *in vitro* whereas addition of S9 prepared from mouse (the species least sensitive to ETU) liver reduced the incidence of malformations. These results are consistent with a direct effect that is ablated when ETU is removed by metabolism.

Khera (1987) concluded that ETU-induced foetal malformations were unrelated to maternal thyroid function. Whilst the exact MoA is not known, recent studies in rats where ETU has been used to model anorectal malformations indicate that it has a direct effect on genes involved in development (Mi *et al*, 2014; Wang *et al*, 2011).

**Table A2-5: Studies investigating the effect of thyroid hormones on ETU-induced developmental toxicity in the rat**

| Study design   | Findings relevant for developmental toxicity  | Comments   | Reference              |
|--|---|--|------------------------|
| Pregnant rats (up to 16/group) were administered ETU, T3/T4 or sodium iodide from GD 7-20, by gavage in water, in the following combinations:<br>T3: 20 µg/kg + T4: 100µg/kg<br>NaI 333 µg/kg<br>ETU 20 mg/kg<br>ETU 20 mg/kg + NaI<br>ETU 20 mg /kg + T3/T4<br>ETU 40 mg/kg<br>ETU 40 mg/kg + NaI<br>ETU 40 mg/kg + T3/T4 | The teratogenic response to ETU was reduced for some malformations (micrognathia, cleft palate, syndactyl, ablepharia) when T3/T4 was co-administered, but not for malformations such as hydrocephaly, meningocele, short and kinky tail. Sodium iodide co-administration did not provide any protective effect.  | The results indicate the teratogenic effect of ETU may in part be secondary to the thyroid toxicity of ETU.  | Emmerling (1978)       |
| Rats (6-12 per group) were rendered hypothyroid by removal thyroids and parathyroids (TPTX). Pregnant TPTX and euthyroid (sham operated) rats were administered ETU (40 mg/kg bw/day) and /or T4 from GD 7-15, by gavage in water.   | 84-100% of the foetuses in all litters from the groups given ETU were malformed regardless of the thyroid status of the dams. 10% of the foetuses of TPTX dams that were not given ETU were malformed. No malformations were noted among the foetuses of the other groups not given ETU.<br><br>Malformations, after ETU was given to euthyroid rats, were mostly of CNS, rib, and tail changes, often in the presence of clubbed foot.<br><br>TPTX rats given ETU also had a high incidence of oedema, micrognathia, cleft palate and micromelia. These latter | Results indicate that foetal malformations were unrelated to the alteration in thyroid function in the maternal rat. However, hypothyroidism altered the spectrum of malformations in response to ETU.<br><br>Thyroidectomy also caused increased malformations but these were thought to be the results of maternal stress. | Lu and Staples, (1978) |

|  |  |  |                          |
|--|--|--|--------------------------|
|  | malformations were not seen in TPTX rats not given ETU. There was a high incidence of delayed ossification of the skull of foetuses from all groups given ETU and in TPTX rats (related to body weight).   |  |                          |
| Pregnant rats (5 per group) were administered ETU by gavage in water, at 0, or 60 mg/kg bw/day, on GD 13; in combination with the metabolic inhibitor SKF-525A (SKF) and the antithyroid drug methimazole (MMI). Further groups were pretreated with the MFO inducers phenobarbital (PB) or methylcholanthrene (MC) before ETU (60 mg/kg bw/day on GD 13). | MMI and SKF, alone or in combination were not teratogenic. MMI+SKF+ETU, or MMI + ETU, or SKF+ETU increased the incidence and severity of malformations compared to the group given only ETU. Pretreatment with PB or MC had no effect on the incidence of ETU-induced malformations. | Results indicate that ETU <i>per se</i> is responsible for malformations. Inhibition of ETU metabolism increases rate of malformations by inhibiting removal of ETU. SKF is an inhibitor of P450. MMI and ETU are thought to be metabolized via P450 and FMN therefore MMI may be a competitive inhibitor of P450 in the presence of ETU. The lack of effect of PB/MC may have been due to insufficient doses, inability to reduce the foetal levels of ETU or the P450 isoforms induced by PB/MC may not be involved in ETU metabolism. | Khera and Iverson (1981) |

**Table A2-6: Studies investigating the direct effect of ETU on developmental toxicity in the rat**

| Study design  | Findings relevant for developmental toxicity   | Comments   | Reference                        |
|---|--|--|----------------------------------|
| Rat foetal neuronal and non-neuronal cells were grown in the presence of ETU  | ETU at concentrations greater than 0.5mM caused necrosis of neuronal cells and a reduction in the formation of neurites and fascicles. Non-neuronal cells were unaffected.   | Study indicates a direct effect on neuronal cells  | Khera (1987)                     |
| Rat embryos at GD 9.5 were incubated for 48 h with ETU or methimazole to determine possible direct effects on rat embryos of the two thyroid antagonists. | Both ETU and methimazole inhibited development of the embryos. At 0.5mM and above, ETU caused abnormalities. Most commonly of the neural tube. Methimazole also caused abnormalities at 0.5mM and above but the spectrum of changes was different from ETU. The concentration at which methimazole disturbed rat embryogenesis was higher than that which is reached in treated hyperthyroid patients. | Both of the thyroid antagonists affected development, but with different effects. The authors concluded that ETU has a direct effect on the rat embryo rather than through thyroid hormone changes.  | Stanisstreet <i>et al</i> (1990) |
| Rat embryos at GD 10 were incubated for 48 h with ETU to determine possible morphological changes.  | A dose-related inhibition of crown-rump length, protein & DNA content, somite number and increased abnormalities were seen from 0.04mM ETU. Abnormalities included hydrocephalus, decreased mandibular size, decreased telencephalon size, abnormal dorsiflexion and sub-ectodermal blisters. Osmolarity of the exocoelomic fluid was lowered.   | The abnormalities seen here in vitro are seen at the same sites as those seen in rats after in vivo exposure to ETU. The authors suggested that ETU alters osmotic balance in the embryo and this may contribute towards the formation of defects. | Daston <i>et al</i> (1987)       |

Comparison of the dose responses for the teratogenicity of ETU and the effects on T4 shows an order-of-magnitude difference also implying that different MoAs may be responsible. The NOAEL for the ETU teratogenicity is 5 mg/kg bw/day, with the LOEL being about 15 mg/kg bw/day (Anonymous, 2015d) whilst the NOAEL and LOEL for effects on T4 were 0.2 and 2 mg/kg bw/day respectively (Anonymous, 2013).

Mancozeb itself is not teratogenic when dosed at non-maternally toxic doses (up to 160 mg/kg bw/day, Anonymous, 2015d). The overall LOEL for effects of mancozeb on the rat thyroid was estimated to be 15 mg/kg bw/day (see analysis in Annex 1), indicating that thyroid hormones were likely to be reduced at the high dose of 160 mg/kg bw/day in the developmental toxicity study of Anonymous (2015d). Plasma T4 was measured in blood samples from the toxicokinetic phase of the preliminary developmental toxicity study on mancozeb (Anonymous, 2015c). Measurements were made at 2, 4, and 6 hours. At 4 hours, T4 levels in the 160 and 120 mg/kg bw/day groups were 23-40% lower than control values. However, there was no consistent dose response and changes were not statistically significant. Sample sizes were small (n=3) as the study was not designed to investigate this and did not have sufficient statistical power to draw a clear conclusion. However, results indicate that there may have been a weak effect on thyroid hormones at doses where there was no effect on development.

The large difference between doses of mancozeb where effects occur on thyroid hormones and the doses that can be reached in developmental toxicity studies before maternal toxicity occurs provides support for the absence of a link between thyroid hormones and developmental toxicity.

Comparison of ETU with other thyroid hormone antagonists shows that potent thyroid antagonists such as PTU and methimazole, unlike ETU, cause effects on the brain in experimental animal species but there is no indication that thyroid antagonists commonly cause teratogenicity. Shibutani *et al* (2009) observed impaired brain development with PTU and methimazole but not external malformations. Mallela *et al* (2014) treated rats and mice with PTU or methimazole in a developmental toxicity study, but did not observe gross external malformations or histopathological malformations. Axelstad *et al* (2008) also observed effects on behaviour and memory in a developmental neurotoxicity study on PTU, but no external or visceral malformations. The absence of morphological developmental effects at doses where developmental neurotoxicity is observed indicates that the reduction in thyroid hormones does not lead to commonly lead to external/visceral malformations.

In conclusion, ETU does not cause developmental neurotoxicity in rats, at doses where thyroid hormones are reduced. Although ETU is teratogenic in rats, similar effects are not seen in rabbits or mice. Several lines of evidence indicate that the morphological effects on rat foetuses are caused by a direct MoA and not via thyroid hormone reduction.

### **Human relevance**

The effects of mancozeb/ETU in experimental animals and humans also depends upon absorption, distribution, metabolism and excretion in those species. Effective removal of ETU via metabolism and excretion means that internal exposure to ETU is reduced. The bioconversion of mancozeb to ETU is 7% on a weight basis, similar to the bioconversion factor for other ethylenebisdithiocarbamates (EBDC). In monkeys, oral doses were very poorly absorbed (Emmerling, 1978). The spectrum of metabolites produced was similar in laboratory and farm animals indicating similar metabolism of mancozeb across species. The pharmacokinetics and metabolism of ETU have been studied in mice, rats, guinea pigs, cats, and monkeys. These studies have shown that ETU is rapidly excreted, primarily in the urine and more quickly in mice than in rats. Half-lives for elimination from maternal blood were 5.5 and 9.4 hours in mice and rats, respectively (Ruddick *et al*, 1977). Literature studies indicate that mancozeb and ETU are also rapidly absorbed and eliminated after oral administration in humans. The elimination half-life of ETU was estimated to be 19-23 hours in humans (Aprea *et al*, 1996; Lindh *et al*, 2008).

The metabolism of ETU across species has been compared in two *in vitro* studies (the studies are discussed in more detail in Annex 1). Saghir *et al* (2005) compared rat, mouse and human using liver S9 as a source of metabolising enzymes. Zhu (2015) compared rat, mouse, dog, rabbit and human using primary hepatocytes as the source of metabolising enzymes. The results of the two studies were similar in that metabolism in the rat was lower than in humans. However, metabolism in mouse hepatocytes in Zhu (2015) was lower than in rat hepatocytes whilst the opposite occurred in Saghir *et al* (2005). The latter result concurs with *in vivo*

comparisons of rat and mouse metabolism where metabolism is clearly greater in mice. Metabolism in dog and rabbit appears similar to humans. The *in vitro* metabolism studies show that the metabolism of ETU in hepatocytes increases in the following order: rats < mice < humans, with rabbits and dogs being similar to humans (Saghir *et al*, 2005; Zhu, 2015).

Metabolism of ETU is likely to play a major role in the sensitivity of different species to the developmental toxicity of ETU. Metabolism in humans appears more efficient than rodents, indicating that ETU may be readily removed in humans. These results indicate that humans are more similar to insensitive species than sensitive species (rats).

An analysis of the margin of exposure for mancozeb and developmental toxicity shows that the NOAEL for embryo/foetal development is 160 mg/kg bw/day (the highest dosage level tested in Anonymous, 2015d) compared with current reference values of: AOEL 0.035 mg/kg bw/day; ADI 0.05 mg/kg bw/day and ARfD 0.6 mg/kg bw/day (Review Report for mancozeb: SANCO/4058/2001-rev. 4.4 July 2009) demonstrating a large margin for all values. Epidemiology and medical studies have not shown that exposure to mancozeb is associated with developmental effects (See main document Sections 10.7-10.10).

### **Conclusions**

Mancozeb and ETU do not cause developmental neurotoxicity in offspring when administered to pregnant rats. Mancozeb does not cause structural developmental abnormalities when administered to pregnant rats or rabbits. Although ETU is teratogenic, several lines of evidence indicate that this is not related to its MoA in the thyroid. Epidemiology studies also show that in humans, mancozeb does not cause developmental toxicity. The weight of evidence therefore indicates that the risk of developmental toxicity after exposure of humans to mancozeb is very low.

### **Additional references**

Axelstad M, Hanse PR, Boberg J, Bonnichsen M, Nellemann C, Lund SP, Hougaard KS, and Hass U (2008). Developmental neurotoxicity of propylthiouracil (PTU) in rats: relationship between transient hypothyroxinemia during development and long-lasting behavioural and functional changes. *Toxicol Appl. Pharmacol.* 232(1), 1-13.

Benavides VC, Mallela MK, Booth CJ, Wendler CC and Rivkees SA (2012). Propylthiouracil is teratogenic in murine embryos. *PLoS. One.* 7(4), e35213.

Bos MWS 2014 Physical and chemical properties of the active substance mancozeb. Cerexagri B.V. Rotterdam, The Netherlands, Report No. DL 14-006 GLP, Unpublished

Boyages SC and Halpern JP (1993). Endemic cretinism: toward a unifying hypothesis. *Thyroid* 3(1), 59-69.

Brosvic GM, Taylor JN and Dihoff RE (2002). Influences of early thyroid hormone manipulations: delays in pup motor and exploratory behavior are evident in adult operant performance. *Physiol Behav.* 75(5), 697-715.

Cranefield PF (1962). The discovery of cretinism. *Bull. Hist Med.* 36, 489-511.

Crofton KM, Ding D, Padich R, Taylor M and Henderson D (2000). Hearing loss following exposure during development to polychlorinated biphenyls: a cochlear site of action. *Hear. Res.* 144(1-2), 196-204.

Daston GP, Ebron MT, Carver B and Stefanadis JG (1987). *In vitro* teratogenicity of ethylenethiourea in the rat. *Teratology* 35(2), 239-245.

Daston GP (1997). Advances in understanding mechanisms of toxicity and implications for risk assessment. *Reprod. Toxicol* 11(2-3), 389-396.

Diepenhorst PC 1994 Vapour pressure of the Test Substance Mancozeb. Elf Atochem Report No. DL 93-029 GLP, Unpublished

Emmerling (1978). The effects of thyroid hormones on the teratogenic potential of ethylenethiourea in rat.

- Haddow JE, Palomaki GE, Allan WC, Williams JR., Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD and Klein RZ (1999). Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N. Engl. J. Med.* 341(8), 549-555.
- Kato Y, Odanaka Y, Teramoto S, Matono O (1976). Metabolic fate of ethylenethiourea in pregnant rats. *Bulletin of Environmental Contamination and Toxicology*, 16, 546.
- Khera KS (1973). Ethylenethiourea: teratogenicity study in rats and rabbits. *Teratology*, 7, 243-252.
- Khera KS (1987). Ethylenethiourea: a review of teratogenicity and distribution studies and an assessment of reproduction risk. *Crit Rev. Toxicol* 18(2), 129-139.
- Khera KS and Iverson F (1981). Effects of pretreatment with SKF-525A, N-Methyl-2-thioimidazole, sodium phenobarbital, or methyl cholanthrene on ethylenethiourea-induced teratogenicity in rats. *Teratology* 24(2), 131-137.
- Larsson KS, Arnander C, Cekanova E and Kjellberg M (1976). Studies of teratogenic effects of the dithiocarbamates maneb, mancozeb, and propineb. *Teratology* 14(2), 171-183.
- Lu MH and Staples RE (1978). Teratogenicity of ethylenethiourea and thyroid function in the rat. *Teratology* 17(2), 171-178.
- Maarsingh, P 2005 Hazard Assessment Studies Explosivity, Oxidizing, Flamability and Auto-flammability of Mancozeb TK. Cerexagri B.V. Rotterdam, The Netherlands, Report No. DL 04-092 GLP, Unpublished
- Mallela MK, Strobl M, Poulsen RR, Wendler CC, Booth CJ and Rivkees SA (2014). Evaluation of developmental toxicity of propylthiouracil and methimazole. *Birth Defects Res. B Dev. Reprod. Toxicol.* 101(4), 300-307.
- Mi J, Chen D, Ren X, Jia H, Gao H and Wang W (2014). Spatiotemporal expression of Wnt5a during the development of the striated muscle complex in rats with anorectal malformations. *Int. J. Clin. Exp. Pathol.* 7(5), 1997-2005.
- Ntzani EE, Chondrogiorgi M, Ntritsos G, Evangelou E, Tzoulaki I, (2013). Literature review on epidemiological studies linking exposure to pesticides and health effects. EFSA supporting publication 2013:EN-497, 159 pp.
- Ruddick JA, Newsome WH, Iverson F (1977). A comparison of the distribution, metabolism and excretion of ethylenethiourea in the pregnant mouse and rat. *Teratology*, 16, 159-162.
- Shibutani M, Woo GH, Fujimoto H, Saegusa Y, Takahashi M, Inoue K, Hirose M and Nishikawa A (2009). Assessment of developmental effects of hypothyroidism in rats from in utero and lactation exposure to anti-thyroid agents. *Reprod. Toxicol.* 28(3), 297-307.
- Stanisstreet M, Herbert LC and Pharoah PO (1990). Effects of thyroid antagonists on rat embryos cultured in vitro. *Teratology* 41(6), 721-729.
- Teramoto S, Shingu A, Kaneda M, Saito R (1978). Teratogenicity studies with ethylenethiourea in rats, mice and hamsters. *Congenital Anomalies*, 18, 11.
- Wang W, Jia H, Zhang H, Chen Q, Zhang T, Bai Y and Yuan Z (2011). Abnormal innervation patterns in the anorectum of ETU-induced foetal rats with anorectal malformations. *Neurosci. Lett.* 495(2), 88-92.
- Wasser 1995b Determination of the Appearance of Technical and Pure Mancozeb Anadiag S.A., Haguenau, France RF 4124 04 GLP, Unpublished
- WHO (2012). State of the Science of Endocrine Disrupting Chemicals. Eds: Bergman A, Heindel JJ, Jobling S, Kidd KA and Zoeller RT.

**ANNEX III: SUPPLEMENTARY DATA ON THE DEGRADANTS OF MANCOZEB****Aquatic bioaccumulation of the degradant ETU**

The log Kow for the major degradant of mancozeb, ETU, has been estimated by QSAR analysis. The values calculated are in the negative for pH 5.5, 7, and 9, therefore the same conclusions can be drawn for ETU as were drawn for mancozeb.

**Table A3-1: Summary of relevant information on aquatic bioaccumulation**

| Method  | Test Substance         | Results  | Remarks   | Reference                           |
|---|------------------------|--|---|-------------------------------------|
| Predicted value (ACD Labs version 12.01)<br><br>Non-GLP | Ethylenethiourea (ETU) | Log Kow = -0.66 (pH 5.5)<br>Log Kow = -0.66 (pH 7.0)<br>Log Kow = -0.66 (pH 9.0) | Acceptable. ETU is included in the residue definition, therefore these data are required. | Anonymous (2014) Study 2014/1321435 |

**Table A3-2: Toxicity endpoints for the degradants of mancozeb**

| Guideline and GLP                               | Substance (purity in % w/w) | Species                    | Endpoint Effect                      | Exposure    |          | Results          |                      | Reference                 | Submitted for original approval (O) or renewal (N) |
|---|-----------------------------|----------------------------|--------------------------------------|-------------|----------|------------------|----------------------|---------------------------|--|
|   |                             |                            |                                      | Design      | Duration | Endpoint         | Toxicity (mg a.s./L) |                           |  |
| <b>Fish Acute Toxicity</b>                      |                             |                            |                                      |             |          |                  |                      |                           |  |
| similar to OECD 203 GLP                         | ETU (purity: 100%)          | <i>Oncorhynchus mykiss</i> | Mortality                            | Static      | 96h      | LC <sub>50</sub> | > 490                | Anonymous, 1982a          | O  |
| OECD 203 GLP                                    | ETU (purity 99.9%)          | <i>Oncorhynchus mykiss</i> | Mortality                            | Static      | 96h      | LC <sub>50</sub> | > 500                | Anonymous, 2001           | O  |
| OECD 203 GLP                                    | EU (purity 90.8%)           | <i>Oncorhynchus mykiss</i> | Mortality                            | Static      | 96h      | LC <sub>50</sub> | > 122                | Anonymous, 2001a          | O  |
| <b>Fish/Aquatic vertebrate Chronic Toxicity</b> |                             |                            |                                      |             |          |                  |                      |                           |  |
| Similar to OECD 231                             | ETU (purity 99.9%)          | <i>Xenopus laevis</i>      | Development. Amphibian Metamorphosis | Semi-static | 28d      | NOEC             | 10                   | Anonymous, 2002           | O  |
| <b>Invertebrate Acute Toxicity</b>              |                             |                            |                                      |             |          |                  |                      |                           |  |
| OECD 202 GLP                                    | ETU (purity 97.7%)          | <i>Daphnia magna</i>       | Immobilisation                       | Static      | 48h      | EC <sub>50</sub> | 49                   | Hutchinson & Spare, 1982b | O  |

| Guideline and GLP  | Substance (purity in % w/w) | Species                                  | Endpoint Effect | Exposure     |          | Results                        |                      | Reference            | Submitted for original approval (O) or renewal (N) |
|--|-----------------------------|--|-----------------|--------------|----------|--------------------------------|----------------------|----------------------|--|
|  |                             |  |                 | Design       | Duration | Endpoint                       | Toxicity (mg a.s./L) |                      |  |
| OECD 202 GLP   | ETU (purity 97.7%)          | <i>Americamysis bahia</i>                | Immobilisation  | Static       | 48h      | EC <sub>50</sub>               | 11                   | Soucy, 2008          | N  |
| OECD 202 GLP   | ETU (purity 99.6%)          | <i>Daphnia magna</i>                     | Immobilisation  | Static       | 48h      | EC <sub>50</sub>               | 21.6                 | Hisgen, 2000         | O  |
| OECD 202 GLP   | EU (purity 90.8%)           | <i>Daphnia magna</i>                     | Immobilisation  | Static       | 48h      | EC <sub>50</sub>               | > 985                | Palmer et al., 2001b | O  |
| <b>Invertebrate Chronic Toxicity</b>                                 |                             |  |                 |              |          |                                |                      |                      |  |
| Similar to OECD 211  | ETU (purity 96.2%)          | <i>Daphnia magna</i>                     | Reproduction    | Flow-through | 21d      | NOEC                           | 2.0                  | Graves, 1995         | O  |
| <b>Algal Toxicity</b>  |                             |  |                 |              |          |                                |                      |                      |  |
| OECD 201 GLP   | ETU (purity 99.6%)          | <i>Pseudokirchneriella subcapitata</i> * | Growth rate     | Static       | 72h      | E <sub>r</sub> C <sub>50</sub> | 93.8                 | Reuschenbach, 2000   | O  |
| OECD 201 GLP   | EU (purity 90.8%)           | <i>Selenastrum capricornutum</i> *       | Growth rate     | Static       | 72h      | E <sub>r</sub> C <sub>50</sub> | > 119                | Palmer, 2001c        | O  |
| <b>Theoretical degradant endpoints based on QSAR calculations</b>    |                             |  |                 |              |          |                                |                      |                      |  |
| Performed by the applicant using the software ECOSAR V 1.1 (U.S.EPA) | EBIS                        | Fish                                     | Mortality       | N/A          | N/A      | LC <sub>50</sub>               | 0.183                | N/A                  | N  |
|  |                             | <i>Daphnia</i>                           | Immobilisation  |              |          | EC <sub>50</sub>               | 0.210                |                      |  |
|  |                             | Algae                                    | Growth rate     |              |          | E <sub>r</sub> C <sub>50</sub> | 0.102                |                      |  |

\*Currently known as *Raphidocelis subcapitata*

### Reply from the Applicant on the classification of relevant metabolites in order to determine the 'rapid degradability' classification of mancozeb

Harmonized classification is available for all relevant degradants of mancozeb (with exclusion of glycolic acid, which can be self-classified as non-toxic based on the relevant aquatic toxicity data for this metabolite) and has therefore to be adopted for classification purposes within the EU.

The metabolite EBIS is legally classified within the EU with H400 (Aquatic acute 1) and H410 (Aquatic Chronic 1) according to Annex VI of (EC) No 1272/2008 (CLP). Regarding the other relevant metabolites of mancozeb, no environmental hazard classification is given according to Annex VI of (EC) No 1272/2008 (CLP) (Table 1).

**Table 1: Acute and chronic classification of the relevant degradants of mancozeb**

| Degradant (CAS No.)                      | Study type            | Findings [mg/L] | DT <sub>50</sub> (or DT <sub>90</sub> /3.322 where behaviour is biphasic) | Triggered classification and labelling      | Reference  |
|--|-----------------------|-----------------|---|---|--|
| EBIS (33813-20-6)                        | --                    | --              | 0.5 – 10.9 days <sup>1</sup>  | <b>Aquatic acute hazard cat. 1 (H400)</b>   | legal classification of EBIS in Annex VI of (EC) No 1272/2008 (CLP)  |
|  | --                    | --              |   | <b>Aquatic chronic hazard cat. 1 (H410)</b> |  |
| EDA (1,2-Ethanediamine) (107-15-3)       | --                    | --              | Not calculable  | <b>No aquatic acute hazard cat.</b>         | legal classification of EDA in Annex VI of (EC) No 1272/2008 (CLP)   |
|  | --                    | --              |   | <b>No aquatic chronic hazard cat.</b>       |  |
| Ethanolamine (2-Aminoethanol) (141-43-5) | --                    | --              | 20.2 days   | <b>No aquatic acute hazard cat.</b>         | legal classification of ethanolamine in Annex VI of (EC) No 1272/2008 (CLP)  |
|  | --                    | --              |   | <b>No aquatic chronic hazard cat.</b>       |  |
| Glycolic acid (79-14-1)                  | 48-h EC <sub>50</sub> | 44.0            | 2060 days   | <b>No aquatic acute hazard cat.</b>         | Japanese Environment Agency (NR), Acute Immobilization Test of Glycolic acid to Daphnia magna Report Nr. 1998-生22    |
|  | 21-d NOEC             | 4.38            |   | <b>No aquatic chronic hazard cat.</b>       | Japanese Environment Agency (NR), Reproduction Inhibition Test of Glycolic acid to Daphnia magna Report No: 1998-生23 |
| Ethylene glycol (107-21-1)               | --                    | --              | 11.9 days <sup>2</sup>  | <b>No aquatic acute hazard cat.</b>         | legal classification of ethylene glycol in Annex VI of (EC) No 1272/2008 (CLP)                                       |
|  | --                    | --              |   | <b>No aquatic chronic hazard cat.</b>       |  |
| Oxalic acid (possibly M1) (144-62-7)     | --                    | --              | 37.8 days <sup>3</sup>  | <b>No aquatic acute hazard cat.</b>         | legal classification of oxalic acid in Annex VI of (EC) No 1272/2008 (CLP)   |
|  | --                    | --              |   | <b>No aquatic chronic hazard cat.</b>       |  |

<sup>1</sup> = Decline calculated on total amount in water + sediment phase

<sup>2</sup> = DT50 calculated tentatively on 2 sample points

<sup>3</sup> = Study had two incubations; maximum occurred in one incubation at study end, but in the other incubation the substance declined before end to allow tentative DT50 calculation (three sample points from study end)

Note that EU and ETU were not further considered as it was already confirmed by CRD that you agree with our conclusion and no further data/evaluation is required:

„In conclusion, neither EU or ETU fulfil the criteria for classification for ‘hazardous to the aquatic environment’.”

In conclusion, only the metabolite EBIS must be considered as environmentally hazardous in the evaluation of ready biodegradability of the parent compound. Regarding its environmental behaviour, EBIS is rapidly formed from mancozeb and maximum half-lives of < 1 day are reported for the water phase before the metabolite will be converted to the non-toxic ETU. Longer half-lives, as given in the table above, are related to the total water-sediment system. For the compartment water EBIS can therefore be classified as rapidly degradable too.

Moreover, looking at the known mode of action of EBDCs like mancozeb, this is explained in the literature by the transient formation of early intermediate products like EBIS (often named DIDT, forming other intermediates like ethylene diisothiocyanate) and their unspecific reaction with cell constituents such as thiol-containing enzymes (Ludwig & Thorn, 1960; Kaars Sijpesteijn, 1984).

Hence, as EBDCs like mancozeb act via their early intermediate products, the classification of mancozeb into Aquatic Acute Hazard Cat. 1 (H400) and Aquatic Chronic Hazard Cat. 1 (H410) already considers the aquatic toxicity of EBIS (which has the same classification). Therefore, the consideration of the classification of both molecules (mancozeb and EBIS) within the evaluation of the rapid degradability of mancozeb would overestimate the risk for the environment.

In conclusion, apart from EBIS the aquatic metabolites of mancozeb are not hazardous to aquatic environment. The classification of EBIS is already covered by the classification of mancozeb and therefore mancozeb can be assessed as rapidly degradable.

## References

Graves D, Mank M, Swigert J (1995). Ethylenethiourea (ETU): A flow-through life-cycle toxicity test with the cladoceran (*Daphnia magna*). Generated by: Wildlife International, Inc. Submitted by: Rohm and Haas Company, ER Company file No.85.14. Published.

Hisgen M (2000). Determination of the acute effect on the swimming ability of the water flea *Daphnia magna* STRAUS. BASF Aktiengesellschaft, Ludwigshafen, Germany. BASF RegDoc# 2000/1017216. Unpublished. IIA, 8.2.5.

Kaars Sijpesteijn, A. (1984). Mode of action of some traditional fungicides. Pages 135-153 in: Mode of Action of Antifungal Agents. A. P. J. Trinci and J. F. Ryley, eds. Cambridge University Press, Cambridge.

Ludwig, R.D. & Thorn, G.D. (1960). Chemistry and mode of action of Dithiocarbamate fungicides. Adv. Pest Control Res. 30, 219-252.

Reuschenbach P (2000). Determination of the inhibitory effect on the cell multiplication of unicellular green algae. BASF, Aktiengesellschaft, Ludwigshafen, Germany. BASF RegDoc# 2000/1017191, Unpublished. IIA, 8.2.7.

Soucy K (2008). Ethylenethiourea - acute toxicity to mysids (*Americamysis bahia*) under static conditions, following OPPTS guideline 850.1035. Springborn Smithers Study No. 13921.6103. KCA 8.2.4.2/01.